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Abstract 
 
As a first generation of compounds, the nucleosides adenosine 8, cytidine 11, guanosine 9, 
inosine 116 and uridine 12, as well as the sugar ᴅ-(-)-ribose 100, were transformed into the 
corresponding 5’-O-(tert-butyldiphenylsilyl)- and 5’-O-(4,4’-dimethoxytrityl)-derivatives. 
These were subsequently protected as acetyl, benzoyl and allyl derivatives at various positions 
on the molecules, to give a range of twenty five unique compounds for biological testing.  
 
The nucleoside and corresponding ᴅ-(-)-ribose derivatives were evaluated for their 
antibacterial activity against two Gram-positive (Staphylococcus aureus ATCC 25923 and 
Bacillus cereus DL5) and two Gram-negative bacteria (Pseudomonas aeruginosa ATCC 
27853 and Escherichia coli ATCC 25922), for their anti-HIV activity against strain HLTVIIIB 
as well as for their anticancer properties, by evaluating inhibition of cell proliferation in two 
adherent (HT-29 and Caco-2) and three suspension (HL-60, Jurkat and K-562) cell lines. 
From these screens, and based on the 2,3,5-triphenyltetrazolium chloride (TTC) assay, it was 
found that 5’-O-(tert-butyldiphenylsilyl)uridine 107, 5’-O-(tert-butyldiphenylsilyl)-1'-O-
methoxy-ᴅ-(-)-ribose 102 and tert-butyldiphenylsilyl alcohol 145 exhibited antimicrobial 
activity towards only the Gram-positive bacteria when compared to the ciprofloxacin 153 
control. None of the compounds tested showed any antiviral activity when assayed against 
HIV; however, all compounds indicated some form of toxicity to the uninfected cells. 
Subsequent cell proliferation studies indicated pronounced activity against both the adherent 
and suspension cancer cell lines for 5’-O-(tert-butyldiphenylsilyl)uridine 107, 5’-O-(tert-
butyldiphenylsilyl)cytidine 134, tert-butyldiphenylsilyl alcohol 145, 5’-O-(4,4’-
dimethoxytrityl)uridine 126 and 4,4’-dimethoxytrityl alcohol 147. Our initial screen indicated 
that ᴅ-(-)-ribose derivatives do not show any significant general biological activity; whereas 
(tert-butyldiphenylsilyl)-protected nucleoside derivatives and the corresponding tert-
butyldiphenylsilyl alcohol control are intrinsically more bio-active. 
 
From the data reported for the anti-bacterial and the cell proliferation studies, we concluded 
that the nucleoside showing the most promising results was uridine 12 and our mini structure-
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activity study on the uridine derivatives found that the best position for performing 
modifications to the nucleoside was at the 5'-OH position on the sugar ring. As such, this 
would become the initial focus for the synthesis of the second generation compounds. The 
second generation compounds included a series of ten uridine 12 and five 5-methyluridine 
233 derivatives which were protected on the primary alcohol with a range of different silicon-
containing protecting groups. At the same time, we used a general procedure to synthesize a 
series of fourteen silanols for use as control compounds. 
 
The uridine 12, 5-methyluridine 233 and corresponding silanol derivatives were screened for 
their antibacterial activity against the same two Gram-positive and two Gram-negative 
bacteria as above, as well as for their anticancer properties, by evaluating inhibition of cell 
proliferation in a series of six adherent cell lines (five human: Hs683, MCF-7, PC-3, SKMEL-
28, U373, and one murine: B16F10) cell lines. The data obtained for our TTC assay showed 
that converting the base in 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-
6H-furo[3,2-f][1,3,5,-2,4]trioxadisilocin-8-yl]-pyrimidine-2,4(1H,-3H)dione 234 to the 5-
methyl derivative 254 caused a corresponding loss in antibacterial activity for the compound, 
whereas oxidising the secondary alcohol on the 2'-position of the sugar ring to give compound 
239 caused a corresponding increase in antibacterial activity. As such, we concluded that 1-
[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,-2,4]trioxadisilo-
cin-8-yl]pyrimidine-2,4(1H,3H)dione 239 was the compound with the best antibacterial 
activity out all of the first and second generations of nucleoside derivatives assayed. The 
results obtained in the TTC assay, were supported by our scanning electron (SEM) and 
confocal scanning electron (CSLM) microscopy studies. Interestingly, the CSLM study 
suggests that the synthetic compound 239 is bacteriocidal and is inactivating cells, not simply 
inhibiting their growth. From the inhibition of cell proliferation assay performed on the fifty 
combined first and second generation derivatives and their corresponding controls, we found 
that the six most active compounds (5'-O-(tert-butyldiphenylsilyl)adenosine 142, 5'-O-(tert-
butyldiphenyl-silyl)cytidine 134, 5'-O-(tert-butyldiphenylsilyl)uridine 107, 2',3'-O-diacetyl-5'-
O-(tert-butyl-diphenylsilyl)uridine 123, 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine 
127 and 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,-5,2,4]trioxa-disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 235) had mean IC50 
values of approximately 24-28 μM.   
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PART 1 - FIRST GENERATION COMPOUNDS 
 
Synthesis and Biological Testing of Various 
Nucleoside and ᴅ-(-)-Ribose Derivatives 
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Chapter 1: 
Introduction 
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1.1 GENERAL INTRODUCTION: BASES, NUCLEOSIDES AND NUCLEOTIDES 
 
As a class, the bases, sugar-coupled nucleosides and the phosphorylated-nucleosides, the 
nucleotides, may be considered as the most important metabolites of the cell. The nucleotides 
are found primarily as the monomeric units, comprising the major nucleic acids of the cell: 
ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). However, they are also required 
for numerous other important functions within the cell.
1
  
 
1.1.1 Base, Nucleoside and Nucleotide Structures and Nomenclature 
 
The nucleosides and nucleotides found in all cells are derivatives of the heterocyclic 
compounds, purine 1 and pyrimidine 2.
1
 These heterocyclic compounds are illustrated in 
Figure 1. 
 
N
N N
H
N
N
N
Purine
1
Pyrimidine
2  
 
Figure 1 Structures of purine and pyrimidine heterocycles 
 
It is the chemical basicity of the purine and pyrimidine heterocycles that has given them the 
common term "bases".1 There are five major bases found in the DNA and RNA of cells. The 
derivatives of purine are known as adenine 3 and guanine 4, and the derivatives of pyrimidine 
are known as thymine 5, cytosine 6 and uracil 7. The common abbreviations used for these 
five bases are: A, G, T, C and U.
1
 The structures of each of the five bases are shown for 
clarity in Figure 2. 
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Adenine
3
Guanine
4
Thymine
5
Cytosine
6
Uracil
7  
 
Figure 2 Structures of the five major purine and pyrimidine bases 
 
There are also several other less common bases found in DNA and RNA, with 5 -
methylcytosine observed as the primary modified base. A variety of other modified bases 
occur in the transfer RNA strands (tRNA).
1 
 
The purine and pyrimidine bases in the cells are linked to carbohydrates and in this form are 
termed nucleosides. The bases described in detail above are coupled to either ᴅ-ribose or 2'-
deoxy-ᴅ-ribose through a β-N-glycosidic bond between the anomeric carbon of the ribose and 
the N9-position of a purine or the N1-position of a pyrimidine base.1 The carbon atoms of the 
ribose ring are designated with a prime mark (') to distinguish them from the backbone 
numbering used in the bases. 
 
This gives rise to the five major nucleosides: 
 two  purine-based nucleosides - adenosine 8 and guanosine 9 
 three pyrimidine-based nucleosides - thymidine 10, cytidine 11 and uridine 12 
which are illustrated in Figure 3. 
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Cytidine
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Uridine
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Figure 3 Structures of the five major nucleosides
2 
 
The base can exist in two distinct orientations about the N-glycosidic bond, which are 
illustrated through the use of adenosine 8 in Figure 4 below. These conformations are 
identified as syn (syn-8) and anti (anti-8).1 In naturally-occurring nucleosides, the anti 
conformation predominates, and as such will be the representation of choice used throughout 
this thesis. 
 
N
N N
N
NH2
O
OHOH
HO
syn-Adenosine
syn-8
N
NN
N
NH2
O
OHOH
HO
anti-Adenosine
anti-8  
 
Figure 4 Possible orientations about the N-glycosidic bond for adenosine 81 
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Nucleosides are found in the cell primarily in their phosphorylated form and are termed 
nucleotides. The most common site of phosphorylation of the nucleotides is on the 5'-carbon 
position of ribose.
3a
 Nucleotides can exist in the mono-, di- or tri-phosphorylated forms. The 
different levels of phosphorylation are highlighted in Figure 5 by comparison of the various 
forms of adenosine, namely: adenosine 8, adenosine-5'-monophosphate 13, adenosine-5'-
diphosphate 14 and adenosine-5'-triphosphate 15. 
 
N
NN
N
NH2
O
OHOH
HO
Adenosine
8
N
NN
N
NH2
O
OHOH
O
Adenosine-5'-monophospate
13
P
O
O-
-O
N
NN
N
NH2
O
OHOH
O
Adenosine-5'-diphospate
14
P
O
O-
OP
O
HO
O-
N
NN
N
NH2
O
OHOH
O
Adenosine-5'-triphospate
15
P
O
O-
OP
O
O
O-
P
O
-O
O-
 
 
Figure 5 Various phosphorylated forms of adenosine 8
3a 
 
Nucleotides are given distinct abbreviations to allow for easy identification of their structure 
and state of phosphorylation. Using the example of adenosine illustrated in Figure 5,
3a
 
 adenosine-5'-monophosphate 13 is abbreviated as AMP 
 adenosine-5'-diphosphate 14 is abbreviated as ADP 
 adenosine-5'-triphosphate 15 is abbreviated as ATP 
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Note that the use of these abbreviations assumes that the nucleotide is in the 5'-
phosphorylated form. 
 
As observed in Figure 5, the di- and tri-phosphates of the nucleotides are linked by an acid 
anhydride series of bonds. The acid anhydride bonds have a high ΔG0' (Gibbs Free Energy) 
for hydrolysis, giving them a high potential to transfer the phosphate group to other 
molecules.
1
 In a nutshell, it is this property of the nucleotides that results in their involvement 
in group transfer reactions within the cell. 
 
The nucleotides found in DNA are unique from those found in RNA. In DNA the ribose 
exists in the 2'-deoxy form and the abbreviations of the nucleotides contain a "d" 
designation.
3a
 The structures of the deoxyribonucleotides are illustrated in Figure 6. 
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Figure 6 Structures of the deoxyribonucleotides present in DNA 
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The abbreviations used for DNA are given here in Figure 7, again using the derivatives of 
adenosine: 
 2'-deoxyadenosine 20 is abbreviated as dA 
 2'-deoxyadenosine-5'-monophosphate 16 is abbreviated as dAMP 
 2'-deoxyadenosine-5'-diphosphate 21 is abbreviated as dADP 
 2'-deoxyadenosine-5'-triphosphate 22 is abbreviated as dATP 
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Figure 7 Various phosphorylated forms of deoxyadenosine 20 
 
The nucleotide uridine is never found in DNA (ie: it is only present in RNA). Thymine is 
almost exclusively found in DNA, with thymine present in transfer RNA (tRNA) but not in 
ribosomal RNA (rRNA) or messenger RNA (mRNA). 
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1.1.2 Watson-Crick Model for Base-Pairing in DNA 
 
In 1953, using X-ray diffraction data obtained from crystals of DNA, James Watson and 
Francis Crick proposed a model for the structure of DNA. This model was subsequently 
verified using additional nuclear magnetic resonance and spectroscopic data.
3b
 The model 
predicted that DNA would exist as a helix of two complementary anti-parallel strands, wound 
around each other in a rightward direction and were stabilized by hydrogen bonding (H-
bonding) between the bases in the adjacent strands.  
 
In the Watson-Crick model, the bases are in the interior of the helix aligned at a nearly 90
o
 
angle relative to the axis of the helix. Purine bases form H-bonds with pyrimidine bases, in 
the crucial phenomena of base-pairing (shown in Figure 8 below). Using experimental data, 
they were able to show that in any given molecule of DNA, the concentration of adenine 3 
equals the concentration of thymine 5, and the concentration of cytosine 6 equals the 
concentration of guanine 4. This pattern gives rise to A-T base-pairs containing two H-bonds 
and G-C base-pairs containing three H-bonds between the corresponding bases.3b These are 
illustrated as the hashed bonds drawn in red in Figure 8.  
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Figure 8 Chemical representation of the Watson-Crick base pairs found in DNA
3b
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The anti-parallel nature of the helix stems from the orientation of the individual strands. From 
any position in the helix, one strand is orientated in the 5' - > 3' direction, and the other strand 
is orientated in the 3' - > 5' direction. On the exterior surface, the double helix of DNA 
contains two deep grooves between the ribose-phosphate chains. The grooves are of unequal 
size, due to the asymmetry of the deoxyribose rings as well as the structurally distinct nature 
of the upper surface of the base-pair relative to the lower surface. These are referred to as the 
major and minor grooves.
3b
 The most common of the several forms of the DNA double helix 
that have been shown to exist (not discussed in detail in the thesis) is illustrated in Figure 9. 
 
 
 
Figure 9 Diagrammatic representation of base-pairing observed in the DNA double-helix
3b 
 
Many modified nucleotides are also encountered outside of the context of DNA and RNA 
where they serve several other important biological functions. These functions include: 
 serving as energy stores for future use in phosphate transfer reactions (which are 
predominantly carried out by ATP)
1
 
 forming a portion of several important coenzymes, such as NAD+, NADP+, FAD and 
coenzyme A
1
 
 serving as mediators of numerous important cellular processes, such as secondary 
messengers in signal transduction events. The predominant secondary messenger is 
3',5'-cyclic-adenosine-monophosphate (cAMP), which is a cyclic derivative of AMP 
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formed from ATP, that is involved in passing signal transduction events from the cell 
surface to internal proteins (e.g.: cAMP dependent protein kinase)
1
 
 controlling enzymatic reactions through allosteric effects on enzyme activity1 
 having a role as endogenous ligands of G protein-coupled purinergic receptors1b 
 serving as activated intermediates in numerous biosynthetic reactions. These activated 
intermediates include S-adenosylmethionine (S-AdoMet) which is involved in methyl 
transfer reactions, as well as the many sugar coupled nucleotides (nucleosides) which 
are involved in glygogen and glycoprotein synthesis.
1
 
 
Numerous base, nucleoside and nucleotide analogues have been chemically synthesized and 
these have found various biological uses based on their often interesting therapeutic potential. 
The biological applications of the nucleosides are discussed in detail in Section 1.2, and as 
such, are excluded from this section.  
 
Synthetic analogues of both the bases and the nucleotides have been utilized to inhibit specific 
enzymatic activities, an example of this is in the use of these analogues as anti-tumour agents. 
These work because they effectively interfere with the synthesis of DNA and thereby 
preferentially kill the rapidly dividing tumour cells.
4
 Some of the base analogues commonly 
used in chemotherapy are: (i) 6-mercaptopurine 25, (ii) 5-fluorouracil 26 and (iii) 6-
thioguanine 27 (structures shown in Figure 10).
4
 Each of the compounds 25, 27 and 28 
disrupts the normal DNA replication process by interfering with the formation of the correct 
Watson-Crick base-pairs. 
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Figure 10 Synthetic base analogues used in cancer chemotherapy or the treatment of gout 
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Additional applications of the bases and nucleotides in current medicine include the use of 
several purine analogues for the treatment of gout. The most common is allopurinol 28 
(Figure 10), which resembles hypoxanthine. Allopurinol inhibits the activity of xanthine 
oxidase, an enzyme involved in de novo purine biosynthesis.4 Several other nucleotide 
analogues are used after organ transplantation in order to suppress the immune system and 
reduce the likelihood of transplant rejection by the host.  
 
1.2 INTRODUCTION TO BIOLOGICAL APPLICATIONS OF NUCLEOSIDES - 
 WITH A CLOSER LOOK AT CURRENT NUCLEOSIDE BASED DRUGS 
 
Nucleosides and their analogues are of enormous importance. They are an established class of 
clinically useful medicinal agents possessing antiviral and anticancer activity; at the same 
time they are one class of compounds worthy of further investigation as antibacterial agents 
since some derivatives have shown moderate to good activity against specific bacterial 
strains.
4
 This has led to our interest in the search for new nucleoside derivatives that may be 
screened for broad-spectrum biological activity. Please note that in the proceeding sections, 
we will not give a detailed discussion to the carbohydrate portions of the nucleoside 
molecules themselves, even though the carbohydrates are used as reference molecules for 
some of the biological assays conducted. The field of medicinal carbohydrate chemistry is 
very rich and for a more comprehensive read, please refer to the recently published 
"Carbohydrate-Based Drug Discovery" edited by Wong (2006, Wiley-VCH) and 
"Carbohydrate Drug Design" edited by Klesov, Witczak and Platt (2006, American Chemical 
Society Symposium Series).  
 
1.2.1 Nucleoside Derivatives Used in the Treatment of Viral Diseases 
 
Viral diseases remain among the greatest causes of human morbidity and economic loss for 
both the developed and the developing nations. The leading cause of GP/doctor’s room 
consultations is for infectious disease problems, with the average person in the developed 
countries having between two and six viral infections per year.
5 
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The current antiviral drug armamentarium comprises almost 40 compounds that have been 
officially approved for clinical use.
6
 Most of the approved drugs date from the last five years, 
and at least half of them are used in the treatment of human immunodeficiency virus (HIV) 
infections. The other antivirals that are currently available are primarily used for the treatment 
of hepatitis B virus (HBV), hepatitis C virus (HCV), herpes virus [herpes simplex virus 
(HSV), varicella-zoster virus (VSV), and cytomegalovirus (CMV)], influenza virus and 
respiratory syncytial virus (RSV) infections.
6
  
 
HIV/AIDS has become the most devastating pandemic in recorded history. It has killed 40 
million people in the last 20 years and the World Health Organization (WHO) estimated that 
at least 14 000 new infections occurred daily in 2001.
7
 According to figures from the WHO 
2002 statistics, an estimated 36.1 million people worldwide are presently infected with HIV 
and they estimate there will be up to 100 million new infections in the next 10 years.
8
 Most 
HIV infections occur in the developing world, and the adverse social and economic impact of 
the HIV/AIDS pandemic, particularly in the developing world, is unprecedented. 
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Figure 11 Selected examples of nucleoside based drugs currently used in the treatment of 
HIV
8 
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To date, 19 drugs have been formally approved for the treatment of HIV infections. They are 
classified as: (i) the nucleoside reverse transcriptase inhibitors, (ii) the nucleotide reverse 
transcriptase inhibitors, (iii) the non-nucleoside reverse transcriptase inhibitors, (iv) the 
protease inhibitors and (v) the viral entry inhibitors.
8
 The large number of nucleoside-based 
anti-HIV drugs available has been inspirational to our synthesis and examples of the 
nucleoside based drugs for the treatment of HIV are shown in Figure 11. 
 
1.2.2 Nucleoside Derivatives Used in the Treatment of Cancer 
 
Approximately one in four deaths in the United States are caused by cancer, and in 2005 
cancer overtook heart disease as the top killer of Americans under the age of 85.
9
 Despite 
dramatic advances in our understanding of the underlying biology of the disease, cancer death 
rates have remained constant, at roughly 200 deaths per 100 000 people, over the last thirty 
years - highlighting the need for new therapeutic agents.
10 
 
The biosynthesis of nucleotides is the limiting process in cell proliferation. Many of the 
enzymes involved in these pathways are highly active in cancer cells, but barely detectable in 
non-proliferating cells. Thus, nucleoside analogues that inhibit nucleotide biosynthesis are of 
great interest for cancer chemotherapy.  
 
The nucleoside analogue 5-fluoro-2’-deoxyuridine 36 is an inhibitor of thymidylate synthase 
and has been used clinically for the treatment of leukemia and colorectal cancer for more than 
three decades. More recently, gemcitabine (2’,2’-difluoro-2’-deoxycytidine) 37 has shown 
great promise for the treatment of pancreatic cancer. ʟ-(-)-3’-Oxa-2’,3’-dideoxycytidine 38 
showed interesting activity against hepatocellular and prostate tumours which are generally 
difficult to treat, and is thus a promising new clinical candidate.
11
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Figure 12 Examples of nucleoside analogues investigated for the treatment of cancer 
 
1.2.3 Nucleoside Derivatives Used as Antibiotics 
 
Since the first known use of antibiotics by the Chinese more than 2 500 years ago, a research 
field with immense importance for the welfare of mankind has been developed. After a 
decrease in interest in this topic by the end of the 20
th
 century, the occurrence of multi-
resistant strains of bacteria and the so-called “superbugs” over the past 30 years induced a 
revival of antibiotics research.
12
 Today the most devastating of the bacterial diseases is 
tuberculosis, with an estimated 2 million people dying from it each year.
12 
 
Nucleoside antibiotics are found in a large structural variety featuring nucleosides in 
conjugation with other components, such as peptides, lipids, extra carbohydrate moieties and 
many more, sometimes unusual compositions. The structural features of nucleosides in 
particular indicate their potential for interacting and interfering with DNA and RNA and the 
related enzyme machinery.
12
 Examples of nucleoside containing antibiotics are outlined in 
Figure 13. 
 
P a g e  | 16 
 
O
OH
OH
HN
O
O
O
HO
HO
NH
O
CH2 8-11
O
N
OH
HO
HO
HO
NH
O
O
Tunicamycin
39
O
O
H
N OHN
OH
OH
O
OH
N
O
NH2
NH
O
O
O
Capuramycin
42
HO
HOOC
H
N
H
N
O
N
H
O
S
N
O
NH2
H
N
O
O
HO
OH
NH
O
O
Mureidomycin A
41
H
N
N
H
O
O
N
H
N
H
HOOC
O
HN
O
N
O
H2N
OH
N
NH
O
OOH
S
Sansanmycin
40
 
 
Figure 13 Nucleoside antibiotics (nucleoside core highlighted in blue)
12 
 
Many of these nucleoside antibiotic structures show promising activities against several 
bacterial strains and thus have great potential as antibacterial agents. However, they do suffer 
from a number of disadvantages, such as poor adsorption, complexity, chemical lability, 
moderate cell entry ability and most importantly, lack of selectivity and cross-activity in 
mammalian cells.
12
 Hence, no nucleoside agent is in current clinical use for antibacterial 
treatment. 
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Clearly the ability to synthesize modified nucleosides has favourably impacted a wide range 
of biomedical research, including the clinical treatment of disease. They have advanced our 
understanding of many vital biochemical processes involving nucleotides and nucleic acids. 
As such, methods for the synthesis of modified nucleosides are of general interest and 
widespread importance. 
 
1.3 CONFORMATIONALLY RESTRICTED NUCLEOSIDE ANALOGUES 
 
Despite the wide number of nucleoside analogues reported, only a few effective compounds 
have been obtained. This inactivity may be due to either low intracellular metabolism into the 
corresponding nucleotide derivatives or lack of activity of such a nucleotide on the target 
enzyme.
13
 In the course of the search for new agents with a higher therapeutic index, the 
conformation equilibrium of nucleosides is considered as essential.
13 
 
Three different classes of conformationally restricted nucleoside analogues have been 
described: (i) bicyclic and tricyclic nucleosides having a bridge between two positions of the 
furanose ring, (ii) cyclonucleosides having a bridge between the heterocyclic base and the 
furanose ring, and (iii) cyclic phosphoesters having a bridge extending from the phosphorus 
atom of the nucleotide to either the heterocyclic base or the furanose ring.
13 
 
1.3.1 Class 1 - The Bicyclic and Tricyclic Nucleosides 
 
In the case of the bicyclic nucleosides of class (i), the ring fusion to the 2’,3’-positions of the 
glycone moiety having either C,O-connections such as compounds 43-52, O,O-connections 
such as compounds 53-55 or C,C-connections such as compounds 56-62 have been reported. 
in a number of recent publications.
13-17 
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Figure 14 Examples of bicyclic nucleosides with the ring fusion at the 2’,3’-positions 
(nucleoside: A = adenosine, C = cytidine, G = guanosine, T = thymidine and U = uridine)
13-17 
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In the case of the bicyclic nucleosides of class (i), few examples of the ring fusion to the 
3’,4’-positions of the glycone moiety have been reported. One example is a C,C-connection, 
found in compound 63, and illustrated in Figure 15. 
 
O Base
HO
OH
Base = A, C, G, T, U
63  
Figure 15 Example of a bicyclic nucleoside with the ring fusion at the 3’,4’-positions18 
 
Also in the case of the bicyclic nucleosides of class (i), a few examples of the ring fusion to 
the 2’,4’-positions of the glycone moiety have been reported. Both C,O-connections and C,C-
connections have been observed. Examples 64 and 65 are outlined in Figure 16. 
 
O Base
HO
O
HO
Base = U
O Base
HO
OH
Base = U
64 65  
Figure 16 Examples of a bicyclic nucleoside with the ring fusion at the 2’,4’-positions19-20 
 
1.3.2 Class 2 - The Cyclonucleosides 
 
The second class of conformationally restricted nucleoside analogues are the 
cyclonucleosides. The cyclonucleosides bear additional linkages between the heterocyclic 
ring and the sugar moiety. Although cyclonucleosides were the target of chemists for 
conformational studies as early as the 1960s, the scientific literature is sparse on their 
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application against biological targets. However, a few of the obtained compounds have been 
shown to possess a wide range of antiviral or antitumour properties. The more common 
cyclonucleosides with known biological activities are illustrated in Figure 17, with the 
biological testing performed highlighted below each compound.
21 
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Figure 17 Structural diversity of a range of bioactive cyclonucleosides
21 
 
P a g e  | 21 
 
1.3.3 Class 3 - The Cyclic Phosphoesters 
 
The third class of conformationally restricted nucleoside analogues are the cyclic 
phosphoesters, having a bridge extending from the phosphorus atom of the nucleotide to 
either the heterocyclic base or the furanose ring. 
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Figure 18 Representative example of a cylic phosphoester
15 
 
Further extensions to this class include the cyclic dinucleotides, where the bridge extends 
from the phosphorus atom of the first nucleotide to either the base or the furanose ring of a 
second nucleotide. This sub-category has been extensively covered as far as synthetic 
preparations are concerned;
22-27
 however little or no biological testing has been undertaken to 
determine if the class has antibiotic, antiviral or anticancer activity.  
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Figure 19 Examples of cyclic dinucleotides
22-27 
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In general, this sub-category has been used to mimic, modulate and even stabilize secondary 
nucleic acid structures. Through the incorporation of the cyclic dinucleotides into 
oligonucleotides, an artificial bending of the standard nucleic acid structure and thereby a 
preorganization for the formation of secondary nucleic acid structures other than duplexes and 
triplexes is possible.
14
 For example, incorporation of these dinucleotides into oligonucleotides 
might result in stabilized secondary structures, like the three-way junction shown below in 
Figure 20.
28
 
 
[B=B]3'
5' [B=B]
5'
3'
 
 
Figure 20 Schematic representations of secondary structures, like bulges (depicted on the left) 
and three-way junctions (depicted on the right)
28 
 
In our literature search it became apparent that although there were various nucleoside 
derivatives that contained bicyclic and tricyclic ring systems, few of them had been further 
used for any biological testing. This suggested a niche area for our work as we fostered a keen 
interest in the possibility of testing our synthetic derivatives.  
 
Owing to our previous experience with ring closing metathesis (RCM),
29-33
 we thought it 
pertinent to investigate the possibility of forming fused bicyclic systems onto the 2’ and 3’ 
positions of the sugar ring of our nucleosides utilizing this methodology. This approach will 
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be outlined in more detail later in this chapter, but first we felt it necessary to introduce the 
concept of ring closing metathesis for the non-expert reader. 
 
1.4 INTRODUCTION TO RING CLOSING METATHESIS  
 
Olefin metathesis is a unique carbon skeleton redistribution in which unsaturated carbon-
carbon bonds are rearranged in the presence of metal carbene complexes.
34
 With the advent of 
efficient catalysts, this reaction has emerged as a powerful tool for the formation of C-C 
bonds in chemistry. The number of applications of this reaction has dramatically increased in 
the past few years. Of particular significance, this type of metathesis utilizes no additional 
reagents beyond a catalytic amount of metal carbene and the only other product from the 
reaction is, in most cases, a volatile olefin such as ethylene.  
 
Olefin metathesis can be utilized in three closely related types of reactions (Scheme 1): (i) 
ring-opening metathesis polymerization (ROMP), (ii) ring closing metathesis (RCM) and (iii) 
acyclic cross metathesis for polymer formation (ADMET).
35
 Of specific interest to us is the 
use of RCM. 
 
R1 R2 R1
R2+
(i)
(ii)
(iii)
 
 
Scheme 1 Different forms of olefin metathesis
35 
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The disclosure by Grubbs that ruthenium carbene complexes of the general type 88 (Figure 
21) are highly active single component catalysts for all types of alkene metathesis reactions 
denoted a real breakthrough and triggered an avalanche of interest in this transformation.
36
 
Their activity is usually lower than that of Schrock’s molybdenum alkylidene 89; however, 
the “late” transition metal compounds designed by Grubbs show a large tolerance towards an 
array of functional groups and give ease of handling, due to a reasonable stability against 
oxygen, water and minor impurities in solvents. This renders them exceedingly practical tools 
for RCM-type reactions.
37
 The synthesis of the modified nucleosides for the PhD project will 
use RCM as the key step in ring formation, with the Grubbs second generation catalyst 90 
being the preferred catalyst for use. 
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Figure 21 Known metathesis catalysts 
 
1.5 AIMS FOR PART 1 
 
1.5.1 Fused Bicyclic Systems 
 
As mentioned earlier, we thought it pertinent to investigate the possibility of forming fused 
bicyclic systems onto the 2’ and 3’ positions of the sugar ring of our nucleosides utilizing the 
RCM methodology that we were already familiar with. The proposed synthesis in Scheme 2 
below highlights the critical RCM step and shows the bicyclic ring systems that we hoped to 
prepare in order to do biological activity investigations. 
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Scheme 2 Synthesis for 2’,3’-bicyclic ring system, showing key RCM step  
 
1.5.2 Structure-Activity Relationships 
 
At the same time, we wished to investigate the structure activity relationships (SAR) involved 
when the various OH and NH positions on the nucleosides and ᴅ-(-)-ribose derivatives were 
protected sequentially with different protecting groups. The idea was that from this data we 
would be able to determine on which positions in the molecules it was essential to have free 
OH/NH binding sites in order to maintain the activity of the compounds. 
 
For this study we decided to use ᴅ-(-)-ribose as the model system and to look at a range of 
five different nucleosides: adenosine, cytidine, guanosine, inosine and uridine. The general 
approach to our SAR study is outlined in Figure 22. Structures 94-96 outline the approach 
taken for the model system, ᴅ-(-)-ribose, and structures 97-99 show an example of the 
nucleoside approach, for uridine derivatives specifically. 
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Figure 22 General overview of our intended SAR study 
 
Full details for the synthesis of a series of 25 nucleoside derivatives (based on adenosine, 
cytidine, guanosine, inosine and uridine), as well as some sugar derivatives (based on ᴅ-(-)-
ribose) are given in the proceeding Results and Discussion section (Chapter 2). The specific 
experimental details are provided separately in Appendix A (General Synthetic Procedures) 
and Appendix B (Experimental Procedures Relating to Chapter 2), along with selected NMR 
spectra which are given as Supporting Information (Relating to Chapter 2), available on the 
attached DVD. 
 
All information pertaining to the biological testing of this first generation of compounds is 
provided in the Results and Discussion section (Chapter 3). The specific experimental details 
and general bacteriology protocols used are provided separately in Appendix C 
(Experimental Procedures Relating to Chapter 3), for ease of reading. Selected graphs 
pertaining to the anti-bacterial, anti-HIV and cell proliferation assays, as well as selected 
photographs of the setups used, are provided as Supporting Information which is included 
on the attached DVD. 
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Chapter 2: 
Results and Discussion for Synthesis 
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CONTRIBUTIONS TO THIS CHAPTER 
All of the syntheses and compound characterization described in this chapter were performed 
by Ms J.-L. Panayides, while under the supervision of Prof W.A.L. van Otterlo. The work was 
undertaken in the School of Chemistry which forms part of the Molecular Sciences Institute at 
the University of the Witwatersrand. 
 
 
2.1 CHAPTER OVERVIEW 
 
This chapter describes in detail the transformation of the nucleosides adenosine, cytidine,  
guanosine, inosine and uridine, as well as the sugar ᴅ-(-)-ribose, into the corresponding 5’-O-
(tert-butyldiphenylsilyl)- and 5’-O-(4,4’-dimethoxytrityl)-protected derivatives. These 
nucleoside derivatives were subsequently modified with the inclusion of acetyl, benzoyl and 
allyl functional groups at various positions on the molecules, to yield a range of 25 unique 
compounds for biological testing.  
 
Full experimental details for this section, including reaction setup used and analysis of all 
NMR, IR, LRMS and HRMS data, as well as optical rotations, MP and Rf values can be found 
in Appendix A (General Synthetic Procedures) and Appendix B (Experimental Procedures 
Relating to Chapter 2) below. Selected NMR spectra are attached for perusal in the 
Supporting Information provided on the attached DVD. 
 
2.2 RESULTS AND DISCUSSION 
 
As discussed in the introduction (Chapter 1, Section 1.5) the general synthetic aims were sub-
divided into two parts: (i) the use of ring closing metathesis (RCM) to form 2’,3’-fused 
bicyclic ring systems, and (ii) the use of various protecting groups to conduct a structure-
activity study. 
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2.2.1 Strategy Towards Fused Bicyclic Ring Systems 
 
2.2.1.1 The Model System: ᴅ-(-)-Ribose Derivatives 
 
In order to develop a strategy that could be utilized to form 2’,3’-fused bicyclic ring systems 
on nucleosides, we began our work with a model study of ᴅ-(-)-ribose 100, as the starting 
material was significantly cheaper than the corresponding nucleosides and the methodology 
developed could theoretically be used for all of the nucleosides we wished to study. An 
overview of the approach used is shown in Scheme 3. 
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5'OSi
1*
2*
3*
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Scheme 3 Synthetic methodology for preparation of 2’,3’-fused bicyclic ring systems: (i) cat. 
H2SO4, MeOH, 4 
o
C, 72 h, 100 %, (ii) 1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 20 h, 
used as “crude”, (iii) 2.2 eq. allyl bromide, 2.2 eq. NaH, DMF, rt, 20 h, 68 % over 2 steps, (iv) 
various attempts, 0 % 
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1’-O-Methoxy-ᴅ-(-)-ribose 101 was prepared according to the procedure outlined in 
Chattopadhyaya and co-workers.
38 
In this procedure, ᴅ-(-)-ribose 100 was methylated in the 
anomeric position by the reaction of a methanolic solution of the ribose with a catalytic 
amount of sulfuric acid at 4 
o
C, after which time the solution was neutralized by passage 
through Amberlyst A-21 resin, as shown in Step (i) of Scheme 3. Chattopadhyaya and co-
workers
38
 obtained the desired product in 98 % yield after a 24 h reaction period. Our best 
yield to date is 100 %, which was obtained after 72 h at 4 
oC on a 33.3 mmol scale. 1’-O-
Methoxy-ᴅ-(-)-ribose 101 was obtained as a very viscous pale yellow oil. 
 
The spectroscopic data obtained for compound 101 correlated well with the literature values 
(
1
H and 
13
C NMR).
26
 The final assignments were confirmed using COSY, HSQC and DEPT-
135 NMR spectra and the positions of the 2’,3’ and 5’-OH peaks were confirmed with a D2O 
wash. The α:β ratio was determined on the 1H NMR spectrum using the newly formed 
methoxy peak as the reference peak. The α:β ratio of 1:4 was based on the integrations of 
OMe-α (3.28 ppm) and OMe-β (3.22 ppm).  
 
The 1’-O-methoxy-ᴅ-(-)-ribose 101 was then deprotonated at the more reactive 5’-OH 
position using pyridine as both the solvent and the base for the reaction, as shown in Step (ii) 
of Scheme 3. The protection of the primary alcohol with the tert-butyldiphenylsilyl chloride 
was catalysed by the addition of DMAP. After purification, the desired 5’-O-(tert-
butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 102 was obtained complexed to pyridine and 
as such was used “crude” in subsequent reactions. Thus, no percentage yield was calculated 
for the yellow semi-solid foam isolated. 
 
The formation of the compound 102 and pyridine complex was determined through 
spectroscopic analysis. The addition of the TBDPS group was confirmed by the presence of 
the tert-butyl peak [multiplet at 0.96-1.26 ppm, integrating for 9 H as the –C(CH3)3 protons] 
and the aromatic peaks at 7.35-7.39 ppm (2 H), 7.40-7.48 ppm (4 H) and 7.62-7.71 ppm (4 H) 
in the 
1
H NMR spectrum. This was supported by the presence of the two peaks for the tert-
butyl group (18.75 ppm and 16.54 ppm) as well as the new aromatic peaks (126.87-134.46 
ppm) in the 
13
C NMR spectrum. The α:β ratio of 2:9 was determined using the OMe peaks as 
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the reference peaks in the 
1
H NMR spectrum, with 3.31 ppm representing OMe-α and 3.18  
ppm representing OMe-β. The peaks corresponding to the pyridine complex were also 
assigned in both the 
1
H and 
13
C NMR spectra and it was decided that the pyridine had 
complexed to the 5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 102 and was not 
merely a contaminant in the spectrum, based on the lack of 2’,3’-OH peaks in the 1H NMR 
spectrum and our inability to remove the excess pyridine, even after prolonged periods under 
high vacuum with heating. HRMS confirmed the presence of the 5’-O-(tert-
butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 102 fragment, as a peak corresponding to [M 
+ 23]
+
 was observed at 425.17547, which when the 23 for sodium was removed, corresponded 
well with the calculated value for [M]
+
 402.18625. 
 
As outlined in Step (iii) of Scheme 3, both the 2’-OH and the 3’-OH were allylated via the 
deprotonation of the secondary alcohols using sodium hydride and the subsequent reaction 
with allyl bromide. The desired product 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-
methoxy-ᴅ-(-)-ribose 103 was obtained after purification as a bright yellow oil in 68 % yield 
over the two steps starting from compound 101. The procedure used was one that was 
modified from the mono-allylatation of nucleoside derivatives, previously performed by 
Lebreton and co-workers
39
 (thymidine analogues) and Chattopadhyaya and co-workers
40
 
(uridine analogues). 
 
The desired compound 103 was identified by the presence of the new peaks for the allyl 
chains in the NMR spectra. In the 
1
H NMR spectrum two multiplets were observed 
corresponding to the new OCH2 groups at 3.51-3.62 ppm and 4.03-4.17 ppm respectively. 
The internal alkene protons were observed as a multiplet at 5.85-5.96 ppm, while the terminal 
alkene protons were observed as a multiplet at 5.08-5.42 ppm. The presence of the allyl 
groups were mirrored in the 
13
C NMR spectrum: 71.68 and 72.41 ppm (OCH2 groups), 114.09 
and 117.32 ppm (CH=CH2) and 133.91 and 134.66 ppm (CH=CH2). As before, the α:β ratio 
of 1:4 was determined using the OMe peaks as the reference peaks in the 
1
H NMR spectrum, 
with 3.45 ppm representing OMe-α and 3.36  ppm representing OMe-β. The presence of the 
alkene protons in the allyl chain was further substantiated by the presence of the band for the 
C-H stretch of the CH=CH2 observed at 3072 cm
-1
 in the infrared spectrum. Final 
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confirmation for the synthesis of the molecule came as the HRMS showed a peak at 
505.23807, which corresponds to a [M + 23]
+
 peak.  
 
The attempted RCM reaction is shown in Step (iv) of Scheme 3. A number of different 
reaction conditions were used to perform the RCM reaction; however, none of them yielded 
any of the desired 2’,3’-fused bicyclic compound 104. The attempts are summarized in Table 
1 below. 
 
Table 1 Reaction conditions used for the RCM on compound 104 
Catalyst Solvent Temperature Time Yield of 104 
5 mol % Grubbs II 90 CH2Cl2 rt 22 h 0 % 
5 + 5 mol % Grubbs II 90 CH2Cl2 rt + reflux 23 h + 22 h 0 % 
5 + 5 mol % Grubbs II 90 toluene 60 
o
C 23 h + 5 h 0 % 
5 + 5 mol % Grubbs II 90 toluene 80 
o
C + reflux 21 h + 4 h 0 % 
8 + 8 mol % Grubbs II 90 toluene microwave 50 
o
C 10 + 10 min 0 % 
10 mol % Grubbs I CH2Cl2 rt 23 h 0 % 
 
Due to the unfortunate failure of the RCM on the tert-butyldiphenylsilyl (TBDPS) protected 
derivative,
*
 we decided to repeat the synthesis with our other protecting group 4,4’-
dimethoxytrityl (DMT) in order to determine if the RCM problem was general to this class of 
compounds, or if it was specific to only compound 103. The synthetic route is outlined in 
Scheme 4.  
 
 
  
                                                          
* Due to the time constraints of the project, a number of other strategies for the synthesis of the bicyclic systems 
that were considered were in fact not attempted. However, these approaches may provide a useful starting point 
for anyone repeating this work. These approaches could include the use of the "Hoveyda catalyst" as well as 
looking at titanium (Ti(OPr
i
)4) or acid-mediated chelation reactions in more detail. This would shed some light 
on whether or not it is in fact the other functionalities on the substrate itself which are impeding the catalytic 
cycle. Furthermore, alkyne methathesis-hydrogenation could possibly be attempted, however after considering 
this approach, we felt that it was less appropriate for small ring systems - as the strict steric strain imposed by 
they alkyne in the ring system would be significant in effect. 
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Scheme 4 Synthetic methodology for preparation of 2’,3’-fused bicyclic ring systems: (i) 1 eq. 
DMT-Cl, 0.1 eq. DMAP, pyridine, rt, 20 h, used as “crude”, (ii) 2.2 eq. allyl bromide, 2.2 eq. 
NaH, DMF, rt, 20 h, 0 % or 3.2 eq. allyl ethyl carbonate 148, 3 mol % Pd(dba)2 149, 20 mol 
% dppb, THF, reflux, 1 h, 0 % 
 
The preparation of compound 101 has been described previously in Scheme 4, step (i). The 
1’-O-methoxy-ᴅ-(-)-ribose 101 was then deprotonated at the more reactive 5’-OH position 
using pyridine as both the solvent and the base for the reaction. This is outlined in Step (ii) of 
Scheme 3 and the protection of the primary alcohol with the 4,4’-dimethoxytrityl chloride 
was then catalysed by the addition of DMAP. After purification, the desired 5’-O-(4,4’-
dimethoxytrityl)-1’-O-methoxy-ᴅ-(-)-ribose 105 was obtained complexed to pyridine and as 
such was used “crude” in subsequent reactions. Thus, no percentage yield was calculated for 
the viscous yellow oil that was isolated. 
 
Using the same approach as before for the TBDPS-protected compound 102, the compound 
105 was identified based on its NMR spectral data. New peaks were observed in the 
1
H NMR 
spectrum at 3.73-3.77 ppm and in the aromatic region from 6.86 to 7.46 ppm, corresponding 
to the two new methoxy groups and to the aromatic rings respectively. The aromatic protons 
were observed as a doublet of doublets at 6.86 ppm with J = 8.85 and 13.08 Hz and as a 
doublet at 7.08 ppm with J = 8.78 Hz. Due to the similar coupling constants for each of these 
peaks, they are assumed to lie directly next to each other in the molecule and can be assigned 
as H-3* and H-2* respectively. The remaining aromatic protons were identified as a multiplet 
at 7.15-7.46 ppm containing H-6*, H-7* and H-8*. The α:β ratio could not be determined for 
this compound as all of the peaks in the spectrum overlapped. Without one set of the 
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corresponding α and β peaks to measure integrations on, the ratio could unfortunately not be 
determined. The required peaks corresponding to the DMT protecting group were also 
observed in the 
13
C NMR spectrum. The two new methoxy groups were observed as a peak at 
54.99 ppm and the aromatic protons were observed as eight peaks between 108.05 and 157.79 
ppm. The new quaternary carbon was distinctive and was observed at 83.58 ppm. The peaks 
corresponding to the pyridine complex were also assigned in both the 
1
H and 
13
C NMR 
spectra and it was decided that the pyridine had complexed to the 5’-O-(4,4’-dimethoxytrityl)-
1’-O-methoxy-ᴅ-(-)-ribose 105 and was not merely a contaminant in the spectrum based on 
our inability to remove the excess pyridine even after prolonged periods under high vacuum 
with heating. HRMS confirmed the presence of the 5’-O-(4,4’-dimethoxytrityl)-1’-O-
methoxy-ᴅ-(-)-ribose 105 fragment as a peak corresponding to [M + 23]+ was observed at 
489.18781, which when the 23 for sodium was removed, corresponded well with the 
calculated value for [M]
+
 466.19915. 
 
Step (ii) of Scheme 4 highlights the attempted allylation reaction on the “crude” 5’-O-(4,4’-
dimethoxytrityl)-1’-O-methoxy-ᴅ-(-)-ribose 105. Our initial attempts at the allylation reaction 
involved the use of the standard conditions employed for the preparation of the equivalent 
TBDPS-protected derivative. We used sodium hydride as the base to deprotonate the 2’ and 
3’-OH groups and then reacted them with allyl bromide at rt overnight. The desired 
compound 106 was not isolated, even after further purifications by distillation. It appeared as 
though all of the starting material had decomposed into unidentifiable compounds that did not 
contain the DMT group. Assuming that this method was too harsh for our system, we then 
attempted the far gentler palladium-catalysed allylation reaction described by Nielsen and co-
workers for use on a similar system.
26 
 
For the palladium-catalysed allylation reaction, the protected ribose 105 and the allyl ethyl 
carbonate 148 (prepared as described in the experimental Appendix B) were prepared as a 
solution in THF. To this solution was then added a pre-formed mixture of the two catalysts, 
bis(dibenzylideneacetone) palladium(0) 149 (prepared as described in the experimental 
Appendix B) and bis(diphenylphosphino)butane in THF. After refluxing and subsequent 
purification by column chromatography, unfortunately none of the desired product 106 was 
obtained.  
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To date we have not found any references as to why this reaction would not occur. Due to the 
inability to form the di-allylated derivative, we were unable to attempt the RCM on this 
system in order to try and determine why the other RCM reaction of the 2’,3’-O-diallyl-5’-O-
(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 103 would not work. 
 
As our model study utilizing derivatives of ᴅ-(-)-ribose 100 to devise a successful strategy for 
ring closing metathesis had not been entirely unambiguous, we decided to continue with the 
project by utilizing the strategy developed for the synthesis of nucleoside derivatives. We 
hoped that we would be able to use the di-allylated nucleoside derivatives to determine 
whether the failed RCM on the 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-
ᴅ-(-)-ribose 103 was to be a general problem or not. 
 
Note: A possible explanation to our observed failure when attempting the RCM reactions may 
be rooted in the fact that we were attempting the reactions on a cis di-allylated ribose 
derivative as opposed to a trans derivative. The cis derivative places the allyl chains in closer 
proximity which may make it difficult for the ruthenium insertion required for the catalytic 
cycle to commence. Furthermore, the product of the cis-methathesis reaction would most 
likely be more sterically strained than the trans product and therefore be less likely to form. 
Sporadic literature references to this cis-trans dilemma exist.
26b-26c 
 
2.2.1.2 Pyrimidine-Based Nucleosides – Focusing on Uridine 
 
The first class of nucleosides we investigated were those containing the pyrimidine ring 
system as the base. The representative example we began with was uridine 12 and the 
synthetic strategy employed is described in Scheme 5.  For this strategy we used only the 
TBDPS group as our model study on ᴅ-(-)-ribose derivatives had shown that these would 
allylate, whereas the DMT protected ᴅ-(-)-ribose derivatives would not. 
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Scheme 4.5 Synthetic methodology for preparation of 2’,3’-fused bicyclic ring systems: (i) 
1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 22 h, 100 %, (ii) various approaches were 
attempted 
 
The first step in the synthesis was to protect the most reactive alcohol, namely the primary 
alcohol in the 5’ position of the sugar ring, as shown in Step (i) of Scheme 5. This was done 
by stirring the uridine 12 and the catalyst DMAP with pyridine, which serves as both the 
solvent and the base for the reaction. The pyridine deprotonates the alcohol and then allows 
for reaction with the tert-butyldiphenylsilyl chloride, giving HCl off as the by-product to the 
reaction (which was observed by the formation of a white precipitate of pyridinium 
hydrochloride salt). The desired product, 5’-O-(tert-butyldiphenylsilyl)uridine 107 was 
obtained in 100 % yield after purification, as a white foam. 
 
This experimental procedure was obtained from the one used by Manoharan and co-workers
41
 
to form the structurally similar 5’-O-(tert-butyldiphenylsilyl)-2,2’-anhydro-5-methyluridine. 
A number of previous attempts had been made to perform the protection using imidazole as 
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the base, along with the uridine and tert-butyldiphenylsilyl chloride as a solution in DMF, as 
outlined in Sproat and co-workers.
42
 However, we found the imidazole/DMF procedure gave 
little, if any of the desired product in our hands. Instead, we found that the pyridine method 
described above gave consistently high yields. 
 
The formation of the 5’-O-(tert-butyldiphenylsilyl)uridine 107 was corroborated through the 
use of NMR spectroscopy. In the 
1
H NMR spectrum a new singlet peak integrating for 9 H 
was observed at 1.08 ppm for the tert-butyl group. Several new peaks were also observed in 
the aromatic region of the spectrum: a multiplet at 7.37-7.44 ppm integrating for 6 H 
(assigned as H-3* and H-4*) and a doublet of doublts at 7.65 ppm integrating for 4 H 
(assigned as H-2*). Similarly, in the 
13
C NMR spectrum, new peaks were observed for the 
tert-butyl group (19.45 ppm is found to be C(CH3)3 and 27.20 is found to be C(CH3)3) and the 
aromatic rings (128.21 ppm is C-3*, 130.29 ppm is C-4*, 132.26 ppm is C-1* and the peak at 
135.65 ppm is C-2*). The peaks were assigned with certainty through the use of COSY, 
HSQC and DEPT-135 spectroscopy. We found that our 
13
C NMR data correlated well to that 
reported by Sproat and co-workers,
42
 despite the different methodology used to obtain the 
desired product. Notably, in the IR spectrum, two bands were observed at 700 and 764 cm
-1
 
indicating the presence of an aromatic ring with five adjacent protons and another band was 
observed at 1362 cm
-1
 corresponding to a tert-butyl group [-C(CH3)3]. HRMS confirmed the 
presence of the [M + 1]
+
 peak at 483.19407, which correlates to the calculated value for [M]
+
 
of 482.18730. 
 
We then attempted the allylation reaction on our newly formed 5’-O-(tert-
butyldiphenylsilyl)uridine 107, as outlined in Step (ii) of Scheme 5. The first attempt we 
made was using sodium hydride as the base for deprotonation of the 2’ and 3’ hydroxyl 
groups, which was followed by subsequent reaction with allyl bromide. This procedure was 
modified from the work done by Lebreton and co-workers
39
 and Chattopadhyaya and co-
workers
40
 for performing mono-allylations on deoxy-thymidine and deoxy-uridine and 
derivatives. Unfortunately, none of the desired 2’,3’-O-diallyl-5’-O-(tert-
butyldiphenylsilyl)uridine 108 was isolated after purification by column chromatography. 
Instead a mixture of N- and O- allylated products (110 and 111) were obtained. 
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The formation of the first isomer was confirmed through the use of NMR and HRMS 
spectroscopy. In the 
1
H NMR spectrum new peaks were observed for the allyl groups: the N-
CH2 formed part of a multiplet at 3.68-4.24 ppm, the O-CH2 was observed as a multiplet 
integrating for 2 H at 4.53-4.57 ppm, the CH=CH2 protons (both N- and O-allyl) formed part 
of a multiplet at 5.10-5.30 ppm and the CH=CH2 protons (both N- and O-allyl) formed part of 
the multiplet at 5.73-5.93 ppm. The 
13
C NMR spectrum also showed the presence of the new 
peaks for the allyl chains. The N-allyl was identified by the N-CH2 peak which is 
characteristically found at 43.50 ppm, the CH=CH2 peak was observed at 119.07 ppm and the 
CH=CH2 peak was observed at 133.82 ppm. The O-allyl was identified by the O-CH2 peak 
which is characteristically found at 71.72 ppm, the CH=CH2 peak was observed at 118.52 
ppm and the CH=CH2 peak was observed at 131.90 ppm. In the HRMS the molecular ion was 
calculated at 562.24991 and in the spectrum was found at 562.26234. 
 
In a similar manner, the formation of the second isomer was again confirmed through the use 
of NMR and HRMS spectroscopy. Characteristic peaks in the 
1
H NMR spectrum include a 
multiplet integrating for 2 H at 3.89-3.97 ppm for N-CH2, a mulitplet at 4.08-4.73 ppm 
containing the O-CH2 protons, a multiplet at 5.12-5.48 ppm containing the CH=CH2 protons 
for both allyl chains and a multiplet at 5.85-5.88 ppm containing the CH=CH2 protons for 
both allyl chains. Characteristic peaks in the 
13
C NMR spectrum for the N-allyl chain are: 
43.08 ppm (N-CH2) and 118.88 ppm (CH=CH2), whereas characteristic peaks for the O-allyl 
chain are 71.61 ppm (O-CH2) and 118.05 ppm (CH=CH2). The peaks at 131.76 and 132.14 
ppm account for the CH=CH2 protons for both the N- and O-allyl chains, although 
assignments could not be distinguished with the data available. In the HRMS the molecular 
ion was calculated at 562.24991 and in the spectrum was found at 562.24544. 
 
Unfortunately, even with the information on hand, we could not differentiate between 3-N-
allyl-2’-O-allyl-5’-O-(tert-butyldiphenylsilyl)uridine 110 and 3-N-allyl-3’-O-allyl-5’-O-(tert-
butyldiphenylsilyl)uridine 111. As such, we could not assign the individual isomers with 
absolute certainty and we believe that this could be investigated at a later stage through the 
use of NOE spectroscopy. 
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Our second attempt at the synthesis of 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)uridine 
108 involved the use of palladium catalysis, as described by Jin and co-workers
43
 for the 
allylation of the 2’-OH on a similar uridine derivative and as described previously in Section 
2.2.1.1. A solution was prepared containing 5 mol % of the 1,4-bis(diphenylphosphino)butane 
and 1 mol % of the bis(dibenzylideneacetone) palladium(0) 149 in THF. To this solution was 
then added dropwise a solution of the protected uridine 107 and the allyl ethyl carbonate 148. 
After reaction at rt overnight, unreacted starting material was still observed by tlc. Thus 
further portions of the dppb, 148 and 149 were added and the reaction was stirred for a further 
5 h. Following purification by column chromatography it was found that none of the desired 
compound 108 had formed, instead all that had been isolated from the reaction was the N-
allylated byproduct 109. 
 
The formation of 3-N-allyl-5’-O-(tert-butyldiphenylsilyl)uridine 109 was confirmed by 1H 
and 
13
C NMR spectroscopy. The characteristic peaks for the allyl chain were observed as 
follows: N-CH2 was found as part of a multiplet at 4.16-4.55 ppm, CH=CH2 as part of a 
multiplet at 5.80-5.95 ppm and CH=CH2 was found as a multiplet integrating for 2 H at 5.18-
5.29 ppm. In a similar manner, the characteristic peaks for the newly formed allyl chain were 
also observed in the 
13
C NMR spectrum. The N-CH2 was observed at 43.04 ppm, the 
CH=CH2 was observed at 118.18 ppm and the CH=CH2 was found at 132.54 ppm. 
 
The third attempt involved the same palladium catalysed methodology employed in the 
second method, with the only difference being the catalyst loading. We attempted to force the 
reaction to go to completion by using 10 mol % dppb and 5 mol % Pd(dba)2 149. 
Unfortunately none of the desired compound 108 was isolated after column chromatography. 
The N- and O-allylated byproducts 109, 110 and 111 were all isolated instead. The 
compounds were characterized in the same manner as described previously. 
  
Having had no success synthesizing the 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)uridine 
108
42b
, we could obviously not attempt the ring closing metathesis reaction to form the 2’,3’-
fused bicyclic system. We then decided to proceed and prepare the 2’,3’-diallyl derivatives of 
the purine-based nucleosides in order to test out our so-far unsuccessful RCM approach. 
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2.2.1.3 Purine-Based Nucleosides – Focusing on Guanosine and Inosine 
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Scheme 6 Synthetic methodology for preparation of 2’,3’-fused bicyclic ring systems: (i) 2 eq. 
N,N-dimethylformamide dimethyl acetal, DMF, rt, 27 h, 79 %, (ii) 1 eq. DMT-Cl, 0.1 eq. 
DMAP, pyridine, rt, 25 h, 69 %, (iii) 3.2 eq. allyl ethyl carbonate 148, 0.03 eq. Pd(dba)2 149, 
0.2 eq. dppb, THF, reflux, 75 min, 85 %, (iv) 0.05 eq. Grubbs II 90, CH2Cl2, rt, 22 h, then 
0.05 eq. Grubbs II 90, CH2Cl2, reflux, 22 h, 0 % or (iv) 0.05 eq. Grubbs II 90, toluene, 60 
o
C, 
23 h, then 0.05 eq. Grubbs II 90, toluene, reflux, 5 h, 0 % 
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The initial choice for a purine based nucleoside was guanosine 9 as there appeared to have 
been more literature data available on its synthetic reactions. We believed this would be 
beneficial to our synthetic strategy as we had previously had some problems handling the 
nucleosides. The approach taken for the synthesis of the 2’,3’-diallyl derivative and the 
subsequent formation of the 2’,3’-fused bicyclic system is outlined in Scheme 6. 
 
As outlined in Step (i) of Scheme 6, the primary amine on the purine base can be protected as 
a N,N-dimethylmethylimine through the reaction of the starting material, guanosine 9, and 
N,N-dimethylformamide dimethyl acetal. The desired compound, 6-N-(N,N-
dimethylmethylimine)guanosine 112 was thus obtained in 79 % yield after purification. The 
procedure used was modified from the work done by Sproat and co-workers,
42
 wherein they 
performed a one-pot multiple protection of guanosine 9 to give 5’-O-(tert-butyldiphenylsilyl)-
6-N-(N,N-dimethylmethylimine)guanosine. 
 
The synthesis of the desired compound, 6-N-(N,N-dimethylmethylimine)guanosine 112, was 
confirmed by the presence of the new peaks for the N,N-dimethylmethylimine group in both 
the proton and carbon NMR spectra. In the 
1
H NMR spectrum, the two N-CH3 groups were 
observed as two new singlets, each integrating for 3 H, at 3.03 and 3.15 ppm, while the imine 
proton (N=CH-N) was observed as a singlet integrating for 1 H at 8.04 ppm. Similarly, the 
new peaks were observed in the 
13
C NMR spectrum as N-CH3 peaks at 34.64 and 40.64 ppm 
and C=CH-N at 136.96 ppm. This analysis was supplemented by the presence of the new 
band at 1700 cm
-1
 in the IR spectrum, which accounts for the characteristic imine (C=N) 
stretch. Finally, HRMS confirmed the characterization as the calculated mass for the 
molecular ion was 338.13387 and the [M + 1]
+
 peak was observed at 339.14123, which 
correlated well. 
 
Step (ii) of Scheme 6 shows the selective protection of the primary alcohol at the 5’-position, 
which is known to be more reactive than the other secondary alcohols present in the sugar 
ring. The primary alcohol was deprotonated using pyridine, which acted as both the base and 
the solvent for the reaction. This was then treated with the catalyst DMAP, before reaction 
with the 4,4’-dimethoxytrityl chloride at rt overnight. The desired compound, 5’-O-(4,4’-
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dimethoxytrityl)-6-N-(dimethylmethylimine)guanosine 113, was subsequently obtained as a 
white powder in 69 % yield after purification. The procedure used for the reaction was 
adapted from that reported for the synthesis of 5’-O-(4,4’-dimethoxytrityl)-2’-O-(2-
(triphenylmethylthio)ethyl)-N2-isobutyrylguanosine by Jin and co-workers.43 
 
The formation of the 5’-O-(4,4’-dimethoxytrityl)-6-N-(dimethylmethylimine)guanosine 113 
was confirmed by the presence of the new methoxy and aromatic protons in the 
1
H NMR 
spectrum, as well as by the disappearance of the triplet integrating for 1 H at 5.80 ppm 
assigned as OH-5’ in the previous compound. The characteristic methoxy groups were 
observed as a singlet integrating for 6 H at 3.72 ppm, while the new aromatic protons were 
observed as a doublet of doublets integrating for 4 H at 6.83 ppm (H-3*), as well as a 
multiplet integrating for 7 H at 7.20-7.26 pp (H-2*, H-6* and H-8*) and a multiplet 
integrating for 2 H at 7.28-7.31 ppm (H-7*). Similarly, in the 
13
C NMR spectrum, the 
characteristic methoxy groups were observed at 55.06 ppm and the new aromatic carbons 
were observed at 113.19 ppm (C-3*), over the range of 126.74-135.58 (C-1*, C-2*, C-5*, C-
6*, C-7* and C-8*) and at 144.90 (C-4*). Supporting evidence was obtained from the 
aromatic bands observed in the IR spectrum at 699 and 760 cm
-1
 indicating five adjacent 
aromatic protons, at 826 cm
-1
 indicating two adjacent aromatic protons and at 3090 cm
-1
 
indicating the presence of an aromatic ring system. Final confirmation of the structure came 
from the peak at 641.27182 ([M + 1]
+
) in the HRMS spectrum which corresponds well to the 
calculated value of 640.26455 for the molecular ion. 
 
Outlined in Step (iii) of Scheme 6 is the allylation reaction performed on the two secondary 
alcohols on the sugar ring. In initial attempts at the reaction using standard conditions, the 
alcohols in the 2’ and 3’-positions on the ring were deprotonated using sodium hydride as the 
base, and were then reacted with excess allyl bromide. Unfortunately, the reactions were 
unsuccessful and we often isolated decomposition products. Thus, the reaction was then 
carried out using the previously described palladium-catalysed conditions.
43
 Under these 
conditions the guanosine derivative 113 and allyl ethyl carbonate 148 (synthesis described in 
the experimental, Appendix B) were dissolved in THF and to this solution was then added a 
second solution containing 20 mol % of the 1,4-bis(diphenylphosphino)butane and 3 mol % 
of the Pd(dba)2 catalyst 149 (preparation described in Appendix B). After refluxing and 
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subsequent purification by column chromatography, the desired compound, 2’,3’-O-diallyl-
5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)-guanosine 114, was obtained as 
a yellow foam in 85 % yield.  
 
The formation of 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-dimethylmethyl-
imine)guanosine 114 was confirmed by the disappearance of the peaks for the OH-2’ (broad 
singlet at 5.58 ppm) and OH-3’ (broad singlet at 5.26 ppm) present in the 1H NMR spectrum 
for compound 113, and the appearance of the characteristic peaks for the allyl chains. The 
new peaks were observed as two doublets at 4.44 and 4.96 ppm respectively, each integrating 
for 2 H and each assigned as an OCH2 group. Also observed was a multiplet at 5.08-5.23 ppm 
integrating for 4 H and identified as the two CH=CH2 groups and a multiplet at 5.79-5.97 ppm 
integrating for 2 H and identified as the two CH=CH2 groups. Similarly, in the 
13
C NMR 
spectrum, new peaks appeared at 86.78 and 87.94 ppm for the OCH2 groups, at 116.92 and 
119.12 ppm for the CH=CH2 groups and at 130.17 and 130.29 ppm for the CH=CH2 groups. 
 
Having the di-allylated compound, 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-
dimethylmethylimine)guanosine 114 in hand, we could finally attempt the ring closing 
metathesis reaction as outlined in Step (iv) of Scheme 6. The first method employed for the 
reaction was to prepare a solution of the diene 114 in dichloromethane and then to react this 
with 5 mol % Grubbs II catalyst 90 at rt for 22 h, however, after this time NMR spectroscopy 
on a sample of crude product confirmed the presence of only unreacted starting material, so a 
further 5 mol % of Grubbs II catalyst 90 was added and the reaction mixture was refluxed 
overnight. Unfortunately, after purification, none of the desired ring-closed product 115 was 
obtained. 
 
A second attempt was made at the RCM, this time the diene (2’,3’-O-diallyl-5’-O-(4,4’-
dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)guanosine 114)  was heated to 60 oC in 
toluene before the addition of 5 mol % of Grubbs II catalyst 90. After stirring overnight, 
NMR spectroscopy on the crude product again confirmed the presence of unreacted starting 
material, so a further 5 mol % of Grubbs II catalyst 90 was added and the reaction was 
refluxed for 5 hours. Unfortunately, none of the desired ring-closed product 115 was obtained.  
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Due to a lack of material and time constraints, we decided not to continue with attempts at 
RCM on the 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)-
guanosine 114 system,
†
 but to instead focus on the synthesis on the similar, but structurally 
simpler, inosine (116) derivatives. The approach taken for the synthesis of the diene required 
for RCM is outlined in Scheme 7. 
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Scheme 7 Synthetic methodology for preparing 2’,3’-fused bicyclic ring systems: (i) 1 eq. 
DMT-Cl, 0.1 eq. DMAP, pyridine, rt, 21 h, 78 %, (ii) 2.2 eq. allyl bromide, 2.2 eq. NaH, 
DMF, rt, 21 h, 0 % 
 
In Step (i) of Scheme 7, one can see the protection of the primary alcohol in the 5’-position of 
the sugar ring. We employed the same methodology as used previously in the preparation of 
the ᴅ-(-)-ribose 100 and guanosine 9 derivatives, whereby the primary alcohol was 
                                                          
†
 For further information on possible RCM reactions, please refer to footnote on page 33. 
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deprotonated using pyridine as both the base and solvent, and the reaction was then carried 
out under catalytic DMAP conditions with 4,4’-dimethoxytrityl chloride. The desired 
compound, 5’-O-(4,4’-dimethoxytrityl)inosine 117, was obtained in 78 % yield after 
purification by recrystallisation. 
 
The formation of 5’-O-(4,4’-dimethoxytrityl)inosine 117 was identified through the use of 
NMR, IR and HRMS spectroscopy. In the 
1
H NMR spectrum, characteristic new peaks were 
observed for the two methoxy groups, as a singlet integrating for 6 protons at 3.69 ppm, and 
for the aromatic rings, as a dd integrating for 4 protons at 6.83 ppm (H-3*), as a multiplet 
integrating for 7 protons at 7.12-7.14 ppm (H-2*, H-6* and H-8*) and as a multiplet 
integrating for 2 protons at 7.35-7.39 ppm (H-7*). Similarly, in the 
13
C NMR spectrum, 
characteristic new peaks were observed for the two methoxy groups (55.04 ppm) and for the 
aromatic rings (113.16, 126.70, 127.81, 127.83, 129.73, 144.86, 145.80 and 158.08 ppm - for 
assignments please refer to the experimental in Appendix B below). The new quaternary 
carbon situated between the three aromatic rings of the DMT protecting group was observed 
at 85.53 ppm. The band for the new methoxy group was observed at 2836 cm
-1
 and the bands 
for the aromatic rings were found at 702 and 755 cm
-1
 (5 adjacent aromatic protons), 827 cm
-1
 
(2 adjacent aromatic protons) and 3033 cm
-1
 (aromatic protons). Final evidence for the 
formation of the desired compound 117 was given by the HRMS spectrum, in which a peak 
was observed at 593.1995 which, when 23 is removed for the sodium additive, correlated well 
to the calculated value for the molecular ion of 571.21823. 
 
Outlined in Step (ii) of Scheme 7 is the allylation reaction attempted on the two secondary 
alcohols on the sugar ring. The allylation reaction was only attempted once and for this 
attempt we chose to use the more rigorous reaction conditions described below in favour of 
the gentle palladium-catalysed method described above, in order to try and force the reaction 
to occur in good yield so that we had sufficient material to attempt the RCM reactions. For the 
allylation reaction, we took the protected inosine derivative 117 (as a solution in DMF) and 
deprotonated the secondary alcohols in the 2’ and 3’-positions using sodium hydride as our 
base. We then attempted to react the material with excess allyl bromide; unfortunately, after 
purification we found that none of the desired 2’,3’-O-diallyl-5’-O-(4,4’-
dimethoxytrityl)inosine 118 had formed. We believe that the starting material decomposed 
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under the harsh sodium hydride conditions employed for the reaction. Due to time constraints 
we were unfortunately not able to repeat the reactions and attempt the RCM reaction. 
 
As shown in Schemes 3-7, there were a number of difficulties associated with the synthesis of 
the 2’,3’-O-diallylated ᴅ-(-)-ribose derivatives (103 and 106) and nucleoside derivatives 
(108, 114 and 118). As the RCM on both the 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-
O-methoxy-ᴅ-(-)-ribose 103 and the 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-
dimethylmethylimine)guanosine 114 systems were unsuccessful, at this point in the project 
we decided to stop our investigation into the preparation of 2’,3’-fused bicyclic systems and 
instead focus on the synthesis of derivatives for our structure-activity study. The work 
completed towards the fused bicyclic systems was however not in vain, as all compounds 
synthesized en route to the bicyclic systems were subsequently included in the structure-
activity study. 
 
2.2.2 Synthesis of Compounds to Conduct a Structure-Activity Study 
 
2.2.2.1 The Model System: ᴅ-(-)-Ribose Derivatives 
 
In order to develop a strategy that could be utilized on the nucleoside derivatives, we began 
our work with a model study of ᴅ-(-)-ribose 100, as the starting material was significantly 
cheaper than the corresponding nucleosides. An overview of the approach used is shown in 
Scheme 8. The conversion of the ᴅ-(-)-ribose 100 into 1’-O-methoxy-ᴅ-(-)-ribose 101 is 
described in detail in Section 2.2.1.1 above. 
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Scheme 8 Synthetic methodology for preparation of ᴅ-(-)-ribose derivatives: (i) 1.1 eq. 
TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 20 h, used “crude”, (ii) 3 eq. acetic anhydride, 5 eq. 
pyridine, rt, 19 h, 71 % over two steps 
  
The full description for the reaction shown in Step (i) of Scheme 8 above is discussed in 
detail in Section 2.2.1.1 above as the same reaction was used in Step (ii) of Scheme 3. Step 
(ii) of Scheme 8 shows the protection of the secondary alcohols in the 2’ and 3’ positions on 
the sugar ring as acetyl groups. This reaction was carried out using pyridine as both the base 
and the solvent for the reaction. The desired compound, 2’,3’-O-diacetyl-5’-O-(tert-
butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 119, was obtained as a viscous orange oil in 
71 % yield over the two steps. 
 
The formation of the desired compound 119 was induced through the use of various 
spectroscopic methods. In the 
1
H NMR spectrum, the peaks corresponding to the OH-2’ and 
OH-3’ were replaced by new peaks for the acetyl groups. These new peaks were observed as 
two multiplets, each integrating for 3 H at 2.00-2.06 ppm and at 2.09-2.14 ppm, which were 
assigned as the two new CH3 groups. We would have expected two singlets for the two new 
methyl groups, but instead observed two multiplets – we believe that this is caused by the 
presence of the α/β anomers in ᴅ-(-)-ribose and the fact that the peaks for the anomers are 
overlapping. Using the 1’-O-methoxy peaks, observed as a singlet at 3.34 ppm for OCH3 (β) 
and as a singlet at 3.38 ppm for OCH3 (α), we were able to determine the anomeric ratio as 
α:β  = 1:3. In a similar manner, the new groups were also observed in the 13C NMR spectrum, 
the two new methyl groups were found at 20.88 and 22.57 ppm and the two new carbonyl 
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groups were found at 169.91 and 170.89 ppm respectively. Supporting data was obtained 
from the IR spectrum, where a new band was observed at 1747 cm
-1
 accounting for the new 
C=O stretch, as well as from the HRMS where a peak was observed at 509.19582, which 
when 23 is removed for the sodium additive, correlates well to the calculated value of 
486.20738 for the desired compound 2’,3’-O-diacetyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-
methoxy-ᴅ-(-)-ribose 119. 
 
In a similar manner to that described in Scheme 8, the second group of DMT-protected ᴅ-(-)-
ribose 100 derivatives were prepared. The synthesis is shown schematically in Scheme 9 
below. The conversion of the ᴅ-(-)-ribose 100 into 1’-O-methoxy-ᴅ-(-)-ribose 101 is 
described in detail in Section 2.2.1.1. 
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Scheme 9 Synthetic methodology for preparation of ᴅ-(-)-ribose derivatives: (i) 1 eq. DMT-
Cl, 0.1 eq. DMAP, pyridine, rt, 20 h, used “crude”, (ii) 3 eq. acetic anhydride, 5 eq. pyridine, 
rt, 19 h, 77 % over two steps 
  
The full description for the reaction shown in Step (i) of Scheme 9 is discussed in detail in 
Section 2.2.1.1 as the same reaction was used in Step (i) of Scheme 4. Step (ii) of Scheme 9 
highlights the protection of the secondary alcohols in the 2’ and 3’ positions on the sugar ring 
as acetyl groups. The conditions used involved the presence of pyridine to act as both the base 
and the solvent for the reaction and the use of acetic anhydride as the acetyl group donor. The 
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desired compound, 2’,3’-O-diacetyl-5’-O-(4,4’-dimethoxytrityl)-1’-O-methoxy-ᴅ-(-)-ribose 
120, was obtained in 77 % yield over the two steps as a viscous orange oil. 
The formation of 2’,3’-O-diacetyl-5’-O-(4,4’-dimethoxytrityl)-1’-O-methoxy-ᴅ-(-)-ribose 
120 was identified by the disappearance of the peaks for the 2’and 3’ hydroxyl groups in the 
1
H NMR spectrum at 3.80-3.95 and 4.73-5.25 ppm, and the appearance of the new multiplet 
integrating for 6 H at 2.01-2.14 ppm accounting for the two new methyl groups in the 
molecule. In the same manner, new peaks were observed at 20.80 and 20.99 ppm (two new 
methyl groups) and at 169.89 and 170.88 ppm (two new carbonyl groups) in the 
13
C NMR 
spectrum. The α:β ratio was found to be 1:3 by correlating the integrations for the methoxy 
group on the sugar ring in the 
1
H NMR spectrum, the peak at 3.38 ppm was for OCH3 (β) and 
the peak at 3.45 ppm was for OCH3 (α). The identification of the compound isolated from the 
reaction was further confirmed as 120 by the HRMS spectrum, wherein the peak observed at 
573.20916 is found to be [M + 23]
+
 and correlated well to the calculated value for the 
molecular ion of 550.22028. 
 
Shown in Scheme 10, are the synthesis of two ᴅ-(-)-ribose 100 derivatives containing the 
same protecting group on all three of the hydroxyls on the sugar ring. The conversion of the 
ᴅ-(-)-ribose 100 into 1’-O-methoxy-ᴅ-(-)-ribose 101 is described in detail in Section 2.2.1.1 
above. 
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Scheme 10 Synthetic methodology for preparing ᴅ-(-)-ribose derivatives: (i) 4.5 eq. acetic 
anhydride, 7.5 eq. pyridine, rt, 22 h, 94 %, (ii) 3.3 eq. allyl bromide, 3.3 eq. sodium hydride, 
DMF, rt, 23 h, 100 % 
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Step (i) of Scheme 10 shows the protection of the secondary alcohols, OH-2’ and OH-3’, as 
well as the protection of the primary alcohol, OH-5’, with acetyl groups. This reaction was 
performed by deprotonating the hydroxyl groups on the sugar ring of 1’-O-methoxy-ᴅ-(-)-
ribose 101 with pyridine and then allowing them to react with acetic anhydride overnight, to 
give the desired compound 2’,3’,5’-O-triacetyl-1’-O-methoxy-ᴅ-(-)-ribose 121 in 94 % yield 
as a yellow oil. 
 
The formation of 2’,3’,5’-O-triacetyl-1’-O-methoxy-ᴅ-(-)-ribose 121 was confirmed based on 
the disappearance of the hydroxyl peaks at 4.05-4.25 ppm, 4.75-4.80 ppm and 4.93-4.99 ppm, 
as assigned previously in the 
1
H NMR spectrum for compound 101. The three new methyl 
groups, from the acetyl groups that had been added to the molecule were observed as a 
multiplet integrating for 9 H at 2.02-2.14 ppm. The α:β ratio was found to be 1:3 based on the 
integrations for 1’-O-methoxy group on the sugar ring – OCH3 (β) was observed as a singlet 
at 3.38 ppm, while OCH3 (α) was observed as a singlet at 3.45 ppm. In a similar manner to the 
1
H NMR spectrum, new peaks were observed in the 
13
C NMR spectrum for the three new 
acetyl groups: the three methyl groups were found as both the α and β anomers, grouped 
together at 20.67, 20.71, 20.75, 20.94 and 20.95 ppm; the three carbonyl groups were also 
found as both the α and β anomers, grouped together at 169.83, 169.87, 170.09, 170.64, 
170.76 and 170.83 ppm. Supporting evidence for the formation of compound 121 was given 
by the presence of new bands in the IR spectrum, with one at 1680 cm
-1
 assigned as C=O, one 
at 1738 cm
-1
 assigned as –CO-O- and the band at 2998 cm-1 assigned as –CO-CH3. Final 
evidence for the formation of the desired compound 121 was given by the HRMS spectrum, 
in which a peak was observed at 313.08943 which, when 23 is removed for the sodium 
additive, correlates well to the calculated value for the molecular ion of 290.10017. 
 
Outlined in Step (ii), Scheme 10 is allylation of all the hydroxyl groups on the sugar ring of 
1’-O-methoxy-ᴅ-(-)-ribose 101. The reaction occurs by the deprotonation of the primary 
alcohol OH-5’ and the secondary alcohols OH-2’ and OH-3’ using sodium hydride as the 
base, which was followed by reaction with allyl bromide. The desired compound, 2’,3’,5’-O-
triallyl-1’-O-methoxy-ᴅ-(-)-ribose 122 was obtained as a yellow oil in quantitative yield. 
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The synthesis of the desired compound, 2’,3’,5’-O-triallyl-1’-O-methoxy-ᴅ-(-)-ribose 122, 
was confirmed by the presence of the new peaks for the allyl chains in both the proton and 
carbon NMR spectra. In the 
1
H NMR spectrum, the three new signals for the OCH2 groups 
were observed overlapping as a multiplet from 4.01-4.17 ppm integrating for 6 H. The alkene 
protons were observed as a multiplet integrating for 3 H at 5.14-5.23 ppm which was assigned 
as the CH=CH2 protons trans to the R group, as a multiplet integrating for 3 H at 5.24-5.36 
ppm which was assigned as the CH=CH2 protons cis to the R group and finally as a multiplet 
integrating for 3 H at 5.84-5.98 ppm assigned as the CH=CH2 protons. Similarly, in the 
13
C 
NMR spectrum the new signals for the OCH2 groups were observed as six peaks (one for each 
of the three new OCH2 carbons in the α anomer and one for each of the three new OCH2 
carbons in the β anomer) over the range 70.51-72.64 ppm. The new signals for the alkene 
groups were observed as three peaks for CH=CH2 (β) at 116.99, 117.63 and 117.73 ppm, as 
three peaks for CH=CH2 (α) at 117.28, 117.35 and 117.86 ppm and as five peaks at 134.61, 
134.65, 134.86, 134.96 and 135.28 ppm accounting for CH=CH2 (both α and β).  
 
The α:β ratio was found to be 1:3 based on the integrations in the 1H NMR spectrum for 1’-O-
methoxy group on the sugar ring – OCH3 (β) was observed as a singlet at 3.36 ppm, while 
OCH3 (α) was observed as a singlet at 3.45 ppm. Substantiating evidence for the formation of 
compound 122 was given by the new bands in the IR spectrum: 869, 920 and 991 cm
-1
 for 
RCH=CH2, 1647 cm
-1
 for the C=C and 3080cm
-1
 for the C=CH2. The identification of the 
compound isolated from the reaction was further confirmed as 122 by the HRMS spectrum, 
wherein the peak observed at 307.15160 is found to be [M + 23]
+
 and correlates well to the 
calculated value for the molecular ion of 284.16237 when the value of 23 for the sodium 
additive is taken into account. 
 
Having completed the model study on ᴅ-(-)-ribose 100 (as shown in Scheme 8, Scheme 9 
and Scheme 10) without any major problems, we were then able to move onto the preparation 
of the pyrimidine-based nucleoside derivatives. The nucleosides chosen for this study were 
uridine 12 and cytidine 11. 
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2.2.2.2 Pyrimidine-Based Nucleosides – Focusing on Uridine and Cytidine 
 
The first of the pyrimidine-based nucleosides that we chose to work on was uridine 12. This 
nucleoside was chosen as we had previously worked with it on our attempted synthesis of 
2’,3’-fused biclyclic systems, as described in Section 2.2.1.2. Our approach towards the 
synthesis of tert-butyldiphenylsilyl protected derivatives is outlined in Scheme 11. 
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Scheme 11 Synthesis of tert-butyldiphenylsilyl protected derivatives of uridine: (i) 1.1 eq. 
TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 22 h, 100 %, (ii) 3 eq. acetic anhydride, 5 eq. 
pyridine, rt, 20 h, 89 %, (iii) 5 eq. benzoyl chloride, 5 eq. N,N-diisopropylethylamine, 
pyridine, rt, 2 h, 71 %, (iv) 1.3 eq. benzoyl chloride, 0.04 eq. tetra-butylammonium bromide, 
8 eq. sodium carbonate, CH2Cl2 : H2O, rt, 30 min, 0 % 
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The synthesis of 5’-O-(tert-butyldiphenylsilyl)uridine 107 was described in detail in Section 
2.2.1.2, and was shown schematically in Step (i) of Scheme 5; as such the preparation of this 
compound will not be discussed further here.  
 
In Step (ii) of Scheme 11, we see the protection of the secondary alcohols at the 2’ and 3’ 
positions on the sugar ring with acetyl groups. The experimental procedure involves the use 
of pyridine as both the base and the solvent for the reaction, with acetic anhydride used as the 
acetyl donator. The reaction was carried out at rt and yielded the desired product 2’,3’-O-
diacetyl-5’-O-(tert-butyldiphenylsilyl)uridine 123 as a cream foam in 89 % yield after 
purification. 
 
The synthesis of the desired compound, 2’,3’-O-diacetyl-5’-O-(tert-butyldiphenylsilyl)uridine 
123, was confirmed by the presence of the new peaks for the two new acetyl groups in both 
the proton and carbon NMR spectra. In the 
1
H NMR spectrum, a new multiplet was observed 
at 2.11-2.14 ppm integrating for 6 H, and accounted for the two new methyl groups. The 
position of the acetyl groups on the sugar ring was confirmed by the disappearance of the OH-
2’ and OH-3’ peaks, at 3.38 and 5.47 ppm, in the 1H NMR spectrum for the starting material 
107. In the 
13
C NMR spectrum, new peaks were observed at 20.63 and 20.85 ppm for the two 
new methyl groups, and new peaks were observed at 169.77 and 170.00 ppm for the two new 
carbonyl groups. Supporting evidence for the formation of the desired compound 123 was 
provided by the presence of new bands in the IR spectrum at 1113 and 1223 cm
-1
 which are 
characteristic of a C=O group, and are different in shift to the bands for the amide C=O 
groups shown at positions C-2 and C-4 in the molecule illustrated above. Final confirmation 
for the formation of the compound 123 came from HRMS, where peaks were observed at 
567.21532 and 589.19699, accounting for [M + 1]
+
 and [M + 23]
+
 respectively.  
 
Outlined in Step (iii) of Scheme 11 is the protection of the urea position on the base as a 
benzoyl derivative. Experimentally, the reaction occured through the deprotonation of the 
amide NH using Hünig’s base and the subsequent attack on the benzoyl chloride. In this 
instance, pyridine was used as the solvent for the reaction as the by-product for the reaction is 
gaseous hydrochloric acid, which is trapped by the pyridine in order to prevent decomposition 
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of the newly formed compound. The desired compound, 3-N-benzoyl-2’,3’-O-diacetyl-5’-O-
(tert-butyldiphenylsilyl)uridine 124, was obtained as a yellow foam in 71 % yield after 
purification by column chromatography. 
 
The formation of 3-N-benzoyl-2’,3’-O-diacetyl-5’-O-(tert-butyldiphenylsilyl)uridine 124 was 
confirmed based on the disappearance of the amide NH peak in the 
1
H NMR spectrum of the 
starting material 123, which was originally observed as a broad singlet at 9.39 ppm. As well 
as by the appearance of new peaks in the 
1
H NMR spectrum for the newly formed aromatic 
ring. These were found as part of the multiplet at 7.41-7.48 ppm (H-7*) and as part of the 
multiplet at 7.63-7.67 ppm (H-8*), as well as a characteristic doublet, integrating for 2 H, 
with J = 7.34 Hz, observed at 7.95 ppm (H-6*). Similarly, the new aromatic and carbonyl 
peaks were observed in the 
13
C NMR spectrum as four new peaks in the range 129.32-135.54 
ppm (H-5*, H-6*, H-7* and H-8*) and as one new peak at 168.62 ppm (N-C=O). Supporting 
evidence for the formation of the desired compound 124 was given by the presence of three 
new bands in the IR spectrum at 1632, 1670 and 2932 cm
-1
, which are characteristic for the 
presence of a tertiary amide in the molecule. This was further substantiated by the HRMS 
spectrum, in which two peaks accounting for [M + 1]
+
 and [M + 23]
+
, were observed at 
671.24173 and 693.22317  respectively, based on the calculated value for the molecular ion of 
670.23466. 
 
Step (iv) of Scheme 11 shows the attempted synthesis of 3-N-benzoyl-5’-O-(tert-
butyldiphenylsilyl)uridine 125 using sodium carbonate as the base for specific deprotonation 
of the amide NH, which is based on the procedure used by Sekine
44
 for the synthesis of N3-
benzyol-3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine.  As sodium carbonate is 
insoluble in most organic solvents, the reaction was carried out in a biphasic solution of 
CH2Cl2 : H2O, with tetra-butylammonium bromide added as the phase transfer catalyst. This 
was followed by reaction with benzoyl chloride. Unfortunately, none of the desired 
compound, 3-N-benzoyl-5’-O-(tert-butyldiphenylsilyl)uridine 125, was isolated from the 
reaction mixture. Instead, we were able to confirm by 
1
H NMR, 
13
C NMR and LRMS 
spectroscopy that we had in fact formed the unwanted 2’,3’-O-dibenzoyl-5’-O-(tert-
butyldiphenylsilyl)uridine 150 (Scheme 11). Full details of the 
1
H NMR, 
13
C NMR and 
LRMS spectroscopy are given in Appendix B, Section B.21 and will not be discussed further.  
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Using a similar approach to that outlined in Scheme 11, we then went on to synthesise a range 
of DMT protected uridine derivatives. This approach is shown schematically in Scheme 12 
below. 
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Scheme 12 Synthesis of 4,4’-dimethoxytrityl protected derivatives of uridine: (i) 1.2 eq. 
DMT-Cl,  0.1 eq. DMAP, pyridine, 60 
o
C, 22 h, 83 %, (ii) 3 eq. acetic anhydride, 8 eq. 
pyridine, rt, 24 h, 90 %, (iii) 5 eq. benzoyl chloride, 5 eq. N,N-diisopropylethylamine, 
pyridine, rt, 2 h, 59 %, (iv) 1.3 eq. benzoyl chloride, 0.037 eq. tetra-butylammonium bromide, 
8.3 eq. sodium carbonate, CH2Cl2 : H2O, rt, 30 min, 0 % 
 
Step (i) of Scheme 12 shows the protection of the primary alcohol at the 5’ position of the 
sugar ring with a DMT protecting group. Initial attempts at this synthesis involved the use of 
DABCO and tetra-butylaammonium iodide under solvent free conditions, as described in 
Khalafi-Nezhad and co-workers;
45
 however, under the conditions described, none of the 
desired compound 126 was obtained. We thus attempted the reaction using the conditions 
P a g e  | 57 
 
described by Jin and co-workers
43
 for the formation of 5’-O-(4,4’-dimethoxytrityl)-2’-O-(2-
(trifluoroacetamido)-ethyl)uridine. The reaction was carried out at 60 
o
C, with catalytic 
amounts of DMAP added and using pyridine as both the base and the solvent for the reaction. 
The pyridine traps the HCl by-product formed during the reaction as the pyridine-
hydrochloride salt, which was then removed by crystallization of the salt. The desired 
compound, 5’-O-(4,4’-dimethoxytrityl)uridine 126, was obtained as a cream foam in 83 % 
yield after purification by column chromatography.  
 
The synthesis of the desired compound, 5’-O-(4,4’-dimethoxytrityl)uridine 126, was 
confirmed by the presence of new peaks corresponding to the methoxy groups and the 
aromatic rings in both the proton and IR spectra. In the 
1
H NMR spectrum, a new singlet 
integrating for 6 H was observed at 3.78 ppm, which was identified as the peak corresponding 
to the two new methoxy groups. Other new peaks were observed in the aromatic region as a d 
integrating for 4 H, with J = 8.70 Hz, at 6.83 ppm and as a multiplet integrating for 9 H at 
7.22-7.39 ppm, which were assigned as H-3* and overlapping peaks for H-2*, H-6*, H-7* 
and H-8* respectively. Similarly, new peaks were observed at 2962 cm
-1
 which is 
characteristic for a OCH3 group and at 669, 928 and 1510 cm
-1
 which are specific for aromatic 
rings, with 669 cm
-1
 accounting for 5 adjacent aromatic protons and 928 cm
-1
 accounting for 2 
adjacent aromatic protons. Final confirmation for the formation of the product was given by 
HRMS, in which peaks were observed at 547.20717 and 569.18944, corresponding to [M + 
1]
+
 and [M + 23]
+
 respectively, based on the calculation for the molecular ion peak at 
506.20022. 
 
In Step (ii) of Scheme 12, we see the protection of the secondary alcohols at the 2’ and 3’ 
positions on the sugar ring with acetyl groups. The experimental procedure involved the use 
of acetic anhydride as the acetyl donator and pyridine as both the base and the solvent for the 
reaction. The reaction was carried out at rt and yielded the desired product 2’,3’-O-diacetyl-
5’-O-(4,4’-dimethoxytrityl)uridine 127 as a pale orange foam that did not require further 
purification by column chromatography in 90 % yield. 
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The synthesis of the desired compound, 2’,3’-O-diacetyl-5’-O-(4,4’-dimethoxytrityl)uridine 
127, was confirmed by the presence of the new peaks for the two new acetyl groups in both 
the proton and carbon NMR spectra. In the 
1
H NMR spectrum, two singlets were observed at 
2.13 and 2.14 ppm, each integrating for 3 H, and were assigned to the two new methyl groups 
present in the molecule. Similarly, in the 
13
C NMR spectrum, new peaks were observed at 
20.65 and 20.85 ppm for the methyl groups and at 169.81 and 170.01 ppm for the carbonyl 
groups. Substantiating evidence was provided by the appearance of a band in the IR spectrum 
at 1607 cm
-1
 which is characteristic of the new C=O groups, as it appears at a different shift to 
those for the amide C=O groups on position C-2 and C-4 of the base. Final confirmation for 
the formation of compound 127 came from the HRMS, in which peaks were observed at 
631.22851 for [M + 1]
+
 and at 653.21020 for [M + 23]
+
, based on the calculation for the 
molecular ion peak at 630.22135. 
 
Outlined in Step (iii) of Scheme 12 is the protection of the secondary amide position on the 
base as a benzoyl derivative. Hünig’s base was used to deprotonate the amide and the system 
was then reacted with benzoyl chloride using the conditions described in detail for Step (iii) of 
Scheme 11. The desired compound, 3-N-benzoyl-2’,3’-O-diacetyl-5’-O-(4,4’-dimethoxy-
trityl)uridine 128, was obtained as a yellow foam in 59 % yield after purification by column 
chromatography. 
 
Formation of 3-N-benzoyl-2’,3’-O-diacetyl-5’-O-(4,4’-dimethoxytrityl)uridine 128 was 
confirmed by the presence of extra peaks in the aromatic region of the 
1
H NMR spectrum. 
These were observed as part of a multiplet at 7.27-7.68 ppm integrating for 12 H (containing 
H-11* and H-12*) and as a doublet at 7.96 ppm (J = 8.80 Hz) with a characteristic shift for H-
10*. As well as by the disappearance of the broad singlet at 9.34 ppm assigned as NH, in the 
1
H NMR spectrum for the starting material 127. Similarly, the new aromatic carbons were 
observed as peaks at 129.33 (C-10*), 130.37 (C-11*), 131.56 (C-12*) and 135.32 ppm (C-
9*), and the new carbonyl group was observed as a characteristic peak at 168.68 ppm (N-
C=O) in the 
13
C NMR spectrum. Supporting data for the formation of 128 was obtained from 
the IR spectrum as new bands were observed at 1671 and 2934 cm
-1
 for the newly formed 
tertiary amide. Final characterizing data was obtained from the HRMS, wherein a peak was 
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observed at 757.23653, which when 23 is removed for the sodium additive, correlates well to 
the calculated value of 734.24756 for the molecular ion. 
 
Step (iv) of Scheme 12 highlights the attempted synthesis of 3-N-benzoyl-5’-O-(4,4’-
dimethoxytrityl)uridine 129 using conditions similar to those used in Step (iv) of Scheme 1144 
for the preparation of the corresponding TBDPS derivative.  In this case, we used sodium 
carbonate as the base for deprotonation of the amide NH specifically, which was followed by 
reaction with benzoyl chloride. As sodium carbonate is insoluble in most organic solvents, the 
reaction was carried out in a biphasic solution of CH2Cl2 : H2O, with tetra-butylammonium 
bromide added as the phase transfer catalyst. Unfortunately, as happened before, none of the 
desired compound 129 was isolated from the reaction mixture. 
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Scheme 13 Synthesis of acetyl protected derivatives of uridine: (i) 4.5 eq. acetic anhydride, 
7.5 eq. pyridine, rt, 22 h, 93 %, (ii) 5 eq. benzoyl chloride, 5 eq. N,N-diisopropylethylamine, 
pyridine, rt, 2 h, 93 %, (iii) 4.5 eq. potassium carbonate, MeOH, rt, 2 h, 0 % or 3 eq. p-
TsOH.H2O, CH2Cl2 : MeOH, rt, 24 h, 0 % 
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Using a modified approach to that outlined in Scheme 11 and Scheme 12, we were able to 
synthesise a range of acetyl protected uridine derivatives. This approach is shown 
schematically in Scheme 13. 
 
Initially, as shown in Step (i) of Scheme 13, all three of the alcohols present on the sugar ring 
were protected as the acetyl derivative. This reaction occurred using pyridine as both the base 
and the solvent for the reaction, with acetic anhydride present in excess as the acetyl donor. 
The desired compound, 2’,3’,5’-O-triacetyluridine 130, was obtained as a white foam in 93 % 
yield after purification by column chromatography. 
 
Formation of 2’,3’,5’-O-triacetyluridine 130 was confirmed through the presence of three new 
singlets in the 
1
H NMR spectrum, each integrating for 3 H, and assigned as each of the newly 
formed methyl groups. Similarly, three new peaks were observed at 20.56, 20.65 and 20.79 
ppm, which were assigned as the methyl groups, in the 
13
C NMR spectrum. Also observed, 
were new peaks at 169.84 ppm for the C=O present on the C-2’ and C-3’ positions (originally 
secondary alcohols), and at 170.36 ppm for the C=O present on the C-5’ position (originally 
the primary alcohol). Supporting data was obtained from the IR spectrum, in which peaks 
were observed at 1216 cm
-1
 for -CO-CH3, at 1379 cm
-1
 for the CH3 symmetrical deformation 
and at 1750 cm
-1
 for the new C=O groups. Other supporting data was obtained from the 
HRMS, in which peaks were observed at 371.10849 for [M + 1]
+
 and at 393.09029 for [M + 
23]
+
, based on the calculation for the molecular ion peak at 370.10123. 
 
Outlined in Step (ii) of Scheme 13 is the protection of the secondary amide position on the 
uridine base as a benzoyl derivative. The procedure used was one adapted from that reported 
previously by Kamimura and co-workers.
46-47
 The reaction occured through the deprotonation 
of the amide NH using Hünig’s base and the subsequent attack on the benzoyl chloride. In 
this instance, pyridine was used as the solvent for the reaction as the by-product for the 
reaction is gaseous hydrochloric acid, which was trapped by the pyridine in order to prevent 
decomposition of the newly formed compound. The desired compound, 3-N-benzoyl-2’,3’,5’-
O-triacetyluridine 131, was obtained as a bright yellow foam in 93 % yield after purification 
by column chromatography. 
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The synthesis of the desired compound, 3-N-benzoyl-2’,3’,5’-O-triacetyluridine 131, was 
confirmed through the use of various spectroscopic techniques. The 
1
H NMR spectrum shows 
the disappearance of the broad singlet at 9.61 ppm in the starting material (130) spectrum and 
the appearance of new peaks as part of the mulitplet integrating for 3 H at 7.48-7.53 ppm 
(contains signal for H-3*), as a multiplet at 7.64-7.66 ppm integrating for 1 H (H-4*) and as a 
doublet at 7.95 ppm with J = 7.84 Hz integrating for 2 H (H-2*). Similarly, the 13C NMR 
shows the appearance of new peaks in the aromatic region at 129.35 (C-3*), 130.75 (C-2*), 
131.47 (C-1*) and 135.37 ppm (C-4*), as well as new peaks at 169.76, 169.98 and 170.28 
ppm (corresponding to the three new C=O groups). Supporting evidence for the formation of 
131 was obtained from the IR spectrum as new bands were noted at 775 cm
-1
 which is 
characteristic for 5 adjacent aromatic protons, and at 1540 and 1752 cm
-1
 accounting for the 
presence of a tertiary amide. Final characterizing data was obtained from the HRMS, wherein 
a peak was observed at 497.11584, which when 23 is removed for the sodium additive, 
correlates well to the calculated value of 474.12744 for the molecular ion. The [M + 1]
+
 peak 
was also observed at 475.13429, ensuring our accurate determination of the product for the 
reaction as compound 131. 
 
Shown in Step (iii) of Scheme 13 is the attempted synthesis of 3-N-benzoyluridine 132. The 
initial attempt was to do a base catalysed deprotection on the protected uridine 131, in order to 
remove all three of the acetyl groups simultaneously. The reaction was attempted using excess 
potassium carbonate with a methanolic solution of 131 and reacting at rt for 2 hours. After 
this time consumption of the starting material was noted by tlc, but none of the desired 3-N-
benzoyluridine 132 was isolated from the reaction.  
 
A second attempt was made at the formation of 3-N-benzoyluridine 132, this time using an 
acid-catalysed deprotection procedure (described in Bermejo and co-workers
48
 for the 
synthesis of similar derivatives). The reaction was conducted using excess tosic acid as a 
solution in CH2Cl2 : MeOH. Unfortunately, even after reaction at rt for 24 h, none of the 
desired 3-N-benzoyluridine 132 was isolated from the reaction mixture.  
 
P a g e  | 62 
 
It was at this point that we ended the synthesis of uridine (12) derivatives and began our 
synthesis of the less common derivatives of cytidine (11). The route adopted for the synthesis 
of cytidine (11) derivatives is outlined below in Scheme 14. 
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Scheme 14 Synthesis of derivatives of cytidine: (i) 4 eq. benzoic anhydride, absolute EtOH, 
reflux, 4 h, 97 %, (ii) 1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 23 h, 100 %, (iii) 1.2 eq. 
DMT-Cl, 0.1 eq. DMAP, pyridine, rt, 23 h, 0 %, (iv) 4 eq. benzoic anhydride, absolute EtOH, 
reflux, 4 h, 0 %, (v) 1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 22 h, 0 %, (vi) 1 eq. 
DMT-Cl, 0.02 eq. DMAP, pyridine, rt, 20 h, 0 % or 1.2 eq. DMT-Cl, 0.1 eq. DMAP, 
pyridine, rt, 21 h, 0 % 
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Outlined in Step (i) of Scheme 14 is the protection of the primary amine at the C-4 position of 
the base with a benzoyl group, as described by Townsend and Tipson.
49
 The reaction was 
carried out by the stepwise additions of benzoic anhydride to a refluxing solution of cytidine 
11 in absolute ethanol. After trituration with diethyl ether, the desired compound, 4-N-
benzoylcytidine 133, was obtained as a fluffy white powder in 97 % yield. 
 
The formation of 4-N-benzoylcytidine 133 was confirmed by the presence of new aromatic 
peaks in the 
1
H NMR spectrum, observed as a multiplet integrating for 2 H at 7.46-7.50 ppm 
(H-3*), another multiplet integrating for 1 H at 7.53-7.62 ppm (H-4*) and a doublet, with J = 
7.46 Hz, integrating for 2 H at 8.00 ppm (H-2*). Similarly, new peaks were present in the 
13
C 
NMR spectrum, with the new aromatic carbons observed as peaks at 128.55 (C-2* and C-3*), 
132.85 (C-4*) and 133.21 ppm (C-1*), along with the new peak for the amide C=O present at 
167.44 ppm. Supporting evidence for the presence of the benzoyl group was given by the 
appearance of bands in the IR spectrum: at 670 and 741 cm
-1
 for five adjacent aromatic 
protons, and at 1504 and 1601 cm
-1
 for the new aromatic ring. Final confirmation for the 
formation of 133 was provided by the presence of a peak at 348.11509 ([M + 1]
+
) in the 
HRMS spectrum, which correlates well to the calculated value of 347.11174 for the molecular 
ion. 
 
Shown in Step (ii) of Scheme 14 is the protection of the primary alcohol on the 5’ position of 
the sugar ring as a TBDPS group. The reaction was carried out using pyridine as both the base 
and the solvent for the reaction, with a catalytic amount of DMAP added. The deprotonated 
cytidine 11 was then reacted with excess tert-butyldiphenysilyl chloride at rt overnight. The 
desired compound, 5’-O-(tert-butyldiphenylsilyl)cytidine 134, was obtained as a white foam 
after purification by column chromatography in 100 % yield. 
 
The synthesis of the desired compound, 5’-O-(tert-butyldiphenylsilyl)cytidine 134, was 
confirmed through the use of various spectroscopic techniques. The 
1
H NMR spectrum shows 
the appearance of a new singlet integrating for 9 H at 1.02 ppm for the three equivalent 
methyl goups, as well as the appearance of new signals in the aromatic region: as a multiplet 
at 7.39-7.49 ppm integrating for 6 H (H-3* and H-4*) and as a multiplet at 7.63-7.65 ppm 
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integrating for 4 H (H-2*). Similarly, new peaks were observed in the 
13
C NMR spectrum at 
17.79 ppm for C(CH3)3 and at 26.65 ppm for C(CH3)3 showing the presence of  the new tert-
butyl group. New peaks were also observed for the two aromatic rings at 127.96 (C-3*), 
129.96 (C-4*), 132.27 (C-1*) and 134.96 ppm (C-2*) in the 
13
C NMR spectrum. 
Substantiating evidence was provided by the appearance of new bands in the IR spectrum at 
1109 cm
-1
 for the Si-O stretch and at 3021 cm
-1
 for the aromatic rings. HRMS gave 
supporting data for the formation of compound 134 as a peak was observed at 482.20978 for 
[M + 1]
+
 which correlates well to the calculated value of 481.20330 for the molecular ion. 
 
Step (iii) of Scheme 14 shows the attempted synthesis of 5’-O-(4.4’-dimethoxytrityl)cytidine 
136, through the reaction of cytidine 11 with 4.4’-dimethoxytrityl chloride in the presence of 
catalytic DMAP and pyridine (acting as both the solvent and the base for the reaction). 
Unfortunately, even after numerous attempts at recrystallisation of the mixture obtained after 
column chromatography, none of the desired compound 5’-O-(4.4’-dimethoxytrityl)cytidine 
136 was obtained pure. We were however able to isolate a mixture of compound 136 and a 
triethylamine salt, which were inseparable, as well as some of the 4,4’-dimethoxytrityl alcohol 
147. 
 
Outlined in Step (iv) of Scheme 14 is the first route attempted for the synthesis of 4-N-
benzoyl-5’-O-(tert-butyldiphenylsilyl)cytidine 135. In this route, the compound 134 was 
heated to reflux in absolute ethanol before the stepwise additions of benzoic anhydride. After 
subsequent trituration with diethyl ether, none of the desired compound 135 was obtained. 
Instead, the white powder isolated from the reaction mixture was found to contain only 
unreacted starting material 134. Outlined in Step (v) of Scheme 14 is the second route 
attempted for the synthesis of 4-N-benzoyl-5’-O-(tert-butyldiphenylsilyl)cytidine 135. This 
route shows the reaction of compound 133 with tert-butyldiphenylsilyl chloride in the 
presence of the base and solvent for the reaction, pyridine, as well as catalytic amounts of 
DMAP. Unfortunately, none of the desired compound 4-N-benzoyl-5’-O-(tert-
butyldiphenylsilyl)cytidine 135 was obtained after purification by column chromatography. 
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Finally, shown in Step (vi) of Scheme 14 is the attempted synthesis of 4-N-benzoyl-5’-O-
(4,4’-dimethoxytrityl)cytidine 137. Both methods illustrated involve the use of catalytic 
DMAP and have pyridine present to act as both the base and the solvent for the reaction. In 
both instances, the deprotonation of the primary alcohol in the 5’ position of the sugar ring 
was immediately followed by the reaction with 4,4’-dimethoxytrityl chloride. Differences in 
the two methods come from the differing molar equivalents used for the DMT-Cl and DMAP, 
as well as in the work-up. For the first method shown, the reaction was worked up through a 
number of extractions with a saturated solution of NaHCO3, CHCl3 and brine. A 
recrystallisation was then attempted from EtOH/CHCl3 and Et2O, which was followed by 
purification by column chromatography. In the second method above, the reaction was 
quenched with the addition of EtOH and the residue obtained was recrystallised from hot 
MeOH. None of the desired compound 4-N-benzoyl-5’-O-(4,4’-dimethoxytrityl)cytidine 137, 
was isolated from either attempt at the reaction. 
 
Having completed the synthesis of the uridine 12 derivatives (as shown in Scheme 11, 
Scheme 12 and Scheme 13), as well as having attempted the synthesis of a number of 
cytidine 11 derivatives (as shown in Scheme 14), we then decided to proceed to the 
preparation of the purine-based nucleoside derivatives. The nucleosides chosen for this study 
were guanosine 9, inosine 116 and adenosine 8. 
 
2.2.2.3 Purine-Based Nucleosides – Focusing on Guanosine, Inosine and Adenosine 
 
The first of the purine-based nucleosides that we chose to work on was guanosine 9. This 
nucleoside was chosen as we had previously worked with it on our attempted synthesis of 
2’,3’-fused biclyclic systems, as described in Section 2.2.1.3. Our initial approach towards the 
synthesis of tert-butyldiphenylsilyl- and 4,4’-dimethoxytrityl-protected derivatives is outlined 
in Scheme 15. 
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Scheme 15 Attempted synthesis of derivatives of guanosine: (i) 1.1 eq. TBDPS-Cl, 0.01 eq. 
DMAP, pyridine, rt, 24 h, 0 %, or 1 eq. TBDPS-Cl, 2 eq. imidazole, DMF, rt 48 h, 0 %, (ii) 
1.2 eq. DMT-Cl, 0.01 eq. DMAP, pyridine, 60 
o
C, 20 h, 0 % 
 
Step (i) of Scheme 15 shows the attempted synthesis of 5’-O-(tert-
butyldiphenylsilyl)guanosine 138. Various attempts were made for this synthesis, the first of 
which involved the protection of the primary alcohol in the 5’ position of the sugar ring by 
stirring the guanosine 9 and the catalyst DMAP with pyridine, which serves as both the 
solvent and the base for the reaction. The pyridine deprotonates the alcohol and then allows 
for reaction with the tert-butyldiphenylsilyl chloride, giving HCl off as the by-product to the 
reaction. Unfortunately, none of the desired compound 138 was isolated from the reaction (in 
one attempt, only unreacted guanosine 9 was isolated). Thus, a different approach was 
adopted, in which the guanosine 9 was prepared as a solution in distilled DMF and then 
imidazole was added as the base for the deprotonation, before reaction with tert-
butyldiphenylsilyl chloride, using the procedure outlined in Sproat and co-workers.
42
 
Numerous attempts at recrystallisation of the crude semi-solid failed and each time 
unidentifiable by-products were isolated, with none of the desired 5’-O-(tert-
butyldiphenylsilyl)guanosine 138 being obtained. 
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Outlined in Step (ii) of Scheme 15 is the attempted synthesis of 5’-O-(4,4’-
dimethoxytrityl)guanosine 139. For this reaction, guanosine 9 was dissolved in pyridine and 
the solution was heated to 60 
oC, before the addition of excess 4,4’-dimethoxytrityl chloride 
and a catalytic amount of DMAP, followed by overnight reaction. Unfortunately, the only 
compounds isolated after column chromatography were the 4,4’-dimethoxytrityl chloride 
degradation products and unreacted guanosine 9. Our belief is that if the desired compound 
5’-O-(4,4’-dimethoxytrityl)guanosine 139 had formed, it subsequently decomposed during 
purification. 
 
Having had little success protecting the primary alcohol on the 5’ position of the sugar ring 
directly, we decided to change our approach and re-order the sequence of protection steps. We 
thus began our next synthesis with the protection of the primary amine of the base instead. 
The synthetic approach used is outlined in detail in Scheme 16 on the following page. 
 
Step (i) of Scheme 16 shows the protection of the primary amine on the base using N,N-
dimethylformamide dimethyl acetal. The detailed synthesis was described previously in 
Section 2.2.1.3 as shown in Step (i) of Scheme 6.
42
 The desired compound, 6-N-(N,N-
dimethylmethylimine)guanosine 112, was obtained in 79 % yield after purification. 
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Scheme 16 Synthesis of derivatives of guanosine: (i) 2 eq. N,N-dimethylformamide dimethyl 
acetal, DMF, rt, 27 h, 79 %, (ii) 1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, pyridine, rt, 25 h, 0 %, or 
1 eq. TBDPS-Cl, 2 eq. imidazole, DMF, rt, 20 h, 0 %, (iii) 1 eq. DMT-Cl, 0.1 eq. DMAP, 
pyridine, rt, 25 h, 69 % 
 
Shown in Step (ii) of Scheme 16 is the attempted synthesis of 5’-O-(tert-butyldiphenylsilyl)-
6-N-(N,N-dimethylmethylimine)guanosine 140. Two general approaches were used in these 
attempts, the first of which involved the use of pyridine as the base and solvent for the 
reaction, with catalytic amounts of DMAP added, and this was followed by reaction with 
excess tert-butyldiphenylsilyl chloride. The second approach used involved the use of 
imidazole as the base and DMF as the solvent, which was then followed by reaction with a 
molar equivalent of tert-butyldiphenylsilyl chloride. This approach was modified from the 
work done by Sproat and co-workers
42
 as discussed previously in Section 2.2.1.3. Neither of 
the approaches were successful and none of the desired 5’-O-(tert-butyldiphenylsilyl)-6-N-
(N,N-dimethylmethylimine)guanosine 140 was isolated after purification by either 
recrystallisation or column chromatography. 
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Outlined in Step (iii) of Scheme 16 is the protection of the primary alcohol at the 5’ position 
on the sugar ring with 4,4’-dimethoxytrityl chloride. The detailed synthesis was described 
previously in Section 2.2.1.3 and was shown in Step (ii) of Scheme 6. As described 
previously, the desired compound, 5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-dimethylmethyl-
imine)guanosine 113, was obtained in 69 % yield after purification. 
 
The second of the purine-based nucleosides that we chose to work on was inosine 116. This 
nucleoside was chosen as we had previously worked with it on our attempted synthesis of 
2’,3’-fused biclyclic systems, as described in Section 2.2.1.3. Our initial approach towards the 
synthesis of tert-butyldiphenylsilyl and 4,4’-dimethoxytrityl protected derivatives is outlined 
in Scheme 17. 
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Scheme 17 Synthesis of derivatives of inosine: (i) 1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, 
pyridine, rt, 22 h, 0 %, (ii) 1 eq. DMT-Cl, 0.1 eq. DMAP, pyridine, rt, 21 h, 78 % 
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Step (i) of Scheme 17 outlines the attempted synthesis of 5’-O-(tert-
butyldiphenylsilyl)inosine 141, through protection of the primary alcohol. The reaction was 
attempted a number of times on various scales using pyridine as both the base and the solvent 
for the reaction, with catalytic amounts of DMAP added and followed by reaction with tert-
butyldiphenylsilyl uridine. After purification by column chromatography, none of the desired 
compound 141 was isolated and it appeared as though it had decomposed during purification. 
In another attempt at the reaction, the crude residue was purified by an acid-base extraction 
procedure, but as before, only decomposition products were isolated. Various other attempts 
at the reaction were followed by purification by recrystallisation; unfortunately none of these 
attempts yielded any of the desired product, 5’-O-(tert-butyldiphenylsilyl)inosine 141. 
 
Shown in Step (ii) of Scheme 17 is the protection of the primary alcohol on the 5’ position of 
the sugar ring with a 4,4’-dimethoxytrityl group. The detailed synthesis was described 
previously in Section 2.2.1.3 above, as shown in Step (i) of Scheme 7. As discussed before, 
the desired compound 5’-O-(4,4’-dimethoxytrityl)inosine 117, was obtained in 78 % yield 
after purification. 
 
It was at this point that we concluded the synthesis of inosine (116) derivatives and began our 
synthesis of the less common derivatives of adenosine (8). The route adopted for the synthesis 
of adenosine (8) derivatives is similar to that used for the preparation of the inosine (116) 
derivatives shown above and is outlined schematically below in Scheme 18. Both approaches 
for the synthesis of adenosine derivatives were adapted from work reported by Manoharan 
and co-workers
41
 on the protection of various modified nucleosides and oligonucleotides. 
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Scheme 18 Synthesis of derivatives of adenosine: (i) 1.1 eq. TBDPS-Cl, 0.1 eq. DMAP, 
pyridine, rt, 19 h, 73 %, (ii) 1.2 eq. DMT-Cl, 0.1 eq. DMAP, pyridine, 60 
o
C, 20 h, 0 % 
 
Step (i) of Scheme 18 shows the protection of the primary alcohol on the sugar ring as a 
derivative of tert-butyldiphenylsilyl chloride. The reaction was carried out using pyridine as 
both the base and the solvent for the reaction and with a catalytic amount of DMAP present. 
After purification by column chromatography the desired compound, 5’-O-(tert-
butyldiphenylsilyl)adenosine 142, was obtained as a white foam in 73 % yield. 
 
The formation of the 5’-O-(tert-butyldiphenylsilyl)adenosine 142 was concluded based on the 
presence of new peaks in the 
1
H NMR spectrum: a singlet integrating for 9 H was observed at 
0.99 ppm which correlates to the C(CH3)3 group, a multiplet integrating for 6 H was observed 
at 7.30-7.38 ppm correlating to the H-3* and H-4* protons and a doublet of doublets (with J = 
1.44 and 7.85 Hz) integrating for 4 H was observed at 7.59 ppm which correlates to H-2*. 
Similarly, in the 
13
C NMR spectrum, new peaks were observed that correspond to the tert-
butyl group at 18.68 ppm (C(CH3)3) and 26.44 ppm (C(CH3)3). Other new peaks were 
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observed which correspond to the two new aromatic rings at 127.41 (C-3*), 129.39 (C-4*), 
132.40 (C-1*) and 134.82 ppm (C-2*). Further evidence for the formation of compound 142 
was provided by the bands observed in the IR spectrum at 626 cm
-1
 for the Si-O stretch, at 
670 and 780 cm
-1
 for the five adjacent aromatic protons and at 1522 and 3021 cm
-1
 for the 
newly formed aromatic rings. Final data on the formation of compound 142 was obtained 
from the HRMS, in which a peak was observed at 506.22098 which corresponds to [M + 1]
+
 
when compared to the calculated value of 505.21453 for the molecular ion. 
 
Finally, outlined in Step (ii) of Scheme 18 is the attempted synthesis of 5’-O-(4,4’-
dimethoxytrityl)adenosine 143. The reaction involves the protection of the primary alcohol in 
the 5’ position of the sugar ring, this was attempted utilizing pyridine (as both the base and 
the solvent for the reaction) to deprotonate the primary alcohol in the presence of a catalytic 
amount of DMAP. After warming to 60 
oC the mixture was allowed to react with excess 4,4’-
dimethoxytrityl chloride overnight. Following purification by column chromatography and 
numerous attempts at recrystallisation, the desired compound 143 was always isolated 
contaminated with a triethylamine salt. Unfortunately, no 5’-O-(4,4’-dimethoxytrityl)-
adenosine 143 was obtained in sufficient purity for further biological testing. 
 
Thus having completed the synthesis of the guanosine 9 derivatives (as shown above in 
Scheme 15 and Scheme 16) and having attempted the synthesis of a range of inosine 116 and 
adenosine 8 derivatives (as shown above in Scheme 17 and Scheme 18), we then continued 
with the synthesis of the controls required for our biological assays.  
 
2.2.2.4 Controls for Biological Assays 
 
The controls required for this study were the protecting group derivatives, tert-
butyldiphenylsilanol 145, and 4,4’-dimethoxytrityl alcohol 147. 
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The first protecting group derivative prepared as a control for the biological assays is shown 
in Scheme 19, where Step (i) outlines the synthesis of tert-butyldiphenylsilanol 145, based on 
the approach previously reported by Mullen and Barany.
50
 The reaction occured by dissolving 
the starting material, tert-butyldiphenylsilyl chloride 144, in diethyl ether and then adding to 
it a solution of the base potassium hydroxide in H2O : MeOH. After reaction at rt overnight, 
the mixture was purified by extraction and the desired compound tert-butyldiphenylsilanol 
145 was obtained as a opaque oil in 92 % yield. 
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Scheme 19 Synthesis of the derivative of TBDPS-Cl: (i) 1.1 eq. potassium hydroxide, H2O : 
MeOH, Et2O, rt, 24 h, 92 %  
 
The formation of the tert-butyldiphenylsilanol 145 was confirmed by the presence of a broad 
singlet at 3.53 ppm in the 
1
H NMR spectrum which disappeared when D2O was added to the 
NMR sample. 
13
C NMR spectroscopy did not give any conclusive evidence for the formation 
of the desired product 145, but substantiating evidence was provided by the bands in the IR 
spectrum at 1084 cm
-1
 which corresponds to a C-O stretch from a C-OH group, and at 1331 
cm
-1
 which is characteristic of O-H bending. Further data supporting the formation of 
compound 145 was provided by the peak observed at 279 ([M + 23]
+
), with 55 % abundance 
in the LRMS spectrum, which correlates well to the calculated value for the molecular ion of 
256, when 23 is removed for the sodium additive. HRMS data could not be determined as the 
compound was too volatile for detection. 
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Scheme 20 Synthesis of the derivative of DMT-Cl: (i) 0.5 M NaOH, THF, rt, 30 min, 87 % 
 
The second protecting group derivative synthesized as a control for the biological assays was 
4,4’-dimethoxytrityl alcohol 147. The approach was based on that of Golding and co-
workers
51
 and this approach is shown in Scheme 20. To the 4,4’-dimethoxytrityl chloride 146 
was added a solution of THF and 0.5 M aqueous sodium hydroxide. The reaction was then 
stirred at rt for 30 min, the crude compound being obtained by extraction and then purified by 
column chromatography. After purification, the desired compound 4,4’-dimethoxytrityl 
alcohol 147 was obtained as a yellow-orange semi-solid in 87 % yield. 
 
Formation of 4,4’-dimethoxytrityl alcohol 147 was confirmed by the presence of a broad 
singlet at 2.76 ppm in the 
1
H NMR spectrum which exchanged with deuterium. All other 
peaks were observed as expected in both the 
1
H and 
13
C NMR spectra. Further evidence for 
the formation of the alcohol group was given by the bands appearing at 1115 cm
-1
 (C-O 
stretch from C-OH), 1360 cm
-1
 (O-H bending) and 3504 cm
-1
 (O-H stretchin) in the IR 
spectrum. LRMS data supported the conclusion that compound 147 had been prepared as the 
[M + 23]
+
 peak was observed with 7 % relative abundance in the sample. 
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2.3 CONCLUSIONS 
 
Using our strategy towards fused bicyclic ring systems, we were able to synthesise the diene 
2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 103, but were 
unable to obtain the bicyclic ring system using RCM. The inability to form the ring closed 
product via RCM was also observed for 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-
(N,N-dimethylmethylimine)guanosine 114. Due to the time constraints of the project, we 
decided not to continue along this synthetic route and instead shifted our focus to the 
synthesis of a range of compounds that would be used to conduct a structure-activity study.  
 
For these derivatives, we prepared a series of compounds that had different functional groups 
present on the primary hydroxyls and secondary hydroxyls on the sugar ring, as well as 
different groups present on the primary amines and/or amide groups of the bases. This 
synthesis was performed to obtain a range of sugar derivatives (ᴅ-(-)-ribose 100) and 
nucleoside derivatives (adenosine 8, cytidine 11, guanosine 9, inosine 116 and uridine 12). 
Included in this group were the corresponding protecting group derivatives, tert-
butyldiphenylsilyl alcohol 145 and 4,4’-dimethoxytrityl alcohol 147. 
 
Having the range of synthetic compounds in hand, for both the approach towards the fused 
bicyclic ring systems and those for the structure-activity study, we then moved on to the 
biological testing. For the biological testing, we assayed our range of synthetic compounds for 
inhibitory activity against four bacterial strains, four cancer cell lines and HIV. The results of 
the biological testing are discussed in detail in Chapter 3. 
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Chapter 3: 
Results and Discussion for Biological Testing 
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The cell proliferation studies were done by Mrs H. Apostolellis and Mrs N. Dahan-Farkas, 
while under the supervision of Dr H. Davids. The work was carried out at the Division of 
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University of the Witwatersrand. Dr H. Davids is currently based at the Department of 
Biochemistry and Microbiology at the Nelson Mandela Metropolitan University. We would 
like to thank Mrs N. Dahan-Farkas for the preparation of the graphs reported as Graphs 12-
15 in the proceeding text. 
 
 
3.1 CHAPTER OVERVIEW 
 
In order to determine if the synthetic nucleoside derivatives prepared (synthesis described in 
Chapter 2) possessed general biological activity, we assayed them for antibacterial, antiviral 
and anticancer properties. This chapter begins with our assay of all of the synthetic 
compounds for broad-spectrum antibacterial activity. This is followed by an antiviral assay, 
wherein ten representative examples were selected from all the first generation synthetic 
compounds and were then tested for activity against HIV using a well known whole cell 
assay. Finally, we describe the assay for inhibition of cell proliferation in five cancerous cell 
lines. Seventeen of the first generation synthetic compounds were selected [in order to 
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encompass derivatives of all five nucleosides and the model ᴅ-(-)-ribose] and were then used 
in the assay. 
 
3.2 RESULTS AND DISCUSSION 
 
3.2.1 Antibacterial Assays 
 
For this study we tested fifteen nucleoside derivatives, eight ᴅ-(-)-ribose derivatives and two 
synthetic controls for possible antibacterial activity. Our study involved the use of two Gram-
positive and two Gram-negative bacterial strains. 
 
3.2.1.1 Materials and Methods 
 
 Bacterial Cultures 
 
We chose Staphylococcus aureus (ATCC 25923) and Bacillus cereus (DL5) as our 
representative Gram-positive bacteria.  S. aureus strain ATCC 25923 is a clinical isolate that 
was deposited with the ATCC by the FDA (designation Seattle 1945) and has a biosafety 
level 2 ranking.
52
 S. aureus strain ATCC 25923 is a Gram-positive coccus, with colonies that 
appear very opaque, round, smooth and are golden yellow in colour. It is pathogenic and is 
associated with the frequent occurrence of antibiotic resistance mechanisms. It can cause a 
wide range of illnesses, from minor ones, such as skin infections, to life-threatening ones, 
such as septicemia.   
 
B. cereus strain DL5 is an environmental isolate that was obtained from alkaline wash 
solutions in a South African dairy farm; as described by Lindsay and co-workers.
53-55
 B. 
cereus strain DL5 has been fully characterized and the data deposited, the accession number is 
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AF 363441. B. cereus is a Gram-positive eubacterium that forms endospores and often 
produces rhizoid swirling colonies. It is known to be a foodborne pathogen and a cytotoxin 
producer.  
 
For the study we also used Pseudomonas aeruginosa (ATCC 27853) and Escherichia coli 
(ATCC 25922) as our representative Gram-negative bacteria. P. aeruginosa strain ATCC 
27853 was isolated from blood culture and was deposited at the ATCC by A.A. Medeiros 
(designation Boston 41501) and has a biosafety level 2 ranking.
56
 P. aeruginosa is often 
involved in hospital acquired infections, with symptoms of infection including inflammation 
and sepsis which can be fatal.  
 
E. coli strain ATCC 25922 is a clinical isolate that was deposited with the ATCC by the FDA 
(designations FDA strain Seattle 1946, DSM1103 and NCIB 12210) and has a biosafety level 
1 ranking.
57
 E. coli strain ATCC 25922 is a Gram-negative bacterium which is rod-shaped 
(with motility derived from peritrichous flagella), and has colonies that are round, smooth, 
sharply defined and are translucent pale grey in colour. E. coli strains occur as part of the 
natural flora of the lower intestine and as such are used as indicator organisms for faecal 
contamination in the environment.  
 
All of the bacterial strains were grown from either freezer stocks or freeze-dried swabs, 
maintained on nutrient agar plates at 4 
o
C and sub-cultured every 21 days. Each culture was 
grown in 100 cm
3
 nutrient broth overnight at 37 
o
C. A full description of the procedure used is 
outlined in detail in Appendix C (Section C.1 and Section C.2).  
 
The 18 hour bacterial cultures were used to determine the number of colony forming units 
present per millilitre of culture using the droplet plate technique, with the full procedure 
described in Appendix C (Section C.3). From this technique we calculated the cfu/mL and 
log cfu/mL for each of the four bacterial strains used in the study. We found: 
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 S. aureus ATCC 25923 
-  cfu/mL  = 747 500 000 
-  log cfu/mL  = 8.87 
 
 B. cereus DL5   
-  cfu/mL  = 1 432 500 000 
-  log cfu/mL  =  9.16 
 
 P. aeruginosa ATCC 27853 
-  cfu/mL  = 1 536 666 667 
-  log cfu/mL  =  9.19 
 
 E. coli ATCC 25922 
-  cfu/mL  = 3 375 000 000 
-  log cfu/mL  =  9.53 
 
 Synthetic Compounds 
 
The compounds used in this study were prepared using standard synthetic organic chemistry 
techniques. A full discussion of the results obtained is given in Chapter 2 and the detailed 
experimental procedures used are outlined in Appendix B below. For ease of reading, the 
compounds tested using the TTC assay are grouped according to structural similarities and are 
illustrated below. Figure 23 shows the range of ᴅ-(-)-ribose 100 derivatives.  
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Figure 23 Synthetic compounds tested using TTC assay - ᴅ-(-)-ribose derivatives 
 
Figure 24 highlights the pyrimidine-based nucleosides which are derivatives of uridine 12 
and cytidine 11, while Figure 25 illustrates the purine-based nucleoside derivatives. The latter 
compounds are all derivatives of the nuleosides: guanosine 9, inosine 116 and adenosine 8. 
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Figure 24 Synthetic compounds tested using TTC assay - pyrimidine based nucleosides 
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Figure 25 Synthetic compounds tested using TTC assay - purine based nucleosides 
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Lastly, Figure 26 shows the two protecting group derivatives that were used as controls in the 
assay. 
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Figure 26 Synthetic compounds tested using TTC assay - protecting group derivatives 
 
 Evaluation of Compound Efficacy – Triphenyltetrazolium Chloride (TTC) Assay 
 
The synthetic compounds, controls and the commercially available antibiotic, ciprofloxacin 
153 (Figure 27), were used to prepare 10 000 mg/L, 1 000 mg/L, 100 mg/L, 10 mg/L and 1 
mg/L stock solutions in autclaved deionised water and molecular grade DMSO, as described 
in Appendix C (Section C.5.1). 
 
 
N N
F
OO
HO
NH
153  
Figure 27 Ciprofloxacin 
 
These stock solutions, for the synthetic compounds, controls and ciprofloxacin 153, were then 
used immediately to prepare a series of 16 dilutions in autoclaved nutrient broth, as described 
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in detail in Appendix C (Section C.5.2). The range of antibiotic concentrations used for 
determining minimum inhibitory concentrations (MICs) is universally accepted to be in 
doubling dilutions steps up and down from 1 mg/L as required.
58
 As such, the dilution series 
was prepared as doubling dilutions from 256 mg/L down to 0.008 mg/L and 100 µL of the 
solutions were placed in each well of the 96-well plates. 
 
 
Then solutions containing 10
6
 cfu/mL cells for each of the four bacteria, S. aureus ATCC 
25923, B. cereus DL5, P. aeruginosa ATCC 27853 and E. coli ATCC 25922, were prepared 
by performing serial dilutions on the 18 hour bacterial cultures, as described in detail in 
Appendix C (Section C.5.3). These were then added in 100 µL portions to the wells on the 
96-well plates. We were able to test one compound/antibiotic against all four bacterial strains 
and obtain four replicates for each compound concentration/bacterial strain combination by 
working across four 96-well plates at a time.  
 
 
Also included on each of the plates were a series of controls: (i) the 0 % growth control, (ii) 
the 100 % growth control, (iii) the DMSO controls (10 mg/mL, 100 mg/mL, 250 mg/mL and 
500 mg/mL concentrations) and (iv) the sterility control.  
 
 
Figure 28 Photographs showing the plates before incubation with the TTC dye 
 
Plate1.1            Plate 1.2 
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Once the bacterial strains had been added to the 96-well plates, they were incubated at 37 
o
C 
for 22 hours. Following this time period, the plates were removed from the incubator. To each 
well of the plates was then added 10 µL of a freshly prepared solution of 5 mg/mL 2,3,5 -
triphenyltetrazolium chloride in phosphate buffered saline (PBS autoclaved prior to use in the 
solution). The plates were then incubated for a further 4 hours at 37 
o
C.  
 
 
After this time, solubilisation of the formazan precipitate (pink) was conducted by the 
addition of the following reagents to each well of the 96-well plates: 
 10 µL of 3N HCl(aq) 
 10 µL of 10 % NP-40(aq) 
 25 µL of modified Weaver Reagent [66 % paraffin oil : 33 % CCl4 : 1 % NP-40 (v/v)] 
 
The plates were then incubated at 4 
o
C for a further 20 hours. After incubation, the plates were 
analyzed on an Elisa plate reader, at a wavelength of both 450 nm and 590 nm. From our pilot 
study, we found that the data obtained at wavelength 450 nm was in the correct absorption 
spectrum and gave considerably less variance than data obtained at 590 nm. Therefore, the 
data obtained at 450 nm was used for all subsequent assays performed. Full details for the 
experimental protocol used in the assay is given in Appendix C (Section C.5.4). 
 
Shown in Figure 29 are the photographs showing what the plates of the positive control for 
anti-bacterial activity (we used the commercially available antibiotic ciprofloxacin 153) 
looked like. One can visually see that at higher concentrations of the antibiotic, no 
metabolically active bacterial cells are observed. This is observed as a lack of the pink colour 
in the wells caused by the presence of formazan precipitate.  
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Figure 29 Photographs showing positive controls for antibiotic activity (plate 1.1 and 1.2 
columns show: 1 = 0 % growth, 2 = 100 % growth, 3 = DMSO controls, 4-12 = doubling 
dilutions of test compound; plate 1.2: column 12 = sterility control). 
 
Outlined in Figure 30 is an example of what the corresponding plates for a negative control 
look like. As one can see, all of the wells containing the negative control (ie: no anti-bacterial 
activity) all appear as bright pink-red in colour. This is due to the fact that the clear 2,3,5-
triphenyltetrazolium chloride is reduced to the pink coloured formazan precipitate in the 
metabolically active cells. 
 
 
Figure 30 Photographs showing negative controls for antibiotic activity (plate 1.1 and 1.2 
layout as described in Figure 29, further information given in Figure C.10 and Figure C.11). 
        Plate1.1               Plate 1.2 
  
        Plate1.1               Plate 1.2 
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For the exact layout of the compound dilutions and internal growth and sterility controls 
please refer to Appendix C (Figures C.10 and C.11). 
 
 Statistical Analysis 
 
For each bacterial strain and compound/antibiotic dilution concentration combination four 
replicates were performed (duplicates were run on each plate and the plates were prepared in 
duplicate as well). Four data points were thus obtained for each combination as the 
absorbance for the cells. The data was corrected for the background absorptivity of the 
solution without bacterial growth by referencing the Elisa plate reader to column 1 (the 0 % 
growth control) on the plates.  
 
For the initial determination of activity, the data was typed into Microsoft Excel and the 
average of the four replicates was determined. This average for the absorptions was then 
represented as the percentage of metabolically active cells present for each bacterial strain and 
compound/antibiotic dilution concentration combination, based on the value obtained for the 
100 % growth control (given in column 2 on each plate).  
 
Graphs were then plotted for the four bacterial strains, showing the percentage metabolically 
active cells on the y-axis against the compound/antibiotic concentration on the x-axis. From 
the initial graphs we determined which compounds showed antibacterial activity - any graphs 
displaying percentage metabolically active cells less than 10 % over a range of concentrations 
were classified as being positive hits. 
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3.2.1.2 Results 
 
As described above, fifteen nucleoside derivatives, eight ᴅ-(-)-ribose derivatives and two 
synthetic controls were tested for possible antibacterial activity against two Gram-positive 
(Staphylococcus aureus strain ATCC 25923 and Bacillus cereus strain DL5) and two Gram-
negative (Pseudomonas aeruginosa strain ATCC 27853 and Escherichia coli strain ATCC 
25922) bacteria.  
 
Each individual assay included a number of internal controls:  
 (i)  the 0 % growth control 
 (ii)  the 100 % growth control 
 (iii)  the DMSO controls 
 (iv)  the sterility control.  
 
Included in the study were a number of control compounds, which were added to verify that 
the decomposition products for the synthetic compounds were not in fact the active molecules 
and a commercial antibiotic:  
 (i)  positive control for antibacterial activity (ciprofloxacin 153)  
 (ii) negative controls for each nucleoside: adenosine 8, cytidine 11, guanosine 9,  
inosine 116, uridine 12 and ᴅ-(-)-ribose 100‡ 
 (iii)  protecting group derivative controls (TBDPS-OH 145 and DMT-OH 147)
 *
. 
 
Minimum inhibitory concentrations (MICs) are considered the "gold standard" for 
determining the susceptibility of organisms to antimicrobials and are therefore used to judge 
the performance of all other methods of susceptibility testing.
58
 As such, we decided to 
determine the MIC of our compounds based on a modified version of the standard procedure 
for the determination of minimum inhibitory concentrations reported by Andrews
58
 (which 
describes an amended version of the procedure described in the BSAC Guide to Sensitivity 
Testing).
59
 
                                                          
‡
 Clarification - the nucleosides and protecting group derivatives were included as "negative controls" in order to 
show the relative effects that making changes to the unprotected nucleosides/sugars would incur in the anti-
bacterial assay. This does not imply that they would all specifically have no effect whatsoever on the bacterial 
systems used in this study. 
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The MIC is defined as the lowest concentration of a drug that will inhibit the visible growth of 
an organism after overnight incubation (this period is extended for organisms such as 
anaerobes, which require prolonged incubation time for growth).
58
 For this study, we used the 
microdilution method described in the paper,
58
 but modified the reading and interpretation 
section. We did not "visually" determine bacterial growth, but used the TTC assay reported by 
Damelin
60
 to give us more accurate values for the percentage of metabolically active cells 
present after treatment with the synthetic compounds. As such, for this study, we have defined 
the MIC as the lowest concentration of synthetic compound that shows less than 10 % of the 
bacterial cells having metabolic activity. 
 
The standard procedure published by Andrews
58
 contained tables giving expected MIC ranges 
for control ATCC strains against various commercially available antibiotics. We thus chose 
an antibiotic, in our case ciprofloxacin 153, and three ATCC strains from the publication for 
the initial assay of antibiotic activity. This was done in order to determine that our modified 
protocol was working correctly and allowed us to correlate our results to those obtained using 
the standardized procedure.  
 
Andrews
58
 suggested ranges for MIC determination with ciprofloxacin 153, as 0.004-128 
mg/L for Enterobacteriaceae, 0.015-128 mg/L for Pseudomonas spp. and 0.06-128 mg/L for 
Staphylococci. As such, we chose the range of 0.008-256 mg/L for our compound dilutions. 
As a dilution occurs when the bacteria are added to the compounds on the plate, this gives us 
a working range of 0.004-128 mg/L for the compounds, which corresponds to those 
recommended by Andrews.
58 
 
Using the dilution series we then prepared a standard dilution curve for the antibiotic 
ciprofloxacin 153, against each of the different bacterial strains used in the assay (S. aureus 
strain ATCC 25923, B. cereus strain DL5, P. aeruginosa strain ATCC 27853 and E. coli 
strain ATCC 25922). The curve is shown schematically in Graph 1. 
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Graph 1 Standard curve for ciprofloxacin 153 
 
We were then able to use the standard curve shown in Graph 1 above to determine the 
minimum inhibitory concentration for the antibiotic ciprofloxacin 153. The results obtained 
are reported in Table 2.  
 
Table 2 MICs determined for ciprofloxacin  
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
153 0.5 mg/L 0.5 mg/L 0.5 mg/L 0.016 mg/L 
 
The MICs obtained using our modified procedure correlated well to those reported by 
Andrews.
58
 For S. aureus ATCC 25923 we determined a MIC value of 0.5 mg/L using our 
approach - which corresponds perfectly to the MIC of 0.5 ml/L reported.
 
In the same manner 
our MIC value of 0.5 mg/L, determined for P. aeruginosa ATCC 27853 - correlates well to 
the MIC of 0.25 mg/L reported. Lastly, we determined a MIC value of 0.016 mg/L for E. coli 
ATCC 25922 - which correlates well to the MIC of 0.015 mg/L reported.  
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Andrews
58
 states that the MIC for the control used should be within one two-fold dilution of 
the expected MIC and all of the results we obtained fall within this range. We thus concluded 
that our modification to the procedure had not had a significant effect on the results obtained 
and we could correlate our MICs determined as the lowest concentration with less than 10 % 
of the cells showing metabolic activity to the data published by Andrews, wherein the MIC 
endpoint was determined by visible growth. 
 
The antibacterial activity for the synthetic compounds was determined using the modified 
MIC determination assay, using TTC, as described above. The results obtained for ᴅ-(-)-
ribose and its derivatives are shown below in Table 3. 
 
Table 3 MICs determined for ᴅ-(-)-ribose and its derivatives 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
ᴅ-(-)-ribose 100 No activity No activity No activity No activity 
101 No activity No activity No activity No activity 
102 64 mg/L 32 mg/L No activity No activity 
103 No activity No activity No activity No activity 
105 No activity No activity No activity No activity 
119 No activity No activity No activity No activity 
120 No activity No activity No activity No activity 
121 No activity No activity No activity No activity 
122 No activity No activity No activity No activity 
 
As expected from our negative control, no antibacterial activity was observed for ᴅ-(-)-ribose 
100. Quite surprisingly, however, we did observe activity for 5'-O-(tert-butyldiphenylsilyl)-1'-
O-methoxy-ᴅ-(-)-ribose 102. The compound was active against specifically the Gram-
positive bacterial strains, with a MIC determined for S. aureus of 64 mg/L and a MIC 
determined for B. cereus of 32 mg/L. As shown in the table above, none of the other synthetic 
derivatives of ᴅ-(-)-ribose showed any anti-bacterial activity. 
P a g e  | 93 
 
Using the dilution series we prepared a standard dilution curve for each of the different 
synthetic compounds, against each of the different bacterial strains used in the assay (S. 
aureus strain ATCC 25923, B. cereus strain DL5, P. aeruginosa strain ATCC 27853 and E. 
coli strain ATCC 25922), which was then used to determine the MIC values given in Table 3 
above. The curve for the active compound, 5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-ᴅ-(-
)-ribose 102, is shown schematically in Graph 2. 
 
 
 
Graph 2 Standard  curve for 5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-ᴅ-(-)-ribose 102 
 
These MIC values are significantly higher than those obtained for the commercially available 
antibiotic ciprofloxacin 153, with MICs of 0.5 mg/L for S. aureus and 0.5 mg/L for B. cereus 
respectively. As such it is possible that the reduction in the number of metabolically active 
cells is due to toxic effects caused by the high concentration of compound in solution as 
opposed to the antibacterial activity of the compound itself.  
 
The antibacterial activity for the synthetic compounds was determined using the modified 
MIC determination assay, using TTC, as described above. The results of the TTC assay for 
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the pyrimidine based nucleosides, uridine 12 and cytidine 11, and their derivatives are shown 
below in Table 4. 
 
Table 4 MICs determined for the pyrimidine based nucleoside derivatives 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
Uridine 12 No activity No activity No activity No activity 
107 64 mg/L 32 mg/L No activity No activity 
123 No activity No activity No activity No activity 
124 No activity No activity No activity No activity 
126 No activity No activity No activity No activity 
127 No activity No activity No activity No activity 
128 No activity No activity No activity No activity 
130 No activity No activity No activity No activity 
131 No activity No activity No activity No activity 
     
Cytidine 11 No activity No activity No activity No activity 
133 No activity No activity No activity No activity 
134 No activity No activity No activity No activity 
 
The uridine 12 and cytidine 11 were used as negative controls for the assay as we anticipated 
no anti-bacterial activity to be observed by the un-modified nucleosides. As expected, no 
activity was recorded. From the entire range of pyrimidine based nucleoside derivatives, only 
one derivative showed marked anti-bacterial activity - the 5'-O-(tert-butyldiphenyl-
silyl)uridine 107.  
 
Using the dilution series we prepared a standard dilution curve for each of the different 
synthetic compounds, against each of the different bacterial strains used in the assay (S. 
aureus strain ATCC 25923, B. cereus strain DL5, P. aeruginosa strain ATCC 27853 and E. 
coli strain ATCC 25922), which was then used to determine the MIC values used in Table 4 
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above. The curve for the active compound, 5'-O-(tert-butyldiphenylsilyl)uridine 107, is shown 
schematically in Graph 3. 
 
 
 
Graph 3 Standard curve for 5'-O-(tert-butyldiphenylsilyl)uridine 107 
 
The 5'-O-(tert-butyldiphenylsilyl)uridine 107 was active against only the Gram-positive 
bacterial strains, with a MIC of 64 mg/L observed for S. aureus and a MIC of 32 mg/L 
observed for B. cereus. These MIC values are significantly higher than those obtained for the 
commercially available antibiotic ciprofloxacin 153, with MICs of 0.5 mg/L for S. aureus and 
0.5 mg/L for B. cereus, respectively.  
 
The antibacterial activity for the synthetic purine based nucleoside compounds were 
determined using the modified MIC assay, described in greater detail above. The results of the 
TTC assay for the purine based nucleosides, guanosine 9, inosine 116 and adenosine 8, and 
their derivatives are shown below in Table 5. 
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Table 5 MICs determined for the purine based nucleoside derivatives 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
Guanosine 9 No activity No activity No activity No activity 
112 No activity No activity No activity No activity 
113 No activity No activity No activity No activity 
114 No activity No activity No activity No activity 
     
Inosine 116 No activity No activity No activity No activity 
117 No activity No activity No activity No activity 
     
Adenosine 8 No activity No activity No activity No activity 
142 No activity No activity No activity No activity 
 
The guanosine 9, inosine 116 and adenosine 8 were included as negative controls for the 
assay as we expected no anti-bacterial activity to be observed in the un-modified nucleosides. 
As expected, no activity was recorded for the nucleosides on their own. Unfortunately, we 
also found that none of the synthetic derivatives showed any activity against our Gram-
positive and Gram-negative bacterial strains either. 
 
The antibacterial activity for the synthetic protecting group derivatives were determined using 
the modified MIC assay described above. The results of the TTC assay for the two protecting 
group derivatives are shown below in Table 6. 
 
Table 6 MICs determined for the protecting group derivatives 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
TBDPS-OH 145 128 mg/L 64 mg/L No activity No activity 
DMT-OH 147 No activity No activity No activity No activity 
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Using the dilution series we prepared a standard dilution curve for each of the different 
synthetic compounds, against each of the different bacterial strains used in the assay (S. 
aureus strain ATCC 25923, B. cereus strain DL5, P. aeruginosa strain ATCC 27853 and E. 
strain ATCC 25922), which was then used to determine the MIC values used in Table 6 
above. The curve for the active compound, tert-butyldiphenylsilanol 145 is given in Graph 4. 
 
 
 
Graph 4 Standard curve for tert-butyldiphenylsilanol 145 
 
The tert-butyldiphenylsilanol 145 was active against only the Gram-positive bacterial strains, 
with a MIC of 128 mg/L observed for S. aureus and a MIC of 64 mg/L observed for B. 
cereus. These MIC values are significantly higher than those obtained for the commercially 
available antibiotic ciprofloxacin 153, with MICs of 0.5 mg/L for S. aureus and 0.5 mg/L for 
B. cereus respectively. Unfortunately, the 4,4'-dimethoxytrityl alcohol 147 did not show any 
activity towards our test strains. 
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3.2.1.3 Discussion 
 
For our initial antibacterial screen we were looking at three main points: (i) to investigate 
which group of nucleoside derivatives gave the most promising results and could be used for 
further studies, (ii) to perform a mini structure-activity study in order to determine which 
positions on the molecule were important in order to maintain activity and (iii) to determine if 
the presence of the nucleoside structure was intrinsic for activity 
 
In order for us to adequately investigate which group of nucleoside derivatives gave the most 
promising results, we needed to compare the data obtained for each of our five different 
nucleoside groups. The comparison of the results obtained for the pyrimidine based 
nucleoside derivatives (uridine 12 and cytidine 11) as well as for the purine based nucleoside 
derivatives (guanosine 9, inosine 116 and adenosine 8) are shown in Table 7. 
 
Table 7 Comparison of data obtained from TTC assay for the five nucleoside groups 
Protecting 
Group 
Uridine 
 
Cytidine 
 
Guanosine 
 
Inosine 
 
Adenosine 
 
TBDPS (5'-O) 
 
Activity
* 
No Activity - - No Activity 
DMT (5'-O) 
 
 
Limited 
Activity
*** 
- No Activity
** 
No Activity - 
Bz (4-N) - No Activity - - - 
* MIC values for S. aureus = 64 mg/L and B. cereus = 32 mg/L, ** molecule protected at the 6-N position with a 
N,N-dimethylmethylimine group. 
***
 limited activity is the concentration with approximately 25 % metabolically 
active cells present, for B. cereus = 128 mg/L 
 
From our initial study of the five different nucleosides, we found that the nucleoside showing 
the most promising results was uridine 12. We thus concluded that it would be the nucleoside 
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of choice for subsequent anti-bacterial activity studies, which could not be conducted on all 
five nucleosides due to the time constraints of the project.  
 
Our second goal was to perform a mini structure-activity study in order to determine which 
positions on the molecule were important in order to maintain any antibacterial activity. This 
study was conducted specifically on a range of nucleoside derivatives synthesized from one 
purine nucleoside (guanosine 9) and one pyrimidine nucleoside (uridine 12). We chose to use 
uridine and guanosine specifically due to their ease of handling and less complex syntheses. 
During the initial study described in Table 7 above, we found that adenosine 8, cytidine 11 
and inosine 116 were in general more difficult to handle and less reactive when using our 
chosen protecting groups.  
 
For the mini structure-activity study, we synthesized a range of protected derivatives by doing 
step-wise protection reactions. The results obtained for the anti-bacterial assay performed on 
these compounds are summarized in Table 8. 
 
Table 8 Comparison of MIC results obtained from the structure-activity study 
Nucleoside 5'-OH 2'-OH / 3'-OH 3-N(-NH) or 6-N(-NH2) Results 
Uridine TBDPS   64 mg/L (S. aureus) 
32 mg/L (B. cereus) 
 TBDPS Ac / Ac  Limited Activity
* 
 TBDPS Ac / Ac Bz No Activity 
 
 DMT   No Activity 
 DMT Ac / Ac  No Activity 
 DMT Ac/ Ac Bz No Activity 
 
 Ac Ac / Ac  No Activity 
 Ac Ac / Ac Bz No Activity 
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Nucleoside 5'-OH 2'-OH / 3'-OH 3-N(-NH) or 6-N(-NH2) Results 
Guanosine   DMMI
** 
No Activity 
 DMT  DMMI
**
 No Activity 
 DMT All / All DMMI
**
 No Activity 
*
 Limited Activity = concentration with approximately 50 % metabolically active cells present, 128 mg/L for S. 
aureus and 128 mg/L for B. cereus, 
**
 DMMI = N,N-dimethylmethylimine 
 
For uridine, protection of the primary alcohol with the TBDPS group gives a compound 107 
which exhibits Gram-positive anti-bacterial activity at high concentrations (MIC values of 64-
128 mg/L). The subsequent protection of the secondary alcohols with the acetyl protecting 
groups yields a compound 123 that has limited anti-bacterial activity against Gram-positive 
bacteria (with a MIC outside the range tested, ie:  >128 mg/L), but which shows 
approximately a 50 % reduction in the number of metabolically active cells present after 
treatment with the compound at a concentration of 128 mg/L. Finally, we see that when the 
amide nitrogen is protected with the benzoyl group to give compound 124, no anti-bacterial 
activity is observed whatsoever.  
 
This allowed us to conclude that the best position for performing changes to our nucleosides 
was at the 5'-OH position on the sugar ring. We also deducted that loss of either or both of the 
secondary alcohols (2'-OH and 3'-OH) lead to a reduction in activity of the compounds. From 
this we decided that the differences in the activity of the compounds, when protected at either 
the 2'-OH or the 3'-OH positions, would need to be further investigated at a later stage.  
 
Protection of the free amine and amide positions on the base seemed to eliminate all activity 
in the synthetic molecules. Due to the small sample size, however, we felt that it was too soon 
to conclude that all future nucleoside derivatives needed to have free sites on the base and as 
such felt that it was pertinent to investigate this further.  
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As shown in Table 8 above, uridine 12 again gives the more promising results for the 
antibacterial assay, which supports our previous conclusion that it is the nucleoside of choice 
for use in further assays.  
 
For the third point, we compared the results obtained for the ᴅ-(-)-ribose derivatives with the 
corresponding uridine derivatives. As expected for our negative controls, ᴅ-(-)-ribose 100, 1'-
O-methoxyribose 101 and uridine 12, no antibacterial activity was observed. In fact, for both 
ᴅ-(-)-ribose 100 and 1'-O-methoxyribose 101, we observed an increase in the number of 
metabolically active cells for both of the Gram-positive strains when compared to our 100 % 
growth control. We believe that this may be due to the possibility that the bacteria are using 
the sugar as a food source and it is thus increasing their growth rate. 
 
The comparison of our results obtained for the ᴅ-(-)-ribose derivatives with the 
corresponding uridine derivatives are outlined in Table 9 on the following page. Where 
applicable, MIC values are given as the lowest concentration of synthetic compound that 
shows less than 10 % of the bacterial cells having metabolic activity. 
 
As expected, the limited activity observed with 2',3'-O-diacetyl-5'-O-(tert-
butyldiphenylsilyl)uridine 123 and 5'-O-(4,4'-dimethoxytrityl)uridine 126 were not mirrored 
in the corresponding ᴅ-(-)-ribose derivatives. This suggested that the bases on the nucleoside 
derivatives were necessary for molecular recognition to aid transportation within the cells. 
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Table 9 Comparison of data obtained from TTC assay for the ᴅ-(-)-ribose and uridine 
derivatives 
Starting Material 5'-OH 2'-OH / 3'-OH Results 
1'-O-Methoxyribose TBDPS  64 mg/L (S. aureus) 
32 mg/L (B. cereus) 
Uridine 
 
TBDPS  64 mg/L (S. aureus) 
32 mg/L (B. cereus) 
 
1'-O-Methoxyribose TBDPS Ac / Ac No Activity 
Uridine 
 
TBDPS Ac / Ac Limited Activity
*
 
(128 mg/L S. aureus) 
(128 mg/L B. cereus) 
  
1'-O-Methoxyribose TBDPS All / All No Activity 
Uridine 
 
TBDPS All / All - 
1'-O-Methoxyribose DMT  No Activity 
Uridine 
 
DMT  Limited Activity
**
 
(128 mg/L B. cereus) 
 
1'-O-Methoxyribose DMT Ac / Ac No Activity 
Uridine 
 
DMT Ac / Ac No Activity 
1'-O-Methoxyribose Ac Ac / Ac No Activity 
Uridine Ac Ac / Ac No Activity 
*
 concentration with approximately 50 % metabolically active cells present, 
**
 concentration with approximately 
25 % metabolically active cells present 
 
Surprisingly, we found that the 5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-ᴅ-(-)-ribose 102 
had the same activity against the Gram-positive bacteria as the 5'-O-(tert-
butyldiphenylsilyl)uridine 107 at concentrations of synthetic compound between 32 and 64 
mg/L. Initially we could not explain this finding, as our other research suggested that the 
presence of the nucleoside base was intrinsic for activity. But upon closer investigation, we 
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were able to conclude that the activity observed in both of these cases could be due to the 
hydrolysis of the compounds under biological conditions to yield the free tert-
butyldiphenylsilanol 145.  
 
The protecting group derivatives were subsequently assayed to determine if they had any 
biological activity. As suspected, we found that tert-butyldiphenylsilanol 145 was active 
against the Gram-positive bacteria. We determined that the TBDPS-OH had a MIC value of 
128 mg/L for S. aureus and a MIC value of 64 mg/L for B. cereus. We believe that these 
values are a factor higher than those obtained for 5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-
ᴅ-(-)-ribose 102 and 5'-O-(tert-butyldiphenylsilyl)uridine 107 because the sugar and 
nucleoside molecules are recognized by the bacterial cells and are thus transported into the 
cells more efficiently. 
 
Note that all graphs derived from raw spectrophotometric data used to determine the MIC 
values given in this section have been included on the attached DVD, under Supporting 
Information for Biological Testing (Part 1). 
 
3.2.1.4 Conclusions 
 
From the data reported above, one can conclude that the nucleoside showing the most 
promising results was uridine 12 and as such it would be the nucleoside of choice for our 
subsequent antibacterial activity studies. Our mini structure-activity study on the uridine 
derivatives found that the best position for performing modifications to our nucleosides was at 
the 5'-OH position on the sugar ring and a loss of both of the secondary alcohols (2'-OH and 
3'-OH) and/or the primary amide on the base lead to a reduction in activity of the compounds. 
Lastly, the comparison of ᴅ-(-)-ribose derivatives to the uridine derivatives suggested that the 
bases on the nucleoside derivatives were necessary for molecular recognition to aid 
transportation within the cells.  
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All these conclusions were taken into account when designing the synthesis for our second 
generation of compounds. The synthesis of the second generation compounds are discussed in 
detail in Part 2, Chapter 5 and the results obtained for the anti-bacterial assay are discussed 
in Part 2, Chapter 6. Further studies to determine a possible mode of action for our positive 
hits (from both the first generation and the second generation of synthetic compounds) were 
conducted, and include analysis of the cells by confocal microscopy and SEM. All of the 
results are presented together in Chapter 6, along with our final conclusions for the anti-
bacterial assays. 
 
3.2.2 Antiviral Assays 
 
The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanilide (XTT) assay 
has been used to screen plant extracts, synthetic proteins and synthetic compounds for anti-
HIV activity. The test requires cell culture conditions for the growth of an MT-4 suspension 
cell line and HTLVIIIB virus. The interaction of the cells, virus and potential anti-HIV agent is 
measured by cell viability using the tetrazolium (XTT) salt. Spectrophotometric measurement 
of the yellow salt converting to an orange formazan is indicative of cell viability. The XTT 
assay is a modification of the original MTT assay and the protocol is reviewed by De Clerq.
61 
 
3.2.2.1 Materials and Methods 
 
 Cell Line and  HIV strain 
 
Cell Line:  MT-4 cells (human T-cell leukemia cell line)  Virus:  HTLVIIIB 
 
The uninfected cells and the HTLVIIIB infected continuous H9 cells were obtained from the 
National Institutes of Health AIDS Research and Reference Reagent Program (Bethesda, 
USA) and were used for the assay. 
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 Compounds Used in Assay 
 
N
6
N7a
3a
2
N
NH2
N
3' 2'
1'
O
4'
OHOH
5'OSi
1*
2*
3*
4*
142
5
6
N
NH2
ON
3' 2'
1'
O
4'
OHOH
5'O
134
Si
1*
2*
3*
4*
5
6
NH
O
ON
3' 2'
1'
O
4'
OHOH
5'OSi
1*
2*
3*
4*
107
5
6
NH
O
ON
3' 2'
1'
O
4'
OO
5'OSi
1*
2*
3*
4*
123
OO
5
6
N
O
ON
3' 2'
1'
O
4'
OO
5'OSi
1*
2*
3*
4*
124
OO
5*
O
8*
7*
6*
Si
1
OH
2
3
4
145
NH
6
N7a
3a
2
N
O
NN
3' 2'
1'
O
4'
OHOH
5'O N
1*
5*
6*7*
8*
2*
3*
4*
OMe
OMe
113
NH
6
N7a
3a
2
N
O
N
3' 2'
1'
O
4'
OHOH
5'O
1*
5*
6*7*
8*
2*
3*
4*
OMe
OMe
117
5
6
NH
O
ON
3' 2'
1'
O
4'
OHOH
5'O
1*5*
2*
3*
4*
126
6*7*
8*
OMe
OMe
5
1
OH
2
3
4
67
8
OMe
OMe
147  
Figure 31 Synthetic compounds used in the assay  
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The compounds used in this study were prepared using standard synthetic organic chemistry 
techniques. A full discussion of the synthetic results obtained is given in Chapter 2 and the 
detailed experimental procedures used are outlined in Appendix B. For ease of reading, the 
compounds tested using the XTT assay are grouped according to structural similarities and are 
illustrated above. Figure 31 shows the ten compounds selected for use in this assay. 
  
 Evaluation of Compound Efficacy 
 
The XTT assay is based on the bioreduction of the XTT salt (2,3-bis-[2-methoxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) yielding an orange formazan. 
Bioreduction is enhanced by the presence of an electron coupling agent such as phenazine 
methosulfate (PMS). Formazan production is indicative of the number of viable cells, 
therefore an increase or decrease in cellular viability results in a change in the amount of 
formazan formed, which indicates the degree of cytotoxicity caused by the test compound. 
 
The synthetic compounds were weighed out in 50 mg portions and were then diluted with the 
solvent for the study, in this case DMSO, to obtain a 1000 µL solution. Ten fold dilutions 
were prepared for each compound solution as: 1 / 10, 1 / 100, 1 / 1000 and 1 / 10 000 
dilutions, with the tissue culture medium RPMI-1640 being used as the diluent.  
 
Included in each assay were a number of standard controls: 
 (i)  AZT 29 was included as a positive control for the assay 
 (ii)  Lopinavir 154 was included as a positive control for the assay 
 (iii)  a cell suspension made up in RPMI-1640 medium was used as the untreated 
  (negative) control for the assay 
 (iii)  DMSO controls were included to confirm that the solvents did not affect the 
  results obtained from the assay 
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and each synthetic compound was tested in triplicate as well. The structures for the positive 
controls are shown in Figure 32. 
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O
N
H
O
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O
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O
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Figure 32 Compounds used as positive controls
§
 
 
The in vitro XTT based Toxicology Assay Kit (Sigma-Aldrich), which contains XTT + 1 % 
PMS in 5 mg vials, was used for the assay. The XTT / PMS reagent mixture was prepared 
according to the manufacturer's instructions. The assay was performed according to the 
standard procedures outlined by Scudiero and co-workers
62
, Weislow and co-workers
63
 and 
Cos and co-workers
64
, with modifications as described herein.  
 
Cell counts were performed and uninfected cells were prepared for use in the XTT assay as 
follows: 
 a cell count was performed on exponentially growing MT-4 cells  
 these were diluted using colourless RPMI-1640 to obtain a solution containing 6 × 105 
cells/mL 
 500 µL of the cell suspension, at the final cell concentration required, was added to 
each of the 1000 µL Eppendorf tubes.  
 the tubes were then centrifuged at 1000 rpm for 5 minutes 
                                                          
§
 The two positive controls were chosen based on their structural differences: AZT 29 is a derivative of 5-
methyluridine, whereas Lopinavir 154 is structurally dissimilar as it does not contain a nucleoside or sugar motif 
in the structure. 
P a g e  | 108 
 
 the supernatant was then discarded and 500 µL of the appropriate concentration of 
either the synthetic compound or positive control compound dilutions was added to 
the pellet 
 the tubes were then vortexed gently to reconstitute the cells 
 150 µL of the cell suspension was then added to the wells of the plates 
 this was all performed in triplicate. 
 
The infected cells were prepared using a similar procedure to that described above, with the 
only difference being that: 
 the virus was thawed and dilutions were performed with RPMI to obtain 100-300 
TCID50 
 50 µL of the diluted virus was added to wells containing 100 µL of the initial cell 
suspension, which had been diluted to 6 × 10
5
 cells/mL 
 
The plates containing the cells and the compound dilution series were then incubated at 37 
o
C 
with 5 % CO2 for 5 days. The plates were read at 450 nm, with a reference wavelength of 620 
nm using the Tecan Sunrise ELISA plate reader and Magellan
™
 software, before the addition 
of the XTT dye. 
 
After the incubation time, 20 µL of the XTT / PMS reagent mixture was added to each well of 
the plates and the plates were further incubated at 37 
o
C with 5 % CO2 for 4 hours. The plates 
were again read at 450 nm, with a reference wavelength of 620 nm using the Tecan Sunrise 
ELISA plate reader and Magellan
™
 software.  
 
 Data Analysis 
 
The percentage protection was determined using the recorded absorbance values obtained 
from reading the plates on the Tecan Sunrise ELISA plate reader. The equations outlining 
P a g e  | 109 
 
how the percentage protection was determined are based on those published by Cos and co-
workers
64
 and are described in detail in Appendix D (Section D.6). The results obtained 
using this methodology are represented graphically in the results and discussions, Section 
3.2.2.2 and Section 3.2.2.3. 
 
3.2.2.2 Results 
 
The two control compounds chosen for the study were AZT 29 and Lopinavir 154 (structures 
are given in Figure 32). These known antiviral drugs were chosen in order to confirm that the 
protocol was working correctly and allowed us to correlate our results to those obtained using 
similar procedures and importantly for our study, included examples of both a nucleoside and 
a non-nucleoside based reverse transcriptase inhibitor. The AZT 29 tested demonstrated the 
expected antiviral activity when compared to data reported by Weislow and co-workers
63
 and 
De Clerq and co-workers
65
 The results provided to us are presented graphically in Graph 5. 
 
 
 
Graph 5 Results obtained for control compound: AZT 29 
  
(mM) 
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The Lopinavir 154 tested also demonstrated the expected antiviral activity and was found to 
correlate well to data reported by Kempf and co-workers.
66
 The results we were provided with 
are shown graphically in Graph 6. 
 
 
 
Graph 6 Results obtained for control compound: Lopinavir 154 
 
Shown in Figure 31 are the ten compounds that were tested using the XTT assay. We only 
selected ten compounds from our range of first generation compounds for the assay due to the 
large costs involved in this assay. These ten compounds were chosen in such a way as to be 
representative of the different classes of compounds synthesized. We envisioned that we 
could use these ten compounds for a general screen for HIV activity, with positive results then 
directing us as to which groups of compounds would warrant further investigation, thus 
allowing us to minimize the expense of testing for HIV activity. 
 
The results obtained for the XTT assay are summarized in Table 10 and include a description 
of the compounds as demonstrating either a antiviral effect or a toxic effect towards the 
uninfected cells. All of the data used for determining these values are given in detail on the 
graphs shown in Section 3.2.2.3 and are included on the attached DVD, under Supporting 
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Information. All of the equations used to calculate CC50, EC50 and SI values are described in 
Appendix D (Section D.6). 
  
Table 10 Summary of results obtained from the XTT assay 
Compound Antiviral Effect
* 
EC50 Toxic Effect CC50  SI (CC/EC) 
142 No Cannot be 
calculated 
Yes 0.345 mM Cannot be 
calculated 
134 
 
No Cannot be 
calculated 
Yes 3.33 mM Cannot be 
calculated 
107 
 
No Cannot be 
calculated 
Yes 23.4 mM Cannot be 
calculated 
123 
 
No Cannot be 
calculated 
Yes 23.1 mM Cannot be 
calculated 
124 
 
No Cannot be 
calculated 
Yes 0.191 mM Cannot be 
calculated 
145 
 
No Cannot be 
calculated 
Yes 1.47 mM Cannot be 
calculated 
113 
 
No Cannot be 
calculated 
Yes 5.91 mM Cannot be 
calculated 
117 
 
No Cannot be 
calculated 
Yes 0.0380 mM Cannot be 
calculated 
126 
 
No Cannot be 
calculated 
Yes 1.33 mM Cannot be 
calculated 
147 
 
No Cannot be 
calculated 
Yes 13.7 mM Cannot be 
calculated 
*
 Antiviral effect is defined as ≥ 50 % protection, GENERAL NOTE: EC50 and SI (CC/EC) values for the table 
above could not be calculated as no antiviral effect was observed 
 
Unfortunately, none of the compounds tested using the XTT assay showed any antiviral effect 
against HIV. As such, we decided not to invest any further time or money in the exhaustive 
testing of all of our first generation compounds which we had synthesized in Chapter 2.   
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We did, however, obtain some interesting results from this study, in that a large proportion of 
the synthetic compounds showed toxicity towards the uninfected MT-4 cells. These 
interesting results obtained are discussed fully in Section 3.2.2.3. 
 
3.2.2.3 Discussion 
 
Through testing this range of ten compounds (shown in Figure 31) we aimed to compare: 
 (i)   the five different nucleosides we used for activity 
 (ii)  our tert-butyldiphenylsilyl protecting group derivatives with the 4,4'-  
  dimethoxytrityl group derivatives 
 (iii)  sequentially protected derivatives as a mini structure-activity assay 
 (iv) the results obtained for the nucleoside derivatives with the protecting group 
  controls 
  
To satisfy our first two aims, we initially compared the TBDPS-protected purine nucleoside, 
5'-O-(tert-butyldiphenylsilyl)adenosine 142, with the pyrimidine nucleosides, 5'-O-(tert-
butyldiphenylsilyl)cytidine 134 and 5'-O-(tert-butyldiphenylsilyl)uridine 107. We observed 
that none of the TBDPS-protected compounds showed any antiviral activity at all and 
essentially gave 0 % protection against the virus. Interestingly, however, we did observe that 
5'-O-(tert-butyldiphenylsilyl)adenosine 142 showed marked toxicity against the healthy, 
uninfected MT-4 cells, with a CC50 value of 0.345 mM (345 µM) obtained from the study. 
This is shown by the gradual decrease in the percentage of uninfected cells present at 
concentrations of the compound above 79 µM in Graph 7. 
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Graph 7 Results obtained from XTT assay for 5'-O-(tert-butyldiphenylsilyl)adenosine 142, 
where B = blank and has none of the test compound added 
 
After looking at the TBDPS-protected derivatives, we compared the DMT-protected purine 
nucleosides, 5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)guanosine 113 and 
5'-O-(4,4'-dimethoxytrityl)inosine 117, with the pyrimidine nucleoside, 5'-O-(4,4'-
dimethoxytrityl)uridine 126. We again found that none of the compounds exhibited any of the 
desired antiviral activity and concluded that DMT-protected nucleoside derivatives offered 0 
% protection against the HIVIIIB virus. 
 
Surprisingly, we again noted that the compounds exhibited toxicity towards the uninfected 
MT-4 cells. As shown on Graph 8 and Graph 9, we found that 5'-O-(4,4'-
dimethoxytrityl)inosine 117 and 5'-O-(4,4'-dimethoxytrityl)uridine 126 gave CC50 values of 
0.0380 mM (38.0 µM) and 1.33 mM (1331 µM) respectively. 
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Graph 8 Results obtained from XTT assay for 5'-O-(4,4'-dimethoxytrityl)inosine 117, where 
B = blank and has none of the test compound added 
 
 
 
Graph 9 Results obtained from XTT assay for 5'-O-(4,4'-dimethoxytrityl)uridine 126, where 
B = blank and has none of the test compound added 
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To satisfy our second aim, wherein we wanted to compare sequentially protected derivatives 
as a mini structure-activity assay, we tested: 
 5'-O-(tert-butyldiphenylsilyl)uridine 107 
 2',3'-O-acetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 
 3-N-benzoyl-2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 124 
 
 
 
Graph 10 Results obtained from XTT assay for 3-N-benzoyl-2',3'-O-diacetyl-5'-O-(tert-
butyldiphenylsilyl)uridine 124, where B = blank and has none of the test compound added 
 
Unfortunately, we found that none of the compounds exhibited the desired antiviral activity 
and as such we could not compare which positions on the molecule were essential for activity. 
But the mini-study was not in vain, as we again observed toxicity towards the uninfected MT-
4 cells. In this case we observed that:  
 107, which is protected only on the primary alcohol, has a calculated CC50 value of 
23.4 mM 
 123, which is protected on both the primary and secondary alcohols, has a calculated 
CC50 value of 23.1 mM 
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 124, which is fully protected on the primary and secondary alcohols as well as the 
secondary amide, has a calculated CC50 value of 0.191 mM (shown in Graph 10) 
 
These results were quite interesting – in this case compound 124, which was the most 
lipophillic of the molecules studied (and would therefore have a higher probability of crossing 
the cellular membranes), was actually found to be the most toxic of the compounds in the 
series. Suggesting that high lipophilicity and toxicity are intrinsically linked for these types of 
nucleoside derivatives. 
 
Our final aim was to compare the results obtained for the nucleoside derivatives with those for 
the protecting group derivative controls. These were included in order to determine whether 
the nucleoside derivatives themselves were required for activity, and, if under biological 
conditions the compounds were hydrolysed, i.e.: whether the protecting group derivatives 
themselves were active.  
 
As expected, neither of the protecting group derivatives tested exhibited any antiviral activity. 
But we again noted interesting results concerning the toxicity of the molecules towards the 
uninfected MT-4 cells. From the data obtained, we calculated that the tert-
butyldiphenylsilanol 145 had a CC50 value of 1.47 mM and that the 4,4'-dimethoxytrityl 
alcohol 147  had a CC50 value of 13.7 mM. Graph 11 shows the data obtained for tert-
butyldiphenylsilanol 145. 
 
The CC50 value of 1.47 mM for the tert-butyldiphenylsilanol 145 was considerably higher 
than that obtained for 5'-O-(tert-butyldiphenylsilyl)adenosine 142 of 0.345 mM, but 
significantly less than those obtained for 5'-O-(tert-butyldiphenylsilyl)cytidine 134 (3.33 mM) 
and 5'-O-(tert-butyldiphenylsilyl)uridine 107 (23.4 mM). Due to the vast spread of data 
obtained, no specific conclusion could be deduced and we feel that this problem would need 
to be further investigated.  
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Graph 11 Results obtained from XTT assay tert-butyldiphenylsilanol 145 and where B = 
blank and has none of the test compound added 
 
In a similar manner, the results obtained for the 4,4'-dimethoxytrityl alcohol 147  (CC50 of 
13.7 mM) were compared to those obtained for 5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-
dimethylmethylimine)guanosine 113 (CC50 of 5.91 mM), 5'-O-(4,4'-dimethoxytrityl)inosine 
117 (CC50 of 0.0380 mM) and 5'-O-(4,4'-dimethoxytrityl)uridine 126 (CC50 of 1.33 mM). In 
this case however, the result obtained for the 4,4'-dimethoxytrityl alcohol 147 was always 
significantly higher than those obtained for the nucleoside derivatives. As such, we deducted 
that the nucleoside was necessary for the toxic activity observed and that the hydrolysis 
product on its own was not highly toxic towards uninfected MT-4 cells. 
 
All graphs used to determine the CC50 values given in this section have been included on the 
attached DVD, under Supporting Information. 
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3.2.2.4 Conclusions 
 
We found that none of the range of synthetic nucleoside and protecting group derivatives 
assayed showed any antiviral activity towards HIVIIIB. However, we did observe that a large 
number of the compounds were toxic towards the uninfected MT-4 cells (human T-cell 
leukemia cell line) at millimolar levels. This was quite unexpected and we believed that it 
suggested that our synthetic compounds may be toxic towards specifically cancerous cells. 
This possibility would, however, need to be fully investigated and as such we decided to 
deviate from our initial aims of screening our synthetic derivatives for anti-bacterial and 
antiviral activity, to instead focus on the subsequent screening of all of the "first generation" 
compounds for possible anticancer activity. The results of this exhaustive study are discussed 
in the following sections. 
 
3.2.3 Inhibition of Cell Proliferation 
 
The MTT colorimetric assay was used to determine the cytotoxic activity of the synthetic 
compounds and controls after a 24 hour exposure period to the different cell lines. The MTT 
assay is similar to the TTC assay used to determine anti-bacterial activity and the XTT assay 
used to determine anti-HIV activity, as they are all based on the same principle, that 
tetrazolium structures are bioreduced to formazan structures in metabolically active cells. As 
such, only a very broad description of the methodology used is given in Section 3.2.3.1. 
 
Compounds exhibiting positive results in the MTT assay were then subjected to subsequent 
testing: (i) an Annexin V flow cytometry assay was used to determine whether apoptosis or 
cell necrosis was induced, (ii) both Caspase-3/CPP32 and Caspase-8 colorimetric assays were 
performed to determine caspase expression and (iii) cytochrome c fractions in the 
mitochondrial and cytoplasmic fractions were determined by the enzyme immunometric 
assay.  
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3.2.3.1 Materials and Methods  
 
 Cell Lines 
 
For this assay, five cell lines were used, of which three were suspension lines and two were 
adherent lines. The suspension lines used were: HL-60, K-562 and Jurkat cells, while the 
adherent lines used were HT-29 and Caco-2 cells. White blood cells (WBC) were also 
included in the assay as a control to confirm if the compounds were inhibiting the growth of 
healthy, non-cancerous cells. 
 
The HL-60 suspension cell line is a human leukemic cell line derived from a 36 year old 
woman with acute promyelocytic leukemia at the National Cancer Institute.
67
 It has been 
widely used for laboratory research on how certain kinds of blood cells are formed. The HL-
60 cultured cell line provides a continuous source of human cells for studying the molecular 
events of myeloid differentiation and the effects of physiologic, pharmacologic and virologic 
elements on this process.
68 
 
The Jurkat cell line was established in the late 1970s from the peripheral blood of a 14 year 
old boy with T cell leukemia.
69
 Jurkat cells are an immortalized line of T lymphocyte cells 
that are used to study acute T cell leukemia, T cell signaling and the expression of various 
chemokine receptors susceptible to viral entry.
70
 Jurkat cells are also useful in science because 
of their ability to produce interleukin 2.
70
 The primary use, however, is to determine the 
mechanism of differential susceptibility of cancers to drugs and radiation. 
 
K-562 were the first human immortalized myelogenous leukemia line to be established.
71
 K-
562 cells are non-adherent and of the erythroleukemia type. The line was derived from a 53 
year old female chronic myeloid leukemia (CML) patient in blast crisis.
72
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The HT-29 cell line is an adherent human colorectal adenocarcinoma cell line. HT-29 cells 
are human intestinal epithelial cells.  
 
Caco-2 is an immortalized line of heterogeneous human epithelial colorectal adenocarcinoma 
cells, developed by the Sloan-Kettering Institute for Cancer Research.
73
 The adherent Caco-2 
cell line is widely used with in vitro assays to predict the absorption rate of candidate drug 
compounds across the intestinal epithelial cell barrier.
74
 Caco-2 may also refer to a cell 
monolayer absorption model, where cell-based functional assays may be used as a model for 
assessing intestinal transport of lead compounds in drug discovery.
75 
 
All of the cell lines used in the study were routinely maintained in Dulbecco's Modified 
Eagles Medium supplemented with 5 % heat-inactiviated foetal bovine serum. The cell lines 
were maintained in 75 cm
3
 flasks at 37 
o
C in a 95 % O2 : 5 % CO2 humidified incubator using 
standard culture techniques.  
 
Fresh human white blood cells were isolated according to the Versagene DNA Purification 
Kit standard protocol provided by the supplier. 
 
 Compounds Used in the Inhibition of Cell Proliferation Study 
 
Seventeen of the range of compounds synthesized in Chapter 2 were selected for use in this 
study to encompass derivatives of all five of the different nucleosides and ᴅ-(-)-ribose. 
Compounds used in this study have been re-drawn and grouped according to their structural 
similarities for ease of reading. Figure 33 shows the pyrimidine-based nucleoside derivatives, 
Figure 34 shows the purine-based nucleoside derivatives and Figure 35 shows the derivatives 
of ᴅ-(-)-ribose. 
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Also included in the study were the protecting group derivatives, to act as a control to indicate 
if the protecting group portion of the molecule is causing any observed activity. The 
unmodified nucleosides and ᴅ-(-)-ribose were included as negative controls for the study. 
Camptothecin 155 was included as our positive control as it is a well researched anticancer 
agent. The structures for the control compounds are shown in Figure 36. 
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 Evaluation of Compound Efficacy using the MTT Assay for Cell Viability 
Quantification 
 
The cells used, HL-60, K-562, HT-29, Caco-2 and white blood cells, were counted and 
diluted into fresh media (Dulbecco's Modified Eagles Medium supplemented with 5 % heat-
inactiviated foetal bovine serum) at concentrations of 30 000 cells/well. An aliquot of 180 µL 
was seeded into each well of a 96-well plate. The plates were then placed in an incubator (37 
o
C, 5 % CO2, volume fraction) and the cells were allowed to divide for a period of 24 h.  
 
The cells were exposed to the different classes of synthetic compounds and controls described 
above, with a final concentration of 100 µg/mL in the wells. The 96-well plates were then 
incubated at 37 
o
C for an additional 24 hours to allow the cells to interact with the synthetic 
compounds. After the 24 hour incubation period, the plates were removed from the incubator 
and an aliquot of 50 µL of a 0.5 % 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) in 1 mM phosphate buffered saline (PBS) at pH 7.4, was layered onto the 
media. The plates were again incubated at 37 
o
C for another 2 hours. 
 
After this time, the plates were then centrifuged at 3000 rpm (Afrox Sorvall T 6000D) for 5 
minutes. Following centrifugation, the medium was very carefully aspirated and the formazan 
precipitate obtained was dissolved in 200 µL DMSO. The absorbance was then read at 540 
nm using the Absorbance Labsystems Multiskan MS, version 2.4. 
 
The controls used in the assay consisted of:  
 (i) medium alone without cells giving the 0 % growth control  
 (ii) cells and medium with no test compound added, giving the 100 % growth control 
 (ii) cells and medium with camptothecin 155 added 
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Compounds showing cytotoxicity at a concentration of 100 µg/mL were further diluted in ten-
fold dilutions to obtain the IC50 concentrations. All tests were performed in triplicate. 
 
 Other Assays Conducted 
 
Only compounds exhibiting positive results in the MTT assay were subjected to subsequent 
testing. An Annexin V flow cytometry kit was used to determine whether apoptosis or cell 
necrosis was induced. Caspase-3/CPP32 and Caspase-8 colorimetric assay kits were used to 
determine caspase expression. Cytochrome c fractions in the mitochondrial and cytoplasmic 
fractions were determined by the Enzyme Immunometric Assay (EIA) kit. No further details 
will be provided on the methodology used in these assays, as all protocols were performed 
according to standard instructions provided by the manufacturer's of the kits. 
 
 Data Analysis 
 
The results from the MTT assay are expressed as the concentration of synthetic compound 
required to give a 50 % inhibition (IC50). The Enzfitter and Prism3 programs were used to 
determine the IC50 values for the test compounds. 
 
3.2.3.2 Results of MTT Assay 
 
The assay for inhibition of cell proliferation was broken down into two groups based on the 
type of cells investigated. The initial investigation involved the use of three suspension cell 
lines, HL-60, K-562 and Jurkat cells, with the results obtained compared to those for white 
blood cells (WBC), i.e.: healthy, non-cancerous cells. 
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The positive control used in this assay was the commercial compound camptothecin 155. As 
expected, camptothecin 155 showed inhibition of proliferation for all of the suspension cell 
lines. Surprisingly, however, there was quite a low cell viability for the white blood cells - 
highlighting the toxicity of camptothecin 155 towards healthy, non-cancerous cells. The 
results obtained are given in Table 11.  
 
Table 11 Percentage cell viability of the suspension cell lines when treated with 100 µM 
camptothecin for 24 hours 
Compound HL-60 Jurkat K-562 WBC 
Camptothecin 
155 
23.359 ± 
0.721 % 
8.889 ± 
0.694 % 
39.623 ± 
0.933 % 
34.622 ± 
2.028  % 
 
The pyrimidine-based nucleosides, uridine 12 and cytidine 11, were included as negative 
controls for the assay, as we did not expect them to inhibit the growth of the suspension cell 
lines. The results obtained for the assay of the pyrimidine-based nucleoside derivatives are 
given in detail in Table 12 below. 
 
We observed that 5'-O-(tert-butyldiphenylsilyl)uridine 107 exhibited cytotoxic activity 
towards the suspension cell lines, with the percentage of viable cancer cells between 5 -10 % 
after treatment with 100 µM of the synthetic compound for 24 hours. This shows significantly 
more activity than the positive control, camptothecin 155, which had 9-40 % viable cells 
remaining after the corresponding treatment. Interestingly, we noted that the synthetic 
compound, 5'-O-(tert-butyldiphenylsilyl)uridine 107 had  61.460 ± 4.481 % of the white 
blood cells viable, in comparison to the meagre 34.622 ± 2.028  % viable after treatment with 
the camptothecin 155. This suggests that 5'-O-(tert-butyldiphenylsilyl)uridine 107 shows a 
degree of selective toxicity against the cancer lines with minimal cytotoxicity directed against 
the white blood cells.  
 
The 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 which is protected on the 
secondary alcohols as well as the primary alcohol, showed considerably lower activity than 
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that for the 5'-O-(tert-butyldiphenylsilyl)uridine 107 which is only protected on the primary 
alcohol. For the HL-60 cell line, the percentage of viable cells increased from 5.619 ± 0.348 
% for 5'-O-(tert-butyldiphenylsilyl)uridine 107 to 11.180 ± 0.525 % for 2',3'-O-diacetyl-5'-O-
(tert-butyldiphenylsilyl)uridine 123. In a similar manner, the percentage viable cells increased 
from 6.333 ± 0.601 % to > 50 % (ie: the compound is not active) in the Jurkat cell line, and 
from 9.355 ± 0.108 % to 35.530 ± 2.364 % in the K-562 cell line. This suggests that 
increasing the number of free hydroxyls on the molecules, by protecting the secondary 
alcohols, decreases the activity of the synthetic compounds towards the suspension cell lines. 
What was startling for us, was the discovery that the 2',3'-O-diacetyl-5'-O-(tert-
butyldiphenylsilyl)uridine 123 was able to have activity towards the cancer cell lines, and yet 
to allow all (100.774 ± 2.402 %) of the white blood cells to remain viable after treatment, thus 
showing truly selective toxicity towards the cancer cell lines. 
 
We noted that the 5'-O-(tert-butyldiphenylsilyl)cytidine 134 exhibited cytotoxic activity 
towards the suspension cell lines, with the percentage of viable cells remaining after treatment 
between 16-36 % and the white blood cells at 101.893 ± 2.027 %. These values are 
considerably lower than those obtained for 5'-O-(tert-butyldiphenylsilyl)uridine 107 and 
suggest that uridine is the better target for the further development of lead compounds. 
 
In a similar manner, we observed that the 5'-O-(4,4'-dimethoxytrityl)uridine 126 showed 
selective toxicity towards the cancer cell lines. With a percentage cell viability of 5-9 % 
observed for the suspension cell lines and 82.687 ± 2.088 % observed for the white blood 
cells after treatment for 24 hours with 100 µM of the test compound. As previously noted, the 
activity was significantly reduced when the secondary alcohols were protected. We observed 
that 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine 127 was not active against any of the 
suspension cell lines. 
 
Interestingly, none of the synthetic compounds that were prepared without the tert-
butyldiphenylsilyl or 4,4'-dimethoxytrityl protecting groups showed any activity towards the 
suspension cell lines.  
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Table 12 Percentage cell viability of the suspension cell lines when treated with 100 µM of 
the pyrimidine nucleosides and their derivatives for 24 hours 
Compound HL-60 Jurkat K-562 WBC 
Uridine 
12 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
107 5.619 ±  
0.348 % 
6.333 ±  
0.601 % 
9.355 ±  
0.108 % 
61.460 ±  
4.481 % 
 
123 11.180 ±  
0.525 % 
Compound  
Not Active 
35.530 ±  
2.364 % 
100.774 ±  
2.402 % 
 
126 6.505 ±  
0.483 % 
5.222 ±  
0.977 % 
8.281 ± 
0.246 % 
82.687 ±  
2.088 % 
 
127 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
130 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
131 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
Cytidine 
11 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
134 25.994 ±  
0.623 % 
16.000 ± 
1.323 % 
35.632 ± 
0.947 % 
101.893 ± 
2.027 % 
 
133 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 %  
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The results obtained for the assay of the purine-based nucleoside derivatives are given in 
detail in Table 13. The purine-based nucleosides, guanosine 9, inosine 116 and adenosine 8, 
were included as our negative controls for the assay, as we did not expect them to inhibit the 
growth of the suspension cell lines. 
 
Table 13 Percentage cell viability of the suspension cell lines when treated with 100 µM of 
the purine nucleosides and their derivatives for 24 hours 
Compound HL-60 Jurkat K-562 WBC 
Guanosine 
9 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
112 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
113 29.316 ± 
0.450 % 
8.778 ± 
0.694 % 
Compound  
Not Active 
92.788 ± 
2.688 % 
 
Inosine 
116 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
117 8.309 ± 
0.051 % 
6.833 ± 
0.167 % 
22.957 ± 
0.679 % 
76.474 ± 
1.211 % 
 
Adenosine 
8 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
142 27.864 ± 
0.541 % 
18.333 ± 
1.167 % 
45.530 ± 
0.731 % 
59.262 ± 
2.027 % 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 % after treatment 
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As suggested by the results obtained for the pyrimidine-based nucleoside derivatives, the 
purine-based nucleoside derivatives protected at the primary alcohol with bulky protecting 
groups also showed selective toxicity towards the cancer cell lines.  
 
5'-O-(4,4'-Dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)guanosine 113 showed 
percentage cell viabilities of 29.316 ± 0.450 % for HL-60, 8.778 ± 0.694 % for Jurkat and no 
activity for K-562; relative to the 92.788 ± 2.688 % obtained for the white blood cells. In a 
similar manner 5'-O-(4,4'-dimethoxytrityl)inosine 117 gave percentage cell viabilities of 
8.309 ± 0.051 % for HL-60, 6.883 ± 0.167 % for Jurkat and 22.957 ± 0.679 % for K-562; 
relative to the 76.474 ± 1.211 % obtained from the white blood cells. Also, 5'-O-(tert-
butyldiphenylsilyl)adenosine 142 showed percentage cell viabilities of 27.864 ± 0.541 % for 
HL-60, 18.333 ± 1.167 % for Jurkat and 45.530 ±0.731 % for K-562; relative to that of 
59.262 ± 2.027 % obtained for the white blood cells.  
 
The third group of compounds assayed were those derived from ᴅ-(-)-ribose. These were 
prepared in order to determine if the base on the nucleosides was required for activity in the 
compounds, or if the corresponding sugar derivatives on their own would be sufficiently 
active. The results obtained for the assay of ᴅ-(-)-ribose 100 and its derivatives are given in 
detail in Table 14 below as the percentage cell viability after treatment with 100 µM of 
compound for 24 hours.  
 
We observed that only one of the derivatives of ᴅ-(-)-ribose showed any activity against the 
cancer cell lines. The 5'-O-(4,4'-dimethoxytrityl)-1'-O-methoxyribose 105 gave a percentage 
cell viability of 45.976 ± 0.489 % for the HL-60 cell line and no activity towards the Jurkat 
and K-562 cell lines. After treatment with 5'-O-(4,4'-dimethoxytrityl)-1'-O-methoxyribose 
105, 98.213 ± 2.623 % of the white blood cells were viable. This limited activity for 5'-O-
(4,4'-dimethoxytrityl)-1'-O-methoxyribose 105 and lack of activity for all of the other ᴅ-(-)-
ribose derivatives suggests that the base on the nucleoside would be required in all synthetic 
derivatives which have potential as lead compounds for cancer therapy. 
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Table 14 Percentage cell viability of suspension cell lines when treated with 100 µM ᴅ-(-)-
ribose and its derivatives for 24 hours 
Compound HL-60 Jurkat K-562 WBC 
ᴅ-(-)-Ribose 
100 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
101 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
102 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
103 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
105 45.976 ± 
0.489 % 
Compound  
Not Active 
Compound  
Not Active 
98.213 ± 
2.623 % 
 
122 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 % after treatment 
 
The last class of compounds assayed were the protecting group derivatives, tert-
butyldiphenylsilanol 145 and 4,4'-dimethoxytrityl alcohol 147. These compounds were 
included in our assay as a control in order to determine if the possible products formed by 
hydrolysis within the cells were in fact the active agents. The results are summarized in Table 
15, which indicates that neither of the protecting group derivatives exhibit any activity 
towards the suspension cell lines tested. 
 
  
P a g e  | 132 
 
Table 15 Percentage cell viability of the suspension cell lines when treated with 100 µM of 
the protecting group controls for 24 hours 
Compound HL-60 Jurkat K-562 WBC 
TBDPS-OH 
145 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
DMT-OH 
147 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 % after treatment 
 
As discussed previously, the assay for inhibition of cell proliferation was broken down into 
two groups based on the type of cells investigated. The second assay involved the use of two 
adherent cell lines, Caco-2 and HT-29, with the results obtained again compared to those for 
white blood cells (WBC), ie: healthy, non-cancerous cells. 
 
The positive control used in this assay was again the commercial drug camptothecin 155. As 
expected, camptothecin 155 showed inhibition of proliferation for both of the adherent cell 
lines. Again, we noted that there was quite a low cell viability for the white blood cells - 
highlighting the toxicity of camptothecin 155 towards healthy, non-cancerous cells. The 
results obtained are given in Table 16.  
 
Table 16 Percentage cell viability of the adherent cell lines when treated with 100 µM of 
camptothecin for 24 hours 
Compound Caco-2 HT-29 WBC 
Camptothecin 
155 
12.769 ± 
0.166 % 
11.443 ± 
0.201 % 
34.622 ± 
2.028  % 
 
The results obtained for the assay of the pyrimidine-based nucleoside derivatives against two 
adherent cell lines are given in detail in Table 17. The pyrimidine-based nucleosides, uridine 
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12 and cytidine 11, were included as negative controls for the assay, as we did not expect 
them to inhibit the growth of the suspension cell lines.  
 
We observed that 5'-O-(tert-butyldiphenylsilyl)uridine 107 exhibited cytotoxic activity 
towards the adherent cell lines, with the percentage viable cells for Caco-2 at 37.443 ± 1.007 
% and for HT-29 as 29.373 ± 0.556 %. When compared to the percentage cell viability of 
61.460 ± 4.481 % for the white blood cells, we can conclude that the compound shows a 
degree of selective toxicity towards the cancer cells. 
 
In a similar manner, the percentage cell viability of 26.070 ± 0.173 % for Caco-2 and of 
27.770 ± 1.172 % for HT-29, when compared to the percentage cell viability of 82.687 ± 
2.088 % for the white blood cells, suggests that 5'-O-(4,4'-dimethoxytrityl)uridine 126  also 
shows selective toxicity towards adherent cancer cells.  
 
Both 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 and 2',3'-O-diacetyl-5'-O-(4,4'-
dimethoxytrityl)uridine 127, which are protected on all of the primary and secondary 
alcohols, showed no activity towards the adherent cell lines. This suggests that decreasing the 
number of free hydroxyls on the molecules, through the protection of the secondary alcohols, 
causes a loss in activity towards the adherent cell lines. This correlates to the results observed 
for the suspension cell lines, where the protection of the secondary alcohols also lead to a 
decrease in activity.  
 
We noted that the 5'-O-(tert-butyldiphenylsilyl)cytidine 134 exhibited cytotoxic activity 
towards the adherent cell lines as well, with the percentage of viable cells remaining after 
treatment as 37.200 ± 0.384 %  for Caco-2, 25.593 ± 0.697 % for HT-29 and 101.893 ± 2.027 
% for the white blood cells. This again correlates to the results obtained for the suspension 
cell lines, as previously described. 
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Table 17 Percentage cell viability of the adherent cell lines when treated with 100 µM of the  
pyrimidine nucleosides and their derivatives for 24 hours 
Compound Caco-2 HT-29 WBC 
Uridine 
12 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
107 37.443 ± 
1.007 % 
29.373 ± 
0.556% 
61.460 ± 
4.481 % 
 
123 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
126 26.070 ± 
0.173 % 
27.770 ± 
1.172 % 
82.687 ± 
2.088% 
 
127 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
130 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
131 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
Cytidine 
11 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
134 37.200 ± 
0.384 % 
25.593 ± 
0.697 % 
101.893 ± 
2.027% 
 
133 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 % 
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None of the synthetic compounds that were prepared without the tert-butyldiphenylsilyl or 
4,4'-dimethoxytrityl protecting groups showed any activity towards the suspension cell lines.  
 
The results obtained for the assay of the purine-based nucleoside derivatives are given in 
detail in Table 18. The nucleosides, guanosine 9, inosine 116 and adenosine 8, were again 
included as our negative controls for the assay. 
 
Table 18 Percentage cell viability of the adherent cell lines when treated with 100 µM of the 
purine nucleosides and their derivatives for 24 hours  
Compound Caco-2 HT-29 WBC 
Guanosine 
9 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
112 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
113 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
Inosine 
116 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
117 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
Adenosine 
8 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
142 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 % 
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Interestingly, none of the purine-based nucleoside derivatives showed any activity towards the 
adherent cell lines. This result was surprising as the 5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-
dimethylmethylimine)guanosine 113, 5'-O-(4,4'-dimethoxytrityl)inosine 117 and  5'-O-(tert-
butyldiphenylsilyl)adenosine 142 showed inhibition of cell proliferation for all of the 
suspension cell lines used. 
 
The next group of compounds assayed were those derived from ᴅ-(-)-ribose 100. The results 
obtained for the assay of ᴅ-(-)-ribose and its derivatives are given in detail in Table 19 as the 
percentage cell viability after treatment with 100 µM of compound for 24 hours.  
 
Table 19 Percentage cell viability of adherent cell lines when treated with 100 µM of ᴅ-(-)-
ribose and its derivatives for 24 hours 
Compound Caco-2 HT-29 WBC 
ᴅ-(-)-Ribose 
100 
Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
101 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
102 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
103 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
105 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
 
122 Compound  
Not Active 
Compound  
Not Active 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 %  
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We observed that none of the derivatives of ᴅ-(-)-ribose showed any activity against the 
adherent cancer cell lines. This correlates to the results obtained for the suspension cell lines, 
where only one of the compounds, 5'-O-(4,4'-dimethoxytrityl)-1'-O-methoxyribose 105, 
showed limited activity towards only the HL-60 cell line. This lack of activity again suggests 
that the base on the nucleosides is intrinsic for activity against cancer cell lines. 
 
The last class of compounds assayed were the protecting group derivatives, tert-
butyldiphenylsilanol 145 and 4,4'-dimethoxytrityl alcohol 147. These compounds were 
included in our assay as a control in order to determine if the possible products formed by 
hydrolysis within the cells were in fact the active agents. The results are summarized in Table 
20. 
 
Table 20 Percentage cell viability of the adherent cell lines when treated with 100 µM of the 
protecting group derivatives for 24 hours  
Compound Caco-2 HT-29 WBC 
TBDPS-OH 
145 
6.884 ± 
0.205 % 
5.643 ± 
0.171 % 
Compound  
Not Active 
 
DMT-OH 
147 
13.767 ± 
1.060 % 
13.133 ± 
0.571 % 
Compound  
Not Active 
Note: Synthetic compounds are defined as not active if the cell viability is greater than 50 % after treatment 
 
The tert-butyldiphenylsilanol 145 shows a percentage cell viability of 6.884 ± 0.205 % for 
Caco-2 and a viability of 5.643 ± 0.171 % for HT-29. This result was quite surprising as the 
compound had previously not shown any activity towards the suspension cell lines. In a 
similar manner, the 4,4'-dimethoxytrityl alcohol 147 gave a cell viability of 13.767 ± 1.060 % 
for Caco-2 and 13.133 ± 0.571 % for HT-29, which was again unexpected as the compound 
had also not shown activity towards the suspension cell lines. These new results suggested 
that the small molecule derivatives could possibly be transported into the cells without the 
requirement for the nucleoside groups. However, this could not be substantiated as yet based 
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on the small sample size that we had used and as such would need to be further investigated. 
The synthesis of a "second generation" of compounds based on these findings are discussed in 
detail in Chapter 5. 
 
3.2.3.3 Discussion for Subsequent Assays Performed 
 
Cells are killed by either necrosis or apoptosis. When DNA is damaged in normal cells, it is 
either repaired or the cell undergoes apoptosis. In cancer cells, however, DNA repair does not 
often occur and the apoptotic levels are extremely low.
76
 Only compounds exhibiting positive 
results in the MTT assay (discussed in detail in Section 3.2.3.2 above) were subjected to a 
series of subsequent tests to try and determine the mechanism by which cell death is initiated.  
 
As described in the Materials and Methods, Section 3.2.3.1 above, an Annexin V flow 
cytometry kit was used to determine whether apoptosis or cell necrosis was induced. Caspase-
3/CPP32 and Caspase-8 colorimetric assay kits were used to determine caspase expression. 
Cytochrome c fractions in the mitochondrial and cytoplasmic fractions were determined by 
the Enzyme Immunometric Assay (EIA) kit. As this work was performed by students in the 
Department of Pharmacy and Pharmacology at the University of the Witwatersrand and not 
by myself. A brief overview of a few representative results will thus be given here, as 
opposed to a detailed analysis (which will be given in the MSc dissertations for N. Dahan-
Farkis
77
 and H. Apostolellis
78
). 
 
 Annexin V Assay 
 
Annexin V is a useful tool for the detection of apoptotic cells as it binds preferentially to 
negatively charged phospholipids, such as phosphatidylserine (PS), which then leaves it 
exposed on the outer layer of the plasma membrane of the cell. The translocation of the PS 
occurs in both necrosis and apoptosis - hence, Annexin V is combined with propidium iodide 
(PI). In this assay, the cell staining was assessed using fluorescein isothiocyanate (FITC) 
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labeled Annexin V (which gave green fluorescence) as well as the dye excluded of PI (which 
was negative for red fluorescence). Using this approach, it was possible to detect and 
quantitate the apoptotic cells on a single-cell basis by flow cytometry, and they were able to 
identify: 
 - the intact cells (Annexin V-FITC = negative, PI = negative) 
 - early apoptotic cells (Annexin V-FITC = positive, PI = negative) 
 - late apoptotic or necrotic cells (Annexin V-FITC = positive, PI = positive) 
 
The control, untreated HT-29 cells were mainly Annexin V-FITC and PI negative, indicating 
that they were viable and not undergoing apoptosis [as shown in Graph 12 (ii)]. After a 24 
hour exposure to the commercial control, camptothecin 155, there were two primary 
populations of cells, the first were the viable, non-apoptosing cells (Annexin V-FITC and PI 
negative) and the second group contained the cells undergoing apoptosis (Annexin V-FITC 
positive and PI negative). A small population of cells, 18.7 %, were observed as both Annexin 
V-FITC and PI positive, indicating that they were in end-stage apoptosis [shown in Graph 12 
(iii)]. 
 
The example shown in Graph 12 (ii) is of our synthetic compound, 5'-O-(4,4'-
dimethoxytrityl)uridine 126 incubated with HT-29 cells. After 24 hour exposure, there were 
two populations of cells observed: (i) viable, non-apoptosing cells (Annexin V-FITC and PI 
negative), and (ii) cells undergoing apoptosis (Annexin V-FITC positive and PI negative). 
Similar results were observed for the other active compounds and cell lines combinations 
used. 
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       (i) Control       (ii) 5'-O-(4,4'-Dimethoxytrityl)uridine            (iii) Camptothecin 
                 
 
Graph 12 Annexin V-FITC staining in control and apoptotic HT-29 cells, induced by 
camptothecin 155 and 5'-O-(4,4'-dimethoxytrityl)uridine 126 
 
 Time Dependent Induction of Caspase-3 and Caspase-8 Activity 
 
A specific feature of apoptosis is protein hydrolysis, which involves the activation of 
caspases. First, the initiator caspase, Caspase-8, cleaves and this then activates one of the 
effector caspases, Caspase-3. Once activated, Caspase-3 then cleaves the polypeptides that 
ultimately undergo proteolysis in the apoptotic cells. 
 
Examples of the results obtained for three of our synthetic compounds are shown in Graph 
13, with graph (a) representing HT-29 cells treated with 5'-O-(4,4'-dimethoxytrityl)uridine 
126, graph (b) representing HT-29 cells treated with 5'-O-(tert-butyldiphenylsilyl)uridine 107 
and graph (c) representing Caco-2 cells treated with 5'-O-(tert-butyldiphenylsilyl)cytidine 
134.  
  
Annexin V-FITC 
and PI negative 
Annexin V-FITC  
positive and PI 
negative 
Annexin V-FITC 
and PI positive 
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Graph 13 Time-dependent induction of Caspase-3 and Caspase-8 activity by: (a) HT-29 cells 
treated with 5'-O-(4,4'-dimethoxytrityl)uridine 126, (b) HT-29 cells treated with 5'-O-(tert-
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butyldiphenylsilyl)uridine 107 and (c) Caco-2 cells treated with 5'-O-(tert-butyl-
diphenylsilyl)cytidine 134 
 
Maximal Caspase-8 expression was observed in the HT-29 and Caco-2 cells within 4-8 hours 
of exposure to our synthetic derivatives. After 8 hours, the activity of Caspase-8 declined in 
HT-29 cells treated with 5'-O-(4,4'-dimethoxytrityl)uridine 126 and 5'-O-(tert-
butyldiphenylsilyl)uridine 107, whereas that of Caspase-3 increased, indicating that the 
proteolytic phase of apoptosis was initiated. In the Caco-2 cells, Caspase-8 activity only 
decreased after 12 hours exposure to 5'-O-(tert-butyldiphenylsilyl)cytidine 134. 
 
 Cytochrome c Assay 
 
During apoptosis, cytochrome c has been shown to shift from the mitochondria to the 
cytoplasm. Cytochrome c measurement can therefore lead to a greater understanding of many 
diseases at the cellular level. For this study, the amount of cytochrome c in the cell lysates 
was quantified by a human cytochrome c Elisa assay. 
 
Representative examples of the data obtained for all our synthetic compounds are shown in 
Graph 14 and Graph 15, which show results obtained for the HT-29 and Caco-2 cells when 
treated with 5'-O-(4,4'-dimethoxytrityl)uridine 126, 5'-O-(tert-butyldiphenylsilyl)uridine 107 
and 5'-O-(tert-butyldiphenylsilyl)cytidine 134. 
 
Cytochrome c concentrations were significantly higher in the cytosolic protein fractions (ρ ≤ 
0.05) than in the mictochondrial protein fractions of the HT-29 cells (shown in Graph 14) 
and the Caco-2 cells (shown in Graph 15). The cytochrome c concentration in the cytosol of 
cells treated with camptothecin 155 was significantly higher (ρ ≤ 0.05) than in the cytosol of 
cells treated with the other synthetic compounds.  
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Graph 14 Concentrations of cytochrome c (pg/mg) in the cytosolic and mitochondrial 
fractions of HT-29 cells after treatment with: (a) 5'-O-(4,4'-dimethoxytrityl)uridine 126, (b) 
5'-O-(tert-butyldiphenylsilyl)uridine 107, (c) 5'-O-(tert-butyldi-phenylsilyl)cytidine 134 and 
(d) camptothecin 155, for 24 hours  
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Graph 15 Concentrations of cytochrome c (pg/mg) in the cytosolic and mitochondrial 
fractions of Caco-2 cells after treatment with: (a) 5'-O-(4,4'-dimethoxytrityl)uridine 126, (b) 
5'-O-(tert-butyldiphenylsilyl)uridine 107, (c) 5'-O-(tert-butyldi-phenylsilyl)cytidine 134 and 
(d) camptothecin 155, for 24 hours 
      (a)                    (b)                      (c)                     (d)               (e) Control 
      (a)                    (b)                      (c)                     (d)               (e) Control 
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3.2.3.4 Conclusions 
 
The following synthetic compounds: 
- 5'-O-(tert-butyldiphenylsilyl)uridine 107 
- 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 
- 5'-O-(4,4'-dimethoxytrityl)uridine 126 
- 5'-O-(tert-butyldiphenylsilyl)cytidine 134 
- 5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)guanosine 113 
- 5'-O-(4,4'-dimethoxytrityl)inosine 117 
- 5'-O-(tert-butyldiphenylsilyl)adenosine 142 
- tert-butyldiphenylsilanol 145 
- 4,4'-dimethoxytrityl alcohol 147 
show a degree of selective cytotoxicity against the cancer cell lines tested, with minimal 
cytotoxicity directed against the white blood cells.  
 
The synthetic compounds, described above, also proved to be effective in inducing apoptosis, 
modulating the expression of Caspase-3 and Caspase-8, as well as causing the release of 
cytochrome c from the mitochondria into the cytosol. The cytotoxic effects of these 
derivatives therefore suggest potential for further development in cancer therapy as promising 
lead compounds. 
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Summary: 
Work Completed in Part 1 
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 PART 1 SUMMARY – SYNTHESIS 
 
As described in our aims for part 1, we thought it pertinent to investigate the possibility of 
forming fused bicyclic systems onto the 2’ and 3’ positions of the sugar ring of our 
nucleosides utilizing the ring closing metathesis methodology that we were already familiar 
with. The synthesis in Scheme 21 below highlights the critical RCM step and shows the 
bicyclic ring systems that we hoped to prepare in order to do biological activity 
investigations. 
 
Base
O
OO
HO
Base
O
OO
HO
RCM
Base
O
OO
HO
R R
R = OH, Br, Cl, etc.
91 92 93
Base = A, C, G, T, U
 
 
Scheme 21 Synthesis for 2’,3’-bicyclic ring system, showing key RCM step  
 
Using our planned strategy towards fused bicyclic ring systems, we were able to synthesise 
the various dienes (including 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-
(-)-ribose 103 and 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-dimethylmethyl-
imine)guanosine 114), but were unable to obtain the bicyclic ring systems via our proposed 
ring closing metathesis route. Due to the time constraints of the project, we decided not to 
continue along this synthetic route and instead shifted our focus to the synthesis of a range of 
compounds that would be used to conduct a structure-activity study.  
 
At the same time, we wished to investigate the structure activity relationships (SAR) involved 
when the various OH and NH positions on the nucleosides and ᴅ-(-)-ribose derivatives were 
protected sequentially with different protecting groups. The idea was that from this data we 
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would be able to determine on which positions in the molecules it was essential to have free 
OH/NH binding sites in order to maintain the activity of the compounds. Structures 94-96 
outline the approach taken for the model system, ᴅ-(-)-ribose 100, and structures 97-99 show 
an example of the nucleoside approach, for uridine 12 derivatives specifically. 
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Figure 37 General overview of our intended SAR study 
 
For these derivatives, we prepared a series of compounds that had different functional groups 
present on the primary hydroxyls and secondary hydroxyls on the sugar ring, as well as 
different groups present on the primary amines and/or amide groups of the bases. This 
synthesis was performed to obtain a range of sugar derivatives (ᴅ-(-)-ribose 100) and 
nucleoside derivatives (adenosine 8, cytidine 11, guanosine 9, inosine 116 and uridine 12). 
Included in this group were the corresponding protecting group derivatives, tert-
butyldiphenylsilyl alcohol 145 and 4,4’-dimethoxytrityl alcohol 147. 
 
Having the range of synthetic compounds in hand, for both the approach towards the fused 
bicyclic ring systems and those for the structure-activity study, we then moved on to the 
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biological testing. For the biological testing, we assayed our range of synthetic compounds for 
inhibitory activity against four bacterial strains, four cancer cell lines and HIV.  
 
 PART 1 SUMMARY – BIOLOGICAL TESTING 
 
The nucleoside and corresponding ᴅ-(-)-ribose derivatives were evaluated for their 
antibacterial activity against two Gram-positive (Staphylococcus aureus ATCC 25923 and 
Bascillus cereus DL5) and two Gram-negative bacteria (Pseudomonas aeruginosa ATCC 
27853 and Escherichia coli ATCC 25922).  
 
The results from the TTC assay for anti-bacterial activity showed that 5’-O-(tert-
butyldiphenylsilyl)uridine 107, 5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 102 
and tert-butyldiphenylsilyl alcohol 145 exhibited activity towards only the Gram-positive 
bacteria when compared to the ciprofloxacin 153 control. From the data reported for the anti-
bacterial assay, we concluded that the nucleoside showing the most promising results was 
uridine and as such it would be the nucleoside of choice for our subsequent anti-bacterial 
activity studies. Our mini structure-activity study on the uridine derivatives found that the best 
position for performing modifications to our nucleosides was at the 5'-OH position on the 
sugar ring and that a loss of either or both of the secondary alcohols (2'-OH and 3'-OH) and/or 
the primary amide on the base lead to a reduction in activity of the compounds. Lastly, the 
comparison of ᴅ-(-)-ribose derivatives to the uridine derivatives suggested that the bases on 
the nucleoside derivatives were necessary for molecular recognition to aid transportation 
within the cells.  
 
We found that none of the range of synthetic nucleoside and protecting group derivatives 
assayed showed any antiviral activity towards HIVIIIB. However, we did observe that a large 
number of the compounds were toxic towards the uninfected MT-4 cells (human T-cell 
leukemia cell line) at millimolar levels. This was quite unexpected and we believed that it 
suggested that our synthetic compounds may be toxic towards specifically cancerous cells.  
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This possibility was subsequently investigated in our cell proliferation studies, where most of 
the synthetic compounds were screened for their "anti-cancer" properties against two adherent 
(HT-29 and Caco-2) and three suspension (HL-60, Jurkat and K-562) cell lines. The results of 
this exhaustive study showed that 5'-O-(tert-butyldiphenylsilyl)uridine 107, 5'-O-(4,4'-
dimethoxytrityl)uridine 126 and 5'-O-(tert-butyldiphenylsilyl)cytidine 134 were active against 
both the suspension and the adherent cell lines. Whereas, tert-butyldiphenylsilanol 145 was 
active against only the adherent lines and 4,4'-dimethoxytrityl alcohol 147 was active against 
only the suspension cell lines.  
 
In general, all of the active compounds show a degree of selective cytotoxicity against the 
cancer cell lines tested, with minimal cytotoxicity directed against the white blood cells. The 
synthetic compounds, described above, also proved to be effective in inducing apoptosis, 
modulating the expression of caspase 3 and caspase 8, as well as causing the release of 
cytochrome c from the mitochondria into the cytosol. The cytotoxic effects of these 
derivatives therefore suggest potential for further development in cancer therapy. 
 
For all of the biological testing, we have found that ᴅ-(-)-ribose derivatives, in general, do not 
show any significant biological activity. Whereas (tert-butyldiphenylsilyl)-protected 
nucleoside derivatives and the corresponding tert-butyldiphenylsilyl alcohol control seem to 
be intrinsically bio-active. As such, we extrapolated that a second generation of synthetic 
compounds derived from the nucleoside uridine and containing silyl-protecting groups would 
be the best way to develop promising lead compounds.  
 
We then moved on to the preparation and testing of our second generation of compounds, 
which follows in detail in Part 2 of this thesis. An introduction to our ideas for our second 
generation of compounds is given in Chapter 4 below, followed by the synthesis of the 
compounds (which is discussed in detail in Chapter 5). The results obtained for the 
subsequent anti-bacterial assay are discussed in detail in Chapter 6, with further studies to 
determine a possible mode of action for our positive hits (from both the first generation and 
the second generation of synthetic compounds) included, along with the analysis of the cells 
by confocal microscopy and SEM. The results obtained for the subsequent anti-cancer assays 
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on the second generation of compounds will be presented in Chapter 7. This is followed by 
an overall summary of the work performed on our second generation compounds. 
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PART 2 - SECOND GENERATION COMPOUNDS 
 
Synthesis and Biological Testing of Uridine,  
5-Methyluridine and Silanol Derivatives 
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Chapter 4: 
Introduction 
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4.1 GENERAL INTRODUCTION TO SILICON AND ITS CHEMISTRY 
 
 
 
4.1.1 Basic Silicon Chemistry 
 
Silicon is the 14
th
 element in the periodic table and although it does not occur naturally in free 
form, in its combined forms, it accounts for about 25 % of the Earth’s crust.80 So as not to 
confuse silicon with silicone, a brief definition of each is given below: 
 SILICON – is used to refer to the elemental material 
 SILICONE – refers to materials in which silicon is bonded to oxygen 
 
Silicon forms stronger bonds than carbon to oxygen and the halogens, and weaker bonds to 
carbon and hydrogen. Much of organosilicon chemistry is driven by the formation of strong 
oxygen-silicon or oxygen-fluoride bonds at the expense of other weaker bonds.
81
 In contrast, 
π bonds between silicon and other elements are very weak and may be considered 
unimportant in the applications of silicon to organic synthesis.
81 
 
The bonds between silicon and other atoms are generally significantly longer than those 
between carbon and the corresponding atoms. A good example of this used in organic 
synthesis is found in the fact that the trimethylsilyl group is less sterically demanding than its 
Silicon and carbon are alike in so many ways, and yet, they are so different. This 
dichotomy was behind a good portion of the interest in silicon chemistry in the 20
th
 
century. Other sources of fascination with this element were the endless variety of natural 
silicates in minerals and clays and the remarkable properties of the synthetic silicones. In 
recent decades, silicon has thoroughly penetrated areas as diverse as organic synthesis and 
microelectronics. 
Josef Michl, Editor, Chemical Reviews, 199579 
 
P a g e  | 154 
 
carbon analogue (the tert-butyl group). This is generally ascribed to the increased distance 
between the silicon atom and its point of attachment to the molecule in question.
81 
 
Silicon is considerably more electropositive than carbon; as such carbon-silicon bonds are 
strongly polarized.
81
 The direction of polarization is shown below: 
 
Si (δ+) – C (δ-) 
 
4.1.2 Silicon in Protecting Group Chemistry 
 
The use of organosilyl protecting groups has undergone great growth in the last two decades 
and they are now highly likely to be used in any synthesis of reasonable complexity.
82
 The 
first group to be used extensively was Me3Si 156, but recently bulkier groups such as t-
BuMe2Si 157, (t-hexyl)Me2Si 158 and t-BuPh2Si 159 (Figure 38), which form more stable 
silylated products, have come into fairly widespread use. 
 
Si
156
Si
157
Si
158
Si
159  
 
Figure 38 Various Organosilyl Protecting Groups 
 
Deprotection of compounds containing bulky organosilyl protecting groups is usually 
achieved by treatment with fluoride ion (usually derived from tetra-butylammonium fluoride). 
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The silicon-containing product thus formed is a silanol (Si-OH) species or a silanol/silyl 
fluoride mixture. After isolation of the required organic material, the organosilicon by-product 
is usually discarded of as waste, even on industrial scale.
82 
There are, however, a number of 
publications detailing the recovery and subsequent reconversion of these silanols to the 
starting chlorosilanes.
82
 This work will however not be discussed in the course of this thesis. 
 
4.2 SILICON IN DRUG DISCOVERY 
 
 
 
4.2.1 Bioisosteres – Sila-Substitution of Existing Drugs 
  
In modern medicinal chemistry, current drug developers are often forced to look at the 
existing families of drugs for design inspiration. Some recent data suggests that as little as 
thirty-two scaffolds exist in current use and that these account for as many as half of all the 
compounds which have been approved as drugs by the FDA.
84
 These studies have also shown 
that a relatively small number of functional groups account for the majority of side-chains 
found in drugs today.
85 
 
This has led to the emergence of bioisosteres in drug design. This strategy is exemplified by 
the use of a bioisostere to improve the properties of a molecule and/or obtain new classes of 
compounds without prior art in the patent literature.
83
 Well know examples of bioisosteres are 
shown in the Figure 39. 
 
“Some of the fundamental differences between carbon and silicon can lead to marked 
alterations in the physiochemical and biological properties of the silicon-containing 
analogues…and the resulting benefits can be exploited in the drug design process.” 
Graham A. Showell, Amedis Pharmaceuticals Ltd.83 
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Figure 39 Examples of Classical and Non-Classical Bioisosteres
83
  
 
During the 1970’s Reinhold Tacke pioneered the concept of a “silicon switch” or sila -
substitution in which one or more carbon atoms of an existing molecule could be swapped for 
silicon atoms.
86
 Such a “silicon switch” could be considered as a classical tetravalent 
bioisostere (as illustrated in Figure 39 above).
83
 However, the concept remained widely 
underutilized and it wasn’t until the last decade that the properties of organosilicon agents 
have begun to be more fully utilized in drug discovery and development.
83
 As an example, 
consider that in 2001, less than 1 % of all patent applications in the drug discovery field 
related to compounds containing phosphorus, silicon and the other less common elements.
87 
 
Sila-substitution into drug-like scaffolds provides an exciting approach to search for novel 
drug-like candidates that have beneficial biological properties when compared with similar 
traditional carbon-based scaffolds, and in addition, would have a clear intellectual property 
position.
88 
 
4.2.2 General Properties of Silicon and the Impact in Medicinal Chemistry 
 
It is well known that both carbon and silicon possess four valence electrons. As such, 
similarities with respect to the chemistry of silicon and carbon may therefore be expected, 
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although it is known that in several aspects the two elements differ substantially from one 
another.
83
 Some of the fundamental differences between carbon and silicon that can lead to 
marked alterations in the physico-chemical and biological properties of the silicon-containing 
analogues, which can be exploited in the drug design process, are highlighted in Table 21.
83
 
 
Table 21 The Properties and Potential Benefits of Silicon in Medicinal Chemistry
83
 
Property Difference Potential Benefit 
Atomic Size Altered bond lengths and 
bond angles 
Altered in vitro potency 
Modified selectivity 
Altered rate of metabolism 
 
Electronegativity Increased H-bond strength 
and acidity of silanols 
Improved potency in 
pharmacophores where  
H-bonding is important 
 
Lipophilicity Increased lipophilicity of 
silicon compound 
Improved in vivo half-life 
Enhanced tissue distribution 
 
Novel Chemistry IP opportunities Novel compounds exploiting 
established SAR 
 
4.2.2.1 Atomic Size 
 
Silicon containing bonds are always longer than the corresponding carbon analogues:  
 
 C-C bond length is approximately 1.54 Å vs.  
 C-Si bond length of approximately 1.87 Å86 
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This difference leads to subtle changes in the size and shape of silicon-containing compounds 
when compared with carbon-containing compounds.
88
 This can lead to changes in the way 
that the silicon analogues interact with specific proteins and/or enzymes. This can have a 
marked effect on the compounds pharmacological profile.
83, 88 
 
4.2.2.2 Electronegativity 
 
As carbon is more electronegative than silicon, different bond polarizations occur for carbon 
specific bonds relative to silicon specific bonds. An area in which this has potential benefits 
for the “silicon switch” approach is in hydrogen-bond strength and acidity.83 In this context, 
the hydrogen-bond strength of the silanol is more favourable as a donor than that of the 
carbinol.
88, 89
 As a consequence, in molecules where the carbinol functions as a hydrogen-
bond donor, the use of a silanol moiety can provide the benefit of improved potency.
88,90 
 
4.2.2.3 Lipophilicity 
 
As a general rule, silicon-containing compounds are more lipophilic than their corresponding 
carbon analogues. By altering the lipophilicity of a molecule, one can modify the molecules in 
vivo effects – for example, a small increase in lipophilicity can markedly increase the volume 
of distribution of the molecule, reflecting in increased tissue penetration.
88,91
 As a 
consequence, the silicon-containing molecule will be less prone to hepatic metabolism and the 
plasma half-life of the molecule may be improved (in situations where liver metabolism is 
significant in the original carbon-based compounds).
88
  
 
In addition, lipophilicity plays an important role in the ability of drug candidates to cross the 
blood-brain barrier.
88
 It has been shown that many in silico models predicting blood-brain 
barrier permeation contain a descriptor that relates specifically to lipophilicity.
92 
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4.2.2.4 Novel Chemistry 
 
The chemistry of single bonds heavily dominates the chemistry of silicon, as such, its use as a 
tetrahedral bioisostere of carbon is appropriate. The C=O double bond of a ketone is favoured 
over its hydrated form, whereas the formation of a Si=O double bond is disfavoured over its 
hydrate, the silicon diol.
88
  
 
Organosilicon compounds can be synthesized where the carbon counterparts are much more 
difficult to obtain, or do not exist at all under normal experimental conditions. Using this 
approach allows for the opportunity to identify novel compounds with distinct modes of 
action and possibly unlicensed IP. An area where silicon has been effective in this respect is 
in the design of protease inhibitors.
88 
 
4.2.2.5 Limitations to Sila-Substitutions 
 
Although the incorporation of silicon represents an excellent tetrahedral isostere of carbon, it 
also has some important limitations. The first of which is that there are no direct sila-
equivalents for the following carbon systems: 
 
C=C and C=O 
 
Another major limitation is that silicon cannot form physiologically stable Si-H containing 
compounds. The Si-H bond is not only weaker than its C-H equivalent, but also has reversed 
polarity as shown schematically.
83
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Si (δ+) – H (δ-) 
vs. 
C (δ-) – H (δ+) 
 
As such, the Si-H bond behaves differently to the C-H bond. For example, the Si-H bond is 
easily cleaved by water under non-acidic conditions to yield the corresponding silanol (Si-
OH), whereas the C-H bond would not be cleaved at all under the same conditions.
83 
 
4.2.3 Examples of Drug-Like Compounds with Sila-Substitutions 
 
To date, none of the examples of silicon-containing drugs under clinical review are direct sila-
substitutions of known marketed drugs. However, a significant body of work has been 
performed in this area over the last few years. The summary below will focus on only the true 
silicon switches of known marketed drugs and serves as a brief introduction to the area at 
large. A more in-depth review of the synthetic and medicinal chemistry associated with the 
direct silicon switches of known drugs has been given by Pooni and Showell.
93 
 
4.2.3.1 Sila-Budipine 
 
Budipine 160 is a monoamine uptake inhibitor that has been launched for the treatment of 
Parkinson’s disease. In the late 1980’s Stasch94 reported on the substitution of the carbon 
atom within the core of the 4,4-diphenyl of budipine with a silicon atom, 161.
93
 This 
substitution is shown in Figure 40. 
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Figure 40 Structures of Budipine 160 and Sila-Budipine 161 
 
This sila-analogue showed an increase in lipophilicity, which is important in centrally acting 
drugs (such as those for the treatment of Parkinson’s disease) as they can improve the 
molecules penetration of the blood-brain barrier.
93 
 
4.2.3.2 Sila-Haloperidol 
 
When considering the neuropsychiatric disorder schizophrenia, it is widely accepted that 
changes in neurotransmitter systems (such as the excessive stimulation of dopamine D2 
receptors) are involved, even though the exact pathogenesis is still unclear. Dopamine over-
activity is associated with the psychotic symptoms of schizophrenia such as delusions, 
hallucinations and thought disorders. The antipsychotic agent haloperidol 162 acts by 
blocking the dopamine D2 receptor as well as other serotonin receptors.
93 
 
In 2004 Tacke and co-worker
95
 reported the synthesis of sila-haloperidol 163. After testing 
the binding affinities of the carbon and silicon-derivatives of haloperidol against various 
recombinant dopamine receptors, they were able to show that sila-substitution of haloperidol 
had modulated the receptor selectivity profile,
93
 which suggested that the haloperidol 162 and 
sila-haloperidol 163 would differ substantially in vivo. 
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Figure 41 Stuctures of Haloperidol 162 and Sila-Haloperidol 163 
 
4.2.3.3 Sila-Bexarotene 
 
Bexarotene 164 is a retinoid X receptor (RXR)-selective retinoid agonist that is marketed 
under the name Targretin
TM
. It is currently used in the treatment of cutaneous T-cell 
lymphoma and is undergoing Phase III clinical trials for the treatment of non-small cell lung 
cancer.
93
  
 
Retinoids are analogues of retinoic acid, an active metabolite of vitamin A. The retinoids bind 
to and thus activate retinoid X receptors – causing them to act as transcription factors that 
regulate the expression of genes, which control cell differentiation and proliferation.
93
 Various 
synthetic retinoids have been prepared and then tested for clinical use – Bexarotene 164 is one 
such example.
96
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Figure 42 Stuctures of Bexarotene 164 and Disila-Bexarotene 165 
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Daiss and co-workers
97
 outlined the synthesis and agonist activity screen of a disila-
substituted derivative of bexarotene 165, wherein two of the carbon atoms had been 
substituted with silicon atoms. During the screening for agonist activity using a hRXR β cell-
based luciferase assay, they found that disila-bexarotene 165 had a comparable response to 
bexarotene 164.
93
 As the disila-substitution of the tetrahydronaphthalene core of bexarotene 
gave an equally potent compound in the in vitro assays, this clearly shows that silicon can 
effectively be used as a bioisostere for carbon.
93 
 
4.3 INTRODUCTION TO SILICON IN BIOLOGICAL SYSTEMS 
 
Traditionally the use of silicon in drug discovery has been somewhat limited by the perceived 
toxicity of silicon itself, despite the wealth of chemical diversity and biological functionality 
that silicon affords to the synthetic chemist.  
 
Concerns over the toxicity of silicon have arisen due to the fact that silicon was historically 
regarded as having “metallic” characteristics. When viewing the trends of the group IV 
elements of the periodic table, carbon is considered as strictly non-metallic, silicon as 
essentially non-metallic, germanium as a metalloid and both tin and lead as metallic.
83
 As the 
electropositive elements are ordered, silicon is currently classified as one of the least 
metallic.
88
  
 
In a literature review from 1971, Garson and Kirtchner stated that: “evidence is now available 
to establish that organosilicon compounds per se, are not toxic”.83,98 The current 
toxicological data
83
 now suggests that LD50 results are generally showing similar toxicities for 
the silicon-containing compounds when compared to their direct carbon-containing 
counterparts and the review further concludes that silicon itself conveys no systematic toxic 
liability on chemically stable molecules. 
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Despite this indication to the contrary, to date no silicon-containing drugs have been licensed 
for use in humans by the regulatory authorities in either the United States or the European 
Union. However, one example of a license exists in the former Eastern Europe – for a 
compound silabolin 166 (Figure 43) which is currently used for the treatment of muscle 
wasting diseases. 
 
O
H H
O
H H
Si
Silabolin
166
Si
N N
N
F
F
Flusilazole
167
Silafluofen
168
Si
O
FO
 
 
Figure 43 Silbolin 166 and the Agrochemicals Flusilazole 167 and Silafluofen 168 
 
In addition to silbolin 166, six other organosilicon compounds have been used in human 
clinical trials (compounds 169-174 in Figure 44).
83, 88
 Another two, flusilazole 167 and 
silafluofen 168 (Figure 43) are marketed as agrochemicals and as such have been fully 
considered in terms of their potential effects on human exposure.
88
 Evaluation of the available 
clinical and toxicological data on the compounds shown below supports the hypothesis 
discussed above that silicon is not inherently toxic.
88 
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Figure 44 Silicon based compounds tested for human toxicity 
 
Silperisone 169 is a neuromuscular antagonist for the treatment of muscle spasms.
99
 
Zifrosilone 170 is a neostigmine analogue which functions as an acetylcholinesterase inhibitor 
for the treatment of Alzheimer’s disease.100 Some of the phenyl-containing polysiloxanes 
have been shown to have oestrogenic activity – with cisobitan 171 the most potent.88 
Cisobitan 171 has hormonal agonist activity equivalent to that of oestradiol, but shows a 
lower acute toxicity. The compound has been patented as an anti-infertility agent and has also 
been examined for the treatment of human prostate cancer.
101-103
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Compound Pc4 174 is a silicon-containing phtalocyanine which is currently undergoing Phase 
I clinical trials for the laser photodynamic therapy of cancer.
104
 Compound Am-555S / TAC-
101 175 is an orally active retinoic acid receptor [(RAR)-α/β] agonist, which underwent Phase 
II clinical trials for the treatment of liver cancer in 2004. It had previously undergone Phase I 
clinical trials for the treatment of lung cancer in 1999-2000.
105 
 
One of the most clinically advanced drugs is a kareniticin compound BNP-1350 173, a fourth-
generation compound derived from a novel class of camptothecin 155 analogues. BNP-1350 
173 has successfully completed a number of Phase I clinical trials and was currently in Phase 
II clinical trials for the treatment of recurrent malignant brain tumours and non-small cell lung 
cancer.
106 
  
4.4 BIOLOGICAL APPLICATIONS OF SILICON CONTAINING COMPOUNDS 
 
The section below highlights a selection of a few compounds in the recent synthetic literature 
that have shown either anti-bacterial activity or some activity against cancer cell lines, 
however, it should be noted that these types of compounds have also found to be of relevence 
to other medicinal areas such as the treatment of HIV.
106b
  
 
4.4.1 Synthetic Silicon-Containing Compounds Showing Anti-Bacterial Activity  
 
4.4.1.1 The Silanols 
 
Kim, Baney and co-workers published articles in 2006
107
 and 2007,
108
 as well as a patent in 
2008,
109
 outlining the possible use of trialkylsilanols as a novel class of antimicrobial agents. 
They reported the discovery of a new and unexpected class of powerful biocides based upon 
compounds derived through simple chemistry from silicon intermediates, the “silicon 
alcohols” or silanols.107  
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Antimicrobial screens with the silanols, tert-butanol and siloxanes were conducted against a 
Gram-negative bacterium, Escherichia coli, and a Gram-positive bacterium, Staphylococcus 
aureus.
107
 They found that the number of viable bacteria reduced was more than eight orders 
of magnitude greater than the corresponding alcohols, when the silanol treatments were used. 
Triethylsilanol 175 in particular, exhibited a strong antimicrobial effect at a very low 
concentration within ten minutes of application. Examples of the compounds tested are given 
in Figure 45. 
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OH Si OH OH
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Figure 45 Compounds screened as antimicrobial agents by Kim, Baney and co-workers
107 
 
These novel biocide silanols can be prepared from low cost intermediates derived from the 
commercial processes associated with the silicone industry. Silanols are also considered 
environmentally benign because of their transitory nature and ultimate conversion to CO2, 
SiO2 and H2O.
107
 
 
4.4.1.2 The β-Ethanolamine Derivatives 
 
In 2006, Zablotskaya and co-workers
110
 published an article in which they investigated the 
structure activity relationships that existed between a wide variety of trialkylsilyl substituents 
at the oxygen atom of different β-ethanolamine derivatives (compounds given in Figure 46). 
The compounds were tested for antimicrobial activity using the well diffusion method, in 
Mueller Hinton Agar 2, at concentrations of 0.5 mg / 0.1 mL and 1 mg / 0.1 mL of the 
synthetic compounds. Activity was then determined by measuring the diameter (in 
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millimeters) of zones showing complete inhibition, to give the zone of growth inhibition for 
each sample. The compounds were tested for antimicrobial activity against: 
 Staphylococcus aureus ATCC 25923  (Gram positive bacterium) 
 Bascillus cereus ATCC 117788  (Gram positive bacterium) 
 Proteus mirabilis NCIM2241   (Gram negative bacterium) 
 Escherichia coli ATCC 25922  (Gram negative bacterium) 
 Candida tropicalis ATCC 4563  (fungal strain) 
 Candida albicans ATCC 2091  (fungal strain) 
 
From this study, it was evident that the overall potency of the unsilylated compounds was 
enhanced on the introduction of the silyl group. All of the organosilicon containing β -
ethanolamine methiodides were found to have some activity against at least one of the 
bacterial and fungal strains used. In general, the fungal and Gram-negative strains were more 
resistant to the synthesized compounds when compared to the Gram-positive ones. 
 
[R1R2R3Si OCH2CH2NMe3]
+ I-
 
 
COMPOUND R
1 
R
2 
R
3 
178 CH3 CH3 C3H7 
179 CH3 CH3 C7H15 
180 CH3 CH3 C8H17 
181 CH3 CH3 C10H21 
182 CH3 CH3 C11H23 
183 CH3 CH3 C16H33 
184 C2H5 C2H5 C2H5 
185 C2H5 C4H9 C4H9 
186 CH3 C7H15 C7H15 
187 CH3 C10H21 C10H21 
 
Figure 46 The β-triorganyl(N,N-dimethylaminoethoxy)silane methiodides 178-187 screened 
for anti-bacterial activity by Zablotskaya and co-workers
110 
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Zablotskaya and co-workers
110
 suggested that the enhancement of activity could be 
rationalized on the basis that their structures possessed an Si-O bond, which then increased 
the lipophilicity of the parent alkanolamine. This change would favour the permeation of their 
modified compounds far more efficiently through the lipoid layer of the test microorganism, 
thereby destroying them more aggressively. 
 
4.4.2 Synthetic Silicon Containing Compounds with Activity against Cancer Lines 
 
4.4.2.1 The (2R,3S)-Disubstituted Tetrahydropyranes 
 
In 2005 Padrón and co-workers
111
 published an interesting article in which they showed that 
the tert-butyldimethylsilyl group could act as an enhancer to drug cytotoxicity against human 
tumour cells. 
 
The group constructed a series of enantiomerically pure (2R,3S)-disubstituted 
tetrahydropyranes with diverse functionalities using known methodologies, selected examples 
are given in Figure 47 (compounds 188-199). In addition to the tert-butyldimethylsilyl group, 
other common protecting groups for the hydroxyl functionality, such as allyl, acetate and 
benzoate, were also used to obtain appropriate derivatives (not pictured here).  
 
The pure compounds were then evaluated in vitro against HL60 human leukemia cells and 
MCF7 human breast cancer cells. The synthetic derivatives bearing the tert-butyldimethylsilyl 
group at position 3 of the ring considerably induced cytotoxicity in the cancer cells.
111
 On the 
basis of the growth inhibition parameters, a structure-activity relationship was obtained. 
Overall the results show that the tert-butyldimethylsilyl group may not only be seen as a 
protecting group for organic synthesis, but as a plausible strategy to introduce lipophilicity in 
drugs, which is anticipated to aid in their cellular uptake and may thus act to modulate their 
cytotoxic activity. 
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Figure 47 Compounds screened for cytotoxicity against human tumour cells by Padrón and 
co-workers
111 
 
The group did further studies into the enhancement of drug cytotoxicity by silicon-containing 
groups, by further screening the above compounds and some more advanced derivatives 
against T-47D, HeLa, SW1573, WiDr and A2780 cells in vitro, thus obtaining representative 
results for a wide range of solid tumour cell lines. The results obtained were published in 
2006
112
 and supported the conclusions drawn in the paper discussed above. 
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4.4.2.2 The Silatecans 
 
(20S)-Camptothecin (20S)-155 is the parent of a family of anti-tumour agents that are 
currently on the front lines of cancer chemotherapy. Topotecan 200 has been approved for use 
in the USA and the prodrug irinotecan 201 has been approved for use in the USA, France and 
Japan.
113
 A number of other related agents have shown some promising results and are 
currently in various stages of clinical trials.
113 
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Figure 48 The camptothecin family of anti-tumour agents 
 
Related variants of a cascade radical annulation route, developed by the Curran group
113
, were 
used to prepare a range of new substituted (20S)-7-silylcamptothecins (silatecans). A series of 
unsubstituted 7-silylcamptothecins were also prepared using the standard Friedlander 
methodology.
113
 A selection of these derivatives are outlined in Figure 49. 
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Figure 49 Selected examples of the 7-silylcamptothecins (silatecans) 
 
The camptothecin derivatives were evaluated for their inhibition effects on the growth of 
HL60 (human promyelocytic leukemia), 833K (human teratorcarcinoma) and DC-3F (hamster 
lung) cells in vitro.113 The authors found that all of the new compound were as potent, or 
more potent than camptothecin 155. This is important because even by today’s standards, 
camptothecin 155 is still regarded as a challenging benchmark, whose activity is not easy to 
surpass. The results also showed that the 7-trimethylsilyl-10-camptothecin derivative 206 is 
highly active.
113
  
 
Compound 202 showed superior in vivo chemotherapeutic effects, when compared to 
camptothecin 155, in tumour bearing mice. This superior activity was recorded in terms of 
tumour volume reduction against sarcoma-180 in B6D2F1 mice at several equivalent doses.
113
 
For Lewis lung carcinoma, compound 203 showed a comparable anti-tumour effect to 
camptothecin 155, at a four-fold lower dose. This shows that there is clear promise that the in 
vitro results will be indicative of in vivo activity for this class of compounds. 
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4.4.2.3 The Indomethacin Derivatives 
 
Indomethacin 207 is a non-steroidal anti-inflammatory drug (NSAID) which is indicated for 
use in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis.
114
 Indomethacin 207 has 
also demonstrated activity in the treatment and prevention of human cancer;
115-118
 however, 
the adverse side-effects have limited its use in cancer patients. In a study by West and co-
workers,
114
 the synthesis and biological testing of a series of sila-substituted derivatives 208-
210 of indomethacin 207 was reported, which the researchers had prepared in an effort to 
improve the safety and biological activity of indomethacin. It was shown how an 
organosilicon fragment was introduced into indomethacin 207 by converting the carboxylic 
acid group into a sila-amide (Figure 50).  
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209: R1,R2,R3 = Me, n = 1
210: R1,R2 = Me, R3 = Ph, n = 3
Indomethacin
207
 
 
Figure 50 Structure of indomethacin 207 and the silicon-containing amide derivatives of 
indomethacin 208-210
114 
 
The cell growth inhibitory activity for the sila-indomethacin derivatives 208-210 was 
determined against the human MiaPaCa-2 pancreatic cell line. The sila-derivatives 
demonstrated significant inhibition of cancer cell growth: indomethacin 207 itself had a IC50 
value of 170 μM when tested against the human MiaPaCa-2 cells, whereas West and co-
workers
114
 demonstrated IC50 values of 4.78 μM (210) to 20.0 μM (209) for their sila-
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indomethacin derivatives. Using in vitro pharmacology (enzyme assays) they were also able 
to demonstrate that the sila-indomethacin derivatives 208 and 210 were selective COX-2 
inhibitors that were superior to indomethacin 207. 
 
4.4.2.4 The Nucleoside Derivatives 
 
In a paper investigating the kinetics and biological implications of the silylation-desilylation 
of the triorganosilyl derivatives of some biologically active heterocyclic bases (5-fluorouracil, 
barbituric acid and xanthine derivatives) and uridine, Lukevits and co-workers
119
 showed that 
in contrast to uridine, 5’-O-tert-butyldimethylsilyluridine 229 (Figure 51) exhibited some 
anti-tumour activity. 
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Figure 51 Trialkylsilyl derivatives of some heterocyclic bases and uridine
119 
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The tert-butyldimethylsilyl groups appear able to temporarily block the hydrophilic functions 
of the molecules and do not undergo instant hydrolysis, and were chosen by the group as the 
tert-butyldimethylsilyl chloride is commercially available. The results for the biological trials 
were compared to data obtained for the unsilylated precursors. Lukevits and co-workers
119
 
were able to show that 5’-O-tert-butyldimethylsilyluridine 229 suppressed the development of 
HT-1080 (fibrosarcoma in human lungs – 96 % inhibition at 100 μg/mL) and NiH 3T3 cells 
(fibroblasts in mice – 95 % inhibition at 100 μg/mL) in culture. Under the same conditions, 
uridine 12 showed a complete absence of any activity. 
  
A more recent example of a nucleoside derivative exhibiting anti-cancer activity was reported 
by Fenlon and co-workers.
120
 The paper describes the syntheses and anti-cancer screening 
results for 3’-O-silatranylthymidines (shown in Figure 52). 
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Figure 52 Examples of 3’-O-silatranylthymidines prepared by Fenlon and co-workers120 
 
The diasteriomeric mixture of 3’-O-(trimethylsilatranyl)thymidine 231 was assayed against 
human breast (MDA-MB-435) and central nervous system (SNB-19 and U251) cancer cell 
lines at a fixed concentration (1.0 × 10
-4
 M) of compounds for a 48 hour period. They found 
that the growth percentages from cells treated with compound 231 were: (i) breast 54 % and 
(ii) central nervous system 83 %, when compared to untreated control cells (growth = 100 %). 
In the case of silatranylthymidine 232, no activity was observed in the central nervous system 
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and lung cells, with 81 % growth seen in the breast cell line (which correlates to 19 % 
inhibition of growth). 
  
Since 231 is a mixture of four diasteriomers, it would be expected that each of the individual 
diasteriomers would have different activity, given that it is widely accepted that 
stereochemistry influences pharmacological activity according to the preliminary 
publication.
120
 Work on the synthesis and screening of each of the individual diasteriomers is 
ongoing in the group. 
 
4.5 AIMS FOR PART 2  
 
4.5.1 Synthesis of Nucleoside Derivatives 
 
The results of the biological testing of our "first generation" of compounds described in detail 
in Part 1, Chapter 3, highlighted the concept that molecules containing the silicon protecting 
group (tert-butyldiphenylsilyl, found in 5’-O-(tert-butyldiphenylsilyl)uridine 107 and 5’-O-
(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-ribose 102), were specifically active against the 
Gram-positive bacterial strains, Staphylococcus aureus ATCC 25923 and Bascillus cereus 
DL5. These findings were supported by our literature review (described in detail in Section 
4.4.1), which highlighted the importance of silicon-containing groups in biologically active 
molecules.  
 
In our cell proliferation studies, described in Part 1, we found that 5’-O-(tert-
butyldiphenylsilyl)uridine 107 and 5’-O-(tert-butyldiphenylsilyl)cytidine 134 were active 
against both the suspension (HL-60, Jurkat and K-562) and adherent (HT-29 and Caco-2) cell 
lines assayed. The interest in the use of silicon-protecting groups to enhance the anti-cancer 
properties of synthetic compounds was further supported by our literature review findings 
(discussed in detail in Section 4.4.2).  
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Based on these findings, the decision was taken to synthesise a "second generation" of 
compounds that contained various other silicon protecting groups, to determine if these results 
suggested a general trend of activity or if they were specific to the tert-butyldiphenylsilyl 
group.  
 
From the data reported for the anti-bacterial and the cell proliferation studies as well as 
literature precedent,
120
 we concluded that the nucleoside showing the most promising results 
was uridine 12 and as such it would be the nucleoside of choice for the "second generation 
compounds" to be synthesised. Our mini structure-activity study on the uridine derivatives 
found that the best position for performing modifications to the nucleoside was at the 5'-OH 
position on the sugar ring and as such this would become the initial focus for the synthesis of 
the "second generation compounds". 
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Figure 53 Proposed second generation silicon-protected uridine 12 and 5-methyluridine 233 
derivatives 
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The proposed “second generation compounds” included a series of uridine 12 and 5-
methyluridine 233 derivatives which were protected on the primary alcohol with a range of 
different sized silicon-containing protecting groups. We hoped that this would allow us to find 
the optimally sized silicon-containing protecting group that would impart good biological 
activity. An overview of the proposed synthetic derivatives is given in Figure 53. 
 
4.5.2 Synthesis of Silanols 
 
In Part 1, we were intrigued when we observed that tert-butyldiphenylsilyl alcohol 145 
exhibited similar anti-bacterial activity against the Gram-negative strains. During our 
literature review, we found only one other example of this trend – where it was reported by 
Kim and co-workers
107-109
 that trimethylsilanol 175 and triethylsilanol 176 also exhibited an 
inhibitory effect against one each of the Gram-negative and Gram-positive bacteria. 
 
In our cell proliferation studies, described in Part 1, we found that tert-butyldiphenylsilyl 
alcohol 145 exhibited activity against only the adherent (HT-29 and Caco-2) cell lines 
assayed. To the best of our knowledge, this is the first reported example of a silanol showing 
any anti-cancer activity. As a class, we believed that the silanols would warrant further 
investigation. 
 
As such, we decided to include a range of silanols of varying molecular sizes for evaluation of 
biological activity. We envisaged that we would include a range of all of the different 
“molecular sizes” and also included all of the silicon-containing protecting groups we 
proposed to work with when preparing the nucleoside derivatives as control substances. An 
overview of the proposed silanols to be tested is given in Figure 54. 
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Figure 54 Proposed silanols to be included in the second generation of compounds 
 
4.5.3 Biological Testing 
 
We then envisaged that we would assay all of our second generation silicon-protected uridine 
12 and 5-methyluridine 233 derivatives, and the corresponding silanols, for anti-bacterial 
activity against the same two Gram-negative bacterial strains (Pseudomonas aeruginosa 
ATCC 27853 and Escherichia coli ATCC 25922) and the same two Gram-positive bacterial 
strains (Staphylococcus aureus ATCC 25923 and Bascillus cereus DL5) that were used in 
Part 1.  
 
As an extension to the biological testing, we planned to screen our second generation of 
compounds against a wider range of cancer cell lines than initially used in Part 1 in order to 
more accurately determine their selective ability for the inhibition of cancerous cell 
proliferation. 
 
4.5.4 Summary of Aims 
 
To summarise, the general synthetic aims for our "second generation compounds" were sub-
divided into three parts:  
(i) to synthesise a range of silicon-protected uridine derivatives 
(ii) to synthesise a range of silicon-protected derivatives of 5-methyluridine and  
P a g e  | 180 
 
(iii) to synthesise the range of corresponding silanols. 
 
This was to be followed by the biological testing of our “second generation compounds” 
which would be broken down into two parts: 
(i) to screen our compounds for anti-bacterial activity against two Gram-positive 
and two Gram-negative bacteria 
(ii) to perform cell proliferation studies against a broader range of cancer cell lines 
than initially used. 
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Chapter 5: 
Results and Discussion for Synthesis 
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CONTRIBUTIONS TO THIS CHAPTER 
All of the syntheses and compound characterization described in this chapter were performed 
by Ms J.-L. Panayides, while under the supervision of Prof W.A.L. van Otterlo. The work was 
undertaken in the School of Chemistry which forms part of the Molecular Sciences Institute at 
the University of the Witwatersrand. 
 
 
5.1 CHAPTER OVERVIEW 
 
This chapter outlines the synthesis of a range of uridine and 5-methyluridine derivatives. 
These were prepared through the addition of various silicon-containing protecting groups at 
either the 5'-O-position or tethered to both the 3'-O- and 5'-O-positions on the sugar ring, 
followed by subsequent modifications at either the amide position on the base (3-NH) or at 
the secondary alcohol on the sugar ring (2'-OH). At the same time all of the silyl-chlorides 
used as the silicon-containing protecting groups were converted into the corresponding 
silanols to be used as controls for our subsequent biological assays. In total, a range of 15 
unique nucleoside derivatives and 13 silanols were prepared as a second generation of 
compounds for testing as possible anti-bacterial and/or anti-cancer agents. 
 
5.2 RESULTS AND DISCUSSION 
 
As discussed in the introduction (Chapter 4, Section 4.5.4) the general synthetic aims were 
sub-divided into three parts: (i) the synthesis of uridine derivatives, (ii) the synthesis of 
derivatives of 5-methyluridine and (iii) the synthesis of the corresponding silanols. 
 
Full experimental details for this section, including the reaction setups used and full analysis 
of all NMR, infrared and mass spectral data, as well as optical rotations, melting points and Rf 
values are given in Appendix D (Experimental Procedures – Relating to Chapter 5). NMR 
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spectral data for representative examples of the various classes of compounds prepared in this 
chapter are provided in the Supporting Information provided on the attached DVD. 
 
5.2.1 Synthesis of Uridine Derivatives 
 
We began our synthesis of a range of uridine derivatives by first using the 1,1,3,3 -
tetraisopropyldisiloxane protecting group looking at various modifications to the tethered 
protected system. This was followed by the synthesis of a wide range of uridine derivatives, 
all protected at only the 5'-O-position on the sugar ring with various silicon-containing 
protecting groups - starting with the small dimethyethylsilyl chloride and moving up through 
the range to the very bulky trihexylsilyl chloride group.  We hoped that using a range of 
various sized silicon-containing protecting groups would allow us to determine which size 
range was optimal for biological activity in the compounds. 
 
5.2.1.1 Uridine Derivatives Containing the 3'-O to 5'-O-Tethered Protecting Group 
 
To date, the 1,1,3,3-tetraisopropyldisiloxane protecting group has found frequent use in 
nucleoside chemistry and an overview of the approach used for the synthesis of the tethered 
1,1,3,3-tetraisopropyldisiloxane protected uridine derivatives is shown in Scheme 21. The 
initial step, Step (i), shows the protection of both the 3'-OH and 5'-OH groups on uridine 12 
simultaneously using a small excess of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane in the 
presence of pyridine as both the base and the solvent for the reaction. The reaction mixture 
obtained was evaporated, subjected to extraction procedures and then purified by column 
chromatography. The desired compound, 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-
tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-
dione 234 was obtained as a white foam in 85 % yield.  
 
The spectroscopic data obtained correlated well with the literature values (both 
1
H and 
13
C 
NMR spectra) reported previously by Matsuda and co-workers.
121
 The four CH(CH3)2 protons 
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and twenty four CH(CH3)2 protons were observed together as a multiplet integrating for 28 H 
at 1.02-1.10 ppm in the 
1
H NMR spectrum. In the 
13
C NMR spectrum, the four new SiCH 
carbons were observed as peaks at 12.42, 12.88, 12.93 and 13.33 ppm, while the eight new 
CH3 groups were observed as peaks at 16.76, 16.88, 16.92, 16.99, 17.20, 17.25, 17.34 and 
17.43 ppm respectively. Interestingly, a new Si-CH stretch was also observed in the infrared 
spectrum, at 1247 cm
-1
. 
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Scheme 21 Synthesis of TIPDS derivatives: (i) 1.05 eq. 1,3-dichloro-1,1,3,3-
tetraisopropyldisiloxane, pyridine, 0 
o
C - rt, 21 h, 85 %, (ii) 1.3 eq. benzoyl chloride, 7.7 eq. 
Na2CO3, 0.04 eq. tetrabutylammonium bromide, CH2Cl2 : H2O (1 : 2), rt, 2 h, 99 %, (iii) 2.5 
eq. allyl bromide, 2.5 eq. NaH, THF, rt, 23 h, 21 %, (iv) 2.5 eq. crotyl bromide, 2.5 eq. NaH, 
THF, rt, 23 h, 0 %, (v) 2.5 eq. cinnamyl bromide, 2.5 eq. NaH, THF, rt, 23 h, 0%  
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Step (ii) shows the protection of the 3-N-amide as the corresponding benzoyl derivative. The 
reaction was performed by dissolving the starting material 234, sodium carbonate and 
tetrabutylammonium bromide in a two-phase solution of dichloromethane and distilled water. 
To this mixture was then added the excess benzoyl chloride and the reaction mixture was 
allowed to stir very vigorously at room temperature. The reaction mixture was then purified 
by extraction and the residue obtained was dissolved in 1,2-dichloroethane and allowed to 
stand at room temperature for 66 hours. This step was performed to allow the O-/N-
rearrangement to occur. After this time the residue obtained after evaporation was purified by 
column chromatography. The desired compound 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-
2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4-
(1H,3H)-dione 235 was obtained as a white foam in 99 % yield.  
 
We were able to show that the desired 3-N-benzoyl compound had formed by the 
disappearance of the broad singlet integrating for one proton at 9.64 ppm in the 
1
H NMR 
spectrum of the starting material, and the occurrence of new peaks at 7.50 (t, J = 7.7 Hz), 7.66 
(t, J = 7.4 Hz) and 7.93 ppm (d, J = 7.2 Hz), which were assigned as H-3*, H-4* and H-2* 
respectively. This assignment of structure was further supported by the presence of new peaks 
in the 
13
C NMR spectrum at 129.11 (C-3
*
), 130.43 (C-2
*
), 131.38 (C-1
*
), 135.10 (C-4
*
) and 
168.53 (Ph-C=O) ppm. We also observed the characteristic signal at 762 cm
-1
 in the 
fingerprint region of the infrared spectrum for 5 adjacent aromatic protons. In addition, it was 
found that all assignments reported for compound 235 correlated well to those previously 
reported by Sekine.
122
  
 
Scheme 21, Step (iii) shows the deprotonation of the secondary alcohol at the 2'-position on 
the sugar ring, using sodium hydride as the base in the solvent THF. This was followed by the 
reaction of the O
-
 with an excess of allyl bromide, to give the desired compound 236 as a clear 
oil in 21 % yield after purification by extraction and column chromatography.  
 
The formation of 3-benzoyl-1-[(6aR,8R,9R,9aR)-9-allyl-9-hydroxy-2,2,4,4-tetraisopropyl-
tetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 236 
was indicated clearly in the 
1
H NMR spectrum by the loss of the broad singlet at 2.04 ppm 
P a g e  | 186 
 
assigned as OH-2' for the starting material, and the appearance of the new doublet of doublets 
at 4.39 ppm integrating for 2 H and assigned as OCH2, the two doublet of doublets at 5.21 and 
5.39 ppm, each integrating for 1 H and assigned as CH=CH2 and finally, the multiplet at 5.81-
5.95 ppm integrating for 1 H and assigned as CH=CH2. Similarly, new peaks were observed 
at 71.22, 117.41 and 134.27 ppm in the 
13
C NMR spectrum, correlating to OCH2, CH=CH2 
and CH=CH2 respectively.  
 
As outlined in Step (iv) and Step (v) of Scheme 21, the deprotonated secondary alcohol on the 
2'-position of the sugar ring was also reacted with crotyl- and cinnamyl bromide respectively, 
using the same conditions as outlined for the reaction with allyl bromide (Step (iii), Scheme 
21). Unfortunately, after work-up by extraction and purification by column chromatography, 
neither of these reactions yielded any of the desired compounds 237 and 238. Due to the time 
constraints of the project, this approach was not investigated further. 
 
Shown schematically in Scheme 22 is the oxidation of the secondary alcohol, 2'-OH on the 
sugar ring, followed by attempts made at the derivitisation of the ketone. As stated, Step (i) 
shows the reaction of our protected uridine derivative 234 with the pre-formed oxidation 
complex (prepared from chromium (VI) trioxide, pyridine and acetic anhydride). After 
stirring at rt for two hours, the reaction mixture was added dropwise into stirring ethyl acetate 
and the resulting suspension was pumped through a short silica gel column to remove the 
chromium precipitates. The filtrate obtained was then concentrated to dryness and the residue 
obtained was purified by column chromatography. The desired compound 1-[(6aR,8R,9aR)-
2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilo-cin-8-yl]pyrimi-
dine-2,4(1H,3H)-dione 239 was obtained pure as a white foam in 80 % yield. 
 
NMR spectroscopic data obtained for compound 239 correlated well to that reported by 
Matsuda and co-workers.
121 
 We observed the disappearance of the broad singlet present at 
3.62 ppm, and assigned as OH-2',  in the 
1
H NMR spectrum for the starting material. 
Similarly, a new peak at 204.72 ppm was observed in the 
13
C NMR spectrum accounting for 
the formation of the new carbonyl in the 2'-position of the sugar ring. Interestingly, the 
characteristic new carbonyl group on the sugar ring of the molecule gave rise to a peak at 
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1724 cm
-1
 in the infrared spectrum and caused the optical rotation values to shift from 15.596
o
 
(c = 1.09 in CH2Cl2) for the starting material to -17.822
o
 (c = 1.01 in CH2Cl2) for the newly 
formed product 239. 
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Scheme 22 Synthesis of other TIPDS derivatives: (i) Oxidation complex: 3 eq. chromium (VI) 
trioxide : 6 eq. pyridine : 3 eq. acetic anhydride, CH2Cl2, rt, 2 h, 80 %, (ii) 7 eq. methyl 
triphenylphosphonium bromide, 7 eq. n-butlyllithium, THF, 0 oC - rt, 3 h, 0 %, (iii) 5 eq. 
vinyl magnesium bromide, THF, -60 oC, 20 h, 0 %, (iv) 5 eq. allyl magnesium bromide, THF, 
-60 
o
C, 18 h, 38 % based on recovery of unreacted starting material 
P a g e  | 188 
 
Shown in Step (ii) of Scheme 22 is our attempt at the Wittig reaction to convert the C=O in 
the 2'-position of the sugar ring to a C=CH2. The reaction was performed by stirring the 
methyl triphenylphosphonium bromide in THF until a suspension had formed and then adding 
to this suspension the n-butyllithium. The reaction immediately changed colour and was 
allowed to stir at 0 
o
C until all of the suspended particles had dissolved. To the stirring 
solution was then added compound 239 batch-wise. After 3 hours tlc indicated consumption 
of the starting material, so the reaction was worked-up by extraction and purified by column 
chromatography. Unfortunately, none of the desired compound 240 was obtained after 
chromatography.
121b 
 
Step (iii) of Scheme 22 shows our first attempt at the Grignard addition to compound 239. 
The solution was formed of the starting material 239 in THF and was then cooled to -60 
o
C, 
before the addition of the excess vinyl magnesium bromide. After stirring overnight, the 
reaction mixture was worked-up by extraction and purified by column chromatography. None 
of the desired compound 241, was isolated after purification.
121b 
 
As outlined in Step (iv) of Scheme 22, is the second attempt at the Grignard addition to the 
oxidised TIPDS-uridine derivative 239. Again, a solution was formed of the starting material 
239 in THF and this was cooled to -60 
o
C, before the addition of the excess allyl magnesium 
bromide. The reaction mixture was allowed to stir at -60 
o
C overnight and was then worked-
up by extraction and purified by column chromatography. The desired compound 242 was 
obtained as a clear oil in 38 % yield based on the recovery of unreacted starting material. rac-
1-[(6aR,8R,9S,9aR)-Tetrahydro-9-allyl-9-hydroxy-2,2,4,4-tetraiso-propyl-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 242 was identified by the 
appearance of a broad singlet at 2.48 ppm integrating for 1 H (assigned as OH-2') and by the 
appearance of characteristic peaks for the allyl chain: multiplet integrating for 2 H at 2.70-
2.72 ppm (OCH2), multiplet integrating for 2 H at 5.33-5.37 ppm (CH=CH2) and a multiplet 
integrating for 1 H at 6.05-6.09 ppm (CH=CH2) in the 
1
H NMR spectrum . This was further 
supported by the appearance of new peaks in the 
13
C NMR spectrum at 36.80 ppm for the 
OCH2 group, at 121.10 ppm for the CH=CH2 and at 130.19 ppm for the CH=CH2. Final 
confirmation was given by the presence of a peak assigned as [M + H]
+
 at 527.26033 in the 
HRMS, with C24H43N2O7Si2
+
 requiring a peak of 527.26033. 
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5.2.1.2 Uridine Derivatives with Various 5'-O-Protecting Groups 
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Scheme 23 Synthesis of 5'-O-protected uridine derivatives: General Procedure for Steps (i)-
(viii): 1.1 eq. silyl chloride, 0.1 eq. DMAP, pyridine, rt, 18-22 h, (i) 0 %, (ii) 0 %, (iii) 0 %, 
(iv) 45 %, (v) 88 %, (vi) 27 %, (vii) 99 %, (viii) 31 % 
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The synthesis of 5'-O-protected uridine derivatives is shown in detail in Scheme 23. The 
general procedure used in Steps (i) - (viii) was to fill all glassware required for the reactions 
with a 5 % trimethylsilyl chloride : hexane solution and allow it to stand at room temperature 
overnight. After this time, the glassware was oven-dried, placed under high vacuum and 
allowed to cool to rt under an argon atmosphere. This was step was performed in order to 
“silylate” the surface of the glassware, it was found to have a significant effect and leading to 
improvement on the overall reaction yields.  
 
The uridine 12 and a catalytic amount of DMAP were then stirred with distilled pyridine until 
a solution had formed. To this stirring solution was then added the excess silyl chloride and 
the reaction mixture was allowed to stir at rt overnight (18-22 h). After this time, the reactions 
were worked up by extraction and if required by crude NMR, purified further by column 
chromatography. The results obtained are summarized in Table 21. 
 
Table 21 Reaction conditions and results obtained for the synthesis of 5'-O-protected uridine 
derivatives 
Compound 
Code 
Protecting  
Group 
Further  
Purification 
Percentage 
Yield 
243 Chlorodimethylethylsilane Not Required 0 % 
244 Dimethylvinylchlorosilane Not Required 0 % 
245 Allyldimethylsilyl chloride Not Required 0 % 
246 Triisopropylsilyl chloride Column Chromatography 45 % 
229 tert-Butyldimethylsilyl chloride Column Chromatography 88 % 
247 Chlorotriisobutylsilane Column Chromatography 27 % 
248 Dimethylthexylsilyl chloride Not Required 99 % 
249 Chlorotrihexylsilane Column Chromatography 31 % 
 
The formation of the 5'-O-protected uridine derivatives was confirmed through the use of 
proton and carbon NMR spectroscopy, as well as low and high resolution mass spectrometry.  
Unfortunately, the preparations for compounds 243, 244 and 245 were unsuccessful, with 
none of the desired compounds being obtained. We suspect that this may be due to the 
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unstable nature of the compounds themselves, but this could not be confirmed as none of the 
desired compounds could be isolated after column chromatography. 
 
The preparation of 5'-O-(triisopropylsilyl)uridine 246 was confirmed by the presence of a new 
multiplet in the 
1
H NMR spectrum at 1.04-1.14 ppm integrating for 21 H, accounting for the 
three CH(CH3)2 protons and the eighteen CH(CH3)2 protons. This was supported by the 
presence of two new peaks in the 
13
C NMR spectrum at 11.90 and 17.94 ppm, assigned as the 
CH(CH3)2 and CH(CH3)2 carbons respectively. For the compound C18H33N2O6Si
+
, the HRMS 
required a peak at 401.21024 and we observed a peak at 401.20968 which is effectively the 
[M + H]
+
 peak. 
 
The synthesis of 5'-O-(tert-butyldimethylsilyl)uridine 229 was shown by the presence of 
peaks at 0.12 (6 H, singlet) and 0.92 (9 H, singlet) ppm accounting for Si(CH3)2 and C(CH3)2 
in the 
1
H NMR spectrum. The corresponding peaks were also observed at -5.55 (Si(CH3)2), 
18.40 (C(CH3)2) and 25.90 (C(CH3)2) ppm in the 
13
C NMR spectrum. Final confirmation for 
the formation of the desired compound was given by the presence of a peak at 359.16336 in 
the HRMS which is found to be for [M + H]
+
 (C15H27N2O6Si
+
 requires 359.16329). 
 
5'-O-(Triisobutylsilyl)uridine 247 was identified by the appearance of a doublet of doublets at 
0.67 ppm integrating for 6 H (assigned as the three SiCH2's) as well as by the appearance of 
characteristic peaks in the 
1
H NMR spectrum for the CH(CH3)2 at 0.96 and 1.83 ppm, which 
are assigned as CH(CH3)2  (18 H, doublet, J = 6.6 Hz) and CH(CH3)2 (3 H, septet, J = 6.6 Hz) 
respectively. The formation of 247 was further supported by the appearance of new peaks in 
the 
13
C NMR spectrum at 24.20 ppm for CH(CH3)2, 24.99 ppm for SiCH2 and 26.36/26.43 
ppm for CH(CH3)2. Final confirmation was given by the presence of a peak assigned as [M + 
H]
+
 at 443.25685 in the HRMS, with the M
+
 peak for C21H39N2O6Si
+
 calculated as 443.25719. 
 
Furthermore, the preparation of 5'-O-(dimethylthexylsilyl)uridine 248 was confirmed by the 
presence of a new singlet in the 
1
H NMR spectrum at 0.02 ppm integrating for 6 H, 
accounting for the three Si(CH3)2 protons, as well as a doublet of doublets at 0.75 ppm 
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integrating for 12 H as assigned as CH(CH3)2 plus C(CH3)2, and lastly, a septet at 1.50 ppm 
integrating for 1 H and assigned as the CH(CH3)2 peak. This was supported by the presence of 
five new peaks in the 
13
C NMR spectrum at -3.49, 18.44, 20.20, 25.41 and 34.06 ppm, 
assigned as the Si(CH3)2, C(CH3)2, CH(CH3)2, C(CH3)2 and CH(CH3)2 carbons respectively. 
For the compound C17H31N2O6Si
+
, the HRMS required a peak at 387.19459 and we observed 
a peak at 387.19505 which is effectively the [M + H]
+
 peak. 
 
Finally, the synthesis of 5'-O-(trihexylsilyl)uridine 249 was shown by the presence of peaks at 
0.60-0.65 (multiplet, 6 H), 0.88 (triplet, 9 H) and 1.27-1.30 (multiplet, 24 H) ppm accounting 
for the SiCH2, CH3 and SiCH2CH2CH2CH2CH2CH3 protons respectively, in the 
1
H NMR 
spectrum. The corresponding peaks were observed at 13.32 (SiCH2), 14.09 (CH3) and 
22.56/23.04/31.46/33.23 (SiCH2CH2CH2CH2CH2CH3) ppm in the 
13
C NMR spectrum. Final 
confirmation for the formation of the desired compound was given by the presence of a peak 
at 527.35042 in the HRMS which is found to be for [M + H]
+
 (C27H51N2O6Si
+
 requires 
527.35109). 
 
5.2.2 Synthesis of 5-Methyluridine Derivatives 
 
In order to determine if a methyl group at the 5-position on the base would affect the activity 
of the compounds, we synthesized five derivatives of 5-methyluridine protected at the 5'-O-
position on the sugar ring, which correlated to derivatives previously prepared for uridine. We 
then anticipated that we would be able to compare the activity of the corresponding 5-
methyluridine and uridine derivatives to correlate activity. This biological testing is discussed 
in detail in Chapter 6 (anti-bacterial assays) and Chapter 7 (anti-cancer assays).  
 
Scheme 24, Step (i) shows the preparation of 5'-O-(tripropylsilyl)-5-methyluridine 250 by the 
reaction of uridine 12 with excess chlorotripropylsilane in the presence of a catalytic amount 
of DMAP and pyridine (acting as both the base and the solvent for this reaction). After 
purification by column chromatography, the desired compound 250 was obtained pure as a 
white semi-solid in a low yield of 19 % yield. 
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The synthesis of 5'-O-(tripropylsilyl)-5-methyluridine 250 was shown by the presence of three 
new multiplets in the 
1
H NMR spectrum, at 0.61-0.67 ppm integrating for 6 H, at 0.94-0.99 
ppm integrating for 9 H and at 1.33-1.42 ppm integrating for 6 H, accounting for the SiCH2, 
CH2CH3 and CH2CH3 groups respectively. The corresponding peaks were observed at 12.48 
ppm (SiCH2), 16.73 ppm (CH2CH3) and 18.34 ppm (CH2CH3) in the 
13
C NMR spectrum. 
Final confirmation for the formation of the desired compound 250 was given by the presence 
of a peak at 415.22569 in the HRMS which is found to be for [M + H]
+
 (C19H35N2O6Si
+
 
requires 415.22589). 
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Scheme 24 Synthesis of 5-methyluridine derivatives: (i) 1.1 eq. chlorotripropylsilane, 0.1 eq. 
DMAP, pyridine, rt, 21 h, 19 %, (ii) 1.1 eq. tert-butyldimethylsilyl chloride, 0.1 eq. DMAP, 
pyridine, rt, 20 h, 93 %, (iii) 1.1 eq. dimethylthexylsilyl chloride, 0.1 eq. DMAP, pyridine, rt, 
21 h, 80 %, (iv) 1.1 eq. tert-butyldiphenylsilyl chloride, 0.1 eq. DMAP, pyridine, rt, 20 h, 100 
%, (v) 1.05 eq. 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, pyridine, 0 
o
C - rt, 20 h, 40 % 
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Shown in Step (ii) of Scheme 24 is the protection of the primary alcohol in the 5'-position of 
the sugar ring using tert-butyldimethylsilyl chloride as the protecting group. The reaction 
occurred in the presence of a catalytic amount of DMAP and used pyridine as both the base 
and the solvent for the reaction. The desired compound, 5'-O-(tert-butyldimethylsilyl)-5-
methyluridine 251, was obtained pure as a white powder after extraction and as such no 
further purification was required. The compound 251 was obtained in 93 % yield from its 
direct synthetic precursor, in this case 5-methyluridine 233.  
 
5'-O-(tert-Butyldimethylsilyl)-5-methyluridine 251 was identified by the appearance of two 
singlets at 0.15 and 0.16 ppm integrating for 6 H [assigned as the Si(CH3)2 groups] as well as 
by the appearance of a characteristic singlet at 0.96 ppm, integrating for 9 H, which is 
assigned as the C(CH3)3 group in the 
1
H NMR spectrum. The formation of 251 was further 
supported by the presence of a peak assigned as [M + H]
+
 at 373.17903 in the HRMS, with 
C16H29N2O6Si
+
 requiring a peak at 373.17894. Interestingly, new bands were observed in the 
infrared spectrum, at 1362 and 1388 cm
-1
 for the CH3 symmetrical deformations on the newly 
added tert-butyl group, and other new bands were also observed at 831 cm-1 in the fingerprint 
region and at 1258 cm
-1
 for the Si-CH3 stretching. 
 
Outlined in Step (iii) of Scheme 24 is the reaction of 5-methyluridine 233 with 
dimethylthexylsilyl chloride in the presence of DMAP and pyridine. After stirring at room 
temperature under an argon atmosphere for 21 hours, the reaction was quenched by the 
addition of distilled water and worked-up by extraction. The desired compound, 5'-O-
(dimethylthexylsilyl)-5-methyluridine 252, was obtained pure as a white solid in 80 % yield 
after extraction; thus further purification was not required. 
 
The preparation of 5'-O-(dimethylthexylsilyl)-5-methyluridine 252 was confirmed by the 
presence of three new peaks in the 
1
H NMR spectrum: a singlet at 1.00 ppm integrating for 6 
H and assigned as Si(CH3)2, a doublet of doublets at 1.75 ppm integrating for 12 H and 
assigned as CH(CH3)2 plus C(CH3)2 and finally, a septet at 1.49 ppm integrating for 1 H and 
assigned as CH(CH3)2. For the compound C18H33N2O6Si
+
, the HRMS required a peak at 
401.21024 and we observed a peak at 401.20968, which is effectively the [M + H]
+
 peak. 
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Step (iv) of Scheme 24 shows the reaction of 5-methyluridine 233 with tert-butyldiphenylsilyl 
chloride. The reaction occurs in the presence of a catalytic amount of DMAP and uses 
pyridine as both the base and the solvent for the reaction. The desired compound, 5'-O-(tert-
butyldiphenylsilyl)-5-methyluridine 253, was obtained pure as a white foam after extraction 
and azeotropic distillation of the pyridine using toluene as the co-solvent, in an excellent 
quantitative yield. 
 
The synthesis of 5'-O-(tert-butyldiphenylsilyl)-5-methyluridine 253 was shown by the 
presence of a new singlet at 1.12 ppm (integrating for 9 H) and new multiplets at 7.40 -7.43 
(integrating for 6 H) and 7.68-7.71 ppm (integrating for 4 H), accounting for Si(CH3)3, H-3
*
 
plus H-4
*
 and H-2
*
 respectively, in the 
1
H NMR spectrum. Final confirmation for the 
formation of the desired compound was given by the presence of a peak at 497.20971 in the 
HRMS which is found to be for [M + H]
+
 (C26 H33N2O6Si
+
 requires 497.21024). 
 
Scheme 24, Step (v) shows the preparation of 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-
2,2,4,4-tetraisopropyl-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4-
(1H,3H)-dione 254, by the reaction of 5-methyluridine 233 with excess 1,3-dichloro-1,1,3,3-
tetraisopropyldisiloxane in the presence of pyridine as both the base and the solvent for the 
reaction. The reaction mixture was stirred at room temperature under an argon atmosphere for 
20 hours, was worked-up by extraction and then purified by column chromatography. The 
desired compound 254, was obtained in 40 % yield as a white foam after purification.  
 
Compound 254 was identified by the appearance of a new multiplet at 1.04-1.10 ppm 
integrating for 28 H in the 
1
H NMR spectrum, which was assigned to the four CH(CH3)2 and 
the four CH(CH3)2 groups in the molecule. The formation of 254 was further supported by the 
appearance of new peaks in the 
13
C NMR spectrum at 12.45, 12.57, 12.68 and 12.93 ppm for 
the four CH(CH3)2 carbons, and at 16.81, 16.94, 16.96, 17.04, 17.22, 17.23, 17.33 and 17.41 
ppm for the eight CH(CH3)2 carbons. Final confirmation was given by the presence of a peak 
assigned as [M + H]
+
 at 501.24409 in the HRMS, with C22H41N2O7Si2
+
 requiring a peak at 
501.24468. 
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5.2.3 Synthesis of Various Silanols 
 
Due to the interesting anti-bacterial and anti-cancer assay results obtained for the previously 
tested tert-butyldiphenylsilanol (145), we decided to also synthesize a group of silanols 
ranging in size from dimethylethylsilanol all the way up to triphenylsilanol for further testing. 
These compounds were also important as several of them served as controls for our other 
uridine and 5-methyluridine derivative assays. These silanols correspond to the by-products 
that could be formed by hydrolytic cleavage of the commercially available protecting groups 
when under biological conditions.  
 
Si
R'
ClR''
R'
(i)
Si
R'
OHR''
R'
 
 
Scheme 6.5 General scheme for the synthesis of the silanols (i) 1 eq. silyl chloride, Et2O, 1.1 
eq. KOH in H2O : MeOH (4 : 1), rt, 18 h 
 
The general procedure adopted for the synthesis of the silanols was to prepare a solution of 
the silyl chloride in diethyl ether. To this solution was then added in a single portion, a 
solution of potassium hydroxide in a 4 : 1 mixture of water and methanol. In general, the 
solutions warmed up after the additions and a white precipitate was observed almost 
immediately. The reactions were then allowed to stir at room temperature overnight and were 
worked-up using standard extraction procedures. NMR spectra were obtained of the crude 
mixtures for all silanols prepared in this series and due to their purity, no column 
chromatography was required. 
 
As an example of the procedure to analyze the formation of the silanols, the identification of 
butyldimethylsilanol 258 is discussed in detail below. The same approach was used for all the 
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silanols prepared in this series and as such, they are not all described here – for the full 
analysis, please refer to Appendix D (Experimental Procedures – Relating to Chapter 5). 
 
Table 22 Synthetic yields for the various silanols prepared 
Compound Formed R' R'' Percentage Yield 
255 Methyl  
(-CH3) 
Ethyl  
(-CH2CH3) 
2 % 
176 Ethyl  
(-CH2CH3) 
Ethyl  
(-CH2CH3) 
86 % 
256 Propyl  
[-(CH2)2CH3] 
Propyl  
[-(CH2)2CH3] 
100 % 
257 Isopropyl  
[-CH(CH3)2] 
Isopropyl  
[-CH(CH3)2] 
98 % 
258 Methyl  
(-CH3) 
Butyl  
[-(CH2)3CH3] 
66 % 
259 Butyl  
[-(CH2)3CH3] 
Butyl  
[-(CH2)3CH3] 
98 % 
260 Isobutyl  
[-CH2CH(CH3)2] 
Isobutyl  
[-CH2CH(CH3)2] 
98 % 
261 Methyl  
(-CH3) 
tert-Butyl 
[-C(CH3)3] 
72 % 
262 Methyl  
(-CH3) 
Thexyl 
[-C(CH3)2CH(CH3)2] 
95 % 
263 Hexyl 
[-(CH2)5CH3] 
Hexyl 
[-(CH2)5CH3] 
100 % 
264 Methyl  
(-CH3) 
Cyclohexyl 
(-C6H11) 
92 % 
265 Methyl  
(-CH3) 
Benzyl 
[-CH2(C6H5)] 
90 % 
266 Phenyl 
(-C6H5) 
Phenyl 
(-C6H5) 
93 % 
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Butyldimethylsilanol 258 was identified by the peaks observed as: a singlet at 0.03 ppm 
integrating for 6 H [Si(CH3)2], a multiplet at 1.48-1.53 ppm integrating for 2 H (SiCH2), a 
triplet at 0.88 ppm integrating for 3 H (CH2CH3) and a multiplet at 1.25-1.36 ppm integrating 
for 4 H (SiCH2CH2 and CH2CH3) in the 
1
H NMR spectrum. Unfortunately, the OH peak was 
not observed in the 
1
H NMR spectrum, but the presence of the OH group was confirmed by 
the Si-O band at 1016 cm
-1
, the band for O-H bending at 1412 cm
-1
 and the band for O-H 
stretching at 3575 cm
-1
 which was evident in the infrared spectrum for the compound. The 
13
C 
NMR spectrum for the compound corresponded well to the desired compound, with peaks 
observed at 0.36 (Si(CH3)2), 13.83 (CH2CH3), 18.11 (SiCH2), 25.52 (SiCH2CH2) and 26.39 
(CH2CH3) ppm. 
 
In a similar manner to that described for the series of silanols above, we were able to 
synthesize compound, 1,3-dihydroxy-1,1,3,3-tetraisopropyldisiloxane 268, in 100 % yield 
(shown in Scheme 26). 
 
ClSi
O
Si
Cl
267
(i)
OHSi
O
Si
OH
268  
 
Scheme 26 Synthesis of the TIPDS derivative: (i) 1 eq. silyl chloride, Et2O, 1.1 eq. KOH in 
H2O : MeOH (4 : 1), rt, 18 h, 100 % 
 
5.3 CONCLUSIONS 
 
We made use of an approach used to synthesize a range of tethered 1,1,3,3 -
tetraisopropyldisiloxane protected uridine derivatives. From this group of compounds we 
obtained five molecules that were modified in various positions on the sugar ring as well as at 
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the amide position on the base. We intended to use these compounds as an extension to the 
mini structure-activity relationship determined using the "first generation" of compounds 
synthesized (the biological testing is described in detail in Part 1, Chapter 3). 
 
Using our general approach for the synthesis of 5'-O-silicon protected uridine derivatives, we 
were able to synthesize a further five uridine derivatives and another five 5-methyluridine 
derivatives. At the same time, we derived a general procedure for the conversion of silyl 
chlorides to silanols, and used the procedure to synthesize a series of fourteen silanols, 
ranging from low to high molecular weight and spanning a wide range of chemical space. We 
aimed to screen these compounds for inhibitory activity against four bacterial strains and to 
extend this to include further cell proliferation studies. The results obtained for the bacterial 
assays are discussed in detail in Chapter 6 and the results for the extended cell proliferation 
studies are described in Chapter 7. 
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Chapter 6: 
Results and Discussion for  
Bacteriology and Microscopy 
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CONTRIBUTIONS TO THIS CHAPTER 
All of the antibacterial assays and accompanying statistical analyses were performed by Ms 
J.-L. Panayides, while under the supervision of both Dr D. Lindsay and Prof E.M.C. Rey. The 
work was performed in the School of Molecular and Cellular Biology at the University of the 
Witwatersrand. 
 
 
6.1 CHAPTER OVERVIEW 
  
The "second generation" of uridine, 5-methyluridine and silanol derivatives were evaluated 
for their antibacterial activity against two Gram-positive (Staphylococcus aureus ATCC 
25923 and Bacillus cereus DL5) and two Gram-negative (Pseudomonas aeruginosa ATCC 
27853 and Escherichia coli ATCC 25922) bacteria. The compounds showing the most 
promising results from the antibacterial assays were then used for further studies involving 
scanning electron and confocal microscopy. The results of both the bacterial assays and the 
microscopy are presented in detail in this chapter. 
 
In order to determine if our "second generation" of synthetic uridine, 5-methyluridine and 
silanol derivatives possessed antibacterial properties, we assayed them for inhibitory activity 
against two Gram-positive and two Gram-negative bacterial strains. In total, 14 nucleoside 
derivatives and 12 silanols were screened as our second generation of compounds. We then 
analysed the results obtained for the antibacterial assays of both the "first generation" and the 
"second generation" of compounds and subjected those compounds demonstrating the most 
promising results to a further study involving scanning electron and confocal microscopy.  
 
6.2 RESULTS AND DISCUSSION 
 
This section is broken down into three parts, the first of which contains the results obtained 
for the TTC assays performed on our "second generation" compounds, the second of which 
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presents some of the results obtained from the confocal microscopy that was used to validate 
our results obtained from the TTC assay and the last of which highlights the SEM work 
performed in order to determine a possible site of action for the synthetic compounds. 
 
6.2.1 Antibacterial Assays 
 
6.2.1.1 Materials and Methods 
 
  Bacterial Cultures  
 
As described in detail in Chapter 3, Section 3.2.1.1, we used S. aureus (ATCC 25923) and B. 
cereus (DL5) as our representative Gram-positive bacteria, and P. aeruginosa (ATCC 27853) 
and E. coli (ATCC 25922) as our representative Gram-negative bacteria. All of the bacterial 
strains were grown from either freezer stocks or freeze-dried swabs, maintained on nutrient 
agar plates at 4 
o
C and subcultured every 21 days, with each culture grown up in 100 mL 
nutrient broth overnight at 37 
o
C. A full description of the procedure used is outlined in detail 
in Appendix C (Section C.1 and Section C.2) below. 
 
The 18 h bacterial cultures were used to determine the number of colony forming units 
present per millilitre of culture using the droplet plate technique (the full procedure is given in 
Appendix C, Section C.3 below). From this technique, the calculated cfu/mL and log cfu/mL 
for the four bacterial strains were obtained: 
 
 S. aureus ATCC 25923   cfu/mL = 7.47 × 108  log cfu/mL = 8.87 
 B. cereus DL5    cfu/mL = 1.43 × 109  log cfu/mL = 9.16 
 P. aeruginosa ATCC 27853  cfu/mL = 1.54 × 109  log cfu/mL = 9.19 
 E. coli ATCC 25922   cfu/mL = 3.38 × 109  log cfu/mL = 9.53  
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  Synthetic Compounds 
 
The compounds used in this study were prepared using standard synthetic organic chemistry 
techniques. A full discussion of the results obtained during the synthesis is provided in 
Chapter 5 and the detailed experimental procedures used are given in Appendix D. For ease 
of reading, the compounds tested using the TTC assay are grouped according to structural 
similarities and are illustrated below: 
 as derivatives of uridine (Figure 55) 
 as derivatives of 5-methyluridine (Figure 56) 
 and as silanols (Figure 57) 
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Figure 55 "Second Generation" compounds used in TTC assay - Uridine derivatives 
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Figure 56 "Second Generation" compounds used in TTC assay - 5-Methyluridine derivatives 
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Figure 57 "Second Generation" compounds used in TTC assay - Silanol derivatives 
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  Evaluation of Compound Efficacy – Triphenyltetrazolium Chloride Assay 
 
The synthetic compounds and the control compound, the commercially available antibiotic 
ciprofloxacin 153, were used to prepare 10 000 mg/L, 1 000 mg/L, 100 mg/L, 10 mg/L and 1 
mg/L stock solutions using autoclaved de-ionised water and molecular grade DMSO, as 
described in Appendix C, Section C.5.1. These stock solutions were used immediately to 
prepare a series of 16 standard dilutions in autoclaved nutrient broth. The standard dilutions 
were then used in the triphenyltetrazolium chloride assay, full details of which have already 
been described in Chapter 3, with further descriptions highlighted in Appendix C, Section 
C.5.2. As such, no further explanatory notes will be given here. 
 
  Statistical Analysis 
 
For each bacterial strain and compound/antibiotic dilution concentration combination four 
replicates were performed (duplicates were run on each plate and the plates were prepared in 
duplicate as well). Four absorbance data points were thus obtained for each combination 
(bacterial strain/compound/dilution). The data was corrected for the background absorbance 
of the solution without bacterial growth by referencing the ELISA plate reader to the 0 % 
growth control on the plates.  
 
For the initial determination of activity, the data was typed into Microsoft Excel and the 
average of the four replicates was determined. This average for the absorbances was then 
represented as the percentage of metabolically active cells present for each bacterial strain and 
compound/antibiotic dilution concentration combination, based on the value obtained for the 
100 % growth control specific to each plate.  
 
Graphs were then plotted for the four bacterial strains, showing the percentage metabolically 
active cells on the y-axis against the compound/antibiotic concentration on the x-axis. From 
the initial graphs we determined which compounds showed antibacterial activity and any 
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graphs displaying percentage metabolically active cells less than 10 % over a range of 
concentrations were classified as being positive hits. 
  
6.2.1.2 Results and Discussion 
 
As described above, ten uridine derivatives, five 5-methyluridine derivatives and fourteen 
silanols were tested for possible antibacterial activity against the two Gram-positive and two 
Gram-negative bacteria. The study again used ciprofloxacin 153 as the antibiotic control and 
each individual assay included a number of internal controls:  (i) the 0 % growth control, (ii) 
the 100 % growth control, (iii) the DMSO controls and (iv) a sterility control. 
 
The Minimum Inhibitory Concentrations (MICs) for the synthetic compounds were again 
determined according to the procedure described by Andrews.
58
 The standard curve obtained 
for the antibiotic control, ciprofloxacin 153, was drawn in Chapter 3, as Graph 1, and was 
used to calculate the MICs for ciprofloxacin 153. The results obtained were as follows: 
 
 S. aureus ATCC 25923  0.5 mg/L 
 B. cereus DL5    0.5 mg/L 
 P. aeruginosa ATCC 27853  0.5 mg/L 
 E. coli ATCC 25922   0.016 mg/L 
 
The antibacterial activity for the synthetic compounds was determined using the modified 
MIC determination assay, using TTC, as described in detail in Chapter 3, Section 3.2.1.1. 
The results obtained for the "second generation" of uridine derivatives are shown in Table 23. 
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Table 23 MICs determined for the uridine derivatives 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
Uridine 12 No activity No activity No activity No activity 
246 No activity No activity
# 
No activity
#
 No activity
#
 
229 No activity No activity
#
 No activity No activity 
247 No activity No activity No activity No activity 
248 No activity No activity No activity No activity 
249 No activity No activity No activity No activity 
234 16 mg/L 16 mg/L No activity No activity 
239 8 mg/L 8 mg/L No activity No activity 
235 No activity No activity No activity No activity 
#
 Very high concentrations of the synthetic compound (64-128 mg/L) caused a reduction in the percentage 
metabolically active cells, but not below the standard cut-off value of 10 %  
 
As expected for our negative control, no antibacterial activity was observed for uridine 12. In 
fact, no significant activity was observed for any of the "second generation" compounds 
synthesized with silicon-based protecting groups present at the 5'-O-position on the sugar ring 
(compounds 246-249 and 229). This was quite disappointing as in our initial screen we had 
obtained interesting results for 5'-O-(tert-butyldiphenylsilyl)uridine 107, with MIC values 
obtained of 64 mg/L for S. aureus (ATCC 25923) and 32 mg/L for B. cereus (DL5).  
 
The original data had suggested the possibility of using silicon protected uridine derivatives 
as the starting off point for the synthesis of our second generation of compounds, but it 
appears that the antibacterial activity is not widespread throughout the class of compounds 
and we had unwittingly picked the active species by chance in the first round of testing. 
 
However, our other batch of protected uridine derivatives, those containing two silicon atoms 
in each of the tethered protecting groups (compounds 234, 235 and 239, Table 23 above), 
yielded some very interesting results. For compounds 234 and 230, we again found activity 
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only against in the Gram-positive bacteria, but this time we observed a dramatic improvement 
in the range of active concentrations for the synthetic compounds (when compared to the 
higher concentrations required for activity in the synthetic compounds containing only one 
silicon-protecting group). 
 
Using the dilution series we prepared a standard curve for each of the different synthetic 
compounds, against each of the different bacterial strains used in the assay (S. aureus ATCC 
25923, B. cereus DL5, P. aeruginosa ATCC 27853 and E. coli ATCC 25922), which was 
then used to determine the MIC values quoted in Table 23. The curves for the active 
compounds, 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f]-
[1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 and 1-[(6aR,8R,9aR)-2,2,4,4-
tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4-
(1H,3H)dione 239, are shown schematically in Graph 16 and Graph 17. 
 
 
 
Graph 16 Standard curve for 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyl-
tetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 
 
0
20
40
60
80
100
120
140
P
e
rc
en
ta
ge
 M
et
ab
o
lic
al
ly
 A
ct
iv
e 
C
el
ls
Concentration mg/L
Measurements taken at 450nm 
S. aureus 
ATCC 25923
B. cereus DL5
P.aeruginosa 
ATCC 27853
E. coli ATCC 
25922
P a g e  | 209 
 
 
 
Graph 17 Standard curve for 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239 
 
The MIC values obtained for 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-
6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 were 16 mg/L 
for S. aureus (ATCC 25923) and 16 mg/L for B. cereus (DL5). These values are significantly 
higher than those obtained for the commercially available antibiotic ciprofloxacin 153, with 
MICs of 0.5 mg/L for S. aureus and 0.5 mg/L for B. cereus respectively; however, they do 
show an improvement on the MICs obtained for the active compound in our "first generation" 
of compounds (32-64 mg/L). 
 
Interestingly, when the 2'-O-position on the sugar ring was oxidised to the corresponding 
ketone, we found an increase in antibacterial activity by a single dilution factor. The MIC 
values obtained for 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239 were 8 mg/L for S. aureus 
(ATCC 25923) and 8 mg/L for B. cereus (DL5). This suggests that the 2'-OH on the sugar 
ring is perhaps not required for recognition and transport pathways within the Gram-positive 
bacterial cells, as its conversion to a ketone increases the activity of the synthetic molecules. 
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The antibacterial activity for the synthetic 5-methyluridine derivatives was then determined 
using the modified TTC assay, as described above. The MIC results obtained from the assay 
for 5-methyluridine and its derivatives are shown in Table 24. 
 
Table 24 MICs determined for the 5-methyluridine derivatives 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
5-Methyluridine 233 No activity No activity No activity No activity 
250 No activity No activity No activity No activity 
251 No activity 128 mg/L
 
No activity No activity 
252 No activity No activity
# 
No activity
#
 No activity
#
 
253 No activity No activity No activity No activity 
254 32 mg/L 32 mg/L No activity No activity 
#
 Very high concentrations of the synthetic compound (64-128 mg/L) caused a reduction in the percentage 
metabolically active cells, but not below the standard cut-off value of 10 % 
 
The 5-methyluridine 233 was used as a negative control for the assay as we anticipated no 
antibacterial activity to be observed by the un-modified nucleoside. As expected, no activity 
was observed for the 5-methyluridine 233 in any of the bacterial strains tested.  
 
Using the values obtained for the various compound dilution series, we prepared standard 
curves for each of the different synthetic compounds, against each of the four different 
bacterial strains used in the assay (S. aureus ATCC 25923, B. cereus DL5, P. aeruginosa 
ATCC 27853 and E. coli ATCC 25922). These standard curves were then used to determine 
the MIC values quoted in Table 24.  
 
From the entire range of 5-methyluridine derivatives synthesized and tested, only one 
derivative showed any antibacterial activity - this was found to be the 1-[(6aR,8R,9S,9aR)-
tetrahydro-9-hydroxy-2,2,4,4-tetraisopropyl-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-
methylpyrimidine)-2,4-(1H,3H)-dione 254. This compound was active against only the Gram-
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positive bacteria, with MIC values of 32 mg/L observed for both S. aureus (ATCC 25923) 
and B. cereus (DL5). The standard curve for the active compound 254 is shown schematically 
in Graph 18. 
 
 
 
Graph 18 Standard curve of 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-tetraisopropyl-
6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4-(1H,3H)-dione 254 
 
What is interesting to note from a structure-activity point of view is that the MIC values for 
this series are: 
 (i)  Compound 234 S. aureus ATCC 25923 16 mg/L 
     B. cereus DL5   16 mg/L 
 (ii)  Compound 239  S. aureus ATCC 25923 8 mg/L 
     B. cereus DL5   8 mg/L 
 (iii)  Compound 254  S. aureus ATCC 25923 32 mg/L 
     B. cereus DL5   32 mg/L 
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This suggests that converting the base in uridine to the 5-methyl derivative causes a 
corresponding loss in antibacterial activity for the compound, whereas oxidising the 
secondary alcohol on the 2'-position of the sugar ring causes a corresponding increase in 
antibacterial activity for the compound. As such, we can conclude that 1-[(6aR,8R,9aR)-
2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimi-
dine-2,4-(1H,3H)dione 239 was the best compound out of both the "first generation" and 
"second generation" of nucleoside derivatives for antibacterial activity. 
 
At this point, we then screened all of our silanols for antibacterial activity, based on the 
interesting results obtained for tert-butyldiphenylsilanol 145 in the original assays. The 
antibacterial activity for the synthetic compounds was determined using the modified MIC 
determination assay, described in greater detail in the introductory sections above. The results 
of the TTC assay for the various silanols are given in Table 25. 
 
Table 25 MICs determined for the various silanols 
Compound S. aureus 
ATCC 25923 
B. cereus 
DL5 
P. aeruginosa 
ATCC 27853 
E. coli 
ATCC 25922 
Triethylsilanol 176 No activity No activity No activity No activity 
Tripropylsilanol 256 No activity No activity No activity No activity 
Butyldimethylsilanol 258 No activity No activity No activity No activity 
tert-butyldimethylsilanol 261 No activity No activity No activity No activity 
Tributylsilanol 259 No activity No activity No activity No activity 
Triisobutylsilanol 260 No activity No activity No activity No activity 
Dimethylthexylsilanol 262 No activity No activity No activity No activity 
Trihexylsilanol 263 No activity No activity No activity No activity 
Cyclohexyldimethylsilanol 
264 
No activity No activity No activity No activity 
Benzyldimethylsilanol 265 No activity No activity No activity No activity 
Triphenylsilanol 266 No activity No activity No activity No activity 
1,3-Dihydroxy-1,1,3,3-
tetraisopropyldisiloxane 268 
No activity
#
 64 mg/L No activity
# 
No activity
# 
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#
 Very high concentrations of the synthetic compound (64-128 mg/L) caused a reduction in the percentage 
metabolically active cells, but not below the standard cut-off value of 10 % 
 
In the initial assays, we obtained MIC values for tert-butyldiphenylsilanol 145 of 128 mg/L 
for S. aureus (ATCC 25923) and 64 mg/L for B. cereus (DL5). The tert-butyldiphenylsilanol 
145 was active against only the Gram-positive bacterial strains; however, the MIC values 
were significantly higher than those obtained for the commercially available antibiotic, 
ciprofloxacin 153 (MICs of 0.5 mg/L for both S. aureus and B. cereus). As such, we could not 
rule out the possibility that the reduction in the number of metabolically active cells could be 
due to the toxic effects caused by the high concentration of compound in solution, as opposed 
to the antibacterial activity of the compound itself. 
 
Recently published papers on the use of silanols as a novel class of antimicrobial agents, by 
Kim and co-workers
123,124
 suggested that tert-butyldimethylsilanol could have antibacterial 
properties. Owing to these publications, we had decided to synthesize a range of silanols 
covering a large chemical space and subjected them to our modified TTC assay but the results 
were rather disappointing. 
 
Using the dilution series results for each of these synthetic silanols, we prepared a standard 
dilution curve for each of the different silanols, against each of the different bacterial strains 
used in the assay (S. aureus ATCC 25923, B cereus DL5, P. aeruginosa ATCC 27853 and E. 
coli ATCC 25922). These standard curves were then used to determine the single MIC value 
reported in Table 25. The curve for the only potentially bio-active compound, 1,3-dihydroxy-
1,1,3,3-tetraisopropyldisiloxane 268, is shown schematically in Graph 19. 
 
The 1,3-dihydroxy-1,1,3,3-tetraisopropyldisiloxane 268 showed reductions in the percentage 
of metabolically active cells present at concentrations above 16 mg/L; however, the only 
bacterial strain that could have a MIC determined for this silanol was B. cereus, which only 
dropped below the pre-defined value of 10 % metabolically active cells at a concentration of 
64 mg/L. We speculate that this reduction in cell growth may be caused by a toxic effect that 
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occurs due to the very high concentration of silanol in the solution and as such do not 
consider it a positive hit for antibacterial activity. 
 
 
 
Graph 19 Standard curve for 1,3-dihydroxy-1,1,3,3-tetraisopropyldisiloxane 268 
 
6.2.1.3 Conclusions 
 
From the data reported above, one can conclude that in general the protection of uridine 12 
and 5-methyluridine 233 with silicon-containing protecting groups did not increase the 
antibacterial activity for the group as suggested, based on the results obtained for 5'-O-(tert-
butyldiphenylsilyl)uridine 107. The exception however, occurred when the two silicon atom 
containing 1,1,3,3-tetraisopropyldisiloxane protecting group was used, albeit with a very low 
potency.  
 
We found that converting the base in 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyl-
tetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 to 
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the 5-methyl derivative 254 caused a corresponding loss in antibacterial activity for the 
compound (from 16 mg/L to 32 mg/L for S. aureus and B. cereus respectively), whereas 
oxidising the secondary alcohol on the 2'-position of the sugar ring to give 239 caused a 
corresponding increase in antibacterial activity for the compound (from 16 mg/L to 8 mg/L 
for S. aureus and B. cereus respectively). As such, we have concluded that 1-[(6aR,8R,9aR)-
2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimi-
dine-2,4(1H,3H)dione 239 was the best compound out of both the "first generation" and 
"second generation" of nucleoside derivatives for antibacterial activity. 
 
6.2.2 Confocal Scanning Laser Microscopy (CSLM) 
 
"Biological laser scanning confocal microscopy relies on fluorescence as an imaging mode, 
this is primarily due to the high degree of sensitivity afforded by the technique and coupled 
with the ability to specifically target both structural components and dynamic processes in 
chemically fixed as well as living cells and tissues." 
J. Lippincott-Schwartz 
Cell Biology and Metabolism Branch, National Institutes of Health 
Bethesda, Maryland, USA 
 
Fluorescent dyes are useful in monitoring cell integrity (live versus dead and apoptosis), 
endocytosis, exocytosis, membrane fluidity, protein trafficking, signal transduction and 
enzymatic activity. In this study, our aim was to exploit the use of fluorescent dyes to monitor 
our bacterial cell integrity in order to validate the results obtained for the percentage of 
metabolically active cells using the TTC assay. The protocols used are described in detail in 
the sections which follow. 
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6.2.2.1 Materials and Methods 
 
The two Gram-positive bacterial strains, S. aureus ATCC 25923 and B. cereus DL5, were 
used for the confocal scanning laser microscopy study as these were the bacterial strains that 
had shown the most promising results for bacterial growth inhibition during our TTC assays 
(to determine the percentage of metabolically active cells present after treatment with our 
synthetic compounds). 
 
The full description for the methodology used in this study is provided in Appendix E, 
Section E.1, as the description of the culture conditions, preparation of bacterial suspensions, 
staining techniques and sample analysis using the invert laser scan microscope (LSM 410, 
Carl Zeiss Jena, Germany) are quite extensive. This is separated from the body of the text to 
allow for general ease of reading. 
 
6.2.2.2 Results and Discussion 
 
The untreated control S. aureus ATCC 25923 cells appeared as small groups of cells creating 
microcolonies that were quite spread out over the microscope slide in our CSLM images. As 
expected, all the cells in the untreated control system stained green (viable) after our standard 
overnight culture conditions. This result confirmed that the method we employed for the 
isolation, rinsing and staining of the bacterial cells did not have any detrimental effect on the 
results observed using the LIVE/DEAD® BacLight™ Bacterial Viability Kit. Essentially, our 
100 % growth control showed, as expected, that all the cells were alive, as illustrated in 
Figure 58.  
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CSLM image (i)         CSLM image (ii)  
  
 
Figure 58 Confocal scanning laser image of untreated S. aureus ATCC 25923, with (ii) 
untreated S. aureus ATCC 25923 shown using a 5 × digital zoom to illustrate the 
microcolonies present (Note: 50 % laser intensity, 488 nm and 563 nm excitation wavelengths 
and 63 × oil objective used) 
 
The study included the antibiotic ciprofloxacin 153 as a growth inhibition control (a 0 % 
growth control), which was tested at a concentration of 8 mg/L, as this was mid-range for 
growth inhibition on the standard curve prepared using the TTC assay (described in detail in 
Chapter 3, Section 3.2.1.2 and illustrated as Graph 1). From the CSLM images we found, as 
expected, that under the standard overnight treatment conditions with the known antibiotic 
ciprofloxacin 153, all of the visible S. aureus ATCC 25923 cells stained red (indicating cell 
death). This result is clearly shown in the image represented Figure 59. 
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Figure 59 Confocal scanning laser image of S. aureus ATCC 25923 treated with 
ciprofloxacin 153 (concentration = 8 mg/L) for 18 hours (Note: 50 % laser intensity, 488 nm 
and 563 nm excitation wavelengths and 63 × oil objective used) 
 
The uridine derivative that gave the best overall antibacterial activity with the previously 
reported TTC assay was 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239. This synthetic compound 
was studied using CSLM at two concentrations, 4 mg/L and 32 mg/L.  
 
The concentrations were chosen based on the standard curve prepared for the compound 239 
using the TTC assay. The concentration of 4 mg/L was chosen as it was found to lie half-way 
up the standard curve (at approximately 50 % inhibition of cell growth) and the concentration 
of 32 mg/L was as it was observed in the middle of the range of concentrations that showed 
complete inhibition of bacterial cell growth (it would thus give an idea as to the actual "kill 
ratio" for the synthetic compound). The results obtained after overnight treatment of S. aureus 
ATCC 25923 with at two concentrations of compound 239 are illustrated in Figure 60.  
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    CSLM image (i)          CSLM image (ii) 
  
 
Figure 60 Confocal scanning laser images of S. aureus ATCC 25923 treated with 1-
[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilo-
cin-8-yl]pyrimidine-2,4(1H,3H)dione 239 for 18 hours: (i) concentration = 4 mg/L and (ii) 
concentration = 32 mg/L (Note: 50 % laser intensity, 488 nm and 563 nm excitation 
wavelengths and 63 × oil objective used) 
 
The CSLM study for compound 239 at a concentration of 4 mg/L showed an average of 87 % 
metabolically active cells (green) vs. 13 % dead cells (red), calculated by visually counting 
the red/green cells in five images and then calculating an approximate percentage value for 
the number of metabolically active cells remaining after treatment. The results from the 
CSLM study corresponded well with the data previously obtained using the TTC assay, since 
for compound 239 at a concentration of 4 mg/L, the TTC assay indicated that 90.5 % of the 
cells were still metabolically active (approximately 10 % of the cells had died). Similarly, the 
CSLM study for compound 239 at a concentration of 32 mg/L showed an average of 97 % 
metabolically active cells (green) vs. 3 % dead cells (red), calculated as described above, 
corresponding well to the TTC assay which indicated that an average 1.8 % of the cells were 
still metabolically active (suggesting > 95 % of the cells had died). 
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In CSLM images, B. cereus DL5 appeared as individual cells spread out over the microscope 
slide with no microcolonies observed. All cells in the untreated control system stained green 
(viable) after the overnight culture conditions. This was as expected and confirmed that our 
method for the isolation, washing and staining of the bacterial cells was in no way affecting 
the results obtained using the BacLight Live/Dead Kit (as the 100 % growth control showed 
all cells alive by CSLM). This result is clearly illustrated in Figure 61. 
 
 
 
Figure 61 Confocal scanning laser image of untreated B. cereus DL5 (Note: 50 % laser 
intensity, 488 nm and 563 nm excitation wavelengths and 63 × oil objective used) 
 
We included the antibiotic ciprofloxacin 153 as our growth inhibition control for this study 
and found, as expected, that under overnight treatment conditions with the known antibiotic 
(at a concentration of 8 mg/L) all of the visible B. cereus DL5 cells stained red (indicating cell 
death). This result is clearly shown in the CSLM image Figure 62. 
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Figure 62 Confocal scanning laser image of B. cereus DL5 treated with ciprofloxacin 153 
(concentration = 8 mg/L) for 18 hours (Note: 50 % laser intensity, 488 nm and 563 nm 
excitation wavelengths and 63 × oil objective used) 
 
The uridine based compound that gave the best overall antibacterial activity using the TTC 
assay described previously, 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239, was studied using 
this CSLM procedure. The results obtained after overnight treatment of B. cereus DL5 at two 
concentrations of compound 239 (4 mg/L and 32 mg/L) are illustrated in Figure 63.  
 
The concentration of 4 mg/L was chosen as it was found to occur midway on the standard 
curve (in the range of 50 % inhibition of cell growth) prepared for the compound 239 using 
the TTC assay. The compound concentration of 32 mg/L was also chosen based on the 
standard curve, it was observed in the middle of the range of concentrations that showed 
complete inhibition of bacterial cell growth and so would give an idea as to the actual "kill 
ratio" for the synthetic compound. 
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    CSLM image (i)          CSLM image (ii) 
  
 
Figure 63 Confocal scanning laser images of B. cereus DL5 treated with 1-[(6aR,8R,9aR)-
2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimi-
dine-2,4(1H,3H)dione 239 for 18 hours: (i) concentration = 4 mg/L and (ii) concentration = 
32 mg/L (Note: 50 % laser intensity, 488 nm and 563 nm excitation wavelengths and 63 × oil 
objective used) 
 
The results from the CSLM study for compound 239, calculated by visually counting the 
red/green cells in five images and then calculating an approximate percentage value for the 
number of metabolically active cells remaining after treatment, showed that: 
(i) for compound 239 at a concentration of 4 mg/L, an average of 55 % of the 
cells are metabolically active (green) vs. 45 % dead cells (red) 
(ii) for compound 239 at a concentration of 32 mg/L, an average of 6 % of the 
cells are metabolically active (green) vs. 94 % dead cells (red) 
 
These results corresponded well with the data previously obtained using the TTC assay, 
which showed that: 
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(i)  for compound 239 at a concentration of 4 mg/L, approximately 61.4 % of the 
cells were still metabolically active (approximately 40 % of the cells had died) 
(ii)  for compound 239 at a concentration of 32 mg/L, approximately 3.6 % of the 
cells were still metabolically active (suggesting > 95 % of the cells had died). 
 
6.2.2.3 Conclusions 
 
From the CSLM study performed we validated that the results obtained from the previously 
performed TTC assay for the determination of the percentage of metabolically active cells 
present after treatment with antibiotics and synthetic compounds were accurate 
representations of what was occurring in our overnight bacterial cultures. 
 
Interestingly, the CSLM images for both S. aureus ATCC 25923 and B. cereus DL5 treated 
with compound 239 at various concentrations showed no visible cells stained yellow, thus 
indicating cell injury. This suggests that the synthetic compound 239 is bacteriocidal and is 
inactivating the cells, not simply inhibiting their growth.  
 
Furthermore, the BacLight kit specifically works on membrane integrity and considering that 
we did not observe any yellow stained cells, this could suggest that the compound 239 affects 
the cell membrane itself (possibly by disruption). This evidence would support our earlier 
proposal that the compound 239 is membrane active. 
 
6.2.3 Scanning Electron Microscopy (SEM) 
 
6.2.3.1 Materials and Methods 
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The two Gram-positive bacterial strains, S. aureus ATCC 25923 and B. cereus DL5, were 
selected for the scanning electron microscopy study as these were the bacterial strains that had 
shown the most promising results for bacterial growth inhibition during our TTC assays (to 
determine the percentage of metabolically active cells present after treatment with our 
synthetic compounds). 
 
The full description for the methodology used in this study is provided in Appendix E, 
Section E.2, as the description of the culture conditions, dehydration procedure, critical point 
drying, mounting and sample analysis using the scanning electron microscope (JSM-840, 
JEOL Ltd, Tokyo, Japan) are quite extensive. This is separated from the body of the text to 
allow for general ease of reading. 
 
6.2.3.2 Results and Discussion 
 
       Micrograph a              Micrograph b 
      
Figure 64 Scanning electron micrographs of the untreated control 18 hour bacterial cultures 
(diluted to 10
6
 cfu/mL in nutrient broth) for: (a) S. aureus ATCC 25923 (magnification = 14 
000 ×, probe current = 1 × 10
-9
, keV = 15) and (b) B. cereus DL5 (magnification = 8 000 ×, 
probe current = 3 × 10
-10
, keV = 10) 
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The untreated control S. aureus ATCC 25923 cells appeared as small clusters or 
microcolonies which were composed of smooth spheres approximately 1.0-1.4 µm in 
diameter (shown below in Figure 64, micrograph a), while scanning electron micrographs of 
the control untreated B. cereus DL5 showed individual rods of approximately 2.5-3.0 µm in 
length with smooth surfaces spread out over the filter paper (Figure 64, micrograph b).  
 
The relatively smooth surfaces of the bacterial cells, present for both the untreated S. aureus 
and B. cereus indicate that no cell damage has occurred in our systems, even though it had 
been previously noted that the stringent sample preparation procedures for SEM may result in 
artifact formation.
125
  
 
In comparison, the overnight bacterial cultures that were subsequently treated with an 8 mg/L 
solution of the known antibiotic, ciprofloxacin 153, showed severe cell damage. S. aureus 
ATCC 25923 (Figure 65, micrograph a) showed interesting distortions to the spherical nature 
of the cell (ie: cell shape), while the rods for B. cereus DL5 (Figure 65, micrograph b) 
showed significant surface indentations and in some cases, complete rupturing of the cells.  
 
       Micrograph a              Micrograph b 
     
Figure 65 Scanning electron micrographs of the bacterial cultures which had been treated 
with the known antibiotic ciprofloxacin 153 at a concentration of 8 mg/L for 22 hours: (a) S. 
aureus ATCC 25923 (magnification = 12 000 ×, probe current = 3 × 10-10, keV = 10) and (b) 
B. cereus DL5 (magnification = 15 000 ×, probe current = 3 × 10-10, keV = 10) 
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The next set in the study compared bacterial cells treated with uridine 12 (a negative control 
for the inhibition of cell growth as it did not affect the percentage of metabolically active cells 
present after treatment as determined by the TTC assay) against cells treated with two 
concentrations, both in the active and non-active range, of 5'-O-(tert-butyldiphenyl-
silyl)uridine 107. Results are shown in Figure 66 on the following page. 
 
As expected, S. aureus (Figure 66, micrograph a) and B. cereus (Figure 66, micrograph b) 
cells treated with uridine 12 at a concentration of 0.5 mg/L (selected as it was mid-range on 
the standard curve from the TTC assay) showed prolific bacterial growth. In general, all cells 
for both bacterial strains used, showed no surface indentations or distortions to the cell shape, 
indicating that the unmodified nucleoside had no effect on the bacterial strains tested. 
 
Two concentrations of 5'-O-(tert-butyldiphenylsilyl)uridine 107 were selected for the study 
based on the standard curve obtained using the results from the TTC assay. They were: (i) 
0.25 mg/L which was found midway in the range of no inhibition of growth, and (ii) 64 mg/L 
which was found midway in the range of observed inhibition of cellular growth. As observed 
for the bacteria treated with unmodified uridine 12, the cells treated with low concentrations 
of compound 107 [S. aureus (Figure 66, micrograph c) and B. cereus (Figure 66, 
micrograph d)] showed no surface indentations or observable distortions to the cell shape, 
indicating that at low concentrations outside of the active range for compound 107, there was 
no specific effect on the cellular coatings for the bacterial strains tested.  Note that for B. 
cereus (Figure 66, micrograph d) the rods were surrounded by what appeared to be 
extracellular polymeric substances (EPS). 
 
We found that when S. aureus and B. cereus were treated with high concentrations of 
compound 107 (midway into the active range for the compound), inhibition of growth was 
clearly observed. At the same time, we noted that for S. aureus (Figure 66, micrograph e) the 
cell surface remained smooth, but distortions occurred in the spherical shape of the cells. For 
B. cereus (Figure 66, micrograph f), we observed that the cells had aggregated together, 
appeared to have rough surfaces and had ruptured in a few of the examples. 
P a g e  | 227 
 
              Micrograph a - S. aureus ATCC 25923             Micrograph b - B. cereus DL5 
             Uridine 12 (concentration = 0.5 mg/L)      Uridine 12 (concentration = 0.5 mg/L) 
       
             Micrograph c - S. aureus ATCC 25923            Micrograph d - B. cereus DL5 
         Compound 107 (concentration = 0.25 mg/L)                     Compound 107 (concentration = 0.25 mg/L) 
       
            Micrograph e - S. aureus ATCC 25923            Micrograph f - B. cereus DL5 
         Compound 107 (concentration = 64 mg/L)                       Compound 107 (concentration = 64 mg/L) 
       
Figure 66 Scanning electron micrographs of the bacterial cultures which had been treated 
with the synthetic compounds for 22 hours: (a) magnification = 2 000 ×, probe current = 6 × 
10
-9
, keV = 10, (b) magnification = 2 000 ×, probe current = 6 × 10-10, keV = 10, (c) 
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magnification = 5 000 ×, probe current = 3 × 10
-10
, keV = 10 and (d) magnification = 10 000 
×, probe current = 3 × 10
-10
, keV = 10, (e) magnification = 8 000 ×, probe current = 3 × 10-10, 
keV = 10 and (f) magnification = 5 000 ×, probe current = 6 × 10
-10
, keV = 10 
 
From the TTC assay (described in Section 6.2.1.2), we found that converting the base in 1-
[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]-trioxa-
disilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 to the 5-methyl derivative 254 caused a 
corresponding loss in antibacterial activity for the compound (from 16 mg/L to 32 mg/L for S. 
aureus and B. cereus respectively), whereas oxidising the secondary alcohol on the 2'-position 
of the sugar ring to give compound 239, caused a corresponding increase in antibacterial 
activity for the compound (from 16 mg/L to 8 mg/L for S. aureus and B. cereus respectively). 
As such, we previously concluded that 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-
oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239 
was the best compound for antibacterial activity coming out of both the "first generation" and 
"second generation" of nucleoside derivatives.  
 
We further wished to investigate these findings by conducting a structure activity relationship 
(SAR) study on these compounds (234, 254 and 239) using SEM in order to determine if 
there was some fundamental structural change in the bacteria which would suggest the active 
pathways. For the SAR comparison, the overnight bacterial cultures were subsequently treated 
with solutions of each of the test compounds 234, 254 and 239 at two concentrations of each 
(one in the active range of the compound and one in the non-active range of the compound – 
as shown on the standard curve obtained using the results from the TTC assay). The results 
obtained for S. aureus ATCC 25923 are depicted in Figure 67 and the results obtained for B. 
cereus DL5 are shown in Figure 68. 
 
Two concentrations of 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 were selected for 
the study, based on the standard curve obtained using the results from the TTC assay. They 
were: (i) 0.25 mg/L which was found midway in the range of no inhibition of growth, and (ii) 
32 mg/L which was found midway in the range of observed inhibition of cellular growth.   
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Micrograph a - S. aureus ATCC 25923       Micrograph b – S. aureus ATCC 25923 
             Compound 234 (concentration = 0.25 mg/L)      Compound 234 (concentration = 32 mg/L) 
       
             Micrograph c - S. aureus ATCC 25923            Micrograph d – S. aureus ATCC 25923 
         Compound 254 (concentration = 0.25 mg/L)                     Compound 254 (concentration = 64 mg/L) 
       
            Micrograph e - S. aureus ATCC 25923            Micrograph f – S. aureus ATCC 25923 
         Compound 239 (concentration = 0.12 mg/L)                       Compound 239 (concentration = 32 mg/L) 
       
Figure 67 SAR study with scanning electron micrographs of the S. aureus ATCC 25923 
cultures (treated with the synthetic compounds 234, 254 and 239 for 22 hours): (a) 
magnification = 2 000 ×, probe current = 6 × 10
-10
, keV = 10, (b) magnification = 5 000 ×, 
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probe current = 3 × 10
-10
, keV = 10, (c) magnification = 15 000 ×, probe current = 3 × 10-10, 
keV = 10 and (d) magnification = 10 000 ×, probe current = 3 × 10-10, keV = 10, (e) 
magnification = 2 000 ×, probe current = 3 × 10
-10
, keV = 10 and (f) magnification = 15 000 
×, probe current = 3 × 10
-10
, keV = 10 
 
As observed for the bacteria treated with unmodified uridine 12 (Figure 66, micrograph a 
above), the cells for S. aureus (Figure 67, micrograph a) showed no surface indentations or 
observable distortions to the cell shape, indicating that treatment at low concentrations outside 
the active range for the compound, 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopro-
pyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234, 
had no specific effect on the macroscopic cellular structures for the bacterial strains tested.  
Whereas, we found that when S. aureus (Figure 67, micrograph b) was treated with a high 
concentration of compound 234 (midway into the active range for the compound), we 
observed that the cells had apparently aggregated together (more so than was initially 
observed in the corresponding controls), and although the cell surface remained smooth, 
distortions occurred in the spherical shape of the cells.  
 
In a similar manner, two concentrations of 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-
tetraisopropyl-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4-(1H,-
3H)-dione 254 were selected for the study based on the standard curve obtained using the 
results from the TTC assay. They were: (i) 0.25 mg/L which was found midway in the range 
of no inhibition of growth, and (ii) 64 mg/L which was found midway in the range of 
observed inhibition of cellular growth.  
 
Again, the cells for S. aureus (Figure 67, micrograph c) showed no surface indentations or 
major distortions to the cell shape, indicating that at low concentrations outside the active 
range for the compound, 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-tetraisopropyl-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4-(1H,3H)-dione 254, had 
no specific effect on the cellular surfaces for the bacterial strains tested.  We did however 
observe that when the S. aureus (Figure 67, micrograph d) was treated with a high 
concentration of compound 254 (midway into the active range for the compound), inhibition 
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of growth was clearly observed (based on the TTC assay) and we again noted that, in some 
instances, the cells had apparently aggregated together.  
 
Finally, two concentrations of the active compound, 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-
oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239, 
were selected for the study based on the standard curve obtained previously. They were: (i) 
0.12 mg/L which was found midway in the range of no inhibition of growth, and (ii) 32 mg/L 
which was found midway in the range of observed inhibition of cellular growth.  
  
Interestingly, the differences observed when comparing the concentrations for compound 239 
were much more marked. As observed for the bacteria treated with unmodified uridine 12 
(Figure 66, micrograph a above), the cells for S. aureus (Figure 67, micrograph e) showed 
no surface indentations or any observable distortions to the cell shape, indicating that at low 
concentrations outside the active range for the compound, 1-[(6aR,8R,9aR)-2,2,4,4-
tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4-
(1H,3H)dione 239, had no specific effect on the cellular coatings for the bacterial strains 
tested.   
 
As expected, we found that when the S. aureus (Figure 67, micrograph f) was treated with a 
high concentration of compound 239 (midway into the active range for the compound), 
inhibition of growth was clearly observed. Interestingly, compound 239 was the only S. 
aureus example where we observed that the cells had aggregated together and where the cell 
surface appeared to be rough (when compared to the corresponding control) with rupturing in 
a few examples. The significant bacterial cell wall damage observed may suggest that for the 
active compound 239 a possible difference in the mechanism of action may be occurring for 
the S. aureus bacterial cells. The qualitative evidence, i.e. obvious cellular damage/rupturing 
and cellular aggregation; suggests that compound 239 targets the wall – possibly interacting 
with the wall peptidoglycan molecules and causing cross-linkages between cells. But this 
could not be confirmed by our qualitative observations, as the filtering technique used to 
prepare the samples could also have contributed to the aggregation of cells which was 
observed. 
P a g e  | 232 
 
         Micrograph a – B. cereus DL5        Micrograph b – B. cereus DL5 
             Compound 234 (concentration = 0.25 mg/L)      Compound 234 (concentration = 32 mg/L) 
       
         Micrograph c – B. cereus DL5            Micrograph d – B. cereus DL5 
         Compound 254 (concentration = 0.25 mg/L)                     Compound 254 (concentration = 0.64 mg/L) 
       
           Micrograph e – B. cereus DL5            Micrograph f – B. cereus DL5 
         Compound 239 (concentration = 0.12 mg/L)                       Compound 239 (concentration = 32 mg/L) 
       
Figure 68 SAR study with scanning electron micrographs of the B. cereus DL5 cultures 
(treated with the synthetic compounds 234, 254 and 239 for 22 hours): (a) magnification = 5 
000 ×, probe current = 3 × 10
-10
, keV = 10, (b) magnification = 5 000 ×, probe current = 3 × 
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10
-10
, keV = 10, (c) magnification = 15 000 ×, probe current = 3 × 10-10, keV = 10 and (d) 
magnification = 25 000 ×, probe current = 3 × 10
-10
, keV = 10, (e) magnification = 5 000 ×, 
probe current = 6 × 10
-10
, keV = 10 and (f) magnification = 25 000 ×, probe current = 3 × 10
-
10
, keV = 10 
 
Two concentrations of 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 were selected for 
the study based on the standard curve obtained using the results from the TTC assay. They 
were: (i) 0.25 mg/L which was found midway in the range of no inhibition of growth, and (ii) 
32 mg/L which was found midway in the range of observed inhibition of cellular growth.  
 
As observed for the bacteria treated with unmodified uridine 12 (Figure 66, micrograph b 
above), the cells for B. cereus (Figure 68, micrograph a) showed no surface indentations or 
observable distortions to the cell shape, indicating that at low concentrations outside the 
active range for the compound, 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopro-
pyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234, 
had no specific effect on the cellular coatings for the B. cereus bacteria tested.  Whereas, we 
found that when the B. cereus (Figure 68, micrograph b) was treated with a high 
concentration of compound 234 (midway into the active range for the compound), inhibition 
of growth was clearly observed. At the same time, we observed that although the cell surface 
remained smooth, shortening of the rods had occurred (from an approximate average length of 
6.30 μm in Figure 68, micrograph a, down to an average length of 4.32 μm in Figure 68, 
micrograph b – based on the manual mean random measurement of ten individual rods in 
each micrograph). This shortening of the rod-length usually implies that the compound has an 
effect on the cell wall, similar to the action of penicillin-based antibiotics which affect cell 
wall synthesis.
123b
 The rod-shortening is also an indication of bacterial stress, for example, 
when bacterial cells are starvation-stressed, it is generally noted that they will shrink in size. 
 
In a similar manner, two concentrations of 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-
tetraisopropyl-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4-(1H,-
3H)-dione 254 were selected for the study based on the standard curve obtained using the 
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results from the TTC assay. They were: (i) 0.25 mg/L which was found midway in the range 
of no inhibition of growth, and (ii) 64 mg/L which was found midway in the range of 
observed inhibition of cellular growth.  
 
Again, the cells for B. cereus (Figure 68, micrograph c) showed no surface indentations or 
major distortions to the cell shape; the rods were also surrounded by web-like strands, which 
is suggestive of extracellular polymeric substances (EPS), based on observations of SEM 
micrographs in other studies.
123c
 This indicated that at low concentrations outside the active 
range for the 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-tetraisopro-pyl-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4-(1H,3H)-dione 254, the compound 
had no specific effect on the cellular coatings for the bacterial strains tested.   
 
We did however observe that when B. cereus (Figure 68, micrograph d) was treated with a 
high concentration of compound 254 (midway into the active range for the compound), a 
significant inhibition of bacterial growth occurred. We also noted that, in most instances, the 
rods showed major surface indentations. 
 
Finally, two concentrations of the active compound, 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-
oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239, 
were selected for the study based on the standard curve obtained previously. They were: (i) 
0.12 mg/L which was found midway in the range of no inhibition of growth, and (ii) 32 mg/L 
which was found midway in the range of observed inhibition of cellular growth.  
  
Interestingly, the differences observed when comparing the concentrations for compound 239 
were more severe. As observed for the bacteria treated with unmodified uridine 12 (Figure 
66, micrograph b above), the cells for B. cereus (Figure 68, micrograph e) showed no surface 
indentations or any observable distortions to the cell shape, indicating that at low 
concentrations outside the active range for the compound, 1-[(6aR,8R,9aR)-2,2,4,4-
tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4-
(1H,3H)dione 239, had no specific effect on the cell wall for the bacterial strains tested.   
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As expected, we found that when the B. cereus (Figure 68, micrograph f) was treated with a 
high concentration of compound 239 (midway into the active range for the compound), 
inhibition of growth was clearly observable. Interestingly, compound 239 was the only B. 
cereus example where we also observed not only major indentations on the cell surface, but 
also appeared surface rupturing in a few of the examples. The significant bacterial cell wall 
damage may suggest that for the highly active compound 239 the mode of action against the 
B. cereus bacterial cells correlates directly to cell wall activity. This is supported by the 
qualitative evidence described above, including the shortening of the cells and the obvious 
cell surface damage by caused by distortion.  
 
6.2.3.3 Conclusions 
 
We showed that Gram-positive bacterial cells treated with uridine 12 at a concentration of 0.5 
mg/L showed no inhibition of bacterial growth. In general, all cells for both bacterial strains 
used, showed no surface indentations or distortions to the cell shape, indicating that the 
unmodified nucleoside had no effect on the bacterial strains tested. In comparison, we were 
able to demonstrate that S. aureus ATCC 25923 cells treated with high concentrations of 5'-
O-(tert-butyldiphenylsilyl)uridine 107 showed smooth cell surfaces, but distortions occurred 
in the spherical shape of the cells. In the case of B. cereus DL5, we observed that the cells had 
aggregated together, appeared to have rough surfaces and had ruptured in a few of the 
examples. 
 
From the data reported above (Section 6.2.1.2), we showed that converting the base in 1-
[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxa-
disilocin-8-yl]pyrimidine-2,4(1H,3H)dione 234 to the 5-methyl derivative 254 caused a 
corresponding loss in antibacterial activity for the compound (from 16 mg/L to 32 mg/L for S. 
aureus and B. cereus respectively), whereas oxidising the secondary alcohol on the 2'-position 
of the sugar ring to give 239 caused a corresponding increase in antibacterial activity for the 
compound (from 16 mg/L to 8 mg/L for S. aureus and B. cereus respectively). As such, we 
indicated that 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,-
2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)dione 239 was the compound with the best 
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antibacterial activity out all of the "first generation" and "second generation" of nucleoside 
derivatives. 
 
These results were supported by our SEM studies, in which we were able to show that all of 
the compounds 234, 254 and 239 showed a major reduction in bacterial growth at high 
concentrations. In addition, we were able to visualize how compound 239 was the only 
example, where significant bacterial cell wall damage (major indentations on the cell surface, 
as well as surface rupturing) was observed for both S. aureus ATCC 25923 and B. cereus 
DL5.  
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Chapter 7: 
Results and Discussion for Full Cancer Screens 
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were performed by Ms. J.-L. Panayides, while under the supervision of Prof W.A.L. van 
Otterlo. The work was undertaken in the School of Chemistry which forms part of the 
Molecular Sciences Institute at the University of the Witwatersrand. 
 
 
7.1 CHAPTER OVERVIEW 
 
In order to determine if the synthetic nucleoside derivatives prepared (synthesis described in 
Chapter 2 and Chapter 5) possessed general activity for the inhibition of cancerous cell 
proliferation, they were ten assayed against melanoma, glioma, prostate and breast cancer cell 
lines. A total of 43 first and second generation synthetic compounds and seven control 
compounds were screened against five human cancer cell lines and one mouse cancer cell line 
during the study. 
 
7.2 INHIBITION OF CELL PROLIFERATION STUDY 
 
7.2.1 Materials and Methods 
 
7.2.1.1 Cell Lines and Culture Conditions 
 
For this study, six established adherent cell lines of varying origin were used. The initial 
screen was performed against two human glioma lines (U373 and Hs683) and the compounds 
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showing activity were further subjected to analysis against another three human lines (PC-3, 
MCF-7 and SKMEL-28) and one murine line (B16F10). 
 
Human cancer lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA), the European Collection of Cell Culture (ECACC, Salisbury, UK), and the 
Deutsche Sammlung von Mikroorganismen and Zellkulteren (DSMZ, Braunschweig, 
Germany).  
 
Culture media, supplements and trypsin-EDTA solution were obtained from Gibco-
BRL/Invitrogen (Merelbeke, Belgium). Fetal bovine serum was inactivated before use by 
heating for 1 hour at 56 
o
C. Cells were cultured at 37 
o
C in Falcon tissue culture dishes (Nunc 
Invitrogen, Merelbeke, Belgium) in an incubator containing a 5 % CO2 humidified 
atmosphere. All culture media were supplemented with fetal bovine serum (percentages 
below), 200 IU/mL penicillin, 200 IU/mL streptomycin and 0.1 mg/mL gentamicin. 
 
U373 human glioma cell line 
The U373 MG cell line is a human carcinoma line isolated from the brain epithelium; it was 
derived from a malignant tumour by the “explants technique”.124 As a result of implementing 
STR analysis (DNA profiling) as part of the American Type Culture Collection’s (ATCC) 
routine authentication procedures, the ATCC discovered that some human cell lines were not 
as originally reported by the depositor.
125
 The cell line U373, obtained from the original lab in 
Uppsala has differing genetic properties from the ATCC line (HTB-17) – as such, ATCC has 
stopped distribution of this cell line indefinitely.
125
 The cell line used in this study and 
referred to as U373, was obtained from the ECACC (code 89081403) and is not involved in 
the controversy surrounding its origin. The cell line U373 was cultured in MEM medium 
(DMEM-F12 – Gibco-BRL/Invitrogen: 31330-03) supplemented with 5 % heat inactivated 
fetal bovine serum. 
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Hs683 human glioma cell line 
Hs683 cells were isolated from explant cultures of a glioma taken from the left temporal lobe 
of a 76 year old male Caucasian. Microvilli but no demosomes were observed on the 
monolayer fibroblast of the brain tissue.
126
 This adherent cell line was obtained from the 
ATCC (code HTB-138) and was cultured in RPMI medium (RPMI 1640 – Gibco-
BRL/Invitrogen: 52400-025) supplemented with 10% heat inactivated fetal bovine serum.
127 
 
PC-3 human prostate cancer cell line 
The adherent PC-3 human adenocarcinoma line is typical of the class of “classical” cell lines 
of prostatic cancer, with the PC-3 cell having high metastatic potential when compared to 
other lines of the same class.
128,129
 The PC-3 line was initiated from an advanced androgen 
independent bone metastasis of a grade IV prostatic adenocarcinoma from a 62 year old male 
Caucasian.
130
 The cells exhibit low acid phosphatase and testosterone-5-alpha reductase 
activities, as well as expressing PSA (the prostate specific antigen).
131
 The line used in this 
study was obtained from the DSMZ (code ACC465) and cultured in RPMI medium (RPMI 
1640 – Gibco-BRL/Invitrogen: 52400-025) supplemented with 10 % heat inactivated fetal 
bovine serum. 
 
MCF-7 human breast cancer cell line 
MCF-7 is the acronym for the Michigan Cancer Foundation – 7, referring to the institute in 
Detroit where the cell line was established in 1973 by Soule and co-workers.
132
 MCF-7 is an 
adherent breast adenocarcinoma line isolated from a 69 year old Caucasian woman. The 
primary tumour was an invasive breast ductal carcinoma and the cells were obtained by 
pleural effusion.
133
 This cell line is interesting in that it retained several characteristics of 
differentiated mammary epithelium, including the ability to process estradiol via cytoplasmic 
estrogen receptors and the capability of forming domes. In addition, the cells express the 
WNT7B oncogene.
133
 The MCF-7 line used in this study was obtained from the DSMZ (code 
ACC115) and cultured in RPMI medium (RPMI 1640 – Gibco-BRL/Invitrogen: 52400-025) 
supplemented with 10 % heat inactivated fetal bovine serum. 
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SKMEL-28 human melanoma cell line 
SKMEL-28 is an adherent cell line which was isolated from a malignant melanoma on the 
skin of a 51 year old male patient and deposited with the ATCC by Takahashi.
134
 It has 
polygonal morphology and grows as a monolayer (monoclonal continuous culture).
135
 The 
SKMEL-28 cells used in this study were obtained from the ATCC (code: HTB-72) and were 
cultured in RPMI medium (RPMI 1640 – Gibco-BRL/Invitrogen: 52400-025) supplemented 
with 10% heat inactivated fetal bovine serum. 
 
B16F10 mouse melanoma cell line 
B16F10 is an adherent mixture of spindle-shaped and epithelial-like cells obtained from the 
skin of Mus musculus (mouse).136 The B16F10 cells used in this study were obtained from the 
ATCC (code: CRL-6475) and were cultured in RPMI medium (RPMI 1640 – Gibco-
BRL/Invitrogen: 52400-025) supplemented with 10% heat inactivated fetal bovine serum. 
 
7.2.1.2 Synthetic Compounds Used in the Study 
 
Twenty-two of the range of the “First Generation Compounds” synthesized in Chapter 2, 
twenty-one of the range of the “Second Generation Compounds” synthesized in Chapter 5 
and seven synthetic controls were used in this study. The selection was made to encompass 
derivatives of all five of the different nucleosides and ᴅ-(-)-ribose. Compounds and controls 
used in this study have been grouped according to their structural similarities and re-drawn 
below for ease of reading.  
 
Illustrated in Figure 69 are the general purine (adenosine 8, guanosine 9 and inosine 116) and 
pyrimidine (cytidine 11) based nucleoside derivatives (excluding uridine). Whereas, Figure 
70, shows the uridine 12 and 5-methyluridine 233 derivatives used for our structure-activity 
analysis.  
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Figure 69 Structures of the general purine and pyrimidine based nucleoside derivatives 
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Figure 70a Structures of the uridine 12 and 5-methyluridine 233 derivatives 
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Figure 70b Structures of the uridine 12 and 5-methyluridine 233 derivatives 
 
Illustrated in Figure 71, are the simple derivatives of ᴅ-(-)-ribose 100, while highlighted in 
Figure 72 are all of our synthetic silanols and the 4,4’-dimethoxytrityl control 147. 
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Figure 71 Structures of the ᴅ-(-)-ribose 100 derivatives 
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Figure 72 Structures of the synthetic silanols and the 4,4’-dimethoxytrityl control 147 
 
Narciclasine 269 is a plant growth regulator that has been previously demonstrated by Kiss 
and co-workers, to be proapoptotic to cancer cells at high concentrations (≥ 1 μM).137 In 
addition, it was shown that narciclasine 269 displays potent anti-tumour effects in apoptosis-
resistant as well as apoptosis-sensitive cancer cells by impairing the organization of the actin 
cytoskeleton in cancer cells at concentrations that are not cytotoxic (IC50 values of 30-90 
nM).
138
 In a previous publication,
138
 the group observed that narciclasine 269 displayed potent 
antiproliferative activity, independent of the tumour type and independent of whether the cells 
were of human (IC50 range of 5-99 nM) or rodent origin (IC50 range of 28-35 nM). As such, 
narciclasine 269 was selected as our positive control for the study, which involved the 
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determination of inhibition of cell proliferation in both human and murine cancerous cell 
lines. Figure 73 below shows the chemical structure of narciclasine 269. 
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OH O
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H
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Figure 73 Structure of narciclasine 269  
 
Narciclasine 269 was thus isolated by the Kiss group using their standard protocol, from fresh 
bulbs of Narcissus pseudonarcissus Carlton. The experimental procedure is given in detail in 
the 2007 Neoplasia publication by Kiss and co-workers.139 
 
7.2.1.3 Evaluation of Compound Efficacy using the MTT Assay 
 
Overall cell growth was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) colorimetric assay. Stock solutions were prepared of the synthetic 
compounds in DMSO at 10
-2
 M or 10
-3
 M that were then stored at -20 
o
C until required. The 
MTT colorimetric assay was used to determine the cytotoxic activity of the synthetic 
compounds and controls on the different cell lines, after a 72 hour exposure period to the 
compounds. All determinations were carried out in sextuplicate. 
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The controls used in the assay consisted of:  
 (i) medium alone without cells giving the 0 % growth control  
 (ii) cells and medium with no test compound added, giving the 100 % growth control 
 (ii) cells and medium with narciclasine 269 added. 
 
The MTT assay used here is the same as that described for the inhibition of cell proliferation 
study in Chapter 3, Section 3.2.3.1 above, and similar to the TTC assay (used to determine 
anti-bacterial activity) and the XTT assay (used to determine anti-HIV activity). They are all 
based on the same principle, that tetrazolium structures are bioreduced to formazan structures 
in metabolically active cells. As such, only a very broad description of the methodology will 
be discussed here – however, you may refer to previous publications by the Kiss group for 
more detailed discussions, as required.
139-142
  
 
To perform the assay, cells were allowed to grow in 96-well micro-wells with a flat bottom 
with an amount of 100 μL of cell suspension per well with 5000 to 8000 cells/well depending 
on the cell type used.
143
 Each cell line was seeded in its appropriate culture medium. After a 
24 hour period of incubation at 37 
oC, the culture medium was replaced by 100 μL of fresh 
medium in which the tested compound was previously dissolved, at the following molar 
concentrations: 10
-8
 M, 5.10
-8
 M, 10
-7
 M, 5.10
-7
 M, 10
-6
 M, 5.10
-6
 M, 10
-5
 M, 5.10
-5
 M and 10
-
4
 M. Each experiment was performed in sextuplicate (six times).
143 
 
After 72 hours of incubation at 37 
o
C, with (experimental conditions) or without (control 
conditions) the control compound to be tested, the medium was replaced by 100 μL MTT 
dissolved in RPMI (1640 without phenol red) at a concentration of 0.5 or 1 mg/mL. The 
micro-wells were subsequently incubated for three and a half hours at 37 
o
C and then 
centrifuged at 1300 rpm for 10 minutes. MTT was removed and formazan crystals formed 
were dissolved in 100 μL DMSO. The micro-wells were then shaken for 5 minutes and read 
on a spectrophotometer at wavelength of 570 nm (maximal formazan absorbance).
143 
P a g e  | 248 
 
For each experimental condition, the mean optical density was calculated, allowing the 
determination of the percentage of remaining living cells in comparison to the control. The 
tables in the text show the IC50 (representing the range of concentration of the compound 
tested that resulted in a 50 % inhibition of overall tumour cell growth) for each compound in 
each line investigated. 
 
7.2.1.4 Data Analysis 
 
The results for the MTT assay are expressed as the concentration of the synthetic compound 
that inhibits 50 % of the in vitro global growth of a cell line (IC50), after three days 
incubation. Survival analyses were carried out by means of Kaplan-Meier curves and Gehan’s 
generalized Wilcoxon test. All the statistical analyses were realized using Statistica (Statsoft, 
Tulsa, Oklahoma, USA).
144 
 
7.2.2 Results and Discussion 
 
In our original anti-proliferation studies (discussed in detail in Part 1, Chapter 3) we 
reported percentage cell viabilities for various suspension (HL-60, Jurkat and K562) and 
adherent (Caco-2 and HT-29) cell lines, when treated with a single concentration, 100 µM, of 
the synthetic compounds for 24 hours.  
 
In this study, we only looked at solid/adherent cell lines and not at suspension lines, as the 
results previously reported (Section 3.2.3.2) suggested that our compounds, in general, had a 
lesser effect against the suspension cell lines. Additionally, for this study we wanted to obtain 
a broader sense of our compound activity and as such did not only perform a “snapshot test” 
at one concentration (100 µM), but instead looked across a range of concentrations in order to 
accurately determine IC50 values for the synthetic compounds. 
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As described in Section 7.2.1.2 above, a combination of fifty of the first and second 
generation compounds and controls were screened for possible anti-cancer activity against 
five human and one murine cell line. The IC50 values for the synthetic compounds were 
determined according to the procedure described by Kiss and co-workers.
139-144
  
 
Using the dilution series a standard dilution curve was prepared for the compound 
narciclasine 269, in each of the six established adherent cell lines of varying origin used in the 
assay (graphs prepared separately, but not shown due to space constraints).  
 
 
Graph 20 Standard Curve for narciclasine 269 with the initial HS683 and U373 cell lines 
 
For all synthetic and control compounds, the initial screen was performed against two human 
glioma lines (U373 and Hs683) and the compounds showing activity were subsequently 
screened against another three human lines (PC-3, MCF-7 and SKMEL-28) and one murine 
line (B16F10). The curve shown schematically in Graph 20 is the standard dilution curve for 
narciclasine 269 for the initial screen against the two glioma lines (U373 and Hs683). 
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The group was then able to use the standard curve shown in Graph 20 to determine the IC50 
values for the control narciclasine 269. The full set of results obtained for the control 
narciclasine 269 and incubated with the six cell lines are reported in detail in Table 26. 
 
Table 26 In vitro compound-induced anti-growth effects on various cancer cell lines 
expressed as IC50 values – Narciclasine 
Compound IC50 after 3 days of culture with the compounds 
U373 Hs683 PC-3 MCF-7 SKMEL-28 B16F10 m ± SEM 
269 (nM) 
269 (μM) 
29 
0.029 
40 
0.040 
28 
0.028 
45 
0.045 
37 
0.037 
35 
0.035 
35 ± 6 
0.035 ± 0.006 
 
As expected, narciclasine 269 showed inhibition of proliferation for all six of the cell lines 
screened. For these cell lines the activity range for narciclasine 269 was found to be in the 
nanomolar range; however, the results were converted to micromolar in order to allow for 
comparisons with the data obtained for our synthetic compounds. 
 
As narciclasine 269 is not a commercially available drug, the group wished to compare our 
results to a number of known compounds, marketed for their anti-cancer properties. For this 
study we wished to compare the results obtained to compounds with varying modes of action: 
(i) compound which stops the synthesis of pre-DNA molecular binding blocks - 5-
fluorouracil 270, (ii) compound which effects the synthesis of the mitotic spindles – 
paclitaxel (Taxol) 271 and (iii) compound that acts as an intercalating agent – cisplatin 272.145 
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Figure 74 Structures of commercially available compounds used as comparators
145 
 
The summary of literature data (IC50 values) currently available for the selected cell lines are 
given in Table 27 below for reference purposes.  
 
Table 27 Summary of literature data – IC50 values for commercial cancer drugs and the 
corresponding cell lines 
Compound IC50 values for various cell lines (μM) 
U373 Hs683 PC-3 MCF-7 SKMEL-28 B16F10 
270   0.81 ± 
0.07
146 
0.3 ± 0.1
147 
 
 
 
0.46 ± 
0.14μg/mL148 
271   0.0321
149
 
or 
0.0280
150 
or 
0.0366 ± 
0.0015
146 
0.003 ± 0.002
147
 
or 
0.0024
150 
 
0.042 ± 
0.002
151
 
0.002 ± 
0.001
151
 
272 5
152
 0.4
152
  9
152
 > 10
151
 10.01 ± 
0.03
151 
Note: For cisplatin 272, an IC50 value > 10 μM is usually indicative of an inactive compound
152 
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ᴅ-(-)-Ribose 100, was included as a negative control for the assay of the ᴅ-(-)-ribose 
derivatives. As expected, no inhibition of cell proliferation was observed (IC50 > 100 μM). 
Not surprisingly, the same lack of inhibition of cellular growth was also observed for 1’-O-
methoxy-ᴅ-(-)-ribose 101. The results for the assay are given in detail in Table 28. 
 
Table 28 In vitro compound-induced anti-growth effects on various cancer cell lines 
expressed as IC50 values – Derivatives of ᴅ-(-)-ribose  
Compound IC50 (μM) after 3 days of culture with the compounds 
U373 Hs683 PC-3 MCF-7 SKMEL-28 B16F10 m ± SEM 
100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
101 > 100 > 100 nd nd nd nd nd 
103 42 ± 2 46 ± 3 35 ±1 26 ±1 36 ± 1 37 ± 2 34 ±3 
119 82 ± 1 70 ± 1 34 ± 2 34 ± 1 50 ± 2 47 ± 4 53 ± 8 
120 57 ± 2 69 ± 3 34 ± 1 30 ± 1 59 ± 2 36 ± 1 48 ± 7 
121 > 100 > 100 nd nd nd nd nd 
122 > 100 > 100 nd nd nd nd nd 
Note: nd = not determined 
 
We observed that 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 
103, 2’,3’-O-diacetyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 119 and 
2’,3’-O-diacetyl-5’-O-(4,4’-dimethoxytrityl)-1’-O-methoxy-ᴅ-(-)-ribose 120 (structures 
shown in Figure 71), showed very limited activity against the cancerous cells, giving IC50 
values for the various cell lines ranging between 26-82 μM (relative to 0.02-0.05 μM for 
narciclasine 269). At the same time, we observed that compounds 2’,3’,5’-O-triacetyl-1’-O-
methoxy-ᴅ-(-)-ribose 121 and 2’,3’,5’-O-triallyl-1’-O-methoxy-ᴅ-(-)-ribose 122 (Figure 71) 
were completely ineffective at limiting cellular growth in the selected concentration range. 
This suggests that a bulky and greasy group is required on the 5’-hydroxyl group of the sugar 
ring – as compounds containing such a group (103, 119 and 120) were more effective at 
inhibiting proliferation than those with smaller, less greasy groups in the same position (121 
and 122).  
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Although largely ineffective with regard to anti-cancer activity, almost direct comparisons 
were noted between compounds 119 and 120 (relative to compound 103) – which may 
indicate that the bulky protecting group is not specific for activity, but what is important is 
rather the size of the group and it “fattiness”. 
 
The results of the general “First Generation” compounds of both purine and pyrimidine 
classes are grouped together in Table 29 for ease of reference. The results for the first 
generation of uridine derivatives have been grouped together with the other “Second 
Generation” uridine 12 and 5-methyluridine 253 derivatives in Table 30. 
 
Table 29 In vitro compound-induced anti-growth effects on various cancer cell lines 
expressed as IC50 values – General purine and pyrimidine nucleoside-based derivatives  
Compound IC50 (μM) after 3 days of culture with the compounds 
U373 Hs683 PC-3 MCF-7 SKMEL-28 B16F10 m ± SEM 
8 > 100 > 100 > 100 > 100 > 100 81 ± 4 > 81 
142 44 ± 1 46 ± 3 27 ± 1 26 ± 1 33 ± 1 29 ± 1 24 ± 4 
        
116 > 100 > 100 > 100 > 100 > 100 89 ± 4 > 89 
117 44 ± 1 63 ± 3 66 ± 5 67 ± 2 65 ± 2 34 ± 2 56 ± 6 
        
9 > 100 > 100 > 100 > 100 > 100 86 ± 2 > 86 
112 > 100 > 100 nd nd nd nd nd 
113 77 ± 2 > 100 nd nd nd nd nd 
        
11 > 100 > 100 > 100 > 100 > 100 93 ± 3 > 93 
133 > 100 > 100 nd nd nd nd nd 
134 28 ± 1 40 ± 2 22 ± 1 14 ± 1 26 ± 1 20 ± 2 25 ± 4 
Note: nd = not determined 
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As shown in Table 29, a number of unaltered nucleosides were included in the screen as our 
negative controls. As expected adenosine 8, inosine 116, guanosine 9 and cytidine 11 showed 
no inhibition of cell proliferation whatsoever (with IC50 > 100 μM) for the human cell lines. 
Interestingly however, all of the control compounds showed some activity at very high 
concentrations, 81-93 μM, towards the murine cell line (B16F10).  
 
The adenosine 8 derivative, 5'-O-(tert-butyldiphenylsilyl)adenosine 142 (Figure 69) showed 
some interesting results, with IC50 values of 44 ± 1 μM and 46 ± 3 μM for human glioma lines 
U373 and Hs683 respectively. Based on the activities being lower than 100 μM, the 
compound 142 was further assayed against the remaining four cell lines: PC-3 (27 ± 1 μM), 
MCF-7 (26 ± 1 μM), SKMEL-28 (33 ± 1 μM) and B16F10 (29 ± 1 μM). The mean IC50 
results for the six cell lines (24 ± 4 μM) are approximately eight times higher than the average 
values reported for 5-fluorouracil 270, paclitaxel (Taxol) 271 and cisplatin 272. We 
considered this to be a very exciting result as continuing compound development might result 
in an eight-fold improvement of our derivative, which would place us in the corresponding 
range as the current marketed drugs. 
 
The inosine 116 derivative, 5'-O-(4,4'-dimethoxytrityl)inosine 117 (Figure 69) gave IC50 
values of 44 ± 1 μM and 63 ± 3 μM for human glioma lines U373 and Hs683 respectively. As 
such, the compound 116 was further assayed against the remaining four cell lines. IC50 values 
of 66 ± 5 μM (PC-3 cells), 67 ± 2 μM (MCF-7 cells), 65 ± 2  μM (SKMEL-28 cells) and 34 ± 
2 μM (B16F10 cells) were obtained for compound 116. Unfortunately, none of the IC50 values 
obtained for the remaining human cell lines were significantly lower than those obtained for 
the glioma lines and as the original IC50 values were quite high, they are classified as inactive 
for this study. Interestingly, the IC50 value obtained for the murine line was on average around 
half the concentration required for activity in the five human cell lines.  
 
Two derivatives of guanosine 9 were screened in this assay: 6-N-(N,N-dimethyl-
methylimine)guanosine 112 and 5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)-
guanosine 113 (Figure 69). For both of these compounds, when screened against the glioma 
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lines U373 and Hs683, the IC50 values determined were around the 100 μM mark. As such, 
they were classified as inactive and were not subjected to any additional screens.  
 
The cytidine 11 derivative, 4-N-benzoylcytidine 133 (Figure 69) gave IC50 values greater 
than the 100 μM mark, when screened against the glioma lines U373 and Hs683  and, as such, 
they were classified as inactive for this assay and were not subjected to any additional 
screens. 5'-O-(Tert-butyldiphenylsilyl)cytidine 134 (Figure 69) however, exhibited a number 
of very interesting results. The compound 134 gave IC50 values of 28 ± 1 μM and 40 ± 2 μM 
for human glioma lines U373 and Hs683 respectively. As such, the compound 134 was 
further assayed against the remaining four cell lines. IC50 values of 22 ± 1 μM (PC-3 cells), 14 
± 1 μM (MCF-7 cells), 26 ± 1  μM (SKMEL-28 cells) and 20 ± 2 μM (B16F10 cells) were 
obtained for compound 134. The mean IC50 results for the six cell lines (25 ± 4 μM) are 
approximately eight times higher than the average values reported for 5-fluorouracil 270, 
paclitaxel (Taxol) 271 and cisplatin 272. 
 
The results obtained from the cell proliferation study for the “First Generation” of uridine 12 
derivatives have been grouped together with the “Second Generation” uridine 12 and 5-
methyluridine 253 derivatives in Table 30. 
 
A number of unaltered nucleosides were included in the screen as our negative controls, 
namely, uridine 12 and 5-methyluridine 233. As expected neither of the unaltered nucleosides 
showed any inhibition of cell proliferation (with IC50 > 100 μM) for the human cell lines (as 
shown in Table 30 below). Interestingly, we again noted (as above in Table 29) that both of 
the control compounds showed some activity towards the murine cell line (B16F10) at very 
high concentrations of approximately 88-92 μM.  
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Table 30 In vitro compound-induced anti-growth effects on various cancer cell lines 
expressed as IC50 values – Derivatives of Uridine and 5-Methyluridine 
Compound IC50 (μM) after 3 days of culture with the compounds 
U373 Hs683 PC-3 MCF-7 SKMEL-28 B16F10 m ± SEM 
12 > 100 > 100 > 100 > 100 > 100 92 ± 4 > 92 
107 36 ± 1 35 ± 1 25 ± 1 19 ± 1 24 ± 1 26 ± 2 28 ± 3 
123 32 ± 1 29 ± 1 20 ± 1 11 ± 1 26 ± 1 30 ± 1 25 ± 3 
124 26 ± 1 35 ± 2 28 ± 1 31 ± 1 25 ± 1 8 ± 1 53 ± 8 
126 43 ± 3 39 ± 2 28 ± 1 27 ± 1 31 ± 2 43 ± 1 35 ± 3 
127 40 ± 3 28 ± 5 18 ± 2 10 ± 1 31 ± 1 24 ± 2 25 ± 4 
128 39 ± 1 45 ± 2 28 ± 1 33 ± 1 43 ± 1 41 ± 2 38 ± 3 
130 > 100 > 100 nd nd nd nd nd 
131 > 100 > 100 nd nd nd nd nd 
229 71 ± 2 84 ± 3 > 100 > 100 > 100 > 100 nd 
234 81 ± 4 83 ± 2 28 ± 1 32 ± 1 30 ± 1 27 ± 2 47 ± 11 
235 29 ± 2 29 ± 2 25 ± 1 27 ± 1 28 ± 1 30 ± 1 28 ± 1 
239 71 ± 2 70 ± 4 26 ± 1 25 ± 1 30 ± 1 46 ± 5 45 ± 9 
248 > 100 > 100 nd nd nd nd nd 
        
233 > 100 > 100 > 100 > 100 > 100 86 ± 6 > 86 
251 > 100 77 ± 1 nd nd nd nd nd 
252 68 ± 1 64 ± 2 33 ± 1 31 ± 1 30 ± 1 33 ± 2 32 ± 2 
253 25 ± 1 27 ± 1 24 ± 1 28 ± 1 28 ± 1 38 ± 1 30 ± 3 
254 87 ± 2 91 ± 3 72 ± 2 > 100 > 100 26 ± 2 nd 
Note: nd = not determined 
 
Table 30 shows, that 5'-O-(tert-butyldiphenylsilyl)uridine 107 (Figure 70a) has a mean IC50 
value of 28 ± 3 μM for the average of the six cell lines. When protecting the two secondary 
alcohols on the sugar ring, we found that the mean IC50 value of 25 ± 3 μM for 2',3'-O-
diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 (Figure 70a) was not significantly different 
to that obtained for the unprotected compound 107. This allowed us to conclude that having 
the two secondary alcohols as unprotected alcohols was not essential for activity. However, 
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we found that when the amine on the base was protected with a benzoyl group, as in 
compound 3-N-benzoyl-2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 124 (Figure 
70a), the mean IC50 value of 53 ± 8 μM obtained for the average of the six cell lines had 
nearly doubled when compared to 107 and 123. This indicated that the free amine on the base 
of uridine is essential for cell proliferation activity. 
 
It was hoped to be able to substantiate these findings by a comparative study with the 
corresponding series of compounds, where the tert-butyldiphenylsilyl protecting group on the 
5’-oxygen was exchanged for a 4,4'-dimethoxytrityl protecting group. Unfortunately, the 
results did not mirror those exactly for the tert-butyldiphenylsilyl protecting group series. It 
was found the mean IC50 value for the average of the six cell lines to be 35 ± 3 μM for 5'-O-
(4,4'-dimethoxytrityl)uridine 126, 25 ± 4 μM for 2',3'-O-diacetyl-5'-O-(4,4'-
dimethoxytrityl)uridine 127 and 38 ± 3 μM for 3-N-benzoyl-2',3'-O-diacetyl-5'-O-(4,4'-
dimethoxytrityl)uridine 128 (structures given in Figure 70a). Although the mean IC50 values 
are in a similar concentration range, we did not observe the same doubling of the IC50 value 
when the free amine on the base of uridine was protected. 
 
As a further comparison, 2',3',5'-O-triacetyluridine 130 and 3-N-benzoyl-2',3',5'-O-
triacetyluridine 131 were assayed. In both cases, the compounds gave IC50 values greater than 
the 100 μM mark when screened against the glioma lines U373 and Hs683. As such, they 
were classified as inactive for this assay and were not subjected to any additional screens. 
This result suggested to us that we need a bulky protecting group in the 5’-hydroxyl position 
in order to obtain any inhibition of cell proliferation. 
 
For the next part of our Structure-Activity study, the aim was to investigate if the presence of 
a methyl group on the 5-position of the base in uridine would have any effect on the activity. 
As fulfilment for this, a comparison of three sets of direct derivatives with and without the 5-
methyl group on the base was undertaken. The first example involved 5'-O-(tert-
butyldimethylsilyl)uridine 229 and 5'-O-(tert-butyldimethylsilyl)-5-methyluridine 251 
(Figure 70a).  
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Compound 229 gave IC50 values of 71 ± 2 μM and 84 ± 3 μM for human glioma lines U373 
and Hs683 respectively. As such, the compound 229 was further assayed against the 
remaining four cell lines. Unfortunately, the IC50 values obtained for all four of the cell lines 
were determined to fall above the 100 μM mark and the compound 229 was subsequently 
classified as inactive. Compound 251 did not fare much better, when screened against the 
glioma lines U373 and Hs683, the IC50 values determined were above the 100 μM mark. As 
such, they were classified as inactive and were not subjected to any additional screens – 
broadly suggesting that the 5-methyl group was not directly linked to compound activity. 
 
As an example of what a negative result, i.e.: no observable inhibition of cell proliferation, the 
two standard dilution curves obtained for 5'-O-(tert-butyldimethylsilyl)uridine 229 and 5'-O-
(tert-butyldimethylsilyl)-5-methyluridine 251 are included below as Graphs 21 and 22 
respectively. The results are given for only the initial activity screen in the two glioma lines 
U373 and Hs683. 
 
 
 
Graph 21 Standard Curve for 5'-O-(tert-butyldimethylsilyl)uridine 229 with the initial HS683 
and U373 cell lines 
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Graph 22 Standard Curve for 5'-O-(tert-butyldiphenylsilyl)-5-methyluridine 253 with the 
initial HS683 and U373 cell lines 
 
The second comparative example for direct derivatives with and without the 5-methyl group 
on the base involved 5'-O-(dimethylthexylsilyl)uridine 248 and 5'-O-(dimethylthexylsilyl)-5-
methyluridine 252. In this instance, it was observed that compound 248 gave IC50 values 
greater than the 100 μM mark when screened against the glioma lines U373 and Hs683. As 
such, it was classified as inactive for this assay and was not subjected to any additional 
screens. 
 
In comparison, compound 252 (Figure 70a) gave IC50 values of 68 ± 1 μM and 64 ± 2 μM for 
human glioma lines U373 and Hs683 respectively. As such, the compound 252 was further 
assayed against the remaining four cell lines. IC50 values of 33 ± 1 μM (PC-3 cells), 31 ± 1 
μM (MCF-7 cells), 30 ± 1  μM (SKMEL-28 cells) and 33 ± 2 μM (B16F10 cells) were 
obtained for compound 252. The mean IC50 results for the six cell lines (32 ± 2 μM) are 
approximately ten times higher than the average values reported for 5-fluorouracil 270, 
paclitaxel (Taxol) 271 and cisplatin 272. 
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The third and final comparative example for direct derivatives with and without the 5-methyl 
group on the base involved the previously discussed 5'-O-(tert-butyldiphenylsilyl)uridine 107 
and 5'-O-(tert-butyldiphenylsilyl)-5-methyluridine 253 (Figure 70a). The mean IC50 value for 
the average of the six cell lines was 28 ± 3 μM for compound 107 and 30 ± 3 μM for 
compound 253. As there was no significant difference between the mean IC50 values for the 
two compounds, we concluded that the presence of the 5-methyl group on the base of the 
uridine derivatives did not have a marked effect on the inhibition of cell proliferation. 
 
The last group of compounds investigated in our SAR study were those containing the 1,3-
dihydroxy-1,1,3,3-tetraisopropyldisiloxane protecting group. The simplest of these was 1-
[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxa-
disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 234 (Figure 70b). For compound 234 a mean 
IC50 values for the six cell lines of 47 ± 11 μM was observed (shown schematically in Graph 
23 for the two glioma cell lines).  
 
 
 
Graph 23 Standard Curve for 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetra-
hydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 234 with the 
initial HS683 and U373 cell lines 
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Whereas in compound 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4-(1H,3H)-dione 239 (Figure 70b), which has 
the 2’-hydroxyl group oxidized to a ketone, we observed a mean IC50 values for the six cell 
lines of 45 ± 9 μM. These two results were not significantly different and allowed us to 
conclude that the free 2’-hydroxyl of the sugar ring on its own, is not responsible for any 
activity against the cancerous cell lines tested. 
 
In the derivative with a benzoyl group attached to the amine on the base, 3-benzoyl-1-
[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxa-
disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 235 (Figure 70b), a mean IC50 values for the six 
cell lines of 28 ± 1 μM was observed. This represents a one-third lower active concentration 
than for the corresponding compound 234 which does not contain the benzoyl group (shown 
schematically in Graph 24 for the two glioma cell lines).  
 
 
 
Graph 24 Standard Curve for 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraiso-
propyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 
235 with the initial HS683 and U373 cell lines 
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It was noted that for 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-tetraisopropyl-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4(1H,3H)-dione 254 
(Figure 70b) IC50 values of 87 ± 2 μM (U373 cells), 91 ± 3 μM (Hs683 cells), 72 ± 2 μM 
(PC-3 cells), > 100 μM (MCF-7 cells), > 100  μM (SKMEL-28 cells) and 26 ± 2 μM (B16F10 
cells) were observed. Interestingly, it was observed that compound 254 showed good activity 
towards the murine cell line (B16F10) at a concentration of 26 μM, which was approximately 
one-third of that required in the human cell lines screened. 
 
The final class of compounds screened for their inhibition of cell proliferation is the silanols. 
The results for this study are given in Table 31, along with those obtained for the structurally 
similar protecting group derivative, 4,4’-dimethyoxytrityl alcohol 147. 
 
Table 31 In vitro compound-induced anti-growth effects on various cancer cell lines 
expressed as IC50 values – Protecting group derivatives 
Compound IC50 (μM) after 3 days of culture with the compounds 
U373 Hs683 PC-3 MCF-7 SKMEL-28 B16F10 m ± SEM 
145 70 ± 1 70 ± 5 65 ± 2 53 ± 1 69 ± 1 79 ± 1 66 ± 5 
147 43 ± 1 61 ± 6 43 ± 1 29 ± 1 53 ± 1 44 ± 1 42 ± 5 
176 79 ± 1 85 ± 2 > 100 72 ± 2 94 ± 2 59 ± 4 > 78 
256 > 100 > 100 nd nd nd nd nd 
258 > 100 > 100 > 100 > 100 > 100 88 ± 4 > 88 
259 > 100 > 100 nd nd nd nd nd 
260 > 100 > 100 nd nd nd nd nd 
261 > 100 > 100 nd nd nd nd nd 
262 > 100 > 100 nd nd nd nd nd 
263 81 ± 1 > 100 nd nd nd nd nd 
264 > 100 > 100 nd nd nd nd nd 
265 > 100 > 100 nd nd nd nd nd 
266 63 ± 2 46 ± 2 44 ± 2 33 ± 1 60 ± 1 42 ± 1 45 ± 6 
268 62 ± 3 58 ± 2 46 ± 1 37 ± 2 62 ± 1 58 ± 2 51 ± 6 
Note: nd = not determined 
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Owing to the interesting result obtained in Part 1, where it was shown that tert-
butyldiphenylsilanol 145 was active against the two adherent lines tested (HT-29 and Caco-2), 
we decided to further investigate this result by assaying a range of different molecular weight 
silanols. The compounds tert-butyldiphenylsilanol 145 and 4,4'-dimethoxytrityl alcohol 147 
(Figure 72) were also included in the assay to serve as our controls. 
 
Of the series of fourteen protecting group derivatives tested, only three additional compounds 
showed sufficient activity in our two glioma lines (H373 and Hs683) to warrant further 
investigation in the additional four cell lines (PC-3, MCF-7, SKMEL-28 and B16F10). The 
remaining compounds tripropylsilanol 256, butyldimethylsilanol 258, tributylsilanol 259, 
triisobutylsilanol 260, tert-butyldimethylsilanol 261, dimethylthexylsilanol 262, 
trihexylsilanol 263, cylcohexyldimethylsilanol 264 and benzyldimethylsilanol 265 (structures 
given in Figure 72) were classified as inactive for this assay. 
 
The first of the three “active” compounds was triethylsilanol 176 (Figure 72), which gave 
IC50 values of 79 ± 1 μM and 85 ± 2 μM for human glioma lines U373 and Hs683 
respectively. Additionally, compound 176 gave IC50 values of > 100 μM (PC-3 cells), 72 ± 2 
μM (MCF-7 cells), 94 ± 2  μM (SKMEL-28 cells) and 59 ± 4 μM (B16F10 cells). This 
resulted in a mean IC50 value for the six cell lines of > 78 μM, which was not a significant 
improvement on those obtained for tert-butyldiphenylsilanol 145 (66 ± 5 μM) and 4,4'-
dimethoxytrityl alcohol 147 (42 ± 5 μM). As such, the compound was not considered as an 
improvement and was not investigated further. 
 
The second of the three “active” compounds was triphenylsilanol 266 (Figure 72), which 
gave IC50 values of 63 ± 2 μM and 46 ± 2 μM for human glioma lines U373 and Hs683 
respectively. Additionally, compound 266 gave IC50 values of 44 ± 2 μM  for the PC-3 cells, 
33 ± 1 μM  for the MCF-7 cells, 60 ± 1  μM for the SKMEL-28 cells and 42 ± 1 μM for the 
B16F10 cells. This resulted in a mean IC50 value for the six cell lines of 45 ± 1 μM, which 
was similar to the reported mean IC50 value of 42 ± 5 μM for 4,4'-dimethoxytrityl alcohol 147 
and approximately 20 μM lower than the IC50 value of 66 ± 5 μM for tert-
butyldiphenylsilanol 145. The mean IC50 value for compound 266 equates to being 
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approximately fourteen times higher than the average values reported for 5-fluorouracil 270, 
paclitaxel (Taxol) 271 and cisplatin 272 (Figure 74). 
 
The last of the three “active” compounds was 1,3-dihydroxy-1,1,3,3-tetraisopropyldisiloxane 
268 (Figure 72). It gave IC50 values of: 62 ± 3 μM for U373 cells, 58 ± 2 μM for Hs683 cells, 
46 ± 1 μM  for PC-3 cells, 37 ± 2 μM  for MCF-7 cells, 62 ± 1  μM for SKMEL-28 cells and 
58 ± 2 μM for B16F10 murine cells. This resulted in a mean IC50 value for the six cell lines of 
51 ± 6 μM, which lies in the middle of the reported mean IC50 values for tert-
butyldiphenylsilanol 145 (66 ± 5 μM) and for 4,4'-dimethoxytrityl alcohol 147 (42 ± 5 μM). 
The mean IC50 value for compound 268 ultimately equates to being approximately sixteen 
times higher than the average values reported for 5-fluorouracil 270, paclitaxel (Taxol) 271 
and cisplatin 272. 
 
7.2.3 Conclusions 
 
From the inhibition of cell proliferation assay performed on the combined group of fifty first 
and second generation derivatives and their corresponding controls, we found that the six 
most active compounds had mean IC50 values of approximately 24-28 μM. The results 
obtained are summarized below: 
 
- 5'-O-(tert-butyldiphenylsilyl)adenosine 142 (24 ± 4 μM) 
- 5'-O-(tert-butyldiphenylsilyl)cytidine 134 (25 ± 4 μM) 
- 5'-O-(tert-butyldiphenylsilyl)uridine 107 (28 ± 3 μM) 
- 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 (25 ± 3 μM) 
- 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine 127 (25 ± 4 μM) 
- 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxa-disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 235 (28 ± 
1 μM) 
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As future work specifically aligned with this chapter, the Kiss group will aim to perform 
cellular imaging on the interesting compounds identified above. This will be performed over a 
72 h period at the IC50 value, during which time they will make films to observe and grossly 
decipher the mechanism of action of the molecules (by looking at cell proliferation, cell death, 
cell morphology, vacuoles, etc.). This falls beyond the scope of this thesis and as such will not 
be included here. However, any interesting results obtained from the study will be included in 
follow-up publications in the broader scientific literature.  
 
As a general conclusion, the six compounds identified from this study act as “hit-
compounds”, hidden treasures that could be analyzed in future work from a medicinal 
chemistry point of view; using tools such as Lipinski’s guidelines, cLogP calculations and 
solubility scores to map a route forward for further development of this line of compounds by 
subsequent graduate students. 
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Summary: 
Work Completed in Part 2 
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 PART 2 SUMMARY – SYNTHESIS 
 
As described in our aims for part 2, a decision was taken to synthesise a "second generation" 
of compounds that contained various silicon protecting groups, to determine if the results 
obtained in Part 1, suggested a general trend of biological activity or if they were specific to 
the tert-butyldiphenylsilyl group.  
 
From the data reported for the anti-bacterial and the cell proliferation studies in Part 1, we 
concluded that the nucleoside showing the most promising results was uridine 12 and as such 
it would be the nucleoside of choice for the "second generation compounds" to be 
synthesised. Our mini structure-activity study on the uridine derivatives found that the best 
position for performing modifications to the nucleoside was at the 5'-OH position on the sugar 
ring and this would thus become the initial focus for the synthesis of the "second generation 
compounds". 
 
The proposed “second generation compounds” included a series of uridine 12 and 5-
methyluridine 233 derivatives which were protected on the primary alcohol with a range of 
different sized silicon-containing protecting groups. We hoped that this would allow us to find 
the optimally sized silicon-containing protecting group that would impart good biological 
activity.  
 
Using our general approach for the synthesis of 5'-O-silicon protected uridine derivatives 
(Figure 75), we were able to synthesize a further five uridine derivatives and another five 5-
methyluridine derivatives.  
 
P a g e  | 268 
 
NH
O
ON
O
OHOH
HO
Uridine
12
NH
O
ON
O
OHOH
HO
5-Methyluridine
233
NH
O
ON
O
OHOH
O
NH
O
ON
O
OHOH
OR R
R = Si(i-Pr) / Si(t-Bu)Me2 / Si(i-Bu) / 
Si(thexyl)Me2 / Si(hexyl)3 / Si(tBu)Ph2
R = SiPr3 / Si(t-Bu)Me2 / 
Si(thexyl)Me2 / Si(tBu)Ph2  
 
Figure 75 Proposed second generation silicon-protected uridine 12 and 5-methyluridine 233 
derivatives 
 
We also made use of an approach used to synthesize a range of tethered 1,1,3,3-
tetraisopropyldisiloxane protected uridine derivatives. From this group of compounds we 
obtained five molecules that were modified in various positions on the sugar ring as well as at 
the amide position on the base (Figure 76).  
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Figure 76 Proposed second generation silicon-protected uridine 12 and 5-methyluridine 233 
derivatives 
 
At the same time, we made use of a general procedure for the conversion of silyl chlorides to 
silanols, and used the procedure to synthesize a series of fourteen silanols, ranging from low 
to high molecular weight, and spanning a wide range of chemical space (Figure 77).  
 
Si OH Si OH Si OH Si OH Si OH< < <<
 
Figure 77 Proposed silanols to be included in the second generation of compounds 
 
To summarise, for our "second generation compounds" we were able:  
(iv) to synthesise a range of silicon-protected uridine derivatives 
(v) to synthesise a range of silicon-protected derivatives of 5-methyluridine and  
(vi) to synthesise a range of corresponding silanols. 
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 PART 1 SUMMARY – BACTERIOLOGY AND MICROSCOPY  
 
From the data reported above (Section 6.2.1.2), we were able to conclude that in general the 
protection of uridine 12 and 5-methyluridine 233 with silicon-containing protecting groups 
did not increase the anti-bacterial activity for the parent nucleoside, as suggested based on the 
results obtained for 5'-O-(tert-butyldiphenylsilyl)uridine 107 in Part 1. However, one highly 
active exception was found, when the two silicon atom-containing 1,1,3,3-tetra-
isopropyldisiloxane protecting group was used.  
 
From our TTC assay, we were able to show that converting the base in 1-[(6aR,8R,9R,9aS)-9-
hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-pyri-
midine-2,4(1H,-3H)dione 234 to the 5-methyl derivative 254 caused a corresponding loss in 
anti-bacterial activity for the compound (from 16 mg/L to 32 mg/L for S. aureus and B. 
cereus respectively), whereas oxidising the secondary alcohol on the 2'-position of the sugar 
ring to give compound 239 caused a corresponding increase in anti-bacterial activity for the 
molecule (from 16 mg/L to 8 mg/L for S. aureus and B. cereus respectively). As such, we 
concluded that 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,-
2,4]trioxadisilocin-8-yl]pyrimi-dine-2,4(1H,3H)dione 239 was the compound with the best 
anti-bacterial activity out all of the "first generation" and "second generation" of nucleoside 
derivatives. 
 
These results obtained in the TTC assay, were also supported by our SEM studies. For our 
first SEM study, we showed that Gram-positive bacterial cells treated with uridine 12 at a 
concentration of 0.5 mg/L showed no inhibition of bacterial growth. In general, all cells for 
both bacterial strains used, showed no surface indentations or distortions to the cell shape, 
indicating that the unmodified nucleoside had no effect on the bacterial strains tested. In 
comparison, we were able to demonstrate that S. aureus ATCC 25923 cells treated with high 
concentrations of 5'-O-(tert-butyldiphenylsilyl)uridine 107 showed smooth cell surfaces, but 
distortions occurred in the spherical shape of the cells. For B. cereus DL5, we observed that 
the cells had aggregated together, appeared to have rough surfaces and had ruptured in a few 
of the examples. 
P a g e  | 271 
 
In our second SEM study, we were able to show that all of the compounds 234, 254 and 239 
showed a major reduction in bacterial growth at high concentrations. In addition, we were 
able to visualize how compound 239 was the only example, where significant bacterial cell 
wall damage (major indentations on the cell surface, as well as surface rupturing) was 
observed for both S. aureus ATCC 25923 and B. cereus DL5.  
 
From the CSLM study performed we validated the results obtained from the previously 
performed TTC assay for the determination of the percentage of metabolically active cells 
present after treatment with antibiotics and synthetic compounds were accurate 
representations of what was occurring in our overnight bacterial cultures. And, interestingly, 
we found that the CSLM images for both S. aureus ATCC 25923 and B. cereus DL5 treated 
with compound 239, at various concentrations, showed no visible cells stained yellow 
indicating cell injury. This suggests that the synthetic compound 239 is bacteriocidal and is 
killing the cells, and not simply inhibiting their growth. 
 
 PART 1 SUMMARY – FULL CANCER SCREEN 
 
From the inhibition of cell proliferation assay performed on the fifty first and second 
generation derivatives and their corresponding controls, we found that the six most active 
compounds had mean IC50 values of approximately 24-28 μM. The results obtained are 
summarized below: 
 
- 5'-O-(tert-butyldiphenylsilyl)adenosine 142 (24 ± 4 μM) 
- 5'-O-(tert-butyldiphenylsilyl)cytidine 134 (25 ± 4 μM) 
- 5'-O-(tert-butyldiphenylsilyl)uridine 107 (28 ± 3 μM) 
- 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 (25 ± 3 μM) 
- 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine 127 (25 ± 4 μM) 
- 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxa-disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 235 (28 ± 
1 μM) 
P a g e  | 272 
 
 
 
 
 
 
 
 
 
PART 3 - OVERALL CONCLUSIONS AND 
FUTURE WORK 
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Chapter 8: 
Conclusions and Future Work 
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8.1 GENERAL CONCLUSIONS 
 
As described in our aims for part 1, we thought it pertinent to investigate the possibility of 
forming fused bicyclic systems onto the 2’ and 3’ positions of the sugar ring of our 
nucleosides utilizing the RCM methodology that we were already familiar with. Using our 
planned strategy towards fused bicyclic ring systems, we were able to synthesize the various 
dienes (including 2’,3’-O-diallyl-5’-O-(tert-butyldiphenylsilyl)-1’-O-methoxy-ᴅ-(-)-ribose 
103 and 2’,3’-O-diallyl-5’-O-(4,4’-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)-
guanosine 114, as shown in Figure 78), but were unable to obtain the bicyclic ring systems 
via our proposed RCM route. Due to the time constraints of the project, we decided not to 
continue along this synthetic route and instead shifted our focus to the synthesis of a range of 
compounds that would be used to conduct a structure-activity study.  
 
3' 2'
1'O
4'
OO
5'OSi
1*
2*
3*
4*
103
OMe
NH
6
N7a
3a
2
N
O
NN
3' 2'
1'
O
4'
OO
5'O N
1*
5*
6*7*
8*
2*
3*
4*
OMe
OMe
114  
 
Figure 78 Dienes prepared as precursors for ring-closing metathesis 
 
We wished to investigate the structure activity relationships (SAR) involved when the various 
OH and NH positions on the nucleosides and ᴅ-(-)-ribose derivatives were protected 
sequentially with different protecting groups. The idea was that from this data we would be 
able to determine on which positions in the molecules it was essential to have free OH/NH 
binding sites in order to maintain the activity of the compounds. For these derivatives, we 
prepared a series of compounds that had different functional groups present on the primary 
hydroxyls and secondary hydroxyls on the sugar ring, as well as different groups present on 
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the primary amines and/or amide groups of the bases. This synthesis was performed to obtain 
a range of sugar derivatives [ᴅ-(-)-ribose 100] and nucleoside derivatives (adenosine 8, 
cytidine 11, guanosine 9, inosine 116 and uridine 12). Included in this group were the 
corresponding protecting group derivatives, tert-butyldiphenylsilyl alcohol 145 and 4,4’-
dimethoxytrityl alcohol 147 (shown in Figure 79). 
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Figure 79 Protecting group derivatives 
 
Having the range of synthetic compounds in hand, for both the approach towards the fused 
bicyclic ring systems and those for the structure-activity study, we then moved on to the 
biological testing. For the biological testing, we assayed our range of synthetic compounds for 
inhibitory activity against four bacterial strains, four cancer cell lines and HIV.  
 
The nucleoside and corresponding ᴅ-(-)-ribose derivatives were evaluated for their 
antibacterial activity against two Gram-positive (Staphylococcus aureus ATCC 25923 and 
Bascillus cereus DL5) and two Gram-negative bacteria (Pseudomonas aeruginosa ATCC 
27853 and Escherichia coli ATCC 25922). The results from the TTC assay for antibacterial 
activity showed that 5’-O-(tert-butyldiphenylsilyl)uridine 107, 5’-O-(tert-butyldiphenylsilyl)-
1’-O-methoxy-ᴅ-(-)-ribose 102 and tert-butyldiphenylsilyl alcohol 145 exhibited modest 
activity towards only the Gram-positive bacteria when compared to the ciprofloxacin 153 
control (Figure 80). From the data reported for the antibacterial assay, we concluded that the 
nucleoside showing the most promising results was uridine and as such it would be the 
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nucleoside of choice for our subsequent antibacterial activity studies. Our mini SAR study on 
the uridine derivatives found that the best position for performing modifications to our 
nucleosides was at the 5'-OH position on the sugar ring and a loss of either or both of the 
secondary alcohols (2'-OH and 3'-OH) and/or the primary amide on the base leads to a 
reduction in activity of the compounds. Lastly, the comparison of ᴅ-(-)-ribose derivatives to 
the uridine derivatives suggested that the bases on the nucleoside derivatives were probably 
necessary for molecular recognition to aid transportation within the cells.  
 
3' 2'
1'O
4'
OHOH
5'OSi
1*
2*
3*
4*
102
OMe
5
6
NH
O
ON
3' 2'
1'
O
4'
OHOH
5'OSi
1*
2*
3*
4*
107
N N
F
OO
HO
NH
153
Si
1
OH
2
3
4
145
 
 
Figure 80 Selected compounds screened using the TTC assay for antibacterial activity 
 
We found that none of the range of synthetic nucleoside and protecting group derivatives 
assayed showed any antiviral activity towards HIVIIIB. However, we did observe that a large 
number of the compounds were toxic towards the uninfected MT-4 cells (human T-cell 
leukemia cell line) at millimolar levels. This was quite unexpected and we believed that it 
suggested that our synthetic compounds may be toxic towards specifically cancerous cells. 
This possibility was subsequently investigated in our cell proliferation studies, where most of 
the synthetic compounds were screened for their "anticancer" properties against two adherent 
(HT-29 and Caco-2) and three suspension (HL-60, Jurkat and K-562) cell lines. The results of 
this study showed that 5'-O-(tert-butyldiphenylsilyl)uridine 107, 5'-O-(4,4'-dimethoxy-
trityl)uridine 126 and 5'-O-(tert-butyldiphenylsilyl)cytidine 134 (Figure 81) were active 
against both the suspension and the adherent cell lines. Whereas, tert-butyldiphenylsilanol 
145 was active against only the adherent lines and 4,4'-dimethoxytrityl alcohol 147 was active 
against only the suspension cell lines (illustrated in Figure 81).  
P a g e  | 277 
 
5
6
NH
O
ON
3' 2'
1'
O
4'
OHOH
5'OSi
1*
2*
3*
4*
107
5
6
NH
O
ON
3' 2'
1'
O
4'
OHOH
5'O
1*5*
2*
3*
4*
126
6*7*
8*
OMe
OMe
5
6
N
NH2
ON
3' 2'
1'
O
4'
OHOH
5'O
134
Si
1*
2*
3*
4*
Si
1
OH
2
3
4
5
1
OH
2
3
4
67
8
OMe
OMe
145 147  
 
Figure 81 Selected compounds screened in the inhibition of cell proliferation assay 
 
In general, all of the active compounds show a degree of selective cytotoxicity against the 
cancer cell lines tested, with minimal cytotoxicity directed against the white blood cells. The 
synthetic compounds, described above, also proved to be effective in inducing apoptosis, 
modulating the expression of caspase 3 and caspase 8, as well as causing the release of 
cytochrome c from the mitochondria into the cytosol. The cytotoxic effects of these 
derivatives therefore suggest potential for further development in cancer therapy. 
 
For all of the biological testing, we have found that ᴅ-(-)-ribose derivatives, in general did not 
show any significant biological activity, whereas (tert-butyldiphenylsilyl)-protected 
nucleoside derivatives and the corresponding tert-butyldiphenylsilyl alcohol control seem to 
be intrinsically bio-active. As such, we extrapolated that a second generation of synthetic 
compounds derived from the nucleoside uridine and containing silyl-protecting groups would 
be the best way to develop promising lead compounds.  
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We then moved on to the preparation and testing of our second generation of compounds; a 
decision was taken to synthesise a "second generation" of compounds that contained various 
silicon protecting groups, to determine if the results obtained in Part 1, suggested a general 
trend of biological activity or if they were specific to the tert-butyldiphenylsilyl group. The 
proposed “second generation compounds” included a series of uridine 12 and 5-methyluridine 
233 derivatives which were protected on the primary alcohol with a range of different sized 
silicon-containing protecting groups. We hoped that this would allow us to find the optimally 
sized silicon-containing protecting group that would impart good biological activity.  
 
Using our general approach for the synthesis of 5'-O-silicon protected uridine derivatives, we 
were able to synthesize a further five uridine derivatives and another five 5-methyluridine 
derivatives. Similarly, we made use of a modified approach to synthesize a range of tethered 
1,1,3,3-tetraisopropyldisiloxane-protected uridine derivatives. From this group of compounds 
we obtained five molecules that were modified in various positions on the sugar ring, as well 
as at the amide position on the base. At the same time, we utilized a general procedure for the 
conversion of silyl chlorides to silanols, and used this procedure to synthesize a series of 
fourteen silanols, ranging from low to high molecular weight and spanning a wide range of 
chemical space. 
 
From the data reported above (Section 6.2.1.2), we were able to conclude that in general the 
protection of uridine 12 (Figure 82) and 5-methyluridine 233 (Figure 82) with silicon-
containing protecting groups did not increase the antibacterial activity for the parent 
nucleoside, as suggested based on the results obtained for 5'-O-(tert-
butyldiphenylsilyl)uridine 107 (Figure 82) in Part 1. However, one highly active exception 
was found, when the two silicon atom containing 1,1,3,3-tetraisopropyldisiloxane protecting 
group was used.  
 
From our antibacterial TTC assay, we were able to show that converting the base in 1-
[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxa-
disilocin-8-yl]-pyrimidine-2,4(1H,-3H)dione 234 (Figure 82) to the 5-methyl derivative 254 
(Figure 82) caused a corresponding loss in anti-bacterial activity for the compound (from 16 
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mg/L to 32 mg/L for S. aureus and B. cereus respectively), whereas oxidising the secondary 
alcohol on the 2'-position of the sugar ring to give compound 239 (Figure 82), caused a 
corresponding increase in anti-bacterial activity for the molecule (from 16 mg/L to 8 mg/L for 
S. aureus and B. cereus respectively). As such, we concluded that 1-[(6aR,8R,9aR)-2,2,4,4-
tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,-2,4]trioxadisilocin-8-yl]pyrimidine-
2,4(1H,3H)dione 239 was the compound with the best antibacterial activity out all of the "first 
generation" and "second generation" of nucleoside derivatives. 
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Figure 82 Active compounds identified when screened using the TTC assay for antibacterial 
activity and then taken into SEM and CSLM studies 
 
These results obtained in the TTC assay, were also supported by our SEM studies. For our 
first SEM study, we showed that Gram-positive bacterial cells treated with uridine 12 (Figure 
82) at a concentration of 0.5 mg/L showed no inhibition of bacterial growth. In general, all 
cells for both bacterial strains used, showed no surface indentations or distortions to the cell 
shape, indicating that the unmodified nucleoside had no effect on the bacterial strains tested. 
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In comparison, we were able to demonstrate that S. aureus ATCC 25923 cells treated with 
high concentrations of 5'-O-(tert-butyldiphenylsilyl)uridine 107 (Figure 82) showed smooth 
cell surfaces, but distortions occurred in the spherical shape of the cells. For B. cereus DL5, 
we observed that the cells had aggregated together, appeared to have rough surfaces and had 
ruptured in a few of the examples. 
 
In our second SEM study, we were able to show that all of the compounds 234, 254 and 239 
(Figure 82) showed a major reduction in bacterial growth at high concentrations. In addition, 
we were able to visualize how compound 239 was the only example, where significant 
bacterial cell wall damage (major indentations on the cell surface, as well as surface 
rupturing) was observed for both S. aureus ATCC 25923 and B. cereus DL5.  
 
From the CSLM study performed we validated the results obtained from the previously 
performed antibacterial TTC assay for the determination of the percentage of metabolically 
active cells present after treatment with antibiotics and synthetic compounds were accurate 
representations of what was occurring in our overnight bacterial cultures. Interestingly, we 
found that the CSLM images for both S. aureus ATCC 25923 and B. cereus DL5 treated with 
compound 239 (Figure 82) at various concentrations showed no visible cells stained yellow 
indicating cell injury. This suggests that the synthetic compound 239 is bacteriocidal and is 
killing the cells, not simply inhibiting their growth. 
 
From the inhibition of cell proliferation assay, performed on the fifty first and second 
generation derivatives and their corresponding controls, we found that the six most active 
compounds had mean IC50 values of approximately 24-28 μM. The results obtained are 
summarized below: 
- 5'-O-(tert-butyldiphenylsilyl)adenosine 142 (24 ± 4 μM) 
- 5'-O-(tert-butyldiphenylsilyl)cytidine 134 (25 ± 4 μM) 
- 5'-O-(tert-butyldiphenylsilyl)uridine 107 (28 ± 3 μM) 
- 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 123 (25 ± 3 μM) 
- 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine 127 (25 ± 4 μM) 
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- 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxa-disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 235 (28 ± 
1 μM) 
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Figure 83 Active compounds identified in full inhibition of cell proliferation study 
 
8.2 FUTURE WORK 
 
8.2.1 Current State of the Work 
 
On various instances during the preparation of our “second generation” compounds, we 
isolated compounds in which the silyl protecting groups had added to the uridine sugar ring in 
more than one place. As these side-products were not planned for and due to the time 
constraints of the project, they were not tested for any biological activity. As such, they were 
not included in the body of work discussed in this thesis. However, we feel that in light of the 
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interesting antibacterial and anticancer results obtained for compounds containing two-silicon 
atoms in the protecting group (such as 234, 235 and 239), this group of compounds may be of 
enough interest to re-investigate them fully in the future. To this end, a select few examples 
where we were able to easily isolate the multiple protecting group containing by-products 
have been shown graphically in Figure 84.  
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Figure 84 Selected examples of by-products containing multiple protecting group additions 
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Figure 84 continued Selected examples of by-products containing multiple protecting group 
additions 
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Only one worked example will be included for general reference purposes. The example 
chosen is the preparation of compounds 274, 275 and 276, derived from the simplest of the 
silicon-containing protecting groups, triethylsilyl chloride. The full experimental procedure 
and the spectroscopic data are discussed in detail in Appendix F. 
 
8.2.2 The Way Forward: Part 1 – Multiple Protecting Group Additions 
 
Based on the promising results observed in our biological assays when testing compounds 
containing two silicon atoms (Section 8.1) and when considering the ease of formation of the 
multiple protecting group-containing by-products discussed above (Section 8.2.1), we feel it 
would be important to continue this project by selectively preparing a series of compounds 
with multiple protecting groups of varying steric bulk and lipophilicity (Figure 85).  
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Figure 85 Possible uridine derivatives to be used in future SAR studies for biological activity 
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By doing this we would be able to correlate chemical structures to activity in order to 
determine the following relationships: 
 Differentiate activity on the basis of one vs. two vs. three individual protecting groups, 
each containing a single silicon atom, in order to ascertain if increasing the number of 
silicon atoms directly increases the biological activity of the compounds 
 Differentiate activity on the basis of the steric size of the protecting groups attached 
and the lipophilicity of those groups, to determine which silicon-protecting group 
“molecular size” is optimal for activity 
 Identify which position/s are ideal for activity, for example: the 2’-O-/5’-O-protected 
combination vs. the 3’-O-/5’-O-protected combination 
 Correlate activity for molecules with two silicon-protecting groups (3’-O-
triisopropylsilyl and 5’-O-triisopropylsilyl) against the data previously obtained for 
our second generation compounds containing the two silicon-tethered protecting group 
(2,2,4,4-tetraisopropyldisoloxane) 
 
Once we have the results in hand from our standard biological assays (for antibacterial and 
anticancer activity) – we hope to be able to identify any conclusive link between the structures 
and their activity. This would allow us to ring-fence the most promising “lead-compounds” to 
develop in future generations. 
 
8.2.3 The Way Forward: Part 2 – Modifications to the Sugar Ring Hydroxyl Groups 
 
Moving forward with the best hits from the structure activity screen described in detail above 
(Section 8.2.2), we would proceed with the “lead-compounds” and modify the un-silylated 
hydroxyls of the sugar ring in order to obtain compounds that better fit Lipinski’s guidelines , 
have more favorable solubility indexes and offer good cLogP values. 
 
                                                          
*Lipinski’s Guidelines State: In general, an orally active drug has no more than one violation of the following 
criteria: (i) not more than five H-bond donors, (ii) not more than ten H-bond acceptors, (iii) a molecular weight 
under 500 daltons and (iv) an octanol-water partition coefficient log P less than five.
153-155 
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This could be done in a number of ways, the first step would be to prepare simplified 
derivatives of the lead-compounds where the free hydroxyl group is “blocked” – an example 
of how this could be achieved is given in Scheme 27. 
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Scheme 27 General example of simple methylation reaction on the free hydroxyl group 
 
After biological screening of these compounds, two possible outcomes are foreseeable:  
(i) if it is observed that the activity of the compounds is not negatively affected by 
“blocking” the free hydroxyl group, then this position can be used as a handle on 
which to add solubilising groups to the molecule  
(ii) if however, it is observed that the activity of the compounds is lost by “blocking” the 
free hydroxyl group, we could further investigate the addition of various groups 
containing either H-bond donors or acceptors (to try to mimic the relationship of the 
                                                          
 The types of solubilising groups to be added are entirely dependent on the active compounds themselves – the 
cLogP values would directly influence the type of group that would be required to move the cLogP value into 
the accepted Lipinski range. For example, we would need to look at the active compound to determine if a 
“fatty” group is appropriate or not. 
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free hydroxyl group in the interactions with the active sites) as well as to favorably 
match Lipinski’s guidelines (Scheme 28). 
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Scheme 28 Addition of H-bond donors/acceptors to the molecules where “blocking” the 
hydroxyl causes an inhibition of biological activity 
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A.1 Purification of Solvents 
 
All solvents used for reactions and preparative chromatography were distilled prior to use. 
Solvents used in reactions were pre-dried in their reagent bottles and then distilled over the 
appropriate drying mediums under a nitrogen atmosphere: 
o tetrahydrofuran and diethyl ether were distilled from sodium metal wire and 
benzophenone 
o benzene and toluene were distilled from sodium metal lumps 
o acetonitrile, dichloromethane, N,N-dimethylformamide (stored over 4 Å molecular 
sieves after distillation), methanol and triethylamine were distilled from calcium 
hydride 
o acetic anhydride was distilled from 4 Å molecular sieves 
o pyridine was distilled from potassium hydroxide. 
 
Chloroform was dried by passing it through basic alumina (Merck aluminium oxide, basic, 
activity grade I).  
 
The Grubbs II catalyst 90 was stored in a Schlenk tube under an argon atmosphere. The 
procedure for storing the catalyst was to place the Schlenk tube under vacuum and then under 
argon four to five times to ensure that the system was free from air and it was then stored in 
the dark. 
 
A.2 Experimental Techniques and Equipment Used 
 
All reactions were performed under an inert atmosphere (either nitrogen or argon) using a 
standard manifold line and connected to a vacuum pump. The nitrogen and argon were 
dehydrated by bubbling the gas through sulfuric acid, and then neutralizing by passage 
through sodium hydroxide pellets. The vessels were flame-dried while under vacuum and 
were then allowed to cool to room temperature under the inert atmosphere.  
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Concentration or evaporation in vacuo refers to the removal of solvent under reduced pressure 
(approximately 20 mmHg, 40-50 
o
C) on a rotary evaporator and final drying on an oil pump 
(approximately 1-2 mmHg) at room temperature. Items dried under “high vacuum” were also 
dried using an oil pump (approximately 1-2 mmHg). 
 
Yields are calculated from the immediate synthetic precursor, unless otherwise specified.  
 
The microwave reactor referred to is the CEM Discovery and operating conditions employed 
for the reactions are outlined in the experimental procedures. The Carousel reactor employed 
for certain reaction sequences was manufactured by Radleys Discovery Technologies and is 
sold as the Carousel Reaction Station.  
 
A.3 Chromatographic Separations 
 
Macherey-Nagel Silica gel 60 (particle size 0.063-0.200 mm) was used as the adsorbent for 
conventional preparative chromatography, with a silica to compound ratio of 30:1. The silica 
was packed into a suitable size column; the product was loaded onto the silica surface and 
covered in acid washed sea sand. The elution process was performed using the indicated 
solvent mixtures and was usually performed under standard air pump pressure conditions.  
 
Pre-prepared silica (basified silica) used for column chromatography, where specified in the 
text, was prepared as follows: 
 the silica required for the column was pre-prepared by shaking with a 10 % NEt3 : 
hexane (v/v) solution, used in the ratio of 1 cm3 solution : 1 g silica, for 15 min at rt. 
Thereafter, the silica was dried by removing the solvent in vacuo. 
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The Rf values quoted are those obtained from thin layer chromatography on aluminium-
backed Macherey-Nagel ALUGRAM Sil G/UV254 plates pre-coated with 0.25 mm silica gel 
60 or Aldrich TLC plates, silica gel on aluminum. Spray reagents were used on thin layer 
chromatography plates for the detection of compounds that were not highly UV active. 
General reagents used include acidic vanillin, basic potassium permanganate, acidic ceric 
ammonium sulfate, acidic anisaldehyde and iodine that had been adsorbed onto silica gel. 
Acidic DNPH was used for the detection of ketones and aldehydes specifically. 
 
A.4 Spectroscopic and Physical Data 
 
All melting points were obtained on a Reichert hot-stage microscope and are uncorrected.  
Because of the many possible hydrogen bonds between nucleoside molecules in the 
crystalline state, repeated recrystallisation from different solvents or solvent mixtures can give 
rise to different crystal forms (polymorphism), which have different melting points.
A1
 As 
such, melting points were not determined for any compounds obtained as foams and only 
those compounds that gave truly crystalline material were determined. 
 
Optical rotations on the chiral compounds were obtained on a JASCO Model DIP-370 digital 
polarimeter using a sodium lamp at a wavelength of 589 nm. The compounds were prepared 
as a solution in a 1 cm
3
 volumetric flask using an appropriate solvent. The samples were run 
in a 10 mm cell, using an integration time of 60 sec and calculating the mean value by taking 
ten readings at 30 sec intervals. 
 
Infrared spectra were obtained either on a Bruker Vector 22 spectrometer, or on a Varian 
800FT-IR spectrometer (Scimitar Series). Both solid and liquid samples were run as a thin 
film under high pressure with no additional solvents added. The absorptions are reported on 
the wavenumber (cm
-1
) scale in the 600-3500 cm
-1
 range. The signals are reported: value 
(assignment). 
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Hydrogen nuclear magnetic resonance (
1
H NMR) spectra were recorded on Bruker Advance-
300 and Bruker DRX 400 spectrometers at 300.13 and 400.13 MHz respectively using 
standard pulse sequences. The probe temperature for all experiments was 300  1K. All 
spectra were recorded in deuterated chloroform (CDCl3) in 5 mm NMR spectroscopy tubes 
unless otherwise specified. Chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane as the internal standard. The 
1
H NMR spectroscopy chemical shifts are 
reported: value (number of hydrogens, description of signal, coupling constants in hertz (Hz) 
where applicable, assignment). Abbreviations used: s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, sept = septet, m = multiplet and b = broad. 
 
Decoupled carbon nuclear magnetic resonance (
13
C NMR) spectra were recorded on Bruker 
Advance-300 and Bruker DRX 400 spectrometers at 75 and 100 MHz respectively. Chemical 
shifts are reported on the  scale relative to the central signal of deuterated chloroform taken 
as  77.00 or relative to the signal for deuterated DMSO taken as  39.50. The 
13
C NMR 
spectroscopy chemical shifts are reported: value (assignment).  
 
The 
1
H and 
13
C NMR spectroscopic assignments with the same superscript are 
interchangeable. DEPT-135, HSQC and COSY spectra were routinely used for the complete 
assignment of NMR signals. D2O washes were routinely performed on samples after general 
NMR spectroscopic analysis in order to quantitatively assign the -OH and -NH signals. 
 
High-resolution mass spectra were recorded on a VG7-SEQ Double Focusing Mass 
Spectrometer at 70 eV and 200 A. The polarity was positive, ionization employed was EI, 
with a resolution of 3000, a mass range of 3000 amu (8 kV) and a scan rate of 5 secs / decade. 
Data are quoted: m/z value (relative abundance). 
 
  
P a g e  | 305 
 
A.5 Nomenclature and Numbering of Compounds 
 
The compounds prepared during the course of this project are named in the following 
experimental sections according to systematic nomenclature wherever possible. However, the 
numbering system used to illustrate the diagrams of these compounds is one adopted for 
convenience and is not meant to reflect the systematic numbering of these compounds. 
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Appendix B: 
Experimental Procedures – Relating to Chapter 2 
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B.1 Preparation of 1'-O-methoxy-ᴅ-(-)-ribose [101] 
 
A solution was prepared of ᴅ-(-)-ribose 100 (33.3 mmol, 5.00 g) and 
distilled MeOH (75 cm
3
). The solution was then cooled to 0 
o
C in an 
ice-water bath, before the addition of the acid solution. The acid 
solution was prepared from distilled MeOH (2.5 cm
3
) and 
concentrated H2SO4 (0.35 cm
3
). The acid solution was added portionwise to the ribose 
solution and the mixture was stirred for 5 min. The flask was then stoppered under an argon 
atmosphere and placed in the fridge (4 
o
C) for 72 h. After this time, the solution was 
neutralized by passage through a column of Amberlyst A-21 resin (185 g of resin was placed 
in a 4 cm wide column and was rinsed with 500 cm
3
 MeOH prior to use). The column was 
eluted with MeOH (1000 cm
3
) and the solvent was then removed in vacuo. The desired 
compound 101 [α:β ratio found to be 2:8] was obtained as a very viscous pale yellow oil (5.47 
g, 100 %). 
1
H and 
13
C NMR spectra were also run in D2O and the peaks were found to 
correlate well to those obtained by Chattopadhyaya and co-workers.
40 
 
Rf = 0.36 (10 % MeOH : CH2Cl2);  [α]D
23
 -15.464
o
 (c = 1.94 in MeOH);  νmax/cm
-1
 (thin film) 
1216 (C-O), 2362 (CO2 contaminant from air), 2851 (-OCH3), 3021 (-O-H chelate, H-
bonded), 3674 (-O-H free);  δH (300 MHz, d6-DMSO) 3.22 [2.1 H, s, OCH3 (β)], 3.28 [0.5 H, 
s, OCH3 (α)], 3.33-3.38 [1.7 H, m, H-5’ (β)], 3.45-3.55 [0.8 H, m, H-5’ (α)], 3.66-3.70 [1 H, 
m, H-2’ (α and β)], 3.70-3.77 [1 H, m, H-4’, (α and β)], 3.78-3.85 [1 H, m, H-3’(α and β)], 
4.05-4.25 (0.2 H, br m, OH), 4.62 [0.9 H, s, H-1’ (β)], 4.72 [0.4 H, d, J = 4.25 Hz, H-1’ (α)], 
4.75-4.80 (0.6 H, br s, OH), 4.93-4.99 (0.6 H, br s, OH);  δC (50 MHz, d6-DMSO) 54.26 
[OCH3 (β)], 54.54 [OCH3 (α)], 61.76 [C-5’ (α)], 63.20 [C-5’ (β)], 69.33 [C-3’ (α)], 70.98 [C-
3’ (β)], 71.35 [C-2’ (α)], 74.25 [C-2’ (β)], 83.62 [C-4’ (β)], 85.02 [C-4’ (α)], 102.82 [C-1’ 
(α)], 108.09 [C-1’ (β)];  MS m/z (M + 23+, 100 %) 150.18 (6), 182.13 (14), 188.17 (7), 269.08 
(7), 319.21 (26), 351.05 (24), 663.44 (8), HRMS (+cESI) calculated for C6H12O5: 164.06847, 
found: value not determined as compound was previously reported in the literature.
40 
 
  
3' 2'
1'O
4'
OHOH
5'HO
101
OMe
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B.2 Preparation of 5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-ᴅ-(-)-ribose [102] 
 
The Schlenk tube was filled with 5 % trimethylsilyl chloride : 
hexane and was stored at rt overnight. The glassware was then 
oven dried, placed under high vacuum and allowed to cool to 
rt under an argon atmosphere. The methoxy ribose derivative 
101 (15.8 mmol, 2.59 g) and DMAP (0.1 eq, 1.58 mmol, 
0.193 g) were stirred with distilled pyridine (26 cm
3
) until a 
solution had formed. To this solution was then added the tert-
butyldiphenylsilyl chloride (1.1 eq, 17.4 mmol, 4.52 cm
3
) and the reaction mixture was stirred 
at rt under an argon atmosphere overnight (20 h). After this time, tlc indicated the formation 
of a new spot, so the reaction was quenched with EtOH (25 cm
3
). The solvent was then 
removed in vacuo to yield the desired product 102 [α:β ratio found to be 2:9] as a yellow 
semi-solid foam (6.36 g) that was always complexed with pyridine, as such the compound 
was used “crude” in the subsequent allylation and acetylation reactions and yields were 
determined over two steps.  
 
Rf = 0.19 (10 % EtOH : CH2Cl2);   [α]D
23
 5.5000
o
 (c = 2.00 in EtOH);  νmax/cm
-1
 (thin film) 
709 and 738 (5 adjacent aromatic H), 818 and 1071 (Si-O), 1112 (C-O), 1361 and 1390 
[C(CH3)3], 1427 (Si-C), 1488, 1590 and 1649 (aromatic ring), 2856 (-OCH3), 2960 (C-H 
stretching), 3092 (aromatic H), 3277 (-O-H);  δH (300 MHz, d6-DMSO) 0.96-1.26 [9 H, m, 
C(CH3)3], 3.18 [2.2 H, s, OCH3 (β)], 3.31 [0.6 H, s, OCH3 (α)], 3.48-3.64 [1 H, m, H-2’ (α 
and β)], 3.72-3.90 [2 H, m, H-5’ (α and β)], 3.97-4.03 [2 H, m, H-3’ and H-4’ (α and β)], 
4.68-4.81 [1 H, m, H-1’ (α and β)], 7.35-7.39 (2 H, m, H-4*), 7.40-7.48 (4 H, m, H-3*), 7.62-
7.71 (4 H, m, H-2*), 8.01 (2 H, dd, J = 6.52 and 7.68 Hz, pyridine complex contaminant), 
8.50-8.55 (1 H, m, pyridine complex contaminant), 8.89-8.92 (2 H, m, pyridine complex 
contaminant), OH peaks were not observed;  δC (50 MHz, d6-DMSO) 18.75 [C(CH3)3], 26.54 
[C(CH3)3], 54.29 [OCH3 (β)], 54.56 [OCH3 (α)], 63.00 [C-5’ (α)], 64.04 [C-5’ (β)], 69.24 [C-
3’ (α)], 70.26 [C-3’ (β)], 71.31 [C-2’ (α)], 74.25 [C-2’ (β)], 83.15 [C-4’ (β)], 84.66 [C-4’ (α)], 
102.91 [C-1’ (α)], 108.10 [C-1’ (β)], 126.87 and 127.73 (C-3*), 129.15 and 129.77 (C-4*), 
133.05 (C-2*), 134.46 (C-1*), 135.06 (pyridine complex contaminant), 142.67 (pyridine 
complex contaminant), 145.01 (pyridine complex contaminant);  MS m/z (M + 23
+
, 100 %) 
3' 2'
1'O
4'
OHOH
5'OSi
1*
2*
3*
4*
102
OMe
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123.18 (20), 411.29 (11), 426.30 (28), 427.32 (8), 543.35 (10), 663.43 (9), 664.44 (6), HRMS 
(+cESI) calculated for C22H30O5SiNa
+: 425.17457, found: [M + 23]
+
 425.17547. 
 
B.3 Preparation of 2',3'-O-diallyl-5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-ᴅ-(-)-
ribose [103] 
 
The protected ribose derivative 102 (2.80 mmol, 1.13 g) was 
stirred with distilled DMF (28 cm
3
) until a solution had 
formed. This was then cooled to 0 
o
C in an ice-water bath 
before the addition of the sodium hydride (used as a 60 % 
suspension in oil, 2.2 eq, 6.16 mmol, 0.253 g). The mixture 
was then stirred for 15 min, until effervescence had ceased 
and the allyl bromide (2.2 eq, 6.2 mmol, 0.53 cm
3
) was then 
added. The reaction mixture was then allowed to stir at rt 
under an argon atmosphere overnight (20 h). After this time tlc indicated the formation of a 
new spot, so the solvent was removed by evaporation. The crude residue was then diluted 
with a saturated solution of NH4Cl (100 cm
3
) and extracted with EtOAc (3 × 100 cm
3
). The 
combined organics were then dried over anhydrous Na2SO4, filtered and the solvent was 
removed in vacuo to yield a orange oil. The crude compound was further purified by bulb-to-
bulb distillation and the desired compound 103 [α:β ratio found to be 2:8] was obtained as a 
bright yellow oil (0.918 g, 68 % over two steps). 
 
Rf = 0.23 (10 % EtOH : CH2Cl2);  [α]D
19
 -9.6774
o
 (c = 0.62 in EtOAc);  νmax/cm
-1
 (thin film) 
687 (5 adjacent aromatic H), 702 (CH2 rocking), 740 (5 adjacent aromatic H), 862 and 1223 
(Si-C), 1390 (C-H deformations), 1427 (C-O), 1461 (C-H deformations), 2856 (O-CH3), 2929 
(C-H stretch for CH2), 3015 (aromatic H), 3072 (C-H stretch for C=CH2);  δH (300 MHz, 
CDCl3) 1.04 [9 H, s, C(CH3)3], 3.36 [2.3 H, s, OCH3 (β)], 3.45 [0.3 H, s, OCH3 (α)], 3.51-
3.62 (2 H, m, OCH2 
#
), 3.81-3.84 (1 H, m, H-2’ ##), 3.97-4.01 (1 H, m, H-3’), 4.03-4.17 (2 H, 
m, OCH2 
#
), 4.20-4.24 (3 H, m, H-5’ and H-4’ ##), 4.90 (1 H, br s, H-1’), 5.08-5.42 (4 H, m, 
CH=CH2), 5.85-5.96 (2 H, m, CH=CH2), 7.34-7.43 (6 H, m, H-3* and H-4*), 7.66-7.71 (4 H, 
dd, J = 1.56 and 7.36 Hz, H-2*);  δC (50 MHz, CDCl3) 19.45 [C(CH3)3], 26.99 [C(CH3)3], 
3' 2'
1'O
4'
OO
5'OSi
1*
2*
3*
4*
103
OMe
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55.25 [OCH3 (β)], 55.57 [OCH3 (α)], 64.84 (C-5’), 71.68 (OCH2 
#
), 72.41 (OCH2 
#
), 78.58 
(C-3’), 79.62 (C-2’ ##), 80.81 (C-4’ ##), 102.60 [C-1’ (α)], 106.63 [C-1’ (β)], 114.09 
(CH=CH2), 117.32 (CH=CH2), 127.85 (C-3*), 129.80 (C-4*), 133.91 and 134.66 (CH=CH2), 
135.70 (C-2*), 136.94 (C-1*);  MS m/z (M + 23
+
, 100 %) 253.20 (5), 267.23 (28), 307.26 
(21), 465.32 (30), 506.38 (35), 507.39 (11), 663.44 (9), HRMS (+cESI) calculated for 
C28H38O5SiNa
+
: 505.23807, found: [M + 23]
+
 505.23807. 
Note: Assignments denoted with 
#
 and 
##
 are interchangeable. 
 
B.4 Attempted synthesis of {[(Z,6aS,7R,9R,9aS)-2,5,6a,7,9,9a-hexahydro-7-methoxy-
furo[3,4-b][1,4]dioxocin-9-yl]methoxy}(tert-butyl)diphenylsilane [104] 
 
Method 1: 
A solution was prepared of the diene 103 (0.430 mmol, 0.207 
g) in distilled CH2Cl2 (20 cm
3
) and was subsequently 
degassed using argon for 15 min. Then the 5 mol % of the 
Grubbs II catalyst 90 (0.05 eq, 0.0215 mmol, 0.0181 g) was 
added and the reaction mixture was stirred at rt under an 
argon atmosphere overnight (22 h). After this time, the 
solvent was removed in vacuo to yield a dark brown-black oil. Crude NMR spectroscopy 
confirmed the presence of only unreacted starting material 103. 
 
Method 2: 
A solution was prepared of the diene 103 (0.221 mmol, 0.107 g) and distilled CH2Cl2 (10 
cm
3
). The solution was then degassed using argon for 15 min before the addition of the 
Grubbs II catalyst 90 (0.05 eq, 0.0111 mmol, 0.0096 g). The reaction mixture was then 
allowed to stir at rt under an argon atmosphere overnight (23 h). After this time, tlc only 
indicated the presence of unreacted starting material, so a further 5 mol % Grubbs II catalyst 
104 (0.05 eq, 0.0111 mmol, 0.0096 g) was added. The reaction mixture was then refluxed 
overnight (22 h). After this time the solvent was removed in vacuo and the crude material was 
3' 2'
1'O
4'
OO
5'OSi
1*
2*
3*
4*
104
OMe
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purified by column chromatography (pre-prepared/basified silica and 5 % EtOAc : hexane). 
None of the desired 104 compound was obtained after chromatography. 
 
Method 3: 
A solution was prepared of the diene 103 (0.621 mmol, 0.300 g) in distilled toluene (30 cm
3
) 
and was then degassed using argon for 15 min. The solution was subsequently heated to 60 
o
C, before the addition of Grubbs II catalyst 90 (0.05 eq, 0.0310 mmol, 0.0268 g). The 
reaction mixture was then allowed to stir at 60 
o
C, under an argon atmosphere overnight (23 
h). After this time, tlc indicated the presence of some unreacted starting material, so a further 
portion of Grubbs II catalyst 90 (0.05 eq, 0.0310 mmol, 0.0262 g) was added and the reaction 
mixture was stirred at 60 
o
C for a further 5 h. After this time, tlc indicated no further change, 
so the solvent was removed in vacuo to yield a dark brown-black oil. The crude mixture was 
then purified by column chromatography on the pre-prepared/basified silica, using 5 % 
EtOAc : hexane as the eluant. None of the desired compound 104 was isolated. 
 
Method 4: 
A solution was prepared of the diene 103 (0.219 mmol, 0.106 g) in distilled toluene (10 cm
3
) 
and was then degassed using argon for 15 min. The solution was subsequently heated to 80 
o
C, before the addition of Grubbs II catalyst 90 (0.05 eq, 0.0109 mmol, 0.0097 g). The 
reaction mixture was then allowed to stir at 80 
o
C, under an argon atmosphere overnight (21 
h). After this time, tlc indicated the presence of some unreacted starting material, so a further 
portion of Grubbs II catalyst 90 (0.05 eq, 0.0109 mmol, 0.0099 g) was added and the reaction 
mixture was heated to reflux for a further 4 h. After this time, tlc indicated no further change, 
so the solvent was removed in vacuo to yield a dark brown-black oil. The crude mixture was 
then purified by column chromatography on the pre-prepared/basified silica, using 5 % 
EtOAc : hexane as the eluant. None of the desired compound 104 was isolated after the 
column chromatography. 
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Method 5: 
The diene 103 (0.221 mmol, 0.107 g) was dissolved in distilled toluene (1 cm
3
) and was 
placed in the microwave reaction tube. To this solution was then added Grubbs II catalyst 90 
(0.08 eq, 0.0177 mmol, 0.0191 g). Microwave setup used: 
 
 solvent: toluene 
 mode:   standard 
 power:  50 W 
 temperature: 50 oC 
 pressure: 150 psi maximum 
 run time: 5 min 
 hold time:  5 + 5 min 
 stirring: yes 
 cooling: no 
 
After the two initial 5 min runs, no change was observable by tlc. Thus, a further 8 mol % 
Grubbs II catalyst 90 (0.08 eq, 0.0177 mmol, 0.0159 g) was added and the reaction was run in 
the microwave for a further 10 min. After this time, the solvent was removed in vacuo and the 
crude mixture was purified by column chromatography using the pre-prepared/basified silica 
and 2-5 % EtOAc : hexane for elution. The method seemed to be too harsh for our compounds 
as all by-products isolated lacked the TBDPS protecting group.  
 
Method 6: 
A solution was prepared of the diene 103 (0.214 mmol, 0.103 g) in distilled CH2Cl2 (10 cm
3
). 
The solution was degassed using argon for 10 min before the addition of the Grubbs I catalyst 
(0.1 eq, 0.0214 mmol, 0.0173 g). The reaction mixture was then allowed to stir at rt under an 
argon atmosphere overnight (23 h) and the solvent was then removed in vacuo. Crude NMR 
spectroscopy showed that all of our starting material had decomposed so no further 
purification was undertaken. 
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B.5 Preparation of 5'-O-(4,4'-dimethoxytrityl)-1'-O-methoxy-ᴅ-(-)-ribose [105] 
 
The methoxy ribose derivative 101 (13.6 mmol, 2.24 g) 
and DMAP (0.1 eq, 1.36 mmol, 0.169 g) were stirred 
with distilled pyridine (22 cm
3
) until a solution had 
formed. The solution was then cooled to 0 
o
C in an ice-
water bath before the addition of the 4,4'-dimethoxytrityl 
chloride (1 eq, 13.6 mmol, 4.66 g). The reaction mixture 
was then stirred at rt under an argon atmosphere 
overnight (20 h). After this time, tlc indicated the formation of a new spot, so the reaction was 
quenched by the addition of EtOH (22 cm
3
) and the solvent was removed in vacuo. The 
desired compound 105 [α:β ratio could not be determined as all peaks overlapped] was 
obtained as a viscous yellow oil (6.36 g) that was always complexed with pyridine, as such 
the compound was used “crude” in the subsequent allylation and acetylation reactions and 
yields were determined over two steps.  
  
Rf = 0.23 (10 % EtOH : CH2Cl2);  [α]D
23
 -3.9801
o
 (c = 2.01 in EtOH);  νmax/cm
-1
 (thin film) 
670 (CH2 rocking), 773 (5 adjacent aromatic H), 831 (2 adjacent aromatic H), 1036 (C-O 
stretch C-OH), 1299 (-O-H bend), 1458 (alkanes), 2830 (-O-CH3), 3020 (Ar H), 3613 (O-H);  
δH (300 MHz, d6-DMSO) 2.92-3.43 (5 H, m, H-5’ and OCH3), 3.73-3.77 (7 H, m, H-3’ and 2 
× Ar-OCH3), 3.80-3.95 (3 H, m, H-2’, H-4’ and OH), 4.63 and 4.71 (1 H, two s, H-1’), 4.73-
5.25 (1 H, br s, OH), 6.86 (4 H, dd, J = 8.85 and 13.08 Hz, H-3*), 7.08 (2 H, d, J = 8.78 Hz, 
H-2* 
#
), 7.15-7.46 (7 H, m, H-2* 
#
, H-6*, H-7* and H-8*), 8.02-8.06 (1.4 H, m, pyridine 
complex contaminant), 8.57 (0.7 H, t, J = 7.81 Hz, pyridine complex contaminant), 8.92 (1.4 
H, d, J = 5.13 Hz, pyridine complex contaminant);  δC (50 MHz, d6-DMSO) 54.20 (OCH3), 
54.99 (2 × Ar-OCH3), 63.16 (C-5’), 70.96 (C-3’), 74.23 (C-2’), 79.89 (C-4’), 83.58 [C(Ar)3], 
108.05 (C-1*), 112.71 (C-3*), 126.40 (C-8*), 127.02 (C-6*), 127.38 (pyridine complex 
contaminant), 127.62 (C-7*), 128.89 (C-2*), 140.21 (C-1*), 142.31 (pyridine complex 
contaminant), 145.51 (pyridine complex contaminant), 148.33 (C-5*), 157.79 (C-4*);  MS 
m/z (M
+
, peak not observed) 123.20 (40), 173.15 (16), 187.15 (36), 303.24 (87), 304.25 (22), 
343.23 (15), 357.25 (19), 425.29 (8), 467.24 (7), 531.20 (6), 663.44 (100), 664.45 (51), 
3' 2'
1'O
4'
OHOH
5'O
1*5*
2*
3*
4*
105
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8*
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665.42 (19), 666.46 (5), HRMS (+cESI) calculated for C27H30O7Na
+
: 489.18837, found: [M + 
23]
+
 489.18781. 
Note: Assignments denoted with 
#
 are exchangeable. 
 
B.6 Attempted synthesis of 2',3'-O-diallyl-5'-O-(4,4'-dimethoxytrityl)-1'-O-methoxy-
ᴅ-(-)-ribose [106] 
 
Method 1: 
The protected ribose 105 (2.04 mmol, 0.953 g) was 
stirred with distilled DMF (21 cm
3
) until a solution had 
formed. This solution was then cooled to 0 
o
C in an ice-
water bath before the addition of the sodium hydride 
(used as a 60 % suspension in oil, 2.2 eq, 4.49 mmol, 
0.187 g) and it was subsequently stirred for 15 min until 
effervescence had stopped. Then the allyl bromide (2.2 
eq, 4.5 mmol, 0.39 cm
3
) was added and the reaction mixture was stirred at rt under an argon 
atmosphere overnight (20 h). After this time, tlc indicated the formation of a new spot, so the 
solvent was removed by evaporation. The crude residue was then diluted with a saturated 
solution of NH4Cl (100 cm
3
) and was extracted with EtOAc (3 × 100cm
3
). The combined 
organics were then dried over anhydrous Na2SO4, filtered and the solvent was removed in 
vacuo. The crude compound was further purified by bulb-to-bulb distillation, where two 
different oils were obtained - neither contained the desired product 106. 
 
Method 2: 
The protected ribose 105 (0.656 mmol, 0.306 g) and allyl ethyl carbonate 148 (3.2 eq, 2.10 
mmol, 0.280 g) were dissolved in anhydrous THF (4 cm
3
). A solution of 
bis(dibenzylideneacetone) palladium(0) 149 (0.03 eq, 0.0197 mmol, 0.0113 g) and 
bis(diphenylphosphino)butane (0.2 eq, 0.131 mmol, 0.0591 g) in anhydrous THF (1 cm
3
) was 
added dropwise to the starting material solution. The reaction mixture was then refluxed for 1 
h, after which time the reaction mixture was concentrated under reduced pressure to give a 
3' 2'
1'O
4'
OO
5'O
1*5*
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dark orange oil. The crude oil obtained was then purified by column chromatography using 5-
30 % EtOAc : hexane for elution. None of the desired compound 106 was obtained after 
column chromatography. 
 
B.7 Preparation of 5'-O-(tert-butyldiphenylsilyl)uridine [107] 
 
The flask used to perform the reaction was filled with a 5 % 
trimethylsilyl chloride : hexane (v/v) solution and was allowed 
to stand at rt overnight. After this time, the glassware was 
oven-dried, placed under high vacuum and allowed to cool to 
rt under an argon atmosphere. Then the uridine 12 (8.39 
mmol, 2.05 g) and DMAP (0.1 eq, 0.839 mmol, 0.103 g) were 
stirred with distilled pyridine (10 cm
3
) until a solution had 
formed. To this solution was then added tert-butyldiphenylsilyl chloride (1.1 eq, 9.23 mmol, 
2.40 cm
3
). The reaction mixture was then allowed to stir at rt under an argon atmosphere 
overnight (22 h). After this time a colour change was observed from a clear pale yellow 
solution to form a murky, cream coloured solution. The reaction mixture was diluted with 
CH2Cl2 (80 cm
3
). The organic layer was then extracted with saturated NaHCO3 (2 × 80 cm
3
) 
and brine (80 cm
3
). The combined organics were then dried over anhydrous Na2SO4, filtered 
and evaporated. The crude foam was then purified by column chromatography using the pre-
prepared/basified silica, with 10 % EtOH : CH2Cl2 being used as the eluant. The desired 
compound 107 was obtained as a white foam (4.04 g, 100 %,) and we found that our 
13
C 
NMR spectroscopic data correlated well to that reported by Sproat et. al.42 
 
Rf = 0.81 (20 % EtOH : CH2Cl2);  [α]D
19
 22.400
o
 (c = 2.50 in MeOH);  νmax/cm
-1
 (thin film) 
700 (5 adjacent aromatic H), 740 (CH2 rocking), 764 (5 adjacent aromatic H), 786 
(RHC=CHR cis), 876 (Si-C), 1084 (C-O stretch from C-OH), 1231 (Si-C), 1271 (O-H 
bending), 1362 [-C(CH3)3], 1381 (CH3 deformations), 1390 [-C(CH3)3], 1427 (C-H 
deformations), 1468 (secondary -N-H), 1608 (C=C conjugated with C=O), 1676 (-CONH-), 
1709 (C=O), 1740 (-O-H, H-bonded), 2856 (-O-CH3), 2930 (C-H stretching), 2957 (Ar H);  
δH (300 MHz, CDCl3) 1.08 [9 H, s, C(CH3)3], 3.38 (1 H, br d, J = 5.75 Hz, OH), 3.89 (1 H, d, 
5
6
NH
O
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O
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OHOH
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J = 10.73 Hz, H-5’), 4.08-4.25 (2 H, m, H-4’ and H-5’), 4.30-4.32 (1 H, m, H-2’), 4.35-4.37 
(1 H, m, H-3’), 5.37 (1 H, d, J = 8.08 Hz, H-5), 5.47 (1 H, br s, OH), 5.93 (1 H, d, J = 2.11 
Hz, H-1’), 7.37-7.44 (6 H, m, H-3* and H-4*), 7.65 (4 H, dd, J = 6.09 and 6.09 Hz, H-2*), 
7.97 (1 H, d, J = 8.10 Hz, H-6), 10.38 (1 H, br s, NH);  δC (50 MHz, CDCl3) 19.54 
[C(CH3)3], 27.20 (C(CH3)3), 62.76 (C-5’), 69.35 (C-2’), 75.70 (C-3’), 84.83 (C-4’), 90.50 (C-
1’), 102.53 (C-5), 128.21 (C-3*), 130.29 (C-4*), 132.26 (C-1*), 135.65 (C-2*), 140.38 (C-6), 
151.44 (C-2), 164.06 (C-4);  MS m/z (M
+
, 34 %) 438.24 (3), 481.27 (100), 483.28 (10), 
484.31 (2), 563.21 (5), 639.39 (2), HRMS (+cESI) calculated for C25H31N2O6Si
+
: 483.19459, 
found: [M + 1]
+
 483.19407. 
 
B.8 Attempted synthesis of 2',3'-O-diallyl-5'-O-(tert-butyldiphenylsilyl)uridine [108] 
 
Method 1: 
The protected uridine 107 (1.52 mmol, 0.735 g) was dissolved 
in DMF (15 cm
3
). To this solution was then added sodium 
hydride (used as a 60 % suspension in oil, 5 eq, 7.62 mmol, 
0.308 g) and the mixture was stirred at rt for 15 min. Then 
allyl bromide (5 eq, 7.6 mmol, 0.66 cm
3
) was added and the 
reaction mixture was stirred at rt under an argon atmosphere 
overnight (20 h). After this time the solvent was removed by evaporation and the residue 
obtained was diluted with a saturated solution of NH4Cl (50 cm
3
) and then extracted with 
EtOAc (3 × 50 cm
3
). The combined organics were then dried over anhydrous MgSO4, filtered 
and the solvent was removed in vacuo. The crude mixture was then purified by column 
chromatography using 10-30 % EtOAc : hexane for elution. A mixture of N- and O-allylated 
products were obtained (110 and 111), with none of the desired compound 108 isolated. 
 
Method 2: 
A solution was prepared of the 1,4-bis(diphenylphosphino)butane (0.05 eq, 0.0106 mmol, 
0.0046 g) and the bis(dibenzylideneacetone) palladium(0) 149 (0.01 eq, 0.00213 mmol, 
0.0016 g) in distilled THF (2 cm
3
), with stirring a colour change was observed from a purple 
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to a yellow solution. To this solution was added dropwise a solution of the protected uridine 
107 (0.213 mmol, 0.103 g) and the allyl ethyl carbonate 148 (2 eq, 0.425 mmol, 0.0554 g) in 
THF (5 cm
3
). The reaction mixture was then stirred at rt under an argon atmosphere overnight 
(20 h). After this time, tlc indicated the presence of a lot of unreacted starting material, so a 
further portion of the 1,4-bis(diphenylphosphino)butane (0.05 eq, 0.0106 mmol, 0.0047 g) 
and the bis(dibenzylideneacetone) palladium(0) 149 (0.01 eq, 0.00213 mmol, 0.0017 g) was 
added. After stirring for 2-3 min, another portion of the allyl ethyl carbonate 148 (2 eq, 0.425 
mmol, 0.0582 g) was then added. The reaction mixture was then stirred for a further 5 h. After 
this time, there was no further change by tlc, so MeOH (5 cm
3
) was added to quench the 
reaction mixture. The solvent was then removed in vacuo to yield a bright yellow-lime green 
oil. The crude oil was then purified by column chromatography using 30-40 % EtOAc : 
hexane for elution. None of the desired compound 108 was obtained; instead we isolated 
unreacted starting material 107 and the N-allylated byproduct 109. 
 
Method 3: 
A solution was prepared of the 1,4-bis(diphenylphosphino)butane (0.1 eq, 0.0428 mmol, 
0.0186 g) and bis(dibenzylideneacetone) palladium(0) 149 (0.05 eq, 0.0214 mmol, 0.0122 g) 
in distilled THF (0.5 cm
3
), the solution changed colour from dark purple to bright yellow with 
stirring. To this solution was then added dropwise a solution of the protected uridine 107 
(0.428 mmol, 0.207 g) and allyl ethyl carbonate 148 (5 eq, 2.14 mmol, 0.286 g) in distilled 
THF (2.5 cm
3
). The reaction mixture immediately changed colour from yellow to dark olive 
green and was then stirred at rt under an argon atmosphere overnight (19 h). After this time tlc 
showed the formation of a number of spots, so the reaction mixture was quenched by the 
addition of MeOH (10 cm
3
). The solvent was then removed in vacuo to give a viscous yellow-
green oil. The crude oil was purified by column chromatography using 20-50 % EtOAc : 
hexane for elution. None of the desired compound 108 was obtained after chromatography, 
isolated instead were the N- and O-allylated by products 109, 110 and 111.  
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3-N-Allyl-5’-O-(tert-butyldiphenylsilyl)uridine [109] 
Clear oil: Rf = 0.40 (50 % EtOAc : hexane);  δH (300 
MHz, CDCl3) 1.02-1.08 [9 H, m, C(CH3)3], 1.64 (1 H, br 
s, OH), 2.93 (1 H, br s, OH), 3.85 and 3.99 (2 H, two d, J 
= 12.10 Hz, H-5’), 4.16-4.55 (5 H, m, H-2’, H-3’, H-4’ 
and N-CH2), 5.18-5.29 (2 H, m, CH=CH2), 5.60 (1 H, d, J 
= 8.15 Hz, H-5), 5.80-5.95 (2 H, m, H-1’ and CH=CH2), 
7.39-7.45 (6 H, m, H-3* and H-4*), 7.51-7.69 (4 H, m, H-
2*), 7.78 (1 H, d, J = 8.15 Hz, H-6);  δC (50 MHz, CDCl3) 19.24 [C(CH3)3], 26.97 [C(CH3)3], 
43.04 (N-CH2), 63.19 (C-5’), 70.87 (C-2’ 
#
), 73.03 (C-3’ #), 86.03 (C-4’), 92.00 (C-1’), 
101.75 (C-5), 118.18 (CH=CH2), 128.04 (C-3*), 130.20 (C-4*), 131.33 (C-1*), 132.54 
(CH=CH2), 135.21 (C-2*), 137.43 (C-6), 151.85 (C-2), 162.08 (C-4). 
Note: Assignments denoted with 
#
 are interchangeable. 
 
3-N-Allyl-2’-O-allyl-5’-O-(tert-butyldiphenylsilyl)uridine [110] and 3-N-allyl-3’-O-allyl-5’-
O-(tert-butyldiphenylsilyl)uridine [111] 
 
ISOMER ONE, Pale 
yellow oil: Rf = 0.72 (50 
% EtOAc : hexane);  δH 
(300 MHz, CDCl3) 1.10 
[9 H, s, C(CH3)3], 2.93 (1 
H, d, J = 6.12 Hz, OH), 
3.68-4.24 (7 H, m, H-2’, 
H-3’, H-4’, H-5’ and N-
CH2), 4.53-4.57 (2 H, m, O-CH2), 5.10-5.30 [4 H, m, CH=CH2 (N) and CH=CH2 (O)], 5.51 (1 
H, d, J = 8.12 Hz, H-5), 5.73-5.91 [2 H, m, CH=CH2 (N) and CH=CH2 (O)], 5.99-6.02 (1 H, 
m, H-1’), 7.38-7.44 (6 H, m, H-3* and H-4*), 7.62-7.70 (5 H, m, H-2* and H-6);  δC (50 
MHz, CDCl3) 19.75 [C(CH3)3], 27.37 [C(CH3)3], 43.50 (N-CH2), 63.41 (C-5’), 71.72 (O-
CH2), 74.60 (C-3’), 76.66 (C-2’), 82.83 (C-4’), 90.48 (C-1’), 102.41 (C-5), 118.52 [CH=CH2 
(O)], 119.07 [CH=CH2 (N)], 128.41 (C-3*), 130.55 (C-4*), 131.90 [CH=CH2 (O)], 132.58 (C-
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1*), 133.82 [CH=CH2 (N)], 135.90 (C-2*), 138.06 (C-6), 151.30 (C-2), 162.62 (C-4);  MS 
m/z (M
+
, 2 %) 41.03 (56), 91.06 (34), 135.06 (33), 162.99 (75), 199.04 (58), 255.04 (22), 
333.10 (21), 353.11 (48), 447.14 (10), 505.18 (100), HRMS (EI pos) calculated for 
C31H38N2O6Si: 562.24991, found: [M]
+
 562.26234. 
ISOMER TWO, Bright yellow oil: Rf = 0.86 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 
1.07-1.10 [9 H, m, C(CH3)3], 2.61 (1 H, d, J = 8.92 Hz, OH), 3.89-3.97 (2 H, m, N-CH2), 
4.08-4.53 (7 H, m, H-2’, H-3’, H-4’, H-5’ and O-CH2), 5.12-5.48 [5 H, m, CH=CH2 (N), 
CH=CH2 (O) and H-5], 5.85-5.88 [2 H, m, CH=CH2 (N) and CH=CH2 (O)], 6.01 (1 H, s, H-
1’), 7.29-7.42 (6 H, m, H-3* and H-4*), 7.51-7.75 (4 H, m, H-2*), 7.99 (1 H, d, J = 8.14 Hz, 
H-6);  δC (50 MHz, CDCl3) 19.33 [C(CH3)3], 27.02 [C(CH3)3], 43.08 (N-CH2), 62.14 (C-5’), 
67.96 (C-2’), 71.61 (O-CH2), 81.90 (C-4’), 84.39 (C-3’), 88.12 (C-1’), 101.80 (C-5), 118.05 
[CH=CH2 (O)], 118.88 [CH=CH2 (N)], 128.21 (C-3*), 129.81 (C-4*), 131.76 and 132.14 
[CH=CH2 (N) and CH=CH2 (O)], 133.56 (C-1*), 135.01 (C-2*), 137.78 (C-6), 150.70 (C-2), 
162.45 (C-4);  MS m/z (M
+
, 2 %) 41.02 (56), 91.05 (23), 162.99 (62), 199.04 (95), 235.01 
(100), 255.03 (11), 333.04 (22), 353.08 (40), 447.13 (13), 505.18 (100), 545.21 (18), HRMS 
(EI pos) calculated for C31H38N2O6Si: 562.24991, found: [M]
+
 562.24544. 
Note: Assignments denoted with 
#
 are interchangeable. 
 
B.9 Preparation of 6-N-(N,N-dimethylmethylimine)guanosine [112] 
 
The guanosine 9 (17.7 mmol, 5.02 g) was heated to 120 
o
C under an argon atmosphere, using an oil bath, for 19 
h. After this time, tiny water droplets were observed on 
the neck of the flask, so the system was placed under 
high vacuum and was allowed to cool to rt. The dry 
guanosine was then stirred with distilled DMF (25 cm
3
) 
until a suspension had formed. To this suspension was 
added the N,N-dimethylformamide dimethyl acetal (2 eq, 35.4 mmol, 4.71 cm3). The reaction 
mixture was allowed to stir at rt under an argon atmosphere overnight (27 h). The solvent was 
then removed in vacuo and the crude mixture was obtained as a cream semi-solid. The crude 
mixture was subsequently stirred with MeOH (125 cm
3
) until a solution had formed, it was 
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then allowed to stand at rt for crystallization to begin and was finally cooled in an ice-water 
bath to allow for complete crystallization. The white precipitate was collected by filtration 
and dried under high vacuum (using a drying pistol, over P2O5) for 3 days. The pure 
compound 112 was obtained as a white powder (4.74 g, 79 %). 
 
Rf = 0.15 (10 % MeOH : CHCl3);  [α]D
23
 -35.644
o
 (c = 2.02 in DMSO);  νmax/cm
-1
 (thin film) 
771 (CH2 rocking), 1216 (C-O stretch), 1422 (C-H deformations), 1539 (-CONH-), 1651 
(C=N), 1700 (-CONH-), 3021 (C-H stretching), 3613 (O-H stretching);  δH (300 MHz, d6-
DMSO) 3.03 (3 H, s, N-CH3), 3.15 (3 H, s, N-CH3), 3.51-3.62 (2 H, m, H-5’), 3.88-3.90 (1 H, 
m, H-4’), 4.11-4.13 (1 H, m, H-3’), 4.47-4.51 (1 H, m, H-2’), 5.02 (1 H, t, J = 5.34 Hz, OH-
5’), 5.17 (1 H, br s, OH-3’), 5.40 (1 H, br s, OH-2’), 5.80 (1 H, d, J = 6.08 Hz, H-1’), 8.04 (1 
H, s, N=CH-N), 8.53 (1 H, s, H-2), 11.31 (1 H, br s, NH);  δC (50 MHz, d6-DMSO) 34.64 (N-
CH3), 40.64 (N-CH3), 61.51 (C-5’), 70.48 (C-3’), 73.78 (C-2’), 85.43 (C-4’), 86.76 (C-1’), 
119.78 (C-3a), 136.96 (N=C-N), 149.99 (C-7a), 157.27 and 157.58 (C-4 and C-6), 157.94 (C-
2);  MS m/z (M + 23
+
, 100 %) 269.10 (5), 339.21 (17), 362.26 (17), 467.23 (10), 505.36 (11), 
536.16 (9), 537.19 (5), 633.27 (5), 663.44 (39), 664.45 (22), 665.44 (8), HRMS (+cESI) 
calculated for C13H19N6O5
+
: 339.14114, found: [M + 1]
+
 339.14123. 
 
B.10 Preparation of 5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-dimethylmethylimine)-
guanosine [113] 
 
The protected guanosine derivative 112 (3.21 
mmol, 1.09 g) and DMAP (0.1 eq, 0.321 
mmol, 0.0398 g) were stirred with distilled 
pyridine (10 cm
3
) until a suspension had 
formed. This suspension was then cooled to 0 
o
C in an ice-water bath before the addition of 
the 4,4'-dimethoxytrityl chloride (1 eq, 3.21 
mmol, 1.09 g). The reaction mixture was then warmed to rt and stirred under an argon 
atmosphere overnight (25 h). After this time, tlc indicated the formation of a new spot, so the 
reaction mixture was diluted with CHCl3 (100 cm
3
). The organic layer was extracted with a 
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saturated NaHCO3 solution (100 cm
3
) and the aqueous layer was back-extracted with CHCl3 
(2 × 100 cm
3
). All of the organic layers were then combined and extracted with brine (100 
cm
3
). The combined organics were dried over anhydrous Na2SO4, filtered and evaporated. 
The residue obtained was then dissolved in a 10 CHCl3 : 3 EtOH (60 cm
3
 : 18 cm
3
) mixture. 
The solution obtained was then added dropwise to vigorously stirring Et2O (100 cm
3
) and the 
mixture was triturated for 30 min. After this time the white precipitate was collected by 
filtration and dried under high vacuum (overnight: using a drying pistol, over P2O5). The 
desired product 113 was obtained as a white powder (1.43 g, 69 %). 
 
Rf = 0.40 (10 % EtOH : CH2Cl2);  [α]D
24
 -6.7633
o
 (c = 2.07 in DMSO);  νmax/cm
-1
 (thin film) 
699 (5 adjacent aromatic H), 728 (CH2 rocking), 760 (5 adjacent aromatic H), 826 (2 adjacent 
aromatic H), 1112 (C-O stretching from C-OH), 1356 (O-H bending), 1463 (C-H 
deformations), 1508 (C=N cyclic), 1563 (-CONH-), 1627 (-C=N-), 1661 (-CONH-), 2929 (C-
H stretching), 3090 (Ar H);  δH (300 MHz, d6-DMSO) 3.02 (3 H, s, N-CH3), 3.09 (3 H, s, N-
CH3), 3.17-3.19 (2 H, m, H-5’), 3.72 (6 H, s, 2 × OCH3), 4.01 (1 H, d, J = 3.28 Hz, H-4’), 
4.21-4.24 (1 H, m, H-3’), 4.53 (1 H, t, J = 4.56 Hz, H-2’), 5.26 (1 H, br s, OH-3’), 5.58 (1 H, 
br s, OH-2’), 5.87 (1 H, d, J = 4.48 Hz, H-1’), 6.83 (4 H, dd, J = 4.02 and 8.66 Hz, H-3*), 
7.20-7.26 (7 H, m, H-2*, H-6* and H-8*), 7.28-7.31 (2 H, m, H-7*), 7.94 (1 H, s, N=CH-N), 
8.50 (1 H, s, H-2), 11.39 (1 H, br s, NH);  δC (50 MHz, d6-DMSO) 34.73 (N-CH3), 40.72 (N-
CH3), 55.06 (2 × OCH3), 64.03 (C-5’), 70.38 (C-3’), 73.59 (C-2’), 82.98 (C-4’), 85.53 
(C(Ph)3), 87.13 (C-1’), 113.19 (C-3*), 119.79 (C-3a), 126.74 (C-8*), 127.72 (C-2* 
#
), 127.87 
(C-6* 
#
), 129.73 (C-7* 
#
), 135.54 (C-1* 
##
), 135.58 (C-5* 
##
), 136.72 (N=CH-N), 144.90 (C-
4*), 150.07 (C-7a), 157.32 and 157.73 (C-4 and C-6), 158.09 (C-2);  MS m/z (M + 23
+
, 50 %) 
303.24 (100), 304.27 (23), 641.30 (45), 664.40 (22), 665.39 (5), HRMS (+cESI) calculated 
for C34H37N6O7
+
: 641.27182, found: [M + 1]
+
 641.27182. 
Note: assignments denoted with 
#
 and 
##
 are exchangeable. 
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B.11 Preparation of 2',3'-O-diallyl-5'-O-(4,4'-dimethoxytrityl)-6-N-(N,N-dimethyl-
methylimine)guanosine [114] 
 
The protected guanosine derivative 113 
(0.472 mmol, 0.303 g) and allyl ethyl 
carbonate 148 (3.2 eq, 1.51 mmol, 0.203 g) 
were dissolved in anhydrous THF (4 cm
3
). A 
solution of bis(dibenzylideneacetone) 
palladium(0) 149 (0.03 eq, 0.0142 mmol, 
0.0086 g) and 1,4-bis(diphenylphosphino)-
butane (0.2 eq, 0.0945 mmol, 0.0414 g) in 
anhydrous THF (1 cm
3
) was added dropwise 
to the guanosine derivative solution. The reaction mixture was heated to reflux and was stirred 
for 75 min. The solvent was then removed in vacuo and a yellow foam was obtained. The 
crude foam was purified by column chromatography with 5-50 % EtOAc : hexane, EtOAc, 
CH2Cl2 and MeOH solutions being used for elution. The desired compound 114 was obtained 
after chromatography as a yellow foam (0.289 g, 85 %).  
 
Rf = 0.05 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 3.10 (6 H, s, 2 × NCH3), 3.40 (2 H, 
dd,  J = 3.34 and 9.21 Hz, H-5’), 3.78 (6 H, s, 2 × OCH3), 4.11-4.20 (3 H, m, H-2’, H-3’ and 
H-4’), 4.44 (2 H, d, J = 2.33 Hz, OCH2), 4.96 (2 H, d, J = 5.73 Hz, OCH2), 5.08-5.23 (4 H, m, 
2 × CH=CH2), 5.79-5.97 (2 H, m, 2 × CH=CH2), 6.06-6.09 (1 H, m, H-1’), 6.79-6.82 (4 H, m, 
H-3*), 7.20-7.43 (9 H, m, H-2*, H-6*, H-7* and H-8*), 7.74 (1 H, s, N=CH-N), 8.52 (1 H, s, 
H-2);  δC (50 MHz, CDCl3) 35.38 (NCH3), 41.29 (NCH3), 55.44 (2 × OCH3), 63.71 (C-5’), 
70.60 (C-3’), 72.05 (C-2’), 81.27 (C-4’), 83.89 (C(Ph)3), 85.45 (C-1’), 86.78 and 87.94 (2 × 
OCH2), 113.38 (C-3*), 116.92 (CH=CH2), 119.12 (CH=CH2), 120.27 (C-3a), 127.16 (C-8*), 
128.26 (C-7*), 128.81 (C-6*), 130.23 (C-2*), 130.96 (CH=CH2), 131.00 (CH=CH2), 133.46 
(C-1* 
#
), 133.65 (C-5* 
#
), 135.77 (N=CH-N), 144.65 (C-4), 148.19 (C-7a), 157.12 (C-4 
##
), 
157.65 (C-6 
##
), 158.77 (C-2); LRMS and HRMS data were not determined. 
Note: assignments denoted with 
#
 and 
##
 are exchangeable. 
 
NH
6
N7a
3a
2
N
O
NN
3' 2'
1'
O
4'
OO
5'O
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5*
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B.12 Attempted synthesis of (1E)-N-{9-[(Z,6aS,7R,9R,9aS)-7-{[bis(4-methoxyphenyl)-
(phenyl)methoxy]methyl}-2,5,6a,7,9,9a-hexahydrofuro[3,4-b][1,4]dioxocin-9-yl]-
6,9-dihydro-6-oxo-1H-purin-2-yl}-N,N-dimethylformamidine [115] 
 
Method 1: 
A solution was prepared of the diene 114 
(0.139 mmol, 0.100 g) in distilled CH2Cl2 (10 
cm
3
) and was subsequently degassed using 
argon for 15 min. Then the 5 mol % of the 
Grubbs II catalyst 90 (0.05 eq, 0.00694 mmol, 
0.0059 g) was added and the reaction mixture 
was stirred at rt under an argon atmosphere overnight (22 h). Crude NMR spectroscopy 
confirmed the presence of only unreacted starting material, so a further 5 mol % Grubbs II 
catalyst 90 (0.05 eq, 0.00694 mmol, 0.0061 g) was added. The reaction mixture was then 
refluxed overnight (22 h). After this time the solvent was removed in vacuo and the crude 
material was purified by column chromatography using 5 % EtOAc : hexane as the eluant. 
None of the desired compound 115 was obtained after chromatography. 
 
Method 2: 
A solution was prepared of the diene 114 (0.137 mmol, 0.0985 g) in distilled toluene (10 cm
3
) 
and was then degassed using argon for 15 min. The solution was subsequently heated to 60 
o
C, before the addition of the Grubbs II catalyst 90 (0.05 eq, 0.00684 mmol, 0.0059 g). The 
reaction mixture was then allowed to stir at 60 
o
C, under an argon atmosphere overnight (23 
h). After this time, tlc indicated the presence of unreacted starting material, so a further 
portion of the Grubbs II catalyst 90 (0.05 eq, 0.00684 mmol, 0.0057 g) was added and the 
reaction mixture was refluxed for a further 5 h. After this time, tlc indicated no further 
change, so the solvent was removed in vacuo to yield a dark brown-black oil. The crude 
mixture was then purified by column chromatography, using 5 % EtOAc : hexane as the 
eluant. None of the desired compound 115 was isolated after column chromatography. 
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B.13 Preparation of 5'-O-(4,4'-dimethoxytrityl)inosine [117] 
 
The inosine 116 (7.47 mmol, 2.00 g) and DMAP (0.1 
eq, 0.747 mmol, 0.0923 g) were stirred with distilled 
pyridine (20 cm
3
) until a suspension had formed. This 
was then cooled to 0 
o
C in an ice-water bath before 
the addition of the 4,4'-dimethoxytrityl chloride (1 eq, 
7.47 mmol, 2.53 g). The reaction mixture was then 
allowed to stir at rt, under an argon atmosphere 
overnight (21 h). After this time, tlc indicated the formation of a new spot, so a solution of 
saturated NaHCO3 (200 cm
3
) was added to the reaction mixture and stirred for a few minutes. 
The aqueous reaction mixture was subsequently extracted with chloroform (3 × 200 cm
3
) and 
the combined organics were further extracted with brine (200 cm
3
). The combined organics 
were then dried over anhydrous Na2SO4, filtered and evaporated. The residue obtained was 
dissolved in a EtOH : CHCl3 solution (6 cm
3
 : 30 cm
3
) and then added dropwise to vigorously 
stirred Et2O (200 cm
3
). A white precipitate was immediately observed and after cooling in an 
ice-water bath, was collected by filtration. The white powder was then dried under high 
vacuum and was identified to be pure product 117 (3.31 g, 78 %). 
 
Rf = 0.36 (10 % EtOH : CH2Cl2);  [α]D
24
 -6.6667
o
 (c = 1.05 in DMSO);  νmax/cm
-1
 (thin film) 
702 (5 adjacent aromatic H), 726 (CH2 rocking), 755 (5 adjacent aromatic H), 827 (2 adjacent 
aromatic H), 1082 (C-O stretch from C-OH), 1301 (O-H bending), 1377 (CH3 symmetrical 
deformation), 1464 (C-H deformations), 1509 (Ar H), 1547 (-CONH-), 1584 and 1608 (Ar 
H), 1676 (-C=N-), 1690 (-CONH-), 2836 (O-CH3), 2908 (C-H stretch from CH2 and CH3), 
3033 (Ar H), 3056 (-CONH-);  δH (300 MHz, d6-DMSO) 3.18-3.22 (2 H, m, H-5’), 3.69 (6 
H, s, 2 × OCH3), 4.07 (1 H, d, J = 4.50 Hz, H-4’), 4.23-4.27 (1 H, m, H-3’), 4.59-4.61 (1 H, 
m, H-2’), 5.25 (1 H, br s, OH-3’), 5.61 (1 H, br s, OH-2’), 5.92 (1 H, d, J = 4.44 Hz, H-1’), 
6.83 (4 H, dd, J = 4.27 and 8.62 Hz, H-3*), 7.12-7.24 (7 H, m, H-2*, H-6* and H-8*), 7.35-
7.39 (2 H, m, H-7*), 8.01 (1 H, s, H-2), 8.21 (1 H, s, H-6), 12.39 (1 H, br s, NH);  δC (50 
MHz, d6-DMSO) 55.04 (2 × OCH3), 63.78 (C-5’), 70.31 (C-3’), 73.41 (C-2’), 83.23 (C-4’), 
85.53 (C(Ph)3), 88.02 (C-1’), 113.16 (C-3*), 124.62 (C-3a), 126.70 (C-8*), 127.81 and 127.83 
(C-6* and C-7*), 129.73 (C-2*), 135.55 (C-2), 138.87 (C-6), 144.86 (C-1*), 145.80 (C-5*), 
NH
6
N7a
3a
2
N
O
N
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O
4'
OHOH
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8*
OMe
OMe 117  
P a g e  | 325 
 
148.21 (C-7a), 156.62 (C-4), 158.08 (C-4*);  MS m/z (M + 23
+
, 39 %) 303.24 (100), 304.27 
(23), 505.38 (20), 536.17 (6), 571.12 (30), 594.33 (12), 663.45 (8), HRMS (+cESI) calculated 
for C31H31N4O7
+
: 571.21873, found: [M + 1]
+
 571.21823 and calculated for C31H30N4O7Na
+
: 
593.20067, found: [M + 23]
+
 593.19995. 
 
B.14 Attempted synthesis of 2',3'-O-diallyl-5'-O-(4,4'-dimethoxytrityl)inosine [118] 
 
The protected inosine 117 (0.878 mmol, 0.501 g) was 
stirred with distilled DMF (9 cm
3
) until a solution 
had formed. This solution was then cooled to 0 
o
C in 
an ice-water bath, before the addition of the sodium 
hydride (used as a 60 % suspension in oil, 2.2 eq, 
1.93 mmol, 0.0796 g). This was allowed to stir at 0 
o
C for 15 min, during which time the solution 
changed colour to a dark blue-purple. Then the allyl 
bromide (2.2 eq, 1.9 mmol, 0.17 cm
3
) was added and the solution slowly changed colour to 
orange. The reaction mixture was then allowed to stir at rt under an argon atmosphere 
overnight (21 h). After this time, tlc indicated the formation of a new spot, so the reaction 
mixture was diluted with EtOH and the solvent was removed in vacuo. The crude residue was 
then diluted with a solution of saturated NH4Cl (50 cm
3
) and was extracted with EtOAc (3 × 
50 cm
3
). The combined organics were then dried over anhydrous Na2SO4, filtered and the 
solvent was removed in vacuo. Crude NMR spectroscopy spectroscopy showed no peaks 
present for the desired product 118, instead it seemed as though the starting material had 
decomposed under the harsh conditions employed. 
 
B.15 Preparation of 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)-1'-O-methoxy-ᴅ-(-)-
ribose [119] 
 
The protected ribose 102 (2.70 mmol, 1.09 g) was stirred with distilled pyridine (2 eq, 5.4 
mmol, 0.45 cm
3
) until a solution had formed. The solution was then cooled to 0 
o
C in an ice-
NH
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water bath. To the cooled solution was then added dropwise a 
mixture of distilled acetic anhydride (3 eq, 8.1 mmol, 0.76 
cm
3
) and distilled pyridine (3 eq, 8.1 mmol, 0.65 cm
3
). After 
the addition, the reaction mixture was warmed to rt and was 
stirred under an argon atmosphere overnight (19 h). The 
reaction mixture was then diluted with EtOAc (100 cm
3
) 
while gently stirring and the solution went murky white in 
colour. The reaction mixture was extracted with brine (3 × 
100 cm
3
) and the aqueous layers were combined and extracted with CH2Cl2 (3 × 100 cm
3
). 
The organic layers were combined and extracted with a saturated NH4Cl solution that had 
been basified to pH 10 using NH3 (150 cm
3
). The combined organics were then dried over 
anhydrous MgSO4, filtered and the solvent was removed in vacuo. The compound 119 [α:β 
ratio found to be 1:3] was obtained as a viscous orange oil (0.930 g, 71 % over two steps).  
 
νmax/cm
-1
 (thin film) 687 and 741 (5 adjacent aromatic H), 855 and 1243 (Si-C), 1365 and 
1391 [C(CH3)3], 1428 and 1446 (alkanes), 1472 (CH2 and CH3 deformations), 1747 (C=O), 
2857 (O-CH3), 2891 (C-H stretch), 2999 (C-O), 3072 (aromatic H);  δH (300 MHz, CDCl3) 
1.04-1.07 [9 H, m, C(CH3)3], 2.00-2.06 (3 H, m, COCH3), 2.09-2.14 (3 H, m, COCH3), 3.34 
[2.1 H, s, OCH3 (β)], 3.38 [0.7 H, s, OCH3 (α)], 3.72-3.81 (1 H, m, H-5’), 4.09-4.13 (0.5 H, 
m, H-5’), 4.15-4.35 (1 H, m, H-4’), 4.36-4.39 (0.5 H, m, H-5’), 4.90-4.92 and 5.13-5.15 (1 H, 
m, H-1’), 5.22-5.28 (1 H, m, H-3’ #), 5.30-5.33 and 5.44-5.49 (1 H, m, H-2’ #), 7.34-7.43 (6 
H, m, H-3* and H-4*), 7.67-7.74 (4 H, m, H-2*);  δC (50 MHz, CDCl3) 19.40 [C(CH3)3], 
20.88 (COCH3), 22.57 (COCH3), 25.87 [C(CH3)3], 55.48 [OCH3 (β)], 55.73 [OCH3 (α)], 
63.87 [C-5’ (α)], 64.63 [C-5’ (β)], 71.55 [C-2’ (α) #], 72.14 [C-2’ (β) #], 74.84 [C-3’ (α and β) 
#
], 78.23 [C-4’ (α)], 81.27 [C-4’ (β)], 101.86 [C-1’ (α)], 106.35 [C-1’ (β)], 127.92 (C-3*), 
129.85 (C-4*), 133.31 (C-1*), 135.01 and 135.70 (C-2*), 135.91 (C-1*), 169.91 (C=O), 
170.89 (C=O);  MS m/z (M
+
, peak not observed) 275.13 (6), 307.93 (24), 455.00 (32), 503.93 
(100), 699.87 (10), 798.60 (5), 994.40 (11), HRMS (+cESI) calculated for C26H34O7SiNa
+
: 
509.19660, found: [M + 23]
+
 509.19582. 
Note: Assignments denoted with 
#
 are interchangeable. 
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B.16 Preparation of 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)-1'-O-methoxy-ᴅ-(-)-
 ribose [120] 
 
The protected ribose derivative 105 (2.23 mmol, 1.04 g) 
was stirred with distilled pyridine (2 eq, 4.5 mmol, 0.36 
cm
3
) until a solution had formed and the solution was 
then cooled to 0 
o
C in an ice-water bath. To this cooled 
solution was then added dropwise a mixture of distilled 
acetic anhydride (3 eq, 6.7 mmol, 0.63 cm
3
) and distilled 
pyridine (3 eq, 6.7 mmol, 0.54 cm
3
). The reaction 
mixture was then allowed to warm to rt and was stirred 
under an argon atmosphere overnight (19 h). The reaction was diluted by the addition of 
EtOAc (100 cm
3
) and the solution went murky white. The diluted reaction mixture was then 
extracted with brine (3 × 100 cm
3
) and the combined aqueous layers were extracted with 
CH2Cl2 (3 × 100 cm
3
). All of the organics were combined and extracted with a saturated 
NH4Cl solution that had been basified to pH 10 with NH3 (150 cm
3
). The combined organics 
were then dried over anhydrous MgSO4, filtered and the solvent was removed in vacuo. The 
desired compound 120 [α:β ratio found to be 1:3] was obtained as a viscous orange oil (0.941 
g, 77 % calculated over 2 steps). 
 
νmax/cm
-1
 (thin film) 702 (5 adjacent aromatic H), 727 (CH2 rocking), 755 (5 adjacent 
aromatic H), 829 (2 adjacent aromatic H), 1113 (C-O stretching for C-OH), 1297 (O-H 
bending), 1443 (C-H deformations), 1465 (alkane), 2837 (C-H stretch), 2908 (O-CH3), 2934 
(C-H stretch for CH2), 2956 (-O-H), 3035 (Ar H);  δH (300 MHz, CDCl3) 2.01-2.14 (6 H, m, 
2 × COCH3), 3.38 [0.8 H, s, OCH3 (β)], 3.45 [2.3 H, s, OCH3 (α)], 3.79 (6 H, s, 2 × Ar-
OCH3), 4.10 (1 H, dd, J = 5.45 and 11.41 Hz, H-5’), 4.22-4.28 (1 H, m, H-4’), 4.31-4.38 (1 H, 
m, H-5’), 4.90-4.93 (1H, 2 × s, H-1’), 5.06-5.23 (1 H, m, H-2’), 5.31-5.35 (1 H, m, H-3’), 
6.81-8.84 (4 H, m, H-3*), 7.16-7.28 (4 H, m, H-2*), 7.43-7.45 (5 H, m, H-6*, H-7* and H-
8*);  δC (50 MHz, CDCl3) 20.80 (COCH3), 20.99 (COCH3), 55.24 (OCH3
 ##
), 55.45 (Ar-
OCH3 
##
), 55.64 (Ar-OCH3 
##
), 64.64 (C-5’), 71.74 (C-3’), 74.85 (C-2’), 78.76 (C-4’), 81.62 
[C(Ar)3], 106.45 (C-1’), 113.29 (C-3*), 127.27 (C-8* 
#), 128.00 (C-6* #), 129.34 (C-2*), 
130.26 (C-7* 
#
), 139.70 (C-1*), 147.56 (C-5*), 158.83 (C-4*), 169.89 (C=O), 170.88 (C=O);  
3' 2'
1'O
4'
OO
5'O
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MS m/z (M + 23
+
, 21 %) 245.13 (14), 289.13 (55), 303.13 (100), 1129.20 (26), HRMS 
(+cESI) calculated for C31H34O9Na
+
: 573.20950, found: [M + 23]
+
 573.20916. 
Note: Assignments denoted with 
#
 and 
##
 are interchangeable. 
 
B.17 Preparation of 2',3',5'-O-triacetyl-1'-O-methoxy-ᴅ-(-)-ribose [121] 
 
The methoxy ribose derivative 101 (6.11 mmol, 1.00 g) was stirred 
with distilled pyridine (3 eq, 18.3 mmol, 1.48 cm
3
) until a solution 
had formed and the solution was then cooled to 0 
o
C in an ice-water 
bath. To this cooled solution was then added dropwise a mixture of 
distilled acetic anhydride (4.5 eq, 27.5 mmol, 2.60 cm
3
) and distilled 
pyridine (4.5 eq, 27.5 mmol, 2.22 cm
3
). After the dropwise addition, 
the reaction mixture was allowed to warm to rt and was then stirred under an argon 
atmosphere overnight (22 h). The reaction was quenched by the addition of EtOAc (100 cm
3
) 
with stirring. Then the mixture was extracted with brine (3 × 100 cm
3
) and the combined 
aqueous layers were extracted with CH2Cl2 (3 × 100 cm
3
). All the organic fractions were 
combined and extracted with a solution of NH4Cl that had been basified to pH 10 using NH3 
(150 cm
3
). The combined organics were then dried over anhydrous MgSO4, filtered and the 
solvent was removed in vacuo. The target compound 121 [α:β ratio found to be 1:3] was 
obtained as a yellow oil (1.67 g, 94 %). 
 
νmax/cm
-1
 (thin film) 728 (CH2 rocking), 1194 and 1248 (C-O stretching), 1383 (alkanes), 
1440 (C-H deformations), 1452 (alkanes), 1680 (C=O), 1738 (-CO-O-), 2839 (-O-CH3), 2916 
(C-H stretching), 2940 (C-H stretching from CH2), 2998 (-CO-CH3);  δH (300 MHz, CDCl3) 
2.02-2.14 (9 H, m, 3 × COCH3), 3.38 [2.3 H, s, OCH3 (β)], 3.45 [0.8 H, s, OCH3 (α)], 4.11 
(0.8 H, dd, J = 4.86 and 6.58 Hz, H-5’ #), 4.19-4.26 (0.3 H, m, H-5’ #), 4.28-4.31 (1 H, m, H-
4’), 4.33-4.39 (1.1 H, m, H-5’ #), 4.91 [0.8 H, m, H-1’ (β)], 4.96-5.00 [0.3 H, m, H-2’ (α)], 
5.13-5.14 [0.3H, m, H-1’ (α)], 5.16-5.20 [0.3 H, m, H-3’ (α)], 5.21-5.23 [0.8 H, m, H-2’ (β)], 
5.31-5.35 [0.8 H, m, H-3’ (β)];  δC (50 MHz, CDCl3) 20.67, 20.71, 20.75, 20.94 and 20.95 [3 
× COCH3 (α and β)], 55.42 [OCH3 (β)], 55.79 [OCH3 (α)], 63.63 [C-5’ (α)], 64.57 [C-5’ (β)], 
69.96 [C-3’ (α)], 70.75 [C-2’ (α)], 71.67 [C-3’ (β)], 74.78 [C-2’ (β)], 78.68 [C-4’ (β)], 79.64 
3' 2'
1'O
4'
OO
5'O
121
OO
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[C-4’ (α)], 101.71 [C-1’ (α)], 106.38 [C-1’ (β)], 169.83, 169.87 and 170.09 [3 × C=O (α) ##], 
170.64, 170.76 and 170.83 [3 × C=O (β) ##];  MS m/z no LRMS spectrum was run, HRMS 
(+cESI) calculated for C12H18O8Na
+
: 313.08939, found: [M + 23]
+
 313.08943. 
Note: Assignments denoted with 
#
 represent splitting of the same signal and those with 
##
 are 
interchangeable. 
 
B.18 Preparation of 2',3',5'-O-triallyl-1'-O-methoxy-ᴅ-(-)-ribose [122] 
 
The ribose derivative 101 (6.76 mmol, 1.11 g) was stirred with 
distilled DMF (40 cm
3
) until a solution had formed. The 
solution was then cooled to 0 
o
C in an ice-water bath before the 
addition of the sodium hydride (used as a 60 % suspension in 
oil, 3.3 eq, 22.3 mmol, 0.894 g). The mixture was stirred for a 
few minutes until effervescence had ceased, before the allyl bromide (3.3 eq, 22.3 mmol, 1.93 
cm
3
) was added. The reaction mixture was then stirred at rt under an argon atmosphere 
overnight (23 h). After this time, tlc indicated complete consumption of the starting material, 
so the reaction mixture was diluted with EtOH and all the solvent was removed by 
evaporation. The crude residue obtained was then diluted with a saturated NH4Cl solution 
(150 cm
3
) and extracted with EtOAc (3 × 150 cm
3
). The combined organics were dried over 
anhydrous Na2SO4, filtered and the solvent was removed in vacuo. The expected compound 
122 [α:β ratio found to be 1:3] was obtained pure as a yellow oil (1.92 g, 100 %). 
 
Rf = 0.85 (10 % EtOH : CH2Cl2);  νmax/cm
-1
 (thin film) 725 (CH2 rocking), 869, 920 and 991 
(RCH=CH2), 1159 (C-O), 1371 (alkanes), 1382 (C-OCH3), 1452 (C-H deformations), 1647 
(C=C), 2834 (O-CH3), 2859 (C-H stretch for CH2), 3080 (C=CH2);  δH (300 MHz, CDCl3) 
3.36 [2.3 H, s, OCH3 (β)], 3.45 [0.8 H, s, OCH3 (α)], 3.48-3.60 (2 H, m, H-5’), 3.81-3.83 (1 
H, m, H-2’), 3.86-3.98 (1 H, m, H-3’), 4.01-4.17 (6 H, m, 3 × OCH2), 4.20-4.24 (1 H, m, H-
4’), 4.89 [0.8 H, s, H-1’ (β)], 4.94-4.96 [0.3 H, m, H-1’ (α)], 5.14-5.23 (3 H, m, 3 × CH=CH2, 
proton trans to R group), 5.24-5.36 (3 H, m, 3 × CH=CH2, proton cis to R group), 5.84-5.98 
(3 H, m, 3 × CH=CH2);  δC (50 MHz, CDCl3) 55.26 [OCH3 (β)], 55.57 [OCH3 (α)], 70.51 [C-
5’ (α)], 71.19 [C-5’ (β)], 71.65 [OCH2 at C-2’ (β)
#
], 71.70 [OCH2 at C-3’ (β)
#
], 72.01 [OCH2 
3' 2'
1'O
4'
OO
5'O
122
OMe
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at C-2’ (α)##], 72.07 [OCH2 at C-3’ (α)
##
], 72.41 [OCH2 at C-5’ (β)
#
], 72.64 [OCH2 at C-5’ 
(α)##], 75.66 [C-3’ (α)], 78.42 [C-2’ (α)], 78.56 [C-3’ (β)], 79.95 [C-2’ (β)], 80.57 [C-4’ (β)], 
82.26 [C-4’ (α)], 102.58 [C-1’ (α)], 106.61 [C-1’ (β)], 116.99, 117.63 and 117.73 [3 × 
CH=CH2 (β)], 117.28, 117.35 and 117.86 [3 × CH=CH2 (α)], 134.61, 134.65, 134.86, 134.96 
and 135.28 [3 × CH=CH2 (α and β)];  MS m/z (M + 23
+
, 21 %) 253.18 (5), 267.24 (13), 
460.09 (5), 465.32 (30), 505.35 (100), 506.35 (34), 507.37 (11), 537.35 (7), 663.44 (8), 
664.44 (5), HRMS (+cESI) calculated for C15H24O5Na
+
: 307.15159, found: [M + 23]
+
 
307.15160. 
Note: Assignments denoted with 
#
 and 
##
 are interchangeable. 
 
B.19 Preparation of 2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine [123] 
 
The silylated uridine 107 (8.69 mmol, 4.19 g) was stirred with 
distilled pyridine (2 eq, 17.4 mmol, 1.41 cm
3
) until a solution 
had formed and was then cooled to 0 
o
C in an ice-water bath. 
To this cooled solution was then added dropwise a mixture of 
distilled acetic anhydride (3 eq, 26.1 mmol, 2.50 cm
3
) and 
distilled pyridine (3 eq, 26.1 mmol, 2.11 cm
3
). The reaction 
mixture was then warmed to rt and was stirred under an argon 
atmosphere overnight (20 h). After this time, tlc indicated 
product formation, so EtOAc (400 cm
3
) was added to the reaction mixture and it was stirred 
for a few min. The organic layer was extracted with brine (3 × 400 cm
3
) and the combined 
aqueous layers were back-extracted with CH2Cl2 (3 × 400 cm
3
). All of the organic layers were 
then combined and extracted with saturated NH4Cl that had been basified to pH ~10 using 
NH3 (600 cm
3
). The combined organics were dried over anhydrous MgSO4, filtered and the 
solvent was removed in vacuo. This gave the desired compound 123 as a cream foam (4.39 g, 
89 %). 
 
Rf = 0.42 (50 % EtOAc : hexane);  [α]D
19
 30.000
o
 (c = 0.50 in DMF);  νmax/cm
-1
 (thin film) 
684 (RHC=CHR cis), 706 (5 adjacent aromatic H), 727 (CH2 rocking), 743 (5 adjacent 
aromatic H), 849 (Si-C), 1113 and 1233 (C=O), 1256 (Si-C), 1327 and 1378 (C(CH3)3), 1453 
5
6
NH
O
ON
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(C-H deformation), 1588 (secondary amide), 1635 (C=C conjugated with C=O), 1697 
(secondary amide), 2859 (C-H stretching), 3279 (-CONH-);  δH (300 MHz, CDCl3) 1.07-1.13 
[9 H, m, C(CH3)3], 2.11-2.14 (6 H, m, 2 × COCH3), 3.85 and 4.02 (2 H, two d, J = 11.76 Hz, 
H-5’), 4.18 (1 H, s, H-4’), 5.40-5.47 (2 H, m, H-2’ and H-5), 5.51-5.53 (1 H, m, H-3’), 6.30 (1 
H, d, J = 6.51 Hz, H-1’), 7.35-7.43 (6 H, m, H-3* and H-4*), 7.64-7.74 (5 H, m, H-2* and H-
6), 9.39 (1 H, br s, NH);  δC (50 MHz, CDCl3) 19.50 [C(CH3)3], 20.63 and 20.85 (2 × 
COCH3), 27.15 [C(CH3)3], 63.73 (C-5’), 71.21 (C-3’), 73.31 (C-2’), 83.39 (C-4’), 85.40 (C-
1’), 103.42 (C-5), 128.14 (C-3*), 130.38 (C-4*), 132.76 (C-1*), 135.85 (C-2*), 139.57 (C-6), 
150.80 (C-2), 163.15 (C-4), 169.77 and 170.00 (2 × COCH3);  MS m/z (M + 23
+
, 100 %) 
467.20 (9), 505.30 (26), 506.32 (8), 547.33 (6), 590.34 (38), 591.35 (12), 647.18 (7), 663.45 
(20), 664.45 (11), 670.85 (5), HRMS (+cESI) calculated for C29H34N2O8SiNa
+
: 589.19766, 
found: [M + 1]
+
 567.21532 and [M + 23]
+
 589.19699. 
 
B.20 Preparation of 3-N-benzoyl-2',3'-O-diacetyl-5'-O-(tert-butyldiphenylsilyl)uridine 
[124] 
 
The protected uridine 123 (1.88 mmol, 1.07 g) was 
stirred with distilled pyridine (20 cm
3
) until a pale 
yellow solution had formed. Then the N,N-
diisopropylethylamine (5 eq, 9.41 mmol, 1.64 cm
3
) 
was added and the solution was stirred at rt for 5 min. 
To this solution was added the distilled benzoyl 
chloride (5 eq, 9.41 mmol, 1.10 cm
3
) and a white gas 
was immediately observed. The reaction mixture was 
then allowed to stir at rt under an argon atmosphere for 2 h. After this time the reaction 
mixture had gone a dark burgandy colour and the tlc indicated no further change. The reaction 
mixture was diluted with CH2Cl2 (100 cm
3
) and then extracted with distilled water (3 × 100 
cm
3
). The combined aqueous layers were then extracted with CH2Cl2 (100 cm
3
), subsequently 
dried over anhydrous Na2SO4, filtered and the solvent was removed in vacuo. The crude dark 
red-brown oil was purified by column chromatography and the solvents used for elution were 
10-50 % EtOAc : hexane. After purification, the desired compound 124 was obtained as a 
yellow foam (0.896 g, 71 %). 
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Rf = 0.71 (50 % EtOAc : hexane);  [α]D
22
 18.367
o
 (c = 0.98 in CH2Cl2);  νmax/cm
-1
 (thin film) 
682 (RHC=CHR cis), 701 and 742 (5 adjacent aromatic H), 858 (Si-C), 1113 and 1208 
(C=O), 1235 (Si-C), 1309 and 1377 [C(CH3)3], 1446 (C-H deformations), 1585 (C=C 
conjugated with C=O), 1632 and 1670 (tertiary amide), 1678 (C=C conjugated with C=O), 
2932 (-CONR2);  δH (300 MHz, CDCl3) 1.15 [9 H, s, C(CH3)3], 2.05 (3 H, s, COCH3), 2.10 
(3 H, s, COCH3), 3.87 and 4.05 (2 H, two d, J = 11.85 Hz, H-5’), 4.20 (1 H, d, J = 2.06 Hz, 
H-4’), 5.48-5.55 (3 H, m, H-2’, H-3’ and H-5), 6.24 (1 H, d, J = 5.98 Hz, H-1’), 7.41-7.48 (8 
H, m, H-3*, H-4* and H-7*), 7.63-7.67 (5 H, m, H-2* and H-8*), 7.86 (1 H, d, J = 8.26 Hz, 
H-6), 7.95 (2 H, d, J = 7.34 Hz, H-6*);  δC (50 MHz, CDCl3) 19.52 [C(CH3)3], 20.61 and 
20.81 (2 × COCH3), 27.20 [C(CH3)3], 63.71 (C-5’), 71.21 (C-3’), 73.54 (C-2’), 83.56 (C-4’), 
85.90 (C-1’), 103.23 (C-5), 128.35 (C-3*), 129.32 (C-6*), 130.33 (C-7*), 131.54 (C-4* #), 
132.68 (C-1* 
##
), 135.31 (C-5* 
##
), 135.54 (C-8* 
#
), 135.87 (C-2*), 139.33 (C-6), 149.67 (C-
2), 161.94 (C-4), 168.62 (N-C=O), 169.97 (O-C=O);  MS m/z (M
+
, 23 %) 687.6 (67), 688.7 
(31), 693.0 (21), 1357.2 (100), 1358.4 (59), 1362.4 (32), 1363.4 (26), 1364.5 (16), HRMS 
(+cESI) calculated for C36H39N2O9Si
+
: 671.24193, found: [M + 1]
+
 671.24173 and calculated 
for C36H38N2O9SiNa
+
: 693.22388, found: [M + 23]
+
 693.22317. 
Note: Assignments denoted with 
#
 and 
##
 are interchangeable. 
 
B.21 Attempted synthesis of 3-N-benzoyl-5'-O-(tert-butyldiphenylsilyl)uridine [125] 
 
The protected 
uridine 107 (0.5 
mmol, 0.241 g), 
sodium carbonate 
(8 eq, 4 mmol, 
0.425 g) and tetra-
butylammonium 
bromide (0.04 eq, 
0.02 mmol, 0.0076 g) were dissolved in a two-phase solution of CH2Cl2 : H2O (10 cm
3
 : 20 
cm
3
). Then the benzoyl chloride (1.3 eq, 0.65 mmol, 0.076 cm
3
) was added to the mixture 
with vigorous stirring. The reaction mixture was then stirred at rt for 30 min, after which time 
two spots were observed by tlc. The reaction mixture was then transferred to a separating 
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funnel, the organic phase was collected and the aqueous phase was extracted with CH2Cl2 (3 
× 20 cm
3
). The combined organics were then allowed to stand in the solvent at rt overnight 
(18 h) to allow conversion of the enol derivative to the keto derivative. After this time, tlc 
analysis still showed the presence of the two spots, so the organics were dried over anhydrous 
Na2SO4, filtered and evaporated. The resulting residue was then dissolved in 1,2-
dichloroethane (5 cm
3
) and allowed to stand at rt overnight (19 h), tlc indicated no further 
change, so the solution was heated to 60 
o
C for 15 min and the solvent was then removed in 
vacuo. The residue obtained was then purified by column chromatography using 5-40 % 
EtOAc : hexane for elution. The desired compound 125 was not isolated from the reaction 
mixture, we obtained compound 150 as a white foam (0.183 g) instead.  
 
2’,3’-O-dibenzoyl-5’-O-(tert-butyldiphenylsilyl)uridine [150] 
White foam: Rf = 0.63 (50 % EtOAc : hexane);  δH (300 
MHz, CDCl3) 1.17-1.19 [9 H, m, C(CH3)3], 4.02-4.10 (2 H, 
m, H-5’), 4.42 (1 H, d, J = 2.04 Hz, H-4’), 5.44 (1 H, d, J = 
8.13 Hz, H-5), 5.71-5.75 (1 H, m, H-2’ #), 5.90 (1 H, dd, J = 
2.50 and 5.59 Hz, H-3’ #), 6.58 (1 H, d, J = 6.90 Hz, H-1’), 
7.34-7.54 (12 H, m, H-3*, H-4*, H-7*, H-8*, H-11* and H-
12*), 7.67-7.81 (5 H, m, H-2* and H-6), 7.95-7.96 (4 H, m, H-
6* and H-10*), 8.09 (1 H, br s, NH);  δC (50 MHz, CDCl3) 
19.61 (C-3’), 84.06 (C-4’), 85.82 (C-1’), 103.48 (C-5), 128.32 
and 128.36 (C-3*), 128.69 and 128.75 (C-6* and C-10*), 
129.08 (C-4*), 129.99 and 130.16 (C-7* and C-11*), 130.17 (C-8* and C-12*), 130.51 and 
130.52 (C-8* and C-12*), 131.90 (C-9*), 132.95 (C-5*), 133.86 (C-1*), 135.57 and 135.89 
(C-2*), 139.76 (C-6), 150.57 (C-2), 162.97 (C-4), 165.31 (O-C=O), 165.66 (O-C=O);  MS 
m/z (M
+
, 56 %) 151.80 (10), 303.27 (27), 504.00 (12), 579.13 (23), 707.93 (81), 1397.87 
(100), 1744.13 (22), HRMS (+pESI) calculated for C39H38N2O8Si: 690.23974, HRMS was 
not run on the sample. 
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B.22 Preparation of 5'-O-(4,4'-dimethoxytrityl)uridine [126] 
 
The uridine 12 (2.08 mmol, 0.507 g) was dissolved in 
pyridine (10 cm
3
). To this solution was then added 4,4'-
dimethoxytrityl chloride (1.2 eq, 2.49 mmol, 0.846 g) 
and DMAP (0.1 eq, 0.025 mmol, 0.0033 g). The reaction 
mixture was then stirred at 60 
o
C under an argon 
atmosphere overnight (22 h). After this time tlc indicated 
no further change, so the solvent was removed in vacuo. 
The crude compound was purified by column chromatography using the pre-prepared/basified 
silica, with 0-10 % MeOH : CH2Cl2 used as the elution solutions. The desired fractions were 
combined to yield a cream foam that was dissolved in MeOH (4.5 cm
3
). This solution was 
then added dropwise to a vigorously stirring flask of Et2O (35 cm
3
) and a white precipitate 
was observed. The mixture was then cooled to 0
o
C in an ice-water bath to allow for complete 
crystallization. The white solid was filtered off through a sintered funnel and the mother 
liquor was evaporated and dried in vacuo. The mother liquor yielded the pure product 126 as a 
cream foam (0.947 g, 83 %). 
 
Rf = 0.16 (5 % MeOH : CH2Cl2);  [α]D
19
 0.4950
o
 (c = 2.02 in DMF);  νmax/cm
-1
 (thin film) 
584 (RHC=CHR cis), 669 (5 adjacent aromatic H), 779 (CH2 rocking), 928 (2 adjacent 
aromatic H), 1215 (C-OH stretch), 1464 (CH2 deformations), 1510 (aromatic ring), 1689 (N-
CO- secondary amide), 2962 (-OCH3), 3020 (-NCO-), 3674 (H-bonded OH), 3748 (free OH);  
δH (300 MHz, CDCl3) 3.45-3.49 (2 H, m, H-5’), 3.78 (6 H, s, 2 × OCH3), 4.18-4.20 (1 H, m, 
H-3’), 4.32-4.34 (1 H, m, H-4’), 4.44 (1 H, t, J = 5.24 Hz, H-2’), 5.34 (1 H, d, J = 8.13 Hz, H-
5), 5.95 (1 H, d, J = 3.43 Hz, H-1’), 6.83 (4 H, d, J = 8.70 Hz, H-3*), 7.22-7.39 (9 H, m, H-
2*, H-6*, H-7* and H-8*), 7.90 (1 H, d, J = 8.13 Hz, H-6), NH peak not observed;  MS m/z 
(M + 23
+
, 26 %) 303.23 (100), 304.26 (22), 467.22 (5), 570.28 (8), 663.44 (6), HRMS 
(+cESI) calculated for C30H31N2O8
+
: 547.20749, found: [M + 1]
+
 547.20717 and calculated 
for C30H30N2O8Na
+
: 569.18944, found: [M + 23]
+
 569.18944. 
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B.23 Preparation of 2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine [127] 
 
The protected uridine 126 (3.65 mmol, 2.00 g) was 
stirred with distilled pyridine (5 eq, 18.3 mmol, 1.50 cm
3
) 
until a solution had formed. This solution was then 
cooled to 0
o
C in an ice-water bath. To this solution was 
added dropwise a mixture of distilled acetic anhydride (3 
eq, 11.0 mmol, 1.05 cm
3
) and distilled pyridine (3 eq, 11 
mmol, 0.90 cm
3
). The reaction mixture was then warmed 
to rt and allowed to stir under an argon atmosphere 
overnight (24 h). After this time, tlc indicated product formation, so the reaction mixture was 
diluted with EtOAc (200 cm
3
) and stirred for a few minutes. Then the organic layer was 
extracted with brine (3 × 200 cm
3
). The combined aqueous layers were then extracted with 
CH2Cl2 (3 × 200 cm
3
). All of the organic layers were combined and extracted with saturated 
NH4Cl that had been basified to pH ~10 with NH3 (300 cm
3
). The combined organics were 
dried over anhydrous MgSO4, filtered and the solvent removed in vacuo. The desired product 
127 was obtained as a pale orange foam that did not require further purification (2.06 g, 90 
%). 
 
Rf = 0.24 (50 % EtOAc : hexane);  [α]D
22
 33.645
o
 (c = 1.07 in CH2Cl2);  νmax/cm
-1
 (thin film) 
703 (RHC=CHR cis), 727 (CH2 rocking), 755 (5 adjacent aromatic H), 829 (2 adjacent 
aromatic H), 1375 and 1444 (C-H deformations), 1509 (-CONH-), 1607 (C=O), 1632 (C=C 
conjugated with C=O), 1693 (-CONH-), 2837 (O-CH3), 2875 and 2935 (C-H stretching from 
CH2 and CH3), 3003 (-CO-CH3), 3060 (Ar H), 3101 (-CONH-);  δH (300 MHz, CDCl3) 2.13 
and 2.14 (6 H, two s, 2 × COCH3), 3.50-3.53 (2 H, m, H-5’), 3.82 (6 H, s, 2 × Ar-OCH3), 
4.25-4.27 (1 H, m, H-4’), 5.36 (1 H, d, J = 8.08 Hz, H-5), 5.58-5.60 (1 H, m, H-3’), 5.62-5.65 
(1 H, m, H-2’), 6.28 (1 H, d, J = 6.32 Hz, H-1’), 6.88 (4 H, d, J = 8.09 Hz, H-3*), 7.29-7.40 (9 
H, m, H-2*, H-6*, H-7* and H-8*), 7.73 (1 H, d, J = 8.14 Hz, H-6), 9.34 (1 H, br s, NH);  δC 
(50 MHz, CDCl3) 20.65 and 20.85 (2 × COCH3), 55.44 (2 × Ar-OCH3), 62.91 (C-5’), 71.54 
(C-3’), 73.02 (C-2’), 82.24 (C-4’), 85.54 (C-1’), 87.77 [C(Ar)3], 103.27 (C-5), 113.55 (C-3*), 
127.48 (C-8*), 128.30 (C-6* 
#
), 128.39 (C-7* 
#
), 130.37 (C-2*), 134.98 (C-1*), 139.93 (C-6), 
144.01 (C-5*), 150.80 (C-2), 158.97 (C-4*), 163.14 (C-4), 169.81 and 170.01 (2 × C=O);  
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MS m/z (M + 23
+
, 100 %) 269.07 (6), 303.23 (64), 304.26 (15), 467.24 (10), 536.16 (5), 
569.26 (37), 570.32 (13), 654.28 (38), 663.44 (12), 665.47 (5), HRMS (+cESI) calculated for 
C34H35N2O10
+
: 631.22862, found: [M + 1]
+
 631.22851 and calculated for C34H34N2O10Na
+
: 
653.21057, found: [M + 23]
+
 653.21020. 
Note: assignments denoted with 
#
 are interchangeable. 
 
B.24 Preparation of 3-N-benzoyl-2',3'-O-diacetyl-5'-O-(4,4'-dimethoxytrityl)uridine 
[128] 
 
The protected uridine 127 (0.629 mmol, 0.397 
g) was stirred with distilled pyridine (8 cm
3
) 
until a pale yellow solution had formed. Then 
the N,N-diisopropylethylamine (5 eq, 3.1 mmol, 
0.55 cm
3
) was added and the solution was 
stirred at rt for five min. To this solution was 
then added the distilled benzoyl chloride (5 eq, 
3.1 mmol, 0.37 cm
3
). A white gas was 
immediately liberated and the solution began to visibly darken. The reaction mixture was then 
allowed to stir at rt under an argon atmosphere for 2 h. After this time, tlc indicated no further 
change. The reaction mixture was diluted with CH2Cl2 (40 cm
3
) and extracted with distilled 
water (3 × 40 cm
3
). The combined aqueous layers were then extracted with CH2Cl2 (40 cm
3
). 
The combined organic layers were dried over anhydrous Na2SO4, filtered and evaporated. The 
crude mixture was obtained as a dark red-brown oil that was subsequently purified by column 
chromatography. Eluants used for the column were 10-50 % EtOAc : hexane. The desired 
compound 128 was obtained as a yellow foam (0.272 g, 59 %).  
 
Rf = 0.53 (50 % EtOAc : hexane);  [α]D
22
 18.000
o
 (c = 1.00 in CH2Cl2);  νmax/cm
-1
 (thin film) 
699 (RHC=CHR cis), 727 (CH2 rocking), 758 (5 adjacent aromatic H), 829 (2 adjacent 
aromatic H), 1376 and 1344 (C-H deformations), 1606 (C=O), 1633 (C=C conjugated with 
C=O), 1671 (tertiary amide), 2838 (O-CH3), 2908 (C-H stretching from CH2 and CH3), 2934 
(-CONR2), 2955 (-CO-CH3);  δH (300 MHz, CDCl3) 2.07 and 2.10 (6 H, two s, 2 × COCH3), 
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3.51-3.53 (2 H, m, H-5’), 3.81 (6 H, s, 2 × Ar-OCH3), 4.25 (1 H, d, J = 2.60 Hz, H-4’), 5.45 
(1 H, d, J = 8.24 Hz, H-5), 5.58-5.60 (1 H, m, H-3’), 5.62-5.67 (1 H, m, H-2’), 6.21 (1 H, d, J 
= 6.22 Hz, H-1’), 6.87 (4 H, d, J = 8.76 Hz, H-3*), 7.27-7.68 (12 H, m, H-2*, H-6*, H-7*, H-
8*, H-11* and H-12*), 7.84 (1 H, d, J = 8.23 Hz, H-6), 7.96 (2 H, d, J = 8.80 Hz, H-10*);  δC 
(50 MHz, CDCl3) 20.65 and 20.82 (2 × COCH3), 55.49 (2 × Ar-OCH3), 62.84 (C-5’), 71.50 
(C-3’), 73.40 (C-2’), 82.43 (C-4’), 86.05 (C-1’), 87.88 [C(Ar)3], 103.09 (C-5), 113.63 (C-3*), 
127.56 (C-8*), 128.30 (C-6* 
#
), 128.37 (C-7* 
#
), 129.33 (C-10*), 130.37 (C-11*), 130.78 (C-
2*), 131.56 (C-12*), 134.96 (C-1*), 135.32 (C-9*), 139.71 (C-6), 144.02 (C-5*), 149.70 (C-
2), 159.04 (C-4*), 161.99 (C-4), 168.68 (N-C=O), 169.96 and 169.99 (2 × CO-CH3);  MS m/z 
(M
+
, no peak found) 320.8 (7), 432.6 (11), 449.7 (25), 450.7 (5), 881.4 (100), 882.6 (28), 
886.5 (11), HRMS (+cESI) calculated for C41H38N2O11Na
+
: 757.23678, found: [M + 23]
+
 
757.23653. 
Note: assignments denoted with 
#
 are interchangeable. 
 
B.25 Attempted synthesis of 3-N-benzoyl-5'-O-(4,4'-dimethoxytrityl)uridine [129] 
 
The protected uridine 126 (0.219 mmol, 0.120 
g), sodium carbonate (8.3 eq, 1.82 mmol, 0.194 
g) and tetra-butylammonium bromide (0.037 
eq, 0.0081 mmol, 0.0035 g) were dissolved in a 
biphasic solution of CH2Cl2 : H2O (4.5 cm
3
 : 9 
cm
3
). Then the benzoyl chloride (1.3 eq, 0.3 
mmol, 0.03 cm
3
) was added to the mixture with 
vigorous stirring. The reaction mixture was then stirred at rt for 30 min, after which time 
multiple spots were observed by tlc. The reaction mixture was then transferred to a separating 
funnel by the addition of CH2Cl2 (5 cm
3
). The organic phase was collected and the aqueous 
phase was extracted with CH2Cl2 (3 × 20 cm
3
). The combined organics were then dried over 
anhydrous Na2SO4, filtered and evaporated. The crude mixture was obtained as a pale yellow-
orange oil that darkened to a dark orange red overnight. The crude residue was then purified 
by column chromatography, with 5-50 % EtOAc : hexane used for elution and none of the 
desired compound 129 was isolated. 
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B.26 Preparation of 2',3',5'-O-triacetyluridine [130] 
 
Uridine 12 (4.46 mmol, 1.09 g) was dissolved in distilled pyridine 
(3 eq, 13.4 mmol, 1.08 cm
3
) and the solution was stirred at rt 
under an argon atmosphere for a few minutes. To this solution 
was then added dropwise a solution of distilled pyridine (4.5 eq, 
20.1 mmol, 1.60 cm
3
) and distilled acetic anhydride (4.5 eq, 20.1 
mmol, 1.90 cm
3
). After the addition, the reaction mixture was 
allowed to stir at rt under an argon atmosphere overnight (22 h). 
After this time, tlc indicated product formation, so EtOAc (100 
cm
3
) was added to the reaction mixture and it was allowed to stir for a few min. Then the 
organic layer was extracted with brine (3 × 100 cm
3
) and the combined aqueous layers were 
extracted with CH2Cl2 (3 × 100 cm
3
). All the organic layers were combined and extracted 
with a saturated NH4Cl solution that had been basified to pH ~10 with NH3 (150 cm
3
). The 
combined organics were then dried over MgSO4, filtered and evaporated. The crude 
compound was purified by column chromatography, using EtOAc as the eluant. The desired 
compound 130 was obtained as a white foam after purification (1.54 g, 93 %). 
 
Rf = 0.59  (100 % EtOAc);  [α]D
23
 8.3333
o
 (c = 2.04 in EtOAc);  νmax/cm
-1
 (thin film) 669 
(RHC=CHR cis), 775 (CH2 rocking), 1216 (-CO-CH3), 1379 (-CH3 symmetrical 
deformation), 1457 (C-H deformations), 1540 (-CONH-), 1698 (C=C conjugated with C=O), 
1750 (C=O), 3391 (-CONH-);  δH (300 MHz, CDCl3) 2.11, 2.13 and 2.15 (9 H, 3 × s, 3 × 
CH3), 4.32-4.39 (3 H, m, H-3’ and H-5’), 5.34-5.36 (2 H, m, H-2’ and H-4’), 5.80 (1 H, d, J = 
8.12 Hz, H-5), 6.05 (1 H, d, J = 4.72 Hz, H-1’), 7.41 (1 H, d, J = 8.16 Hz, H-6), 9.61 (1 H, br 
s, NH);  δC (50 MHz, CDCl3) 20.56, 20.65 and 20.79 (3 × CH3), 63.32 (C-5’), 70.36 (C-4’), 
72.89 (C-2’), 80.08 (C-3’), 87.68 (C-1’), 103.59 (C-5), 139.55 (C-6), 150.50 (C-2), 163.19 
(C-4), 169.84 (2 × C=O, on C-2’ and C-3’), 170.36 (C=O on C-5’);  MS m/z (M + 23+, 100 
%) 139.13 (12), 217.15 (13), 259.13 (78), 351.19 (14), 387.98 (22), 394.23 (16), HRMS 
(+cESI) calculated for C15H19N2O9
+
: 371.10851, found: [M + 1]
+
 371.10849 and calculated 
for C15H18N2O9Na
+
: 393.09045, found: [M + 23]
+
 393.09029. 
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B.27 Preparation of 3-N-benzoyl-2',3',5'-O-triacetyluridine [131] 
 
A solution was prepared of the protected uridine 130 
(10.7 mmol, 3.95 g) and distilled pyridine (80 cm
3
). To 
this solution was then added N,N-diisopropylethylamine 
(5 eq, 53.3 mmol, 9.30 cm
3
) and the solution was stirred 
for 10 min. To the stirred solution was then added 
distilled benzoyl chloride (5 eq, 53.3 mmol, 6.20 cm
3
). 
The reaction mixture was stirred at rt under an argon 
atmosphere for 2 h, during which time the solution 
changed colour to a very dark red. After this time, the reaction mixture was diluted with 
CH2Cl2 (390 cm
3
) and extracted with distilled water (3 × 390 cm
3
). The combined aqueous 
layers were then extracted with CH2Cl2 (390 cm
3
). All the organic layers were combined, 
dried over anhydrous Na2SO4, filtered and evaporated. The crude compound was obtained as 
a dark brown semi-solid and was further purified by column chromatography using the pre-
prepared/basified silica. The solvent used for eluting the column was 50 % EtOAc : hexane. 
The desired compound 131 was obtained as a bright yellow foam (4.71 g, 93 %). 
 
Rf = 0.21 (50 % EtOAc : hexane);  [α]D
23
 0.9901
o
 (c = 2.02 in EtOAc);  νmax/cm
-1
 (thin film) 
670 (RHC=CHR cis), 775 (5 adjacent aromatic H), 1375 (-CH3 symmetrical deformation), 
1452 (C-H deformations), 1540 (tertiary amide), 1678 (C=C conjugated with C=O), 1752 
(tertiary amide), 3022 (Ar H);  δH (300 MHz, CDCl3) 2.05, 2.11 and 2.13 (9 H, 3 × s, 3 × 
CH3), 4.37 (3 H, m, H-3’ and H-5’), 5.36-5.40 (2 H, m, H-2’ and H-4’), 5.90 (1 H, d, J = 8.22 
Hz, H-5), 6.02 (1 H, d, J = 4.94 Hz, H-1’), 7.48-7.53 (3 H, m, H-3* and H-6), 7.64-7.66 (1 H, 
m, H-4*), 7.95 (2 H, d, J = 7.84 Hz, H-2*);  δC (50 MHz, CDCl3) 20.56, 20.64 and 20.92 (3 × 
CH3), 63.16 (C-5’), 70.40 (C-4’), 73.11 (C-2’), 80.38 (C-3’), 88.10 (C-1’), 103.44 (C-5), 
129.35 (C-3*), 130.75 (C-2*), 131.47 (C-1*), 135.37 (C-4*), 139.21 (C-6), 149.41 (C-2), 
161.75 (C-4), 168.37 (N-C=O), 169.76, 169.98 and 170.28 (3 × COCH3);  MS m/z (M + 23
+
, 
100 %) 259.13 (11), 475.15 (10), 492.01 (24), 498.24 (25), 499.25 (5), HRMS (+cESI) 
calculated for C22H23N2O10
+
: 475.13472, found: [M + 1]
+
 475.13429 and calculated for 
C22H22N2O10Na
+
: 497.11667, found: [M + 23]
+
 497.11584. 
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B.28 Attempted synthesis of 3-N-benzoyluridine [132] 
 
Method 1: 
The protected uridine 131 (0.410 mmol, 0.195 g) was 
dissolved in distilled MeOH (5 cm
3
) and to this solution was 
then added the potassium carbonate (4.5 eq, 1.85 mmol, 
0.259 g). The reaction mixture was then stirred at rt for 2 h. 
After this time, tlc indicated consumption of the starting 
material, so the inorganic salts were filtered off through celite and rinsed with MeOH. The 
solvent was removed in vacuo to yield a cream solid. The crude material was recrystallised 
from hot MeOH and the cream crystals were collected by filtration and dried under high 
vacuum. NMR spectroscopy showed that none of the desired compound 132 had formed. 
 
Method 2: 
The protected uridine 131 (0.234 mmol, 0.111 g) was stirred with a distilled CH2Cl2 : MeOH 
(9 cm
3
 : 1 cm
3
) mixture until a solution had formed. Then the p-TsOH.H2O (3 eq, 0.700 
mmol, 0.137 g) was added and the reaction mixture was allowed to stir at rt under an argon 
atmosphere for 24 h. After this time the reaction mixture was diluted with CH2Cl2 (10 cm
3
) 
and the organic phase was extracted with saturated NaHCO3 (10 cm
3
). The organics were then 
dried over anhydrous Na2SO4, filtered and the solvent was removed in vacuo. The crude 
residue was obtained as a yellow foam and was subjected to NMR spectroscopy. It was found 
that none of the desired compound 132 had formed. 
 
B.29 Preparation of 4-N-benzoylcytidine [133] 
 
The cytidine 11 (8.25 mmol, 2.01 g) was stirred with absolute EtOH (200 cm
3
) and then 
heated to reflux. To the refluxing solution was then added benzoic anhydride (1 eq, 8.25 
mmol, 1.87 g) and the reaction mixture was stirred at reflux for 1 h. After this time, the 
second amount of benzoic anhydride (1 eq, 8.25 mmol, 1.87 g) was added and the reaction 
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mixture was stirred at reflux for a further hour. Following this 
time, the third amount of benzoic anhydride (1 eq, 8.25 mmol, 
1.87 g) was added and the reaction mixture was stirred at 
reflux for a further hour. Subsequently, the fourth and final 
amount of benzoic anhydride (1 eq, 8.25 mmol, 1.87 g) was 
added and the reaction mixture was stirred at reflux for 
another hour. After this time, the reaction mixture was 
allowed to cool to rt and the solvent was removed in vacuo to yield a white solid. The crude 
compound was triturated with Et2O (200 cm
3
) for approximately 1 h. The solid precipitate 
was then filtered off through a sintered funnel and it was then rinsed with Et2O (3 × 100 cm
3
). 
The precipitate was dried under high vacuum and the desired compound 133 was obtained as 
a fluffy white powder (2.79 g, 97 %). 
 
Rf = 0.31 (10 % EtOH : CH2Cl2);  [α]D
23
 36.585
o
 (c = 2.05 in DMSO);  νmax/cm
-1
 (thin film) 
670 (5 adjacent aromatic H), 690 (RHC=CHR cis), 707 (CH2 rocking), 741 (5 adjacent 
aromatic H), 1114 (C-O stretching from C-OH), 1205 (C-O), 1394 (O-H bending), 1457 (C-H 
deformations), 1504 (Ar H), 1578 (-CONH-), 1601 (Ar H), 1615 (C=C conjugated with 
C=O), 1672 (-CONH-), 3159 (Ar H), 3422 (-CONH-);  δH (300 MHz, d6-DMSO) 3.62-3.74 
(2 H, m, H-5’), 3.92-3.94 (1 H, m, H-4’), 3.97-4.02 (2 H, m, H-2’ and H-3’), 5.09 (1 H, d, J = 
5.39 Hz, OH-3’), 5.22 (1 H, t, J = 4.92 Hz, OH-5’), 5.54 (1 H, d, J = 4.68 Hz, OH-2’), 5.82 (1 
H, d, J = 2.42 Hz, H-1’), 7.34 (1 H, d, J = 5.95, Hz, H-5), 7.46-7.50 (2 H, m, H-3*), 7.53-7.62 
(1 H, m, H-4*), 8.00 (2 H, d, J = 7.46 Hz, H-2*), 8.50 (1 H, d, J = 7.23 Hz, H-6), 11.24 (1 H, 
br s, NH);  δC (50 MHz, d6-DMSO) 59.98 (C-5’), 68.72 (C-3’), 74.64 (C-2’), 84.30 (C-4’), 
90.31 (C-1’), 96.11 (C-5), 128.55 (C-2* and C-3*), 132.85 (C-4*), 133.21 (C-1*), 145.43 (C-
6), 154.75 (C-2), 163.12 (C-4), 167.44 (N-C=O);  MS m/z (M
+
, 18 %) 255.25 (5), 303.20 
(32), 346.19 (100), 459.40 (10), 561.40 (7), 639.38 (18), 640.39 (8), HRMS (+cESI) 
calculated for C16H18N3O6
+
: 348.11901, found: [M + 1]
+
 348.11509. 
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B.30 Preparation of 5'-O-(tert-butyldiphenylsilyl)cytidine [134] 
 
A Schlenk tube was filled with a 5 % trimethylsilyl chloride : 
hexane solution and was stored at rt overnight. The glassware 
was then oven dried, placed under high vacuum and allowed 
to cool to rt under an argon atmosphere. The cytidine 11 (8.51 
mmol, 2.07 g) and DMAP (0.1 eq, 0.851 mmol, 0.106 g) were 
stirred with distilled pyridine (10 cm
3
) until a cream 
suspension had formed. To this suspension was then added the 
tert-butyldiphenylsilyl chloride (1.1 eq, 9.37 mmol, 2.45 cm3). The reaction mixture was then 
allowed to stir at rt under an argon atmosphere overnight (23 h). After this time, the reaction 
mixture was diluted with CH2Cl2 (80 cm
3
) and then extracted with a saturated NaHCO3 
solution (2 × 80 cm
3
) and brine (80 cm
3
). The organic layer was dried over anhydrous 
Na2SO4, filtered and the solvent was removed in vacuo. The crude compound was purified by 
column chromatography using the pre-prepared and basified silica and 10-20 % EtOH : 
CH2Cl2 as the eluant. The desired product 134 was obtained as a white foam (4.08 g, 100 %). 
 
Rf = 0.23 (10 % EtOH : CH2Cl2);  [α]D
19
 24.138
o
 (c = 2.03 in DMF);  νmax/cm
-1
 (thin film) 
670 (RHC=CHR cis), 765 (CH2 rock), 1109 (Si-O), 1216 (C-OH stretch), 1423 (CH2 
deformations or O-H bend), 1523 (NH2), 1650 (N-CO-N), 3021 (Ar H), 3651 (H-bonded 
OH), 3575 (free OH);  δH (300 MHz, d6-DMSO) 1.02 [9 H, s, C(CH3)3], 3.74-3.79 (1 H, m, 
H-5’), 3.90-3.95 (3 H, m, H-2’, H-4’ and H-5’), 4.08-4.11 (1 H, m, H-3’), 5.07 (1 H, d, J = 
6.02 Hz, OH-3’), 5.43 (1 H, d, J = 5.05 Hz, OH-2’), 5.53 (1 H, d, J = 7.41 Hz, H-5), 5.83 (1 
H, d, J = 3.35 Hz, H-1’), 7.15 (2 H, br s, NH2), 7.39-7.49 (6 H, m, H-3* and H-4*), 7.63-7.65 
(4 H, m, H-2*), 7.66 (1 H, d, J = 7.40 Hz, H-6);  δC (50 MHz, d6-DMSO) 18.79 [C(CH3)3], 
26.65 [C(CH3)3], 63.19 (C-5’), 68.88 (C-3’), 74.22 (C-2’), 82.91 (C-4’), 89.31 (C-1’), 93.74 
(C-5), 127.96 (C-3*), 129.96 (C-4*), 132.27 (C-1*), 134.96 (C-2*), 140.59 (C-6), 155.12 (C-
2), 165.46 (C-4);  MS m/z (M
+
, 34 %) 255.23 (5), 327.24 (5), 480.28 (100), 482.32 (10), 
561.37 (6), 639.37 (14), 640.43 (7), HRMS (+cESI) calculated for C25H32N3O5Si
+
: 
482.21057, found: [M + 1]
+
 482.20978. 
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B.31 Attempted synthesis of 4-N-benzoyl-5'-O-(tert-butyldiphenylsilyl)cytidine [135] 
 
Method 1: 
The Schlenk tube was filled with a 5 % trimethylsilyl 
chloride : hexane solution and was stored at rt 
overnight. The glassware was then oven dried, placed 
under high vacuum and allowed to cool to rt under an 
argon atmosphere. The benzoyl-protected cytidine 133 
(5.32 mmol, 1.85 g) and DMAP (0.1 eq, 0.532 mmol, 
0.0666 g) were stirred with distilled pyridine (18.5 cm
3
) until a suspension had formed. To 
this suspension was added the tert-butyldiphenylsilyl chloride (1.1 eq, 5.85 mmol, 1.52 cm3). 
The reaction mixture was then stirred at rt under an argon atmosphere overnight (22 h). After 
this time, tlc indicated the formation of a new spot, so the reaction was quenched by the 
addition of EtOH (20 cm
3
) and the solvent was removed in vacuo. The crude mixture was 
purified by column chromatography using the pre-prepared/basified silica and 10 % EtOH : 
CH2Cl2 for elution. None of the desired compound 135 was isolated after purification. 
 
Method 2: 
The silylated cytidine compound 134 (0.631 mmol, 0.304 g) was dissolved in absolute EtOH 
(15 cm
3
) and was heated to reflux, before the first addition of benzoic anhydride (1 eq, 0.631 
mmol, 0.145 g). The reaction mixture was stirred at reflux for 1 h before the second addition 
of benzoic anhydride (1 eq, 0.631 mmol, 0.142 g). This was repeated for a further two 
additions of benzoic anhydride (addition 3: 1 eq, 0.631 mmol, 0.146 g and addition 4: 1 eq, 
0.631 mmol, 0.147 g), which were added at hourly intervals. After the final addition, the 
reaction mixture was stirred at reflux for another hour and was then allowed to cool to rt. 
After this time the solvent was removed in vacuo to give a cream residue, that was then 
triturated with Et2O (30 cm
3
) for 15 min. After this time the precipitate was filtered off, rinsed 
with further portions of Et2O and then allowed to dry in a desiccator overnight. A white 
powder was obtained from the reaction which contained the unreacted starting material 134. 
None of the desired compound 135 was isolated from the reaction. 
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B.32 Attempted synthesis of 5'-O-(4,4'-dimethoxytrityl)cytidine [136] 
 
The cytidine 11 (12.4 mmol, 3.02 g) and DMAP (0.1 eq, 
1.24 mmol, 0.158 g) were stirred with distilled pyridine 
(30 cm
3
) until a solution had formed. To the solution was 
then added 4,4'-dimethoxytrityl chloride (1.2 eq, 14.9 
mmol, 5.06 g). The reaction mixture was then allowed to 
stir at rt under an argon atmosphere overnight (23 h). 
After this time, the reaction mixture was transferred to a 
round-bottomed flask using EtOH and the solvent was removed in vacuo. The crude 
compound was then purified by column chromatography with the pre-prepared/basified silica 
and 5-20 % EtOH : CH2Cl2 as the eluant. The desired fractions were combined to yield a pale 
yellow foam, which contained a mixture of the desired product and a triethylamine salt 
(confirmed by NMR spectroscopy). The pale yellow foam mixture obtained from the column 
was dissolved in MeOH (25 cm
3
) with gentle heating. This solution was then added dropwise 
to vigorously stirring Et2O (250 cm
3
) and a white precipitate was observed. This was then 
cooled in an ice-water bath to allow for complete crystallization and the solid precipitate was 
filtered off through a sintered funnel. NMR spectroscopy confirmed that the white crystalline 
material obtained by this method was the triethylamine salt. The solvent was removed from 
the mother liquor in vacuo and a pale yellow foam was obtained. NMR spectroscopy again 
confirmed the presence of the desired product, but it was still contaminated with the 
triethylamine salt. The recrystallization procedure was repeated as described above, 
unfortunately the desired compound was again obtained contaminated with the triethylamine 
salt. A different recrystallization procedure was then attempted, where the contaminated foam 
was dissolved in MeOH (25 cm
3
) with gentle heating. This solution was then addeddrop wise 
to vigorously stirring H2O (100 cm
3
) and a white precipitate was immediately observed. The 
white precipitate was collected by filtration and dried in a desiccator, NMR analysis found it 
to be the 4,4’-dimethoxytrityl alcohol. None of the desired compound 136 was isolated from 
the reaction mixture. 
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B.33 Attempted synthesis of 4-N-benzoyl-5'-O-(4,4’-dimethoxytrityl)cytidine [137] 
 
Method 1: 
The benzoyl cytidine 133 (0.726 mmol, 0.252 g) 
and DMAP (0.02 eq, 0.0145 mmol, 0.0024 g) 
were dissolved in pyridine (5 cm
3
). To this 
solution was then added 4,4’-dimethoxytrityl 
chloride (1 eq, 0.726 mmol, 0.243 g) and the 
reaction mixture was stirred at rt under an argon 
atmosphere overnight (20 h). To the reaction 
mixture was then added a saturated solution of NaHCO3 (25 cm
3
) and the mixture was then 
extracted with CHCl3 (3 × 25 cm
3
). The organic layers were then combined and extracted 
with brine (25 cm
3
). The combined organics were dried over anhydrous Na2SO4, filtered and 
the solvent removed in vacuo. The resulting oily residue was then dissolved in a EtOH (3 
cm
3
) and CHCl3 (10 cm
3
) mixture. The solution formed was then added dropwise to 
vigorously stirring Et2O (100 cm
3
) and a precipitate formed. The white precipitate was then 
collected by filtration and NMR spectroscopy confirmed it contained only unreacted starting 
material 133. At the same time, the mother liquor was evaporated and yielded a very viscous 
clear oil, which solidified to give a cream foam under high vacuum. The crude foam was then 
purified by column chromatography on the pre-prepared/basified silica using 5 % EtOH : 
CH2Cl2 for elution. Isolated from the column were both the starting material and trace 
amounts of 4,4’-dimethoxytrityl alcohol. None of the desired compound 137 was isolated 
from the column and we believe that if it had formed it subsequently decomposed under the 
chromatography conditions. 
 
Method 2: 
The benzoyl cytidine 133 (3.87 mmol, 1.35 g) and DMAP (0.1 eq, 0.387 mmol, 0.0496 g) 
were stirred with distilled pyridine (13 cm
3
) until a suspension had formed. The suspension 
was then cooled to 0 
o
C in an ice-water bath before the addition of the 4,4’-dimethoxytrityl 
chloride (1.2 eq, 4.65 mmol, 1.57 g). The reaction mixture was then allowed to stir at rt under 
an argon atmosphere overnight (21 h). After this time it was noted that all of the solid had 
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solubilised to give a clear orange solution and that tlc indicated the formation of new spots. 
The reaction was thus quenched by the addition of EtOH (13 cm
3
) and the solvent was 
removed in vacuo to yield an orange foam. The crude foam was then dissolved in hot MeOH 
(25 cm
3
) and allowed to cool to rt, during which time a white precipitate was observed. The 
mixture was then cooled to 0 
o
C to allow for complete crystallization to occur and the 
precipitate was collected by filtration. At the same time the mother liquor was evaporated and 
the viscous orange oil obtained was dried under high vacuum. NMR spectra obtained for both 
the white precipitate and the orange oil did not show the presence of any sugar ring protons 
for the two compounds. Thus, none of the desired compound 137, was isolated from the 
reaction. 
 
B.34 Attempted synthesis of 5'-O-(tert-butyldiphenylsilyl)guanosine [138] 
 
Method 1: 
Guanosine 9 (1.79 mmol, 0.507 g) and DMAP (0.01 
eq, 0.0232 mmol, 0.0038 g) were dissoved in 
anhydrous pyridine (2.5 cm
3
) and the solution was 
stirred for 15 min at rt before the addition of the tert-
butyldiphenylsilyl chloride (1.1 eq, 2.0 mmol, 0.51 
cm
3
). The reaction mixture was then stirred at rt under an argon atmosphere overnight (24 h). 
After this time, tlc indicated no further change, so the solution was concentrated to a white 
semi-solid residue under reduced pressure. This crude residue was then dissolved in CH2Cl2 
(50 cm
3
) and was extracted with a saturated NaHCO3 solution (2 × 40 cm
3
) and brine (40 
cm
3
). The organic layer was dried over anhydrous Na2SO4, filtered and the solvent was 
removed in vacuo. A clear oil was obtained from the organic phase that was identified to be 
the silanol 145 by NMR spectroscopy. None of the desired compound 138 was isolated from 
the reaction mixture. 
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Method 2: 
Guanosine 9 (1.80 mmol, 0.509 g) was dissolved in distilled DMF (20 cm
3
) and to the 
solution was added imidazole (2 eq, 3.60 mmol, 0.259 g). The solution was stirred for 15 min 
before the addition of the tert-butyldiphenylsilyl chloride (1 eq, 1.8 mmol, 0.47 cm3). The 
reaction mixture was then stirred for 48 h at rt and no change was observed by tlc. The 
reaction mixture was thus heated to 50 
o
C for a further 72 h. After this time, tlc indicated no 
further change, so the reaction mixture was quenched by the addition of EtOH (2 cm
3
) and the 
solvent was removed in vacuo. The crude mixture was obtained as a white semi-solid - 
numerous attempts at recrystallization failed and each time unidentifiable by-products were 
isolated. 
 
Method 3: 
A Schlenk tube was filled with a 5 % trimethylsilyl chloride : hexane (v/v) solution and it was 
stored at rt overnight. All the glassware was then oven dried, placed under high vacuum and 
allowed to cool to rt under an argon atmosphere. Guanosine 9 (1.81 mmol, 0.513 g) and 
DMAP (0.01 eq, 0.023 mmol, 0.0028 g) were stirred with distilled pyridine (2.5 cm
3
) until a 
suspension had formed. To the suspension was then added the tert-butyldiphenylsilyl chloride 
(1.1 eq, 2.0 mmol, 0.52 cm
3
) and the reaction mixture was stirred at rt under an argon 
atmosphere overnight (21 h). After this time tlc showed no further change, so the reaction was 
quenched with the addition of EtOH (5 cm
3
). The solvent was removed in vacuo and the crude 
mixture was obtained as a white solid. NMR analysis found none of the desired peaks for the 
silyl protecting group and showed that starting material 9 had been isolated.  
 
B.35 Attempted synthesis of 5'-O-(4,4'-dimethoxytrityl)guanosine [139] 
 
Guanosine 9 (1.80 mmol, 0.509 g) was dissolved 
in distilled pyridine (10 cm
3
) and the solution was 
heated to 60 
o
C. To the solution was then added 
the 4,4'-dimethoxytrityl chloride (1.2 eq, 2.16 
mmol, 0.756 g) and DMAP (0.01 eq, 0.022 mmol, 
NH
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0.0029 g). The reaction mixture was then stirred at 60 
o
C under an argon atmosphere 
overnight (20 h). After this time, tlc indicated the formation of a new spot, so the reaction 
mixture was allowed to cool to rt and the solvent was removed in vacuo. The crude mixture 
was purified by column chromatography using 10-50 % EtOH : CH2Cl2 as the eluant. 
Unfortunately, the only compounds isolated from the column were 4,4'-dimethoxytrityl 
chloride degradation products and unreacted guanosine, it appeared as though the desired 
compound 139 had decomposed during purification. 
 
B.36 Attempted synthesis of 5'-O-(tert-butyldiphenylsilyl)-6-N-(N,N-dimethylmethyl-
imine)guanosine [140] 
 
Method 1: 
The Schlenk tube was filled with a 5 % 
trimethylsilyl chloride : hexane solution (v/v) and 
was stored at rt overnight. After this time, the 
glassware was oven dried, placed under high 
vacuum and allowed to cool to rt under an argon 
atmosphere. Then the protected guanosine 112 (2.82 mmol, 0.954 g) and DMAP (0.1 eq, 
0.282 mmol, 0.0354 g) were stirred with distilled pyridine (10 cm
3
) until a suspension had 
formed. To this suspension was then added the tert-butyldiphenylsilyl chloride (1.1 eq, 3.1 
mmol, 0.81 cm
3
). The reaction mixture was then allowed to stir at rt under an argon 
atmosphere overnight (25 h). After this time, tlc indicated the formation of a new spot, so the 
reaction was quenched by the addition of EtOH (10 cm
3
) and the solvent was removed in 
vacuo. The crude mixture was purified by column chromatography using the pre-
prepared/basified silica and 10 % EtOH : CH2Cl2 for elution. None of the desired compound 
140 was obtained after column chromatography, instead only degradation products were 
isolated which lead us to believe that the desired compound 140 was decomposing during 
chromatography. 
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Method 2: 
The Schlenk tube was filled with a 5 % trimethylsilyl chloride : hexane solution (v/v) and was 
stored at rt overnight. After this time, the glassware was oven dried, placed under high 
vacuum and allowed to cool to rt under an argon atmosphere. The protected guanosine 112 
(6.73 mmol, 2.28 g) and DMAP (0.1 eq, 0.673 mmol, 0.0823 g) were stirred with distilled 
pyridine (22 cm
3
) until a suspension had formed. To this suspension was then added the tert-
butyldiphenylsilyl chloride (1.1 eq, 7.40 mmol, 1.92 cm
3
) and the reaction mixture was 
allowed to stir at rt under an argon atmosphere overnight (20 h). After this time, tlc indicated 
no further change, so the reaction was quenched by the addition of EtOH (22 cm
3
) and the 
solvent was removed in vacuo. The residue obtained was dissolved in MeOH (50 cm3) with 
gentle heating and this was added dropwise to vigorously stirring H2O (100 cm
3
). A 
precipitate was immediately observed, it was collected by filtration and was then dried in a 
desiccator overnight. NMR spectroscopy showed that the N,N-dimethylmethylimine group 
was missing from the by-product isolated and none of the desired compound 140 was 
obtained. 
 
Method 3: 
The Schlenk tube was filled with a 5 % trimethylsilyl chloride : hexane solution (v/v) and was 
stored at rt overnight. After this time, the glassware was oven dried, placed under high 
vacuum and allowed to cool to rt under an argon atmosphere. The guanosine 9 (1.76 mmol, 
0.500 g) was dissolved in pre-distilled and dried DMF (25 cm
3
). To this solution was then 
added imidazole (2 eq, 3.53 mmol, 0.243 g) and the solution was stirred at rt for 15 min. After 
this time, the tert-butyldiphenylsilyl chloride (1 eq, 1.8 mmol, 0.46 cm3) was added to the 
solution and the reaction mixture was stirred at rt under an argon atmosphere overnight (20 h). 
Following this time, the reaction mixture was quenched by the addition of EtOH (5 cm
3
) and 
the solvent was removed in vacuo. The crude residue obtained was then dissolved in freshly 
distilled MeOH (25 cm
3
) and transferred to an oven dried Schlenk tube. After stirring for a 
few minutes the N,N-dimethylformamide dimethyl acetal (3.5 cm
3
) was added (note: in 
previous attempts at this reaction, 2 eq of the reagent were added, but no product was 
isolated). The reaction mixture was then stirred at rt under an argon atmosphere for 90 h. 
After this time, the solution was diluted with CH2Cl2 (50 cm
3
) and then washed with 0.5 M 
NaHCO3 (2 × 50 cm
3
). The organic fraction was dried over anhydrous Na2SO4, filtered and 
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the solvent was removed in vacuo. The residue obtained was triturated with Et2O (20 cm
3
) for 
30 min and the white precipitate was collected by filtration. The mother liquor was evaporated 
and a clear oil was obtained. NMR spectroscopy confirmed that the clear oil obtained was the 
silanol 145 and that the white precipitate was unreacted starting material 9. 
 
B.37 Attempted synthesis of 5'-O-(tert-butyldiphenylsilyl)inosine [141] 
 
Method 1: 
The Schlenk tube was filled with a 5 % trimethylsilyl 
chloride : hexane solution (v/v) and was stored at rt 
overnight. The glassware was then oven dried, placed 
under high vacuum and allowed to cool to rt under an 
argon atmosphere. The inosine 116 (4.03 mmol, 1.08 g) 
and DMAP (0.1 eq, 0.403 mmol, 0.0498 g) were stirred with distilled pyridine (5 cm
3
) until a 
suspension had formed. To this suspension was then added the tert-butyldiphenylsilyl 
chloride (1.1 eq, 4.43 mmol, 1.15 cm
3
) and the reaction mixture was stirred at rt under an 
argon atmosphere overnight (22 h). After this time, tlc indicated the presence of a new spot, 
so the reaction was quenched by the addition of EtOH (10 cm
3
) and the solvent was removed 
in vacuo. The crude residue was purified by column chromatography using the pre-
prepared/basified silica and 5-15 % EtOH : CH2Cl2 for elution. Only inosine 116 was isolated 
from the column - we have assumed that if the desired product 141 is formed during the 
reaction, it then decomposes on the column. 
 
Method 2: 
The reaction described in method 1 above was repeated (scale: 3.82 mmol, 1.02 g), but 
instead of purification by column chromatography, we attempted to purify the crude residue 
by an acid-base extraction procedure. The crude residue was dissolved in CH2Cl2 (100 cm
3
) 
and this was extracted with 0.5 M HCl (100 cm
3
), followed by distilled water (3 × 100 cm
3
). 
The organic layer was then extracted with 0.5 M NaOH (100 cm3) and distilled water (3 × 100 
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cm
3
). The organic layer was then dried over anhydrous Na2SO4, filtered and the solvent was 
removed in vacuo. As before, only decomposition products were isolated using this method. 
 
Method 3: 
The Schlenk was filled with a 5 % trimethylsilyl chloride : hexane solution (v/v) and was 
stored at rt overnight. The glassware was then oven dried, placed under high vacuum and 
allowed to cool to rt under an argon atmosphere. Then the inosine 116 (11.3 mmol, 3.02 g) 
and DMAP (0.1 eq, 1.13 mmol, 0.140 g) were stirred with distilled pyridine (15 cm
3
) until a 
suspension had formed. To this suspension was added the tert-butyldiphenylsilyl chloride (1.1 
eq, 12.4 mmol, 3.22 cm
3
) and the reaction mixture was stirred at rt under an argon atmosphere 
overnight (20 h). After this time, tlc showed no further change, so the reaction was quenched 
by the addition of EtOH (30 cm
3
) and the solvent was removed in vacuo. NMR spectroscopy 
on the crude residue showed that none of the desired product 141 had formed during the 
reaction. Other attempts at the reaction had employed various methods of recrystallization of 
the crude residue - none of these attempts yielded the desired product 141. 
 
B.38 Preparation of 5'-O-(tert-butyldiphenylsilyl)adenosine [142] 
 
A Schlenk tube was filled with a 5 % trimethylsilyl 
chloride : hexane (v/v) solution and was stored at rt 
overnight in order to silylate the glassware prior to use. 
The Schlenk was then oven dried, placed under high 
vacuum and allowed to cool to rt under an argon 
atmosphere. The adenosine 8 (1.90 mmol, 0.509 g) and 
DMAP (0.01 eq, 0.025 mmol, 0.0049 g) were stirred with 
distilled pyridine (2.5 cm
3
) until a solution had formed. To this solution was then added the 
tert-butyldiphenylsilyl chloride (1.1 eq, 2.1 mmol, 0.55 cm3) and the reaction mixture was 
stirred at rt under an argon atmosphere overnight (19 h). After this time, tlc showed no further 
change so the reaction mixture was transferred to a separating funnel using CH2Cl2 (20 cm
3
). 
The organic layer was extracted with a saturated NaHCO3 solution (2 × 20 cm
3
), which was 
then followed by extraction with brine (20 cm
3
). The organic layer was dried over anhydrous 
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Na2SO4, filtered and the solvent was removed in vacuo to yield the crude product as a white 
foam. The crude sample was purified by column chromatography, using the pre-
prepared/basified silica and 10 % EtOH : CH2Cl2 as the eluant. The desired compound 142 
was obtained pure as a white foam (0.703 g, 73 %). 
 
Rf = 0.44 (10 % EtOH : CH2Cl2);  [α]D
19
 -4.2857
o
 (c = 2.10 in DMF);  νmax/cm
-1
 (thin film) 
626 (Si-O), 670 and 780 (5 adjacent aromatic H), 1109 (C-O stretch), 1216 (O-H bend), 1423 
(CH2), 1522 (Ar H), 1651 (NH2), 3021 (Ar H), 3651 (NH2), 3675 (free OH);  δH (300 MHz, 1 
: 1 CDCl3 : d6-DMSO) 0.99 [9 H, s, C(CH3)3], 3.78 and 3.93 (2 H, two dd, J = 3.91 and 
11.30 Hz, H-5’), 4.03-4.07 (1 H, m, H-4’), 4.34-4.36 (1 H, m, H-3’), 4.59-4.61 (1 H, m, H-
2’), 5.07 (1 H, d, J = 5.40 Hz, OH-3’), 5.45 (1 H, d, J = 5.63 Hz, OH-2’), 5.95 (1 H, d, J = 
4.88 Hz, H-1’), 7.30-7.38 (6 H, m, H-3* and H-4*), 7.59 (4 H, dd, J = 1.44 and 7.85 Hz, H-
2*), 8.08 (1 H, s, H-2
#
), 8.11 (1 H, s, H-6
#
);  δC (50 MHz, 1 : 1 CDCl3 : d6-DMSO) 18.68 
[C(CH3)3], 26.44 [C(CH3)3], 63.52 (C-5’), 69.72 (C-3’), 73.48 (C-2’), 84.11 (C-4’), 87.48 (C-
1’), 119.12 (C-3a), 127.41 (C-3*), 129.39 (C-4*), 132.40 (C-1*), 134.82 (C-2*), 138.51 (C-
2), 149.19 (C-7a), 152.32 (C-6), 155.83 (C-4);  MS m/z (M + 1
+
, 100 %) 136.00 (55), 237.93 
(2), HRMS (+cESI) calculated for C26H32N5O4Si
+
: 506.22181, found: [M + 1]
+
 506.22098. 
Note: assignments denoted with 
#
 are interchangeable 
 
B.39 Attempted synthesis of 5'-O-(4,4'-dimethoxytrityl)adenosine [143] 
 
The adenosine 8 (3.81 mmol, 1.02 g) and DMAP (0.1 
eq, 0.381 mmol, 0.0469 g) were stirred with distilled 
pyridine (10 cm
3
) until a solution had formed. The 
solution was heated to 60 
o
C before the addition of the 
4,4'-dimethoxytrityl chloride (1.2 eq, 4.57 mmol, 1.55 
g). The reaction mixture was then allowed to stir at 60 
o
C under an argon atmosphere overnight (20 h). After 
this time, the reaction mixture was transferred to a round-bottomed flask using EtOH (10 cm
3
) 
and the solvent was removed in vacuo. The crude compound was then purified by column 
chromatography with the pre-prepared/basified silica and 10 % EtOH : CH2Cl2 as the eluant. 
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The desired fractions were combined to yield a cream foam, that contained a mixture of the 
desired product and a triethylamine salt. We attempted further purification to remove the 
triethylamine contaminant by crystallization of the contaminant (as the desired compound did 
not appear to be crystalline). The cream foam mixture obtained from the column was 
dissolved in MeOH (6 cm
3
) with gentle heating. This solution was then added dropwise to 
vigorously stirring Et2O (60 cm
3
) and a white precipitate was observed. This was then cooled 
in an ice-water bath to allow for complete crystallization and the solid precipitate was filtered 
off through a sintered funnel. NMR spectroscopy confirmed that the white crystalline material 
obtained by this method was the triethylamine salt. The solvent was removed from the mother 
liquor in vacuo and a cream foam was obtained. NMR spectroscopy again confirmed the 
presence of the desired product, but it was still contaminated with the triethylamine salt. The 
recrystallization procedure was repeated, unfortunately the desired compound 143 was always 
obtained contaminated with the triethylamine salt. 
 
B.40 Preparation of tert-butyldiphenylsilanol [145] 
 
A solution was prepared of tert-butyldiphenylsilyl chloride 144 (7.33 mmol, 
2.01 g) in Et2O (6 cm
3
). To this solution was then added portionwise a 
solution of KOH (1.1 eq, 8.06 mmol, 0.497 g) in a mixture of H2O : MeOH 
(1 cm
3
 : 4 cm
3
). The reaction mixture warmed up on addition and a white 
precipitate was immediately observed. The reaction mixture was then 
allowed to stir at rt overnight (24 h). After this time, the reaction mixture 
was transferred to a separating funnel and the Et2O layer was removed. The aqueous layer 
was then extracted with further portions of Et2O (3 × 10 cm
3
). All the organic fractions were 
combined, dried over anhydrous MgSO4, filtered and the solvent was removed in vacuo. The 
desired compound 145 was obtained pure as a colourless opaque oil (1.72 g, 92 %). The 
experimental procedure was modified from, and data obtained correlated well to that reported 
Mullen and Barany.
50 
 
νmax/cm
-1
 (thin film) 700 and 764 (5 adjacent aromatic H), 821 (Si-C), 938 and 1029 (Si-O), 
1084 (C-O stretch from C-OH), 1261 (Si-C), 1331 (O-H bending), 1391 (CH3 symmetrical 
OHSi
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deformations), 1589 (aromatic ring), 2857 (C-H stretch from CH3), 3015 (Ar H), 3071 (-OH);  
δH (300 MHz, CDCl3) 1.06 [9 H, s, C(CH3)3], 3.53 (1 H, br s, OH), 7.37-7.41 (6 H, m, H-3* 
and H-4*), 7.67-7.72 (4 H, m, H-2*);  δC (50 MHz, CDCl3) 19.22 [C(CH3)3], 26.77 
[C(CH3)3], 127.92 (C-3*), 129.85 (C-4*), 135.02 (C-2*), 135.73 (C-1*);  MS m/z (M + 23
+
, 
55 %) 269.12 (39), 462.01 (67), 485.21 (30), 536.14 (54), 559.24 (49), 560.30 (27), 633.26 
(48), 663.45 (100), 664.45 (50), HRMS (+cESI) calculated for C16H20OSi: 256.12834, HRMS 
not determined. 
 
B.41 Preparation of 4,4'-dimethoxytrityl alcohol [147] 
 
To the 4,4'-dimethoxytrityl chloride 146 (5.00 mmol, 1.70 g) was added 
a solution of THF : 0.5 M aqueous NaOH (10 cm
3
 THF : 10 cm
3
 NaOH) 
and the reaction mixture was then allowed to stir at rt for 30 min. After 
this time, the reaction mixture was extracted with CH2Cl2 (40 cm
3
). The 
organic layer was then dried over anhydrous Na2SO4, filtered and the 
solvent was removed in vacuo. The crude oil was purified by column 
chromatography using 10 % MeOH : CH2Cl2 for elution. The desired 
compound 147 was obtained as a yellow-orange semi-solid after column 
chromatography (1.40 g, 87 %). Spectroscopic data obtained for the compound was found to 
correlate well to that reported by Bleasdale et.al.
51
 for the similar procedure. 
 
Rf = 0.86 (10 % MeOH : CH2Cl2);  νmax/cm
-1
 (thin film) 702 and 753 (5 adjacent aromatic 
H), 849 (2 adjacent aromatic H), 1115 (C-O stretch from C-OH), 1360 (O-H bending), 1507, 
1581 and 1608 (aromatic ring), 2838 (-OCH3), 3070 (Ar H), 3504 (O-H stretching);  δH (300 
MHz, CDCl3) 2.76 (1 H, br s, OH), 3.79 (6 H, s, 2 × OCH3), 6.82 (4 H, d, J = 8.74 Hz, H-3*), 
7.16 (4 H, d, J = 8.75 Hz, H-2*), 7.25-7.29 (5 H, m, H-6*, H-7* and H-8*);  δC (50 MHz, 
CDCl3) 55.44 (2 × OCH3), 81.62 [C(Ar)3], 113.35 (C-3*), 127.27 (C-8*), 127.96 (C-6* 
#
), 
128.04 (C-7* 
#
), 129.33 (C-2*), 139.65 (C-1*), 147.52 (C-5*), 158.80 (C-4*);  MS m/z (M + 
23
+
, 7 %) 303.23 (100), 304.26 (22), HRMS (+cESI) calculated for C21H20O3: 320.14124, 
HRMS not determined. 
Note: assignments denoted with 
#
 are interchangeable. 
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B.42 Preparation of allyl ethyl carbonate [148] 
 
Method 1: 
The allyl alcohol (73.5 mmol, 5.00 cm
3
) was dissolved in distilled 
CH2Cl2 (50 cm
3
) and the solution was cooled to 0 
o
C in an ice-water 
bath. Then NEt3 (1 eq, 73.5 mmol, 10.3 cm
3
) was added and the solution was stirred for 5 
min. After this time, ethyl chloroformate (1 eq, 73.5 mmol, 7.0 cm
3
) was added dropwise and 
the reaction mixture was stirred at 0 
o
C for 15 min. Then Et2O (100 cm
3
) was added and the 
reaction mixture was stirred for a further 30 min. During this time a very thick white 
precipitate formed (assumed to be the by-product, a triethylamine hydrochloride salt) and the 
solid was then filtered off through a celite plug. The solid precipitate was washed with a 
further portion of cold Et2O (50 cm
3
) and the mother liquor solvent was removed by 
evaporation. The crude mixture was then purified by distillation at atmospheric pressure under 
an argon atmosphere. The pure product 148 was obtained as a clear oil after distillation (2.79 
g, 29 %). 
 
Method 2: 
The allyl alcohol (200 mmol, 13.6 cm
3
) was dissolved in distilled pyridine (50 cm
3
). The 
solution was then cooled to 0 
o
C before the dropwise addition of ethyl chloroformate (1.1 eq, 
220 mmol, 21 cm
3
). A white gas was immediately liberated from the reaction mixture and by 
the end of the addition a white precipitate was observed as well. After the addition the 
reaction mixture was warmed to rt and stirred overnight (20 h). The reaction mixture was then 
poured into a beaker containing crushed ice (100 cm
3
) and 2 M HCl (100 cm
3
). Further 
portions of the 2 M HCl (400 cm
3
 in total) were added until the pH was at 6. The mixture was 
then stirred until all the ice had melted and it was then extracted with CH2Cl2 (3 × 200 cm
3
). 
The combined organics were then extracted with distilled H2O (200 cm
3
). The combined 
organics were dried over anhydrous Na2SO4, filtered and evaporated. The crude mixture was 
purified by distillation at atmospheric pressure, under an argon atmosphere. The pure product 
148 was obtained as a clear oil which boiled at 139 
o
C (2.38 g, 9 %), mixed fractions were 
also obtained but were not re-distilled. 
 
O O
O
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Rf = 0.75 (30 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 740 (CH2 rocking), 933 (RCH=CH2), 
1216 (C-O), 1378 (O-CO-O), 1455 (C-H deformations from CH2 and CH3), 1651 (C=C), 
3021 (C-H stretching or C=CH2);  δH (300 MHz, CDCl3) 1.32 (3 H, t, J = 7.14 Hz, 
OCH2CH3), 4.21 (2 H, q, J = 7.12 and 7.13 Hz, OCH2CH3), 4.62 (2 H, dt, J = 1.32 and 5.76 
Hz, OCH2CH=CH2), 5.31 (2 H, dddd, J = 1.30, 2.65, 10.42 and 13.97 Hz, CH=CH2), 5.93 (1 
H, ddd, J = 7.56, 8.55 and 10.43 Hz, CH=CH2);  δC (50 MHz, CDCl3) 14.43 (CH3), 64.20 
(OCH2CH3), 68.43 (OCH2CH=CH2), 118.93 (CH=CH2), 131.85 (CH=CH2), 155.16 (C=O);  
MS m/z (M
+
, 0.85%) 41.03 (23), 72.08 (10), 100.11 (100), 115.07 (5), 127.04 (6), 173.08 
(13), 199.04 (8), 287.11 (5), HRMS (+cESI) calculated for C6H10O3: 130.06299, found: [M]
+
 
130.11864. 
Data obtained correlated well to that reported by Cravatta et.al.B1 
 
B.43 Preparation of bis(dibenzylideneacetone) palladium(0) [149] 
 
The dibenzylidene acetone stock (20.07 g) was purified by column chromatography using 10-
20 % EtOAc : hexane for elution. After chromatography and drying under high vacuum, the 
pure product was obtained as bright yellow crystals (9.24 g). 
 
Based on the procedure described by Schlosser,
B2
 
a solution of dibenzylidene acetone (3.3 eq, 19.6 
mmol, 4.60 g) and sodium acetate (8 eq, 47.6 
mmol, 3.90 g) was prepared in hot MeOH (150 
cm
3
). To this solution was then added palladium chloride (5.93 mmol, 1.05 g) and the reaction 
mixture was stirred at 40 
o
C, under an argon atmosphere for 4 h. After this time, the solution 
was allowed to cool to rt and then crystallisation was completed in an ice-water bath. The 
dark purple crystals were collected by filtration and subsequently washed with distilled water 
(150 cm
3
), which was followed by distilled acetone (150 cm
3
).The dark purple crystals were 
then dried under high vacuum and were found to be the pure compound 4.111 (3.06 g, 90 %). 
 
O
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m.p. 148-149 
o
C;   νmax/cm
-1
 (thin film) 669 and 768 (5 adjacent aromatic H), 1071 
(RHC=CHR trans), 1216 (C-O stretch), 1541 (C=O), 1652 (C=C conjugated with C=O or 
C=C conjugated with aromatic ring), 3020 (Ar H);  δH (300 MHz, CDCl3) 7.09 (2 H, d, J = 
15.96 Hz, CO-CH=CH-Ar), 7.40-7.42 (6 H, m, H-3* and H-4*), 7.61-7.64 (4 H, m, H-2*), 
7.74 (2 H, d, J = 15.96 Hz, CO-CH=CH-Ar);  δC (50 MHz, CDCl3) 125.65 (CO-CH=CH-Ar), 
128.61 (C-2*), 129.02 (C-3*), 130.71 (C-4*), 135.03 (C-1*), 143.53 (CO-CH=CH-Ar), 
189.13 (C=O). 
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Appendix C: 
Experimental Procedures – Relating to Chapter 3 
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C.1 Growth and Purification of Bacteria from Freezer Stocks 
 
The freezer stocks for S. aureus strain ATCC 25923, B. cereus strain DL5 and P. aeruginosa 
strain ATCC 27853 were defrosted by warming in hands and then standing at room 
temperature until they had completely thawed. The Eppendorff tubes were then gently 
inverted to mix the contents. We then aliquoted the entire 1000 μL into the pre-prepared 
conical flask containing 100 cm
3
 nutrient broth (prepared according to manufacturer's 
instructions and autoclaved at 1 atm /121 
o
C for 20 min). The cultures were then incubated at 
37 
o
C with shaking (100 rpm) overnight.  
 
After this time, the overnight broth cultures were used to prepare three streak plates. This is a 
standard microbiological method used to guarantee culture purity. The  S. aureus and B. 
cereus were grown on standard nutrient agar plates (solution prepared according to 
manufacturer's instructions, autoclaved at 1 atm /121 
o
C for 20 min, poured and then 
incubated at 37 
o
C overnight to check for contamination), whereas the P. aeruginosa was 
grown on nutrient agar plates which had a CFC selective supplement added (the nutrient agar 
solution was prepared according to manufacturer's instructions, then the cefalotin sodium 
supplement was added, the mixture was autoclaved at 1 atm /121 
o
C for 20 min, poured and 
the plates then incubated at 37 
o
C overnight to check for contamination).  
 
The streak plates were incubated at 37 
o
C overnight and checked for colony growth and 
possible contamination. Once we were satisfied that the plates were not contaminated, a single 
colony was removed from the plates and used to inoculate 100 cm
3
 nutrient broth (prepared as 
described previously). The cultures were incubated at 37 
o
C with shaking (100 rpm) 
overnight. Following incubation, the overnight broth cultures were used to prepare another 
three streak plates on nutrient agar for each of the bacteria used (solution prepared according 
to manufacturer's instructions, autoclaved at 1 atm /121 
o
C for 20 min, poured and then 
incubated at 37 
o
C overnight to check for contamination), as well as new freezer stocks 
(described in Section C.3).  
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The plates were incubated at 37 
o
C overnight and checked for contamination. If satisfactory, 
the plates were then sealed with Parafilm, placed inside polyethylene bags and stored at 4 
o
C 
until required. The plates were subcultured every 21 days when in active use and were 
prepared fresh from new freezer stocks when long periods of time elapsed between the assays 
being performed. 
 
 
 
Figure C.1 Examples of the types of streak plates obtained after overnight incubation, 
showing S. aureus strain ATCC 25923 (left) and E. coli strain 25922 (right) 
 
C.2 Growth and Purification of Bacteria from Freeze-Dried Swabs (as delivered by 
ATCC) 
 
The freeze-dried “stick” containing E. coli strain ATCC 25922 was opened aseptically and 
rehydrated with 1000 μL of pre-prepared nutrient broth. This mixture was then transferred to 
a conical flask containing 100 cm
3
 nutrient broth (prepared according to manufacturer's 
instructions and autoclaved at 1 atm /121 
o
C for 20 min). The culture was incubated at 37 
o
C 
with shaking (100 rpm) overnight.  
 
After this time, the overnight broth cultures were used to prepare three streak plates for E. 
coli, on either TBX agar plates (Oxoid, contains: tryptone, bile salts, agar and X-glu) or 
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selective RAPID’ E. coli 2 agar plates (both sets of plates were prepared according to the 
manufacturer's instructions, autoclaved at 1 atm /121 
o
C for 20 min, poured and then 
incubated at 37 
o
C overnight to check for contamination). The streak plates were then 
incubated at 37 
o
C overnight and checked for growth and possible contamination. Once we 
were satisfied that the plates were not contaminated, a single colony (blue/purple) was 
removed from the plates and used to inoculate 100 cm
3
 nutrient broth (prepared as described 
previously). The culture was incubated at 37 
o
C with shaking (100 rpm) overnight.  
 
Following incubation, the overnight broth culture was used to prepare another three streak 
plates for E. coli on nutrient agar (solution prepared according to manufacturer's instructions, 
autoclaved at 1 atm /121 
o
C for 20 min, poured and then incubated at 37 
o
C overnight to check 
for contamination) as well as new freezer stocks (described in Section C.3). The plates were 
incubated at 37 
o
C overnight and then checked for contamination. The plates were sealed with 
Parafilm, placed inside polyethylene bags and stored at 4 
o
C until required. The plates were 
subcultured every 21 days when in active use and were prepared fresh from new freezer 
stocks when long periods of time elapsed between assays being performed. 
 
C.3 Preparation of Freezer Stocks 
 
We began by adding 150 μL of pre-warmed glycerol into 1000 μL Eppendorff tubes and these 
were then autoclaved at 1 atm /121 
o
C for 20 min. The overnight broth cultures prepared in 
Sections C.1 and C.2 above were used to aliquot 850 μL of the culture into the autoclaved 
glycerol under aseptic techniques. The Eppendorff tubes were gently inverted and shaken to 
mix the contents and were then sealed with Parafilm. This procedure was repeated to prepare 
six Eppendorff tubes for each of the four bacteria used (S. aureus ATCC 25923, B. cereus 
DL5, P. aeruginosa ATCC 27853 and E. coli ATCC 25922). The freezer stocks were then 
stored at -20 
o
C until required. 
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C.4 Droplet Plate Technique 
 
Method based on procedure described by Lindsay and von Holy.
123c
 A 0.85 % NaCl(aq) 
solution was prepared and then 9 cm
3
 portions were transferred to test tubes. These were 
capped and autoclaved at 1 atm /121 
o
C for 20 min. One colony for each of the four bacteria 
used in the study (S. aureus ATCC 25923, B. cereus DL5, P. aeruginosa ATCC 27853 and E. 
coli ATCC 25922) was used to inoculate conical flasks containing 100 cm3 of nutrient broth 
(prepared according to the manufacturer's instructions). This was performed in duplicate and 
the cultures were then incubated at 37 
o
C with shaking (150 rpm) for exactly 18 hours.  
 
After this time, 1000 μL of each overnight broth culture was transferred to a test tube 
containing 9 cm
3
 of 0.85 % NaCl(aq) solution. The contents of the tube were mixed thoroughly 
and this tube was then used for a series of serial dilutions, the procedure is outlined in Figure 
C.2. 
 
1000 L ( 6 x 1000 L )
10-1 10-2 10-3 10-4 10-5 10-6 10-7  
 
Figure C.2 Serial dilution series for the droplet plate technique 
 
Following this, 50 μL was taken from each test tube from dilutions 10 -2 to 10-7 and were 
added carefully to each of the six segments of the nutrient agar plate (prepared according to 
the manufacturer's instructions). Once all of the drops were added, the plate was gently 
swirled to spread out the culture. This was performed in duplicate for each of the four 
bacterial strains. The approach used is shown schematically in Figure C.3. 
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10-2
10-3
10-410
-5
10-6
10-7
 
 
Figure C.3 Layout used for the drop plate and example of drop plate obtained for P. 
aeruginosa ATTCC 27853 after overnight growth on a nutrient agar plate 
 
The plates were then incubated at 37 
o
C overnight. After this time, the plates were removed 
from the incubator for colony counting. Unfortunately, for all four of the bacteria, at these 
dilutions there were either too many colonies too count or a lawn had formed. 
 
As such, the method described above was repeated at higher dilutions. As outlined in Figure 
C.4, the serial dilutions were repeated from 10
-1
 to 10
-10
 for the overnight cultures of the four 
bacteria (S. aureus ATCC 25923, B. cereus DL5, P. aeruginosa ATCC 27853 and E. coli 
ATCC 25922).  
 
1000 L ( 9 x 1000 L )
10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10  
 
Figure C.4 Serial dilution series for the droplet plate technique 
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As before, 50 μL was taken from each test tube from dilutions 10-5 to 10-10 and were added 
carefully to each of the six segments of the nutrient agar plate (prepared according to the 
manufacturer's instructions). Once all of the drops were added, the plate was gently swirled to 
spread out the culture. This was performed in duplicate for each of the four bacterial strains. 
The approach used is shown schematically in Figure C.5. 
 
                                   
10-5
10-6
10-710-8
10-9
10-10
 
 
Figure C.5 Layout used for the drop plate and example of drop plate obtained for E. coli 
ATCC 25922 (blue/green colonies) after overnight growth on a TBX plate 
 
The plates were then incubated at 37 
o
C overnight. After this time, the plates were removed 
from the incubator for colony counting. This time, the dilutions were in the correct range and 
we were able to count the number of colonies that had formed on the plates. These values 
were then used to determine the average viable count for the four bacterial strains.  
 
For S. aureus strain ATCC 25923 the plates were prepared in duplicate. We counted 46 
colonies in the 10
-6
 dilution range and 5 colonies in the 10
-7
 dilution range on the first plate. 
On the second plate we counted 25 colonies in the 10
-6
 dilution and 3 colonies in the 10
-7
 
dilution. This gave us four replicates for the data set. 
 
The plate preparation was repeated on a separate day in order to have more accurate and 
reproducible results. The plates for S. aureus strain ATCC 25923 were again prepared in 
duplicate. This time, we counted 40 colonies in the 10
-6
 dilution and 5 colonies in the 10
-7
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dilution on the first plate, and 28 colonies in the 10
-6
 dilution and 3 colonies in the 10
-7
 
dilution on the second plate. This repetition gave four replicates for the data set. 
 
The data from the two days were combined in order to obtain an average for the eight 
replicates present in the complete data set. The calculation for cfu/mL and log cfu/mL is 
shown below. 
 
 cfu/mL  = { [ ( 46 + 50 + 25 + 30 + 40 + 50 + 28 + 30 ) / 8 ] × 10
6
 } × 20 
   = 747 500 000 
 and 
 log cfu/mL = log 747 500 000 
   =  8.87 
 
The same procedure was used for the determination of cfu/mL and log cfu/mL for the other 
bacterial strains. From our calculations, we obtained: 
 
 B. cereus DL5   
-  cfu/mL  = 1 432 500 000 
-  log cfu/mL  =  9.16 
 
 P. aeruginosa ATCC 27853 
-  cfu/mL  = 1 536 666 667 
-  log cfu/mL  =  9.19 
 
 E. coli ATCC 25922 
-  cfu/mL  = 3 375 000 000 
-  log cfu/mL  =  9.53 
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C.5 Determination of Antibacterial Activity through the use of the Triphenyl 
 Tetrazolium Chloride (TTC) Assay  
 
C.5.1 Preparation of Antibiotic/Compound Stock Solutions 
 
Ciprofloxacin is a commercially marketed broad-spectrum antibiotic and was chosen as our 
positive control for the TTC assay. We purchased our ciprofloxacin from Sigma-Aldrich, 
under license of Fluka (code: 17850). Information obtained from the supplier indicated a 
potency of 85 % (ie: 850 µg/mg) for the sample. 
 
The mass required to make a 10 000 mg/L stock solution was calculated from the equation: 
 
    ( 1000 / P ) × V × C = W 
  
 where:  P = potency (µg/mg) 
   V = volume (mL) 
   C = final concentration in multiples of 1000 (mg/L) 
   W = mass of anibiotic (mg) 
 
From the calculation, we determined that 117.65 mg of ciprofloxacin was required to prepare 
the 10 000 mg/L stock solution. For all of the synthetic compounds we used 100 mg of 
material (either solid foam, powder or oil) that was determined on a balance, no densities 
were used, for the preparation of the 10 000 mg/L stock solutions. 
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The accurately weighed material was dissolved in molecular grade DMSO (99.99 % purity), 
this solution was added to a test tube containing 9 cm
3
 autoclaved de-ionised water and mixed 
by vortex (occasionally, gentle heating was required to maintain the solution). The 10 000 
mg/L stock solution was then used in serial dilutions to prepare the 1 000 mg/L, 100 mg/L, 10 
mg/L and 1 mg/L stock solutions. The procedure is outlined in Figure C.6. 
 
1000 L
1 mL DMSO
9 mL H2O
10 000 mg/L
Stock Solution
1000 L 1000 L 1000 L
9 mL H2O 9 mL H2O 9 mL H2O 9 mL H2O
1 000 mg/L
Stock Solution
100 mg/L
Stock Solution
10 mg/L
Stock Solution
1 mg/L
Stock Solution
 
 
Figure C.6 Serial dilution series - preparation of the antibiotic/ compound stock solutions  
 
The stock solutions were prepared fresh, and used immediately for the preparation of the 
antibiotic and compound dilutions as described in detail in Section C.5.2. 
 
C.5.2 Preparation of Antibiotic/Compound Dilution Series 
 
The antibiotic and synthetic compound dilution series were prepared from the stock solutions 
using nutrient broth (prepared according to the manufacturer's specifications and autoclaved 
at 1 atm /121 
o
C for 20 min) as the solvent. The test tubes were prepared prior to use, with 
each one containing 10 mL nutrient broth. 
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10 000 mg/L
Stock Solution
10 mL 
NB
10 mL 
NB
10 mL 
NB
10 mL 
NB
10 mL 
NB
128 mg/L
Solution
64 mg/L
Solution
32 mg/L
Solution
16 mg/L
Solution
256 mg/L
Solution
1 000 mg/L
Stock Solution
10 mL 
NB
10 mL 
NB
10 mL 
NB
8 mg/L
Solution
4 mg/L
Solution
2 mg/L
Solution
10 mg/L
Stock Solution
10 mL 
NB
10 mL 
NB
10 mL 
NB
0.12 mg/L
Solution
0.06 mg/L
Solution
0.032 mg/L
Solution
100 mg/L
Stock Solution
10 mL 
NB
10 mL 
NB
10 mL 
NB
1 mg/L
Solution
0.5 mg/L
Solution
0.25 mg/L
Solution
256 L
1 mg/L
Stock Solution
10 mL 
NB
10 mL 
NB
0.016 mg/L
Solution
0.008 mg/L
Solution
128 L 64 L 32 L 16 L 80 L 40 L 20 L
100 L 50 L 25 L 120 L 60 L 32 L 160 L 80 L
 
 
Figure C.7 Preparation of antibiotic/compound dilution range 
 
The dilution series used ranges from 256 mg/L to 0.008 mg/L. The procedure used was based 
on that used by J.M. Andrews
58
 is shown in detail in Figure C.7. 
 
The solutions were in general prepared 1-3 days prior to use in the TTC assay and as such the 
test tubes were sealed with Parafilm before being stored at 4 
o
C. They were allowed to warm 
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to room temperature and were mixed prior to use (on the rare occasion that a precipitate 
formed that would not re-solubilise at room temperature, the precipitate was solubilised with 
gentle heating). 
 
In order to ensure that there had been no decomposition of the compounds in the process of 
cooling and warming, each time a set of synthetic compound dilutions were prepared, a 
corresponding set of ciprofloxacin stock solutions were also prepared. These were then used 
as a control for the determination of antibiotic activity. This was done using a nutrient agar 
plate, adding 100 µL of the innoculum prepared in Section F.5.3 below and then preparing a 
spread plate. The surface of the plate was then allowed to dry and 20 µL of the ciprofloxacin 
control dilution was added as a drop to the centre of the plate. The test plates were then 
incubated at 37 
o
C overnight. Examples of the plates obtained are outlined below in Figure 
C.8. 
 
 
 
Figure C.8 The ciprofloxacin control dilution is active so one sees a bacterial lawn, with a 
circle of inhibition where the antibiotic was added. This is based on the standard 
microbiological procedure of the spot-on-lawn assay described by Piddock.
C1 
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C.5.3 Preparation of Innoculum 
 
One colony was removed from each of the streak plates that were previously prepared on 
nutrient agar plates and stored at 4 
o
C, as described in Section C.1 and Section C.2. This 
colony was then used to innoculate 100 cm
3
 nutrient broth (prepared according to the 
manufacturer's specifications and autoclaved at 1 atm /121 
o
C for 20 min). This process was 
repeated for each of the bacterial strains used in the study, namely the S. aureus strain ATCC 
25923, B. cereus strain DL5, P. aeruginosa strain ATCC 27853 and E. coli strain ATCC 
25922. All of the flasks were then incubated at 37 
o
C with shaking (150 rpm) for exactly 18 
hours.  
 
A final inoculum of 10
5
 cfu/mL (5 log cfu/mL) was required for the assay, as described by 
J.M. Andrews.
58
 Thus, the 18 hour bacterial cultures were diluted to 10
6
 cfu/mL based on the 
average viable count determined using the droplet plate technique described in Section C.4. 
With a further dilution on the 96-wells plates. The dilution procedure is outlined in Figure 
C.9. 
 
1000 L
108 
cfu/mL
107 
cfu/mL
106 
cfu/ml
1000 L 1000 L
18 hour culture
109 
cfu/mL
 
 
Figure C.9 Dilution series for 18 hour bacterial cultures 
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C.5.4 TTC Assay 
 
The antibiotic/compound dilution series prepared in Section C.5.2 above was added in 100 
µL portions to each well of the 96-well plates (NUNC, 96-well flat-bottomed polystyrene 
plates with lids, certified sterile). Immediately after preparation, the solutions containing 10
6
 
cfu/mL cells for each of the four bacteria, S. aureus, B. cereus, P. aeruginosa and E. coli, 
were added in 100 µL portions to each well of the 96-well plates. 
 
Included on each of the plates were a series of controls: (i) the 0 % growth control (200 µL of 
nutrient broth), (ii) the 100 % growth control (100 µL of nutrient broth and 100 µL of the 
desired bacterial strain at 10
6
 cfu/mL), (iii) the DMSO controls (100 µL of the DMSO control 
and 100 µL of the desired bacterial strain at 10
6
 cfu/mL) and (iv) the sterility control (200 µL 
of autoclaved de-ionised water).  
 
The layout of the 96-well plates used for all compounds tested with the TTC assay is 
illustrated in Figure C.10 and Figure C.11. We were able to test one compound/antibiotic 
against all four bacterial strains and obtain four replicates for each compound 
concentration/bacterial strain combination by working across four 96-well plates. 
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RUN 1 (PLATE 1) / RUN 2 (PLATE 1) 
SASA SA SA SA SA SA SA SA SA SA
SA SA SA SA SA SA SA SA SA SA SA
BC BC BC BC BC BC BC BC BC BC BC
BC BC BC BC BC BC BC BC BC BC BC
PA PA PA PA PA PA PA PA PA PA PA
PA PA PA PA PA PA PA PA PA PA PA
EC EC EC EC EC EC EC EC EC EC EC
EC EC EC EC EC EC EC EC EC EC EC
500
500
500
500
250
250
250
250
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSONB NB
NB NB
NB NB
NBNB
NB NB
NBNB
NB NB
NBNB
256 128 64 32 16 8
256
4 2 1
128
128
128
128
128
128
128
256
256
256
256
256
256
64 32 16 8 4 2 1
64
64
64
64
64
64 32
32
32
32
32
32 16
16
16
16
16
16 8
8
8
8
8
8 4
4
4
4
4
4
2
2
2
2
2
2
1
1
1
1
1
1
 
 
Figure C.10 Layout of 96-well plates for TTC assay  
 
(Code: NB = nutrient broth, SA = S. aureus strain ATCC 25923, BC = B. cereus strain DL5, 
PA = P. aeruginosa strain ATCC 27853, EC = E. coli strain ATCC 25922  and the numbers 
represented in the wells indicate the antibiotic/compound dilution concentration in mg/L 
added to the plate) 
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RUN 1 (PLATE 2) / RUN 2 (PLATE 2) 
SASA SA SA SA SA SA SA SA SA
SA SA SA SA SA SA SA SA SA SA
BC BC BC BC BC BC BC BC BC BC
BC BC BC BC BC BC BC BC BC BC
PA PA PA PA PA PA PA PA PA PA
PA PA PA PA PA PA PA PA PA PA
EC EC EC EC EC EC EC EC EC EC
EC EC EC EC EC EC EC EC EC EC
100
100
100
100
10
10
10
10
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSONB NB
NB NB
NB NB
NBNB
NB NB
NBNB
NB NB
NBNB
0.5 0.25 0.12 0.06 0.032 0.016
0.5
0.008 0.1
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.5
0.5
0.5
0.5
0.5
0.5
0.12 0.06 0.032 0.016 0.008 0.1
0.12
0.12
0.12
0.12
0.12
0.12 0.06
0.06
0.06
0.06
0.06
0.06 0.032
0.032
0.032
0.032
0.032
0.032 0.016
0.016
0.016
0.016
0.016
0.016 0.008
0.008
0.008
0.008
0.008
0.008
0.1
0.1
0.1
0.1
0.1
0.1
H2O
H2O
H2O
H2O
H2O
H2O
H2O
H2O  
 
Figure C.11 Layout of 96-well plates for TTC assay  
 
(Code: NB = nutrient broth, SA = S. aureus strain ATCC 25923, BC = B. cereus strain DL5, 
PA = P. aeruginosa strain ATCC 27853, EC = E. coli strain ATCC 25922  and the numbers 
represented in the wells indicate the antibiotic/compound dilution concentration in mg/L 
added to the plate) 
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Once the bacterial strains had been added to the 96-well plates, they were incubated at 37 
o
C 
for 22 hours. Following this time period, the plates were removed from the incubator. To each 
well of the plates was then added 10 µL of a freshly prepared solution of 5 mg/mL 2,3,5 -
triphenyltetrazolium chloride in phosphate buffered saline (PBS autoclaved prior to use in the 
solution). The plates were then incubated for a further 4 hours at 37 
o
C. 
 
After this time, solubilisation of the formazan precipitate was conducted by the addition of the 
following reagents to each well of the 96-well plates: 
 10 µL of 3N HCl(aq) 
 10 µL of 10 % NP-40(aq) 
 25 µL of modified Weaver Reagent (66 % paraffin oil : 33 % CCl4 : 1 % NP-40 (v/v)) 
 
The plates were then incubated at 4 
o
C for a further 20 hours. After incubation, the plates were 
analyzed on an Elisa plate reader (Titertek Multiskan
®
 PLUS), at both 450 nm and 590 nm. 
From our pilot study, we found that the data obtained at wavelength 450 nm was in the correct 
absorption spectrum and gave considerably less variance than data obtained at 590 nm. 
Therefore, the data obtained at 450 nm was used for all subsequent assays performed. 
 
Note: Digital photographs were taken for each of the plates after they had been scanned on the 
Elisa plate reader. This supplemental information is available on the attached DVD, under 
Supporting Information for Biological Testing (Part 1). 
 
C.6 Antiviral Assays 
 
The percentage protection was determined using the recorded absorbance values obtained 
from reading the plates on the Tecan Sunrise ELISA plate reader. The equations outlining 
how the percentage protection was determined are based on those published by Cos and co-
workers
64
 and are described in detail below. 
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C.6.1 Formula for Percentage of Uninfected Treated Cells 
 
 % of Uninfected Treated Cells = ( Y / A ) × 100 
 
 where: A =  the optical density reading for uninfected and untreated cells (100 %) 
  Y =  the optical density readings at varying concentrations 
 
C.6.2 Formula for the Percentage Protection 
 
 % Protection = [ ( X - B ) / ( A - B ) ] × 100 
  
 where: A =  the optical density reading for the control untreated and uninfected cells 
   (mock-infected) 
  B =  the optical density reading for the control untreated and HIV-infected 
   cells 
  X =  the optical density measured with a given concentration of the test  
   compound in HIV-infected cells 
  
C.6.3 Effective Concentration 
 
EC50 (50 % effective concentration) is defined as the concentration of the test compound that 
achieves a fifty percent protection in infected cultures according to the formula for percentage 
protection.  
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An equation based on linear extrapolation was used to determine the EC50 from the values 
obtained in the experiment: 
 
 EC50 = V - { [ ( W - 50 % ) / ( W - U ) ] × ( V - T ) } 
 
 where: V = the concentration of the test compound that corresponds to the closest 
   percentage above 50 % 
  T =  the concentration of the test compound that corresponds to the closest 
   percentage below 50 % 
  W =  the closest percentage above 50 % 
  U =  the closest percentage below 50 % 
 
C.6.4 Cytotoxic Concentration 
 
CC50 (50 % cytotoxic concentration) is defined as the concentration of the test compound that 
reduces the absorbance of the uninfected (mock-infected) control by fifty percent. 
 
In a similar manner to EC50, the CC50 will be calculated as: 
 
 CC50 = V + { [ ( W - 50 % ) / ( W - U ) ] × ( T - V ) } 
 
 where: V =  the concentration of the test compound that corresponds to the closest 
   percentage below 50 % 
  T =  the concentration of the test compound that corresponds to the closest 
   percentage above 50 % 
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  W =  the closest percentage above 50 % 
  U =  the closest percentage below 50 % 
 
C.6.5 Selectivity Index 
 
The SI (selectivity index) is defined as the ratio:  CC50 / EC50  
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Appendix D: 
Experimental Procedures – Relating to Chapter 5 
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D.1 Preparation of 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-
 6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione [234] 
 
A solution was prepared of uridine 12 (6.87 mmol, 1.68 g) in 
distilled pyridine (20.5 cm
3
). The solution was then cooled to 0 
o
C in an ice-water bath before the addition of the 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane (1.05 eq, 7.2 mmol, 2.3 cm
3
). 
The reaction mixture was then stirred at rt overnight (21 h). 
After this time, the reaction was quenched by the addition of 
distilled water (21 cm
3
). The mixture was then transferred to a 
round-bottomed flask using a small amount of EtOAc and all 
of the solvents were removed by evaporation (60 
o
C). The residue obtained was then 
partitioned between EtOAc (70 cm
3
) and distilled water (2 × 25 cm
3
). The organic layer was 
dried over anhydrous Na2SO4, filtered and evaporated to yield a white foam. The crude foam 
was then purified by column chromatography, using 10-50 % EtOAc : hexane for elution. The 
desired compound 234 was obtained as a white foam (2.80 g, 85 %). 
1
H and 
13
C NMR spectra 
obtained correlated well to those reported by Matsuda and co-workers.
121 
 
Rf = 0.13 (30 % EtOAc : hexane);  [α]D
20
 15.596
o
 (c = 1.09 in CH2Cl2);  νmax/cm
-1
 (thin film) 
693 (RCH=CHR cis), 1091 (C-OH, C-O stretching), 1247 (Si-CH), 1334 (-O-H, O-H 
bending), 1385 [-C(CH3)2, -CH3 symmetrical deformation], 1461 (-CH3, C-H deformation), 
1623 (C=C conjugated with C=O), 1674 (-CONH-), 2894 (C-H, C-H stretching), 2926 (-CH3, 
C-H stretching), 2965 (-O-H), 3097 (-CONH- in solution), 3410 (-CONH- in solution);  δH 
(300 MHz, CDCl3) 1.02-1.10 [28 H, m, 4 × CH(CH3)2 and 4 × CH(CH3)2], 3.62 (1 H, br s, 
OH-2'), 4.00 (1 H, dd, J = 2.5 and 13.2 Hz, H-5'), 4.14-4.25 (3 H, m, H-2', H-4' and H-5'), 
4.32 (1 H, dd, J = 4.7 and 8.8 Hz, H-3'), 5.69-5.73 (1 H, m, H-5), 5.75 (1 H, s, H-1'), 7.77 (1 
H, d, J = 8.1 Hz, H-6), 9.64 (1 H, br s, NH);  δC (50 MHz, CDCl3) 12.42, 12.88, 12.93 and 
13.33 (4 × SiCH), 16.76, 16.88, 16.92, 16.99, 17.20, 17.25, 17.34 and 17.43 (8 × CH3), 60.09 
(C-5'), 68.66 (C-3'), 75.10 (C-2'), 81.83 (C-4'), 90.91 (C-1'), 101.95 (C-5), 139.87 (C-6), 
150.21 (C-2), 163.53 (C-4);  MS m/z (M
+
, 100 %) 487.8 (29), 972.5 (41), 995.6 (22), 1475.4 
(16), 1477.3 (10), 1718.6 (12), HRMS (+cESI) calculated for C21H39N2O7Si2
+
: 487.22903, 
found: [M + H]
+
 487.22848. 
5
6
NH
O
ON
3' 2'
1'
O
4'
OHO
5'O
Si
O
Si
234  
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D.2 Preparation of 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyl-
 tetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-
 dione [235] 
 
The 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraiso-
propyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadi-
silocin-8-yl]pyrimidine-2,4(1H,3H)-dione 234 (12.5 
mmol, 6.02 g), Na2CO3 (96 mmol, 10.1 g) and 
tetrabutylammonium bromide (0.48 mmol, 0.156 g) 
were dissolved in a two-phase solution of CH2Cl2 
(240 cm
3
) and distilled water (480 cm
3
). Then the 
benzoyl chloride (1.3 eq, 16.2 mmol, 1.88 cm
3
) was 
added and the reaction mixture was vigorously stirred at rt for 2 h. The reaction mixture was 
then transferred to a separating funnel using excess CH2Cl2. The organic phase was collected 
and the aqueous phase was further extracted with CH2Cl2 (3 × 480 cm
3
). The combined 
organic layers were then dried over anhydrous Na2SO4, filtered and evaporated. The residue 
obtained was then dissolved in 1,2-dichloroethane (120 cm
3
) with gentle heating and the 
solution was allowed to stand at rt for 66 h. This step was performed to allow the O-/N-
rearrangement to occur. After this time, the solvent was removed in vacuo to yield a very 
viscous pale-yellow oil. The crude mixture was then purified by column chromatography, 
with 5-50 % EtOAc : hexane used for elution. The desired compound 235 was obtained pure 
as a white foam (7.26 g, 99 %) after chromatography. 
1
H and 
13
C NMR spectra obtained 
correlated well to those reported previously by Sekine.
122
 
 
Rf = 0.33 (30 % EtOAc : hexane);  [α]D
20
 27.451
o
 (c = 1.02 in CH2Cl2);  νmax/cm
-1
 (thin film) 
680 (5 adjacent aromatic H), 694 (RHC=CHR cis), 762 (5 adjacent aromatic H), 1079 (C-OH, 
C-O stretching), 1236 (Si-CH), 1337 (-O-H, O-H bending), 1375 (-C(CH3)2, -CH3 
symmetrical deformation), 1466 (-CH3, C-H deformation), 1628 (C=C conjugated with C=O), 
1658 (-CONH-), 2867 (-C-H, C-H stretching), 2926 (-CH3, C-H stretching), 2946 (-O-H);  δH 
(300 MHz, CDCl3) 1.03-1.10 [28 H, m, 4 × CH(CH3)2 and 4 × CH(CH3)2], 2.04 (1 H, br s, 
OH-2'), 4.01 (1 H, dd, J = 2.6 and 13.3 Hz, H-5'), 4.11-4.21 (3 H, m, H-2', H-4' and H-5'), 
4.37 (1 H, dd, J = 4.8 and 8.6 Hz, H-3'), 5.76 (1 H, s, H-1'), 5.80 (1 H, d, J = 8.2 Hz, H-5), 
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7.50 (2 H, t, J = 7.7 Hz, H-3*), 7.66 (1 H, t, J = 7.4 Hz, H-4*), 7.81 (1 H, d, J = 8.2 Hz, H-6), 
7.93 (2 H, d, J = 7.2 Hz, H-2*);  δC (50 MHz, CDCl3) 12.46, 12.87, 13.34 and 14.14 (4 × 
SiCH), 16.77, 16.87, 16.91, 16.98, 17.20, 17.22, 17.30 and 17.39 (8 × CH3), 60.20 (C-5'), 
68.94 (C-3'), 75.16 (C-2'), 82.07 (C-4'), 90.79 (C-1'), 101.77 (C-5), 129.11 (C-3*), 130.43 (C-
2*), 131.38 (C-1*), 135.10 (C-4*), 139.57 (C-6), 148.87 (C-2), 162.08 (C-4), 168.53 (Ph-
C=O);  MS m/z (M
+
, 55 %) 478.96 (16), 607.70 (30), 1197.47 (100), 1792.17 (32), HRMS 
(+cESI) calculated for C28H43N2O8Si2
+
: 591.25525, found: [M + H]
+
 591.25494. 
 
D.3 Preparation of 3-benzoyl-1-[(6aR,8R,9R,9aR)-9-allyl-9-hydroxy-2,2,4,4-tetra-
 isopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-
 2,4(1H,3H)-dione [236] 
 
The 1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraiso-
propyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadi-
silocin-8-yl]pyrimidine-2,4(1H,3H)-dione 235 (0.174 
mmol, 0.103 g) was dissolved in freshly distilled THF 
(1 cm
3
) and to this solution was then added sodium 
hydride (obtained as a 60% suspension in oil, 2.5 eq, 
0.436 mmol, 0.0193 g) in distilled THF (1 cm
3
). The 
solution was allowed to stir at rt for ~10 min, during 
which time the effervescence stopped and the solution went yellow in colour. Allyl bromide 
(2.5 eq, 0.4 mmol, 0.04 cm
3
) was then added and the reaction mixture was allowed to stir 
under an argon atmosphere at rt overnight (23 h). After this time, the solvent was removed by 
evaporation and the residue obtained was dissolved in CH2Cl2 (20 cm
3
). The solution obtained 
was then extracted with saturated NH4Cl (10 cm
3
) and distilled water (10 cm
3
). The organic 
fraction was then dried over anhydrous Na2SO4, filtered and the solvent was removed in 
vacuo. The crude mixture was subjected to column chromatography, with 5-50 % EtOAc : 
hexane solutions used for elution. The desired compound 236 was obtained after 
chromatography as a clear oil (0.0232 g, 21 %).  
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Rf = 0.82 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 1.03-1.09 [28 H, m, 4 × CH(CH3)2 
and 4 × CH(CH3)2], 4.01-4.35 (3 H, m, H-4' and H-5'), 4.39 (2 H, dd, J = 1.2 and 5.3 Hz, 
CH2CH=CH2), 4.52 (1 H, dd, J = 5.0 and 9.1 Hz, H-3'), 5.21 (1 H, dd, J = 1.4 and 10.5 Hz, 
CH=CH2), 5.39 (1 H, dd, J = 1.7 and 17.2 Hz, CH=CH2), 5.64-5.66 (1 H, m, H-2'), 5.73-5.76 
(1 H, m, H-5), 5.76 and 5.97 (1 H, 2 × s, H-1'), 5.81-5.95 (1 H, m, CH=CH2), 7.46 (2 H, t, J = 
7.6 Hz, H-3*), 7.59 (1 H, d, J = 7.4 Hz, H-4*), 7.74 (1 H, d, J = 8.2 Hz, H-6), 8.05-8.10 (2 H, 
m, H-2*);  δC (50 MHz, CDCl3) 12.86, 12.91, 13.12 and 13.41 (4 × SiCH), 16.96, 17.06, 
17.24, 17.27, 17.32, 17.37, 17.44 and 17.50 (8 × CH3), 59.75 (C-5'), 67.99 (C-3'), 71.22 
(CH2CH=CH2), 75.85 (C-2'), 82.42 (C-4'), 88.83 (C-1'), 102.24 (C-5), 117.41 (CH=CH2), 
128.35 (C-3*), 129.54 (C-1*), 129.78 (C-2*), 133.23 (C-4*), 134.27 (CH=CH2), 139.58 (C-
6), 149.62 (C-2), 163.12 (C-4), 164.82 (Ph-C=O). 
 
D.4 Attempted synthesis of 3-benzoyl-1-[(6aR,8R,9R,9aR)-9-crotyl-9-hydroxy-2,2,4,4-
 tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilicon-8-yl]pyrimidine-
 2,4(1H,3H)-dione [237] 
 
Previously prepared compound 235 (0.181 mmol, 
0.107 g) was dissolved in freshly distilled THF (1 
cm
3
). To this solution was then added sodium hydride 
(obtained as a 60 % suspension in oil, 2.5 eq, 0.452 
mmol, 0.0240 g) in THF (1 cm
3
) and the mixture was 
stirred at rt for ~15 min to allow the effervescence to 
stop. After this time, the crotyl bromide (2.5 eq, 0.5 
mmol, 0.05 cm
3
) was added and the reaction mixture 
was stirred at rt under an argon atmosphere overnight 
(23 h). The solvent was then removed by evaporation and the residue obtained was dissolved 
in CH2Cl2 (20 cm
3
), before extraction with saturated NH4Cl (10 cm
3
) and distilled water (10 
cm
3
). The organic layer was dried over anhydrous Na2SO4, filtered and evaporated. The crude 
residue was purified by column chromatography (solvents used for elution were: 5-50 % 
EtOAc : hexane). None of the desired compound 237 was obtained, with a number of 
unidentifiable by-products instead being isolated. 
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D.5 Attempted synthesis of 3-benzoyl-1-[(6aR,8R,9R,9aR)-9-cinnamyl-9-hydroxy-
 2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-
 pyrimidine-2,4(1H,3H)-dione [238] 
 
Compound 235 (0.175 mmol, 0.103 g) was dissolved 
in freshly distilled THF (1 cm
3
) and to this solution 
was then added sodium hydride (obtained as a 60 % 
suspension in oil, 2.5 eq, 0.438 mmol, 0.0192 g) in 
distilled THF (1 cm
3
). The solution was allowed to 
stir at rt for ~10 min, during which time the solution 
stopped effervescing. Cinnamyl bromide/3-bromo-1-
phenyl-1-propene (2.5 eq, 0.438 mmol, 0.0835 g) was 
then added and the reaction mixture was allowed to 
stir at rt under an argon atmosphere overnight (23 h). 
After this time, the solvent was removed by evaporation and the residue obtained was 
dissolved in CH2Cl2 (20 cm
3
). The solution obtained was then extracted with saturated NH4Cl 
(10 cm
3
) and distilled water (10 cm
3
). The organics were then dried over anhydrous Na2SO4, 
filtered and the solvent was removed in vacuo. The crude mixture was subjected to column 
chromatography, with 5-50 % EtOAc : hexane solutions used for elution. Unfortunately, a 
number of possible decomposition fractions were obtained, with none of the desired 
compound 238 isolated. 
 
D.6 Preparation of 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-
 furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione [239] 
 
The oxidation complex was pre-formed by preparing 3 eq of the complex relative to the 
starting material 234. Initially, the chromium (VI) trioxide (3 eq, 6.76 mmol, 0.688 g) was 
dissolved in freshly distilled CH2Cl2 (24 cm
3
). To this solution was added the distilled 
pyridine (6 eq, 16 mmol, 1.1 cm
3
) and the distilled acetic anhydride (3 eq, 6.8 mmol, 0.64 
cm
3
). The mixture was stirred for a few minutes to allow for complete formation of the 
oxidation complex. A solution was then prepared of 234 (2.25 mmol, 1.09 g) in distilled 
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CH2Cl2 (3 cm
3
). The starting material solution was added 
dropwise to the oxidation complex solution with stirring. The 
reaction mixture was then allowed to stir at rt under an argon 
atmosphere for 2 h. After this time, the reaction mixture was 
poured dropwise into stirring EtOAc (180 cm
3
). The 
suspension was then pumped through a short silica gel column, 
using exces EtOAc to rinse the column. The filtrate was 
concentrated to dryness to yield a yellow-brown residue. This 
residue was then purified by column chromatography, with 20-50 % EtOAc : hexane 
solutions used for elution. The desired compound 239 was obtained pure as a white foam 
(0.867 g, 80 %) with the NMR data obtained correlating well to that reported by Matsuda and 
co-workers.
121 
 
Rf = 0.60 (50 % EtOAc : hexane);  [α]D
21
 -17.822
o
 (c = 1.01 in CH2Cl2);  νmax/cm
-1
 (thin film) 
688 (RHC=CHR cis), 1236 (Si-CH), 1391 (-CH3, symmetrical deformation), 1469 (-CH3, C-
H deformation), 1635 (C=C conjugated with C=O), 1696 (-CONH-), 1724 (C=O, sugar ring), 
2894 (-CH3, C-H stretching), 2925 (-CH, C-H stretching), 3259 (-CONH- in solution);  δH 
(300 MHz, CDCl3) 1.03-1.14 [28 H, m, 4 × CH(CH3)2 and 4 × CH(CH3)2], 3.91-3.97 (1 H, 
m, H-4'), 4.13-4.14 (2 H, m, H-5'), 5.00 (1 H, s, H-1'), 5.04 (1 H, d, J = 9.0 Hz, H-3'), 5.76 (1 
H, d, J = 8.0 Hz, H-5), 7.16 (1 H, d, J = 8.0 Hz, H-6), 8.80 (1 H, br s, NH);  δC (50 MHz, 
CDCl3) 12.34, 12.50, 13.02 and 13.67 (4 × SiCH), 16.62, 16.67, 16.76, 16.79, 16.82, 16.86, 
17.22 and 17.37 (8 × CH3), 62.35 (C-5'), 71.81 (C-1'), 79.62 (C-4'), 85.48 (C-3'), 103.19 (C-
5), 143.69 (C-6), 149.22 (C-2), 162.95 (C-4), 204.72 (C=O at C-2');  MS m/z (M + 1
+
, 45 %) 
306.95 (10), 502.87 (100), 516.87 (35), 1004.61 (34), 1524.60 (19), HRMS (+cESI) 
calculated for C21H37N2O7Si2
+
: 485.21338, found: [M + H]
+
 485.21289. 
 
D.7 Attempted synthesis of 1-[(6aR,8R,9aR)-tetrahydro-2,2,4,4-tetraisopropyl-9-
methylene-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-
dione [240] 
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The methyl triphenylphosphonium bromide (7 eq, 1.47 mmol, 
0.523 g) and distilled THF (5 cm
3
) were stirred until a 
suspension formed. This was then cooled to 0 
o
C in an ice-
water bath before the addition of the n-butyllithium 
(concentration determined by titration
3
 prior to use: 0.9 M in 
THF, 7 eq, 1.47 mmol, 1.63 cm
3
). The reaction mixture 
immediately changed colour from a white suspension to a dark 
orange solution and was then stirred for a further 10 min to 
allow all of the precipitate to dissolve. To the solution was then added the 1-[(6aR,8R,9aR)-
2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimi-
dine-2,4(1H,3H)-dione 239 (0.209 mmol, 0.101 g) batch-wise and the foam was rinsed into 
the flask with an additional portion of THF (1 cm
3
). The reaction mixture was then allowed to 
stir at rt under an argon atmosphere for 3 hours. After this time, tlc showed consumption of 
the starting material, so the reaction mixture was extracted with saturated NH4Cl (3 × 10 
cm
3
). The organic fraction was then dried over anhydrous Na2SO4, filtered and evaporated. 
The viscous orange oil obtained was then purified by column chromatography, using 10-15 % 
EtOAc : hexane for elution. Unfortunately, none of the desired compound 240 was obtained 
after chromatography. 
 
D.8 Attempted synthesis of 1-[(6aR,8R,9aS)-tetrahydro-9-hydroxy-2,2,4,4-tetraiso-
propyl-9-vinyl-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-
2,4(1H,3H)-dione [241] 
 
A solution was prepared of 1-[(6aR,8R,9aR)-2,2,4,4-
tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxa-
disilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 239 (0.216 mmol, 
0.104 g) in freshly distilled THF (10 cm
3
) and was cooled to -
60 
o
C, in an acetone bath, using a cryostat. To this solution was 
then added the vinyl magnesium bromide (1.0 M in THF, 5 eq, 
1.1 mmol, 0.15 cm
3
). The reaction mixture was allowed to stir 
at -60 
o
C under an argon atmosphere overnight (20 h). After 
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this time, the reaction mixture was allowed to warm to rt and was then diluted with distilled 
water (10 cm
3
). The solution was then neutralised (pH ~ 7) using 0.5 M HCl(aq) and the THF 
was removed by evaporation. The residue obtained was extracted with EtOAc (3 × 40 cm
3
) 
and the combined organic fractions were dried over anhydrous MgSO4, filtered and 
evaporated. The crude foam obtained was purified by column chromatography (20-30 % 
EtOAc : hexane as eluants). None of the desired compound 241 was isolated after 
chromatography, with only unreacted starting material 239 obtained after purification. 
 
D.9 Preparation of 1-[(6aR,8R,9aS)-9-allyl-tetrahydro-9-hydroxy-2,2,4,4-tetraisopro-
pyl-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidne-2,4(1H,3H)-dione 
[242] 
 
The 1-[(6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-
6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4-
(1H,3H)-dione 239 (0.216 mmol, 0.104 g) was stirred with 
freshly distilled THF (10 cm
3
) until a solution had formed. This 
solution was then cooled to -60 
o
C (acetone bath, cryostat) 
before the addition of the allyl magnesium bromide (1.0 M in 
Et2O, 5 eq, 1.1 mmol, 0.18 cm
3
). The reaction mixture was then 
allowed to stir at -60 
o
C under an argon atmosphere overnight 
(18 h). After this time, tlc indicated no further change, so the reaction mixture was allowed to 
warm to rt. To the warmed reaction mixture was then added distilled water (10 cm
3
) and the 
solution was made to pH ~7 by the dropwise addition of 0.5 M HCl(aq). The THF was then 
removed by evaporation and the resulting aqueous residue was extracted with EtOAc (3 × 40 
cm
3
). The combined organics were dried over anhydrous Na2SO4, filtered and the solvent was 
removed in vacuo. The crude mixture was obtained as a pale yellow semi-solid and it was 
subsequently purified by column chromatography. Solvents used for elution were 20-30 % 
EtOAc : hexane. The desired compound 242 was isolated as a clear oil (0.0299 g, 38 % based 
on recovery of starting material) along with some of the unreacted starting material 239 
(0.0276 g).  
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Rf = 0.57 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 1.04-1.13 [28 H, m, 4 × CH(CH3)2 
and 4 × CH(CH3)2], 2.48 (1 H, br s, OH-2'), 2.70-2.72 (2 H, m, CH2CH=CH2), 3.78-4.25 (4 
H, m, H-3', H-4' and H-5'), 5.33-5.37 (2 H, m, CH=CH2), 5.90 (1 H, s, H-1'), 6.05-6.09 (1 H, 
m, CH=CH2). 7.83 (1 H, d, J = 8.1 Hz, H-6), 9.17 (1 H, br s, NH);  δC (50 MHz, CDCl3) 
11.53, 12.05, 12.40 and 13.20 (4 × SiCH), 15.81, 15.85, 15.89, 16.02, 16.10, 16.24, 16.40 and 
16.53 (8 × CH3), 36.80 (CH2CH=CH2), 59.26 (C-5'), 72.00 (C-3'), 77.89 (C-2' 
#
), 78.65 (C-4' 
#
), 86.54 (C-1'), 100.49 (C-5), 121.10 (CH=CH2), 130.19 (CH=CH2), 139.56 (C-6), 150.03 
(C-2), 161.91 (C-4);  MS m/z (M + 1
+
, 100 %) 151.87 (16), 307.93 (55), 455.00 (16), 485.13 
(56), 544.07 (5), 1042.93 (67), HRMS (+cESI) calculated for C24H43N2O7Si2
+
: 527.26033, 
found: [M + H]
+
 527.26033. 
Note: assignments denoted with # are exchangeable. 
 
D.10 General procedure for the synthesis of 5'-O-silyl protected uridine derivatives 
 
The glassware used in the reaction was filled with a 5 % trimethylsilyl chloride : hexane 
solution and was allowed to stand at rt overnight. After this time, the glassware was oven-
dried, placed under high vacuum and allowed to cool to rt under an argon atmosphere. The 
uridine 12 (usual scale: approximately 1.00 g) and DMAP (0.1 eq) were stirred with distilled 
pyridine (5 cm
3
 : 1.00 g starting material) until a solution had formed. To this solution was 
then added the silyl chloride (1.1 eq). The reaction mixture was then allowed to stir at rt under 
an argon atmosphere overnight (18-22 h). After this time, the reaction was quenched by the 
addition of distilled water (5 cm
3
 : 1.00 g starting material) and the mixture was allowed to 
stir for a few minutes. The reaction mixture was then transferred to a round bottomed flask 
with excess EtOAc and all of the solvents (including the water) were removed by evaporation 
(rotary evaporator set to 60 
o
C). The residue obtained was then partitioned between EtOAc 
(10 cm
3
 : 1.00 g starting material) and distilled water (3 × 10 cm
3
 : 1.00 g starting material). 
The organic fraction was dried over anhydrous Na2SO4, filtered and the solvent was removed 
in vacuo. Crude NMR spectra were obtained to determine if further purification was required.  
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D.10.1 Attempted synthesis of 5'-O-(dimethylethylsilyl)uridine [243] 
 
The synthesis was attempted on a 1.02 g scale with the 
protecting group chlorodimethylethyl silane, according to the 
general procedure described in Section D.10 above. A white 
residue was obtained (0.0062 g) from the organic fraction. Due 
to the low mass of material obtained from the organic fraction, 
the aqueous layer was subsequently dried in vacuo and yellow 
oil was isolated (1.60 g). No further purification of the 
compound was attempted as the crude NMR spectra indicated that none of the desired 
compound 243 was present in either fraction. 
 
D.10.2 Attempted synthesis of 5'-O-(dimethylvinylsilyl)uridine [244] 
 
The synthesis was attempted on a 1.01 g scale and was 
performed according to the general procedure described above 
in Section D.10 using dimethylvinylchlorosilane for the 
protecting group. The only modification was that the base 
imidazole (2 eq) was added, in place of the DMAP catalyst. The 
NMR spectra of the crude residue indicated the presence of 
pyridine. Thus, the residue was further purified by partitioning 
between CH2Cl2 (25 cm
3
) and distilled water (4 × 25 cm
3
), then the organic fraction was dried 
over anhydrous Na2SO4, filtered and the solvent was removed in vacuo. At the same time the 
aqueous fraction was also dried in vacuo. Unfortunately, none of the desired compound 244 
was present in the organic fraction and only unreacted uridine 12 was isolated from the 
aqueous fraction.  
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D.10.3 Attempted synthesis of 5'-O-(allyldimethylsilyl)uridine [245] 
 
The synthesis was attempted on a 1.00 g scale and was 
performed according to the general procedure described 
above in Section D.10 using allyldimethylsilyl chloride for 
the protecting group. The only modification was that the base 
imidazole (2 eq) was added, in place of the DMAP catalyst. 
The NMR spectra of the crude residue indicated the presence 
of pyridine. Thus, the residue was further purified by 
partitioning between CH2Cl2 (25 cm
3
) and distilled water (4 × 25 cm
3
), then the organic 
fraction was dried over anhydrous Na2SO4, filtered and the solvent was removed in vacuo. At 
the same time the aqueous fraction was also dried in vacuo and the crude compound was 
obtained as a viscous yellow oil (1.46 g). Unfortunately, none of the desired compound 245 
was present and only unreacted uridine 12 was isolated from the aqueous fraction. 
 
D.10.4 Preparation of 5'-O-(triisopropylsilyl)uridine [246] 
 
The reaction was performed on a 1.02 g scale using 
triisopropylsilyl chloride as the protecting group. The procedure 
that was used is described in Section D.10 above and the crude 
compound was obtained as a clear glass (1.28 g). Crude NMR 
indicated a mixture of products, so the compound was further 
purified by column chromatography. Solvents used for elution 
were 30-50 % EtOAc : hexane, followed by 100 % EtOAc. The 
desired compound 246 was obtained pure as a cream semi-solid (0.753 g, 45 %) after 
chromatography. At the same time, we isolated some triisopropylsilanol 257 (0.2103 g) from 
the column, which had formed from the excess unreacted silyl chloride. The synthesis of 
triisopropylsilanol 257 is described in detail in Section D.16.4 below. 
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Rf = 0.15 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 1.04-1.14 [21 H, m, 3 × CH(CH3)2 
and 3 × CH(CH3)2], 3.25 (1 H, d, J = 6.3 Hz, OH-2' 
#
), 3.95 (1 H, d, J = 10.2 Hz, H-5'), 4.11-
4.15 (2 H, m, H-4' and H-5'), 4.25-4.32 (2 H, m, H-2' and H-3'), 5.37 (1 H, br s, OH-3' 
#
), 5.68 
(1 H, d, J = 8.1 Hz, H-5), 5.89 (1 H, d, J = 2.3 Hz, H-1'), 8.11 (1 H, d, J = 8.1 Hz, H-6), 10.15 
(1 H, br s, NH);  δC (50 MHz, CDCl3) 11.90 [CH(CH3)2], 17.94 [CH(CH3)2], 60.43 (C-5'), 
69.04 (C-3'), 75.76 (C-2'), 79.60 (C-4'), 90.75 (C-1'), 101.97 (C-5), 139.30 (C-6), 151.11 (C-
2), 163.79 (C-4);  MS m/z (M
+
, 100 %) 167.89 (12), 478.83 (11), 586.94 (15), 800.88 (66), 
822.85 (24), 1219.04 (44), 1418.27 (31), 1618.53 (35), 1818.35 (20), HRMS (+cESI) 
calculated for C18H33N2O6Si
+
: 401.21024, found: [M + H]
+
 401.20968. 
Note: assignments denoted with # are exchangeable. 
 
D.10.5 Preparation of 5'-O-(tert-butyldimethylsilyl)uridine [229] 
 
The reaction was performed on 2.00 g scale, with tert-
butyldiphenylsilyl chloride as the protecting group, according 
to the protocol described in Section D.10 above. Crude NMR 
spectra indicated the formation of pure product and no further 
purification was undertaken. The desired compound 229 was 
obtained as a white foam (2.58 g, 88 %). 
 
Rf = 0.70 (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 690 (RHC=CHR cis), 715 (CH2 
rocking), 829 (Si-CH3), 1130 (-C-OH, C-O stretching), 1252 (Si-CH3), 1330 (-O-H, O-H 
bending), 1362 and 1391 [-C(CH3)3, -CH3 symmetrical deformation], 1462 and 1468 (-CH2 
and -CH3, C-H deformations), 1622 (C=C conjugated with C=O), 1690 (-CONH-), 2928 (-
CH3, C-H stretching), 2954 (-CH2, C-H stretching);  δH (300 MHz, CDCl3) 0.12 [6 H, s, 
Si(CH3)2], 0.92 [9 H, s, C(CH3)3], 3.66 (1 H, br s, OH-2' 
#
), 3.85 and 4.03 (2 H, two d, J = 
11.3, H-5'), 4.14 (1 H, d, J = 5.3 Hz, H-4'), 4.23-4.26 (2 H, m, H-2' and H-3'), 5.52 (1 H, br s, 
OH-3' 
#
), 5.65 (1 H, d, J = 8.1 Hz, H-5), 5.91 (1 H, d, J = 2.1 Hz, H-1'), 8.08 (1 H, d, J = 8.1 
Hz, H-6), 10.53 (1 H, br s, NH);  δC (50 MHz, CDCl3) -5.55 [Si(CH3)2], 18.40 [C(CH3)2], 
25.90 [C(CH3)2], 61.78 (C-5'), 69.21 (C-3'), 75.60 (C-2'), 84.84 (C-4'), 90.23 (C-1'), 102.02 
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(C-5), 140.47 (C-6), 151.29 (C-2), 163.98 (C-4);  MS m/z (M
+
, 100 %) 213.07 (7), 228.87 
(15), 399.60 (7), 783.20 (8), 1173.13 (8), HRMS (+cESI) calculated for C15H27N2O6Si
+
: 
359.16329, found: [M + H]
+
 359.16336. 
Note: assignments denoted with # are exchangeable. 
 
D.10.6 Preparation of 5'-O-(triisobutylsilyl)uridine [247] 
 
The reaction was performed on a 1.03 g scale using 
chlorotriisobutylsilane as the protecting group. The 
procedure that was used is described in Section D.10 above 
and the crude compound was obtained as a white semi-solid 
(1.81 g). Crude NMR indicated a mixture of products, so the 
compound was further purified by column chromatography. 
Solvents used for elution were 30-50 % EtOAc : hexane. The 
desired compound 247 was obtained pure as a white semi-solid (0.498 g, 27 %) after 
chromatography.  
 
Rf = 0.18 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 0.67 (6 H, dd, J = 1.6 and 6.9 Hz, 3 
× SiCH2), 0.96 [18 H, d, J = 6.6 Hz, 3 × CH(CH3)2], 1.83 [3 H, sept, J = 6.6 Hz, 3 × 
CH(CH3)2], 3.46 (1 H, d, J = 5.6 Hz, OH-2' 
#
), 3.82-4.04 (2 H, m, H-5'), 4.13 (1 H, d, J = 5.3 
Hz, H-4'), 4.22-4.23 (2 H, m, H-2' and H-3'), 5.55 (1 H, br s, OH-3' 
#
), 5.70 (1 H, d, J = 8.1 
Hz, H-5), 5.90 (1 H, d, J = 1.0 Hz, H-1'), 8.10 (1 H, d, J = 8.1 Hz, H-6), 10.49 (1 H, br s, 
NH);  δC (50 MHz, CDCl3) 24.20 [3 × CH(CH3)2], 24.99 (3 × SiCH2), 26.36 and 26.43 [3 × 
CH(CH3)2], 60.87 (C-5'), 69.01 (C-3'), 75.47 (C-2'), 84.68 (C-4'), 90.41 (C-1'), 101.912 (C-5), 
140.53 (C-6), 151.17 (C-2), 164.03 (C-4);  MS m/z (M + 1
+
, 92 %) 156.87 (100), 275.07 (12), 
520.80 (16), 641.13 (45), 884.87 (45), 1344.53 (21), 1565.80 (16), 1786.60 (17), HRMS 
(+cESI) calculated for C21H39N2O6Si
+
: 443.25719, found: [M + H]
+
 443.25685. 
Note: assignments denoted with # are exchangeable. 
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D.10.7 Preparation of 5'-O-(dimethylthexylsilyl)uridine [248] 
 
The reaction was performed on a 1.01 g scale using 
dimethylthexylsilyl chloride as the protecting group. The 
procedure that was used is described in Section D.10 above 
and the crude compound was obtained as a white foam. 
Crude NMR spectra indicated the formation of pure product 
and no further purification was undertaken. The desired 
compound 248 was obtained as a white foam (1.59 g, 99 %). 
 
Rf = 0.58 (50 % EtOAc : hexane);  [α]D
23
 -11.000
o
 (c = 1.00 in CH2Cl2);  νmax/cm
-1
 (thin film) 
688 (RHC=CHR cis), 714 (-CH2 rocking), 834 (Si-CH3), 1111 (-C-OH, C-O stretch), 1250 
(Si-CH3), 1364 (-O-H, O-H bending), 1378 and 1393 [-C(CH3)2], 1430 and 1468 (-CH2 and -
CH3, C-H deformations), 1624 (C=C conjugated with C=O), 1697 (-CONH-), 2927 (-CH3, C-
H stretching), 2958 (-CH2, C-H stretching);  δH (300 MHz, CDCl3) 0.02 [6 H, s, Si(CH3)2], 
0.75 [12 H, dd, J = 4.4 and 7.0 Hz, CH(CH3)2 and C(CH3)2], 1.50 [1 H, sept, J = 6.6 Hz, 
CH(CH3)2], 2.04 (1 H, br s, OH-2' 
#
), 3.49 (1 H, br s, OH-3' 
#
), 3.71 and 3.88 (2 H, two d, J = 
11.4 Hz, H-5'), 4.10 (1 H, d, J = 5.4 Hz, H-4'), 4.11-4.14 (2 H, m, H-2' and H-3'), 5.53 (1 H, d, 
J = 8.1 Hz, H-5), 5.77 (1 H, d, J = 2.6 Hz, H-1'), 7.90 (1 H, d, J = 8.1 Hz, H-6), 10.39 (1 H, br 
s, NH);  δC (50 MHz, CDCl3) -3.49 [Si(CH3)2], 18.44 [C(CH3)2], 20.20 [CH(CH3)2], 25.41 
[C(CH3)2], 34.06 [CH(CH3)2], 61.68 (C-5'), 69.29 (C-3'), 75.56 (C-2'), 84.87 (C-4'), 90.15 (C-
1'), 102.04 (C-5), 140.42 (C-6), 151.30 (C-2), 163.97 (C-4);  MS m/z (M
+
, 100 %) 279.05 
(39), 772.58 (17), 794.61 (10), 1176.09 (38), 1368.73 (27), 1562.26 (100), 1754.63 (15), 
1948.74 (30), HRMS (+cESI) calculated for C17H31N2O6Si
+
: 387.19459, found: [M + H]
+
 
387.19505. 
Note: assignments denoted with # are exchangeable. 
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D.10.8 Preparation of 5'-O-(trihexylsilyl)uridine [249] 
 
The reaction was performed on a 1.03 g scale using 
chlorotrihexylsilane as the protecting group. The 
procedure that was used is described in Section D.10 
above and the crude compound was obtained as a clear 
oil (2.12 g). Crude NMR indicated a mixture of 
products, so the compound was further purified by 
column chromatography. Solvents used for elution 
were 30-50 % EtOAc : hexane. The desired compound 249 was obtained pure as a clear semi-
solid (0.695 g, 31 %) after chromatography. 
 
Rf = 0.33 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 0.60-0.65 (6 H, m, 3 × SiCH2), 
0.88 (9 H, t, J = 6.7 Hz, 3 × CH3), 1.27-1.30 (24 H, m, 3 × SiCH2CH2, 3 × SiCH2CH2CH2, 3 × 
CH2CH2CH3 and 3 × CH2CH3), 3.26 (1 H, d, J = 6.4 Hz, OH-2'), 3.82 and 3.98 (1 H, two d, J 
= 10.5 Hz, H-5'), 4.14-4.16 (1 H, m, H-4'), 4.21-4.23 (2 H, m, H-2' and H-3'), 5.41 (1 H, d, J = 
3.6 Hz, OH-3'), 5.69 (1 H, d, J = 8.1 Hz, H-5), 5.90 (1 H, d, J = 1.5 Hz, H-1'), 8.14 (1 H, d, J 
= 8.1 Hz, H-6), 10.25 (1 H, br s, NH);  δC (50 MHz, CDCl3) 13.32 (3 × SiCH2), 14.09 (3 × 
CH3), 22.56 (3 × SiCH2CH2), 23.04 (3 × CH2CH3), 31.46 (3 × CH2CH2CH3), 33.23 (3 × 
SiCH2CH2CH2), 61.14 (C-5'), 69.34 (C-3'), 75.85 (C-2'), 85.20 (C-4'), 90.90 (C-1'), 101.79 
(C-5), 140.49 (C-6), 151.15 (C-2), 163.86 (C-4);  MS m/z (M + H
+
, 100 %) 443.07 (18), 
641.13 (16), 809.40 (51), 1052.93 (53), 1334.07 (11), 1596.53 (20), 1860.20 (14), HRMS 
(+cESI) calculated for C27H51N2O6Si
+
: 527.35109, found: [M + H]
+
 527.35042. 
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D.11 Preparation of 5'-O-(tripropylsilyl)-5-methyluridine [250] 
 
The glassware used in the reaction was filled with a 5 % 
trimethylsilyl chloride : hexane solution and was allowed to 
stand at rt overnight. After this time, the glassware was 
oven-dried, placed under high vacuum and allowed to cool to 
rt under an argon atmosphere. The 5-methyluridine 233 (4.11 
mmol, 1.06 g) and DMAP (0.1 eq, 0.411 mmol, 0.0530 g) 
were stirred with distilled pyridine (5 cm
3
) until a solution 
had formed. To this solution was then added the chlorotripropylsilane (1.1 eq, 4.5 mmol, 0.99 
cm
3
). The reaction mixture was then allowed to stir at rt under an argon atmosphere overnight 
(21 h). After this time, the reaction was quenched by the addition of distilled water (5 cm
3
) 
and the mixture was allowed to stir for a few minutes. The reaction mixture was then 
transferred to a round bottomed flask with excess EtOAc and all of the solvents (including the 
water) were removed by evaporation (rotary evaporator set to 60 
o
C). The residue obtained 
was then partitioned between EtOAc (10 cm
3
) and distilled water (3 × 10 cm
3
). The organic 
fraction was then dried over anhydrous Na2SO4, filtered and the solvent was removed in 
vacuo. The crude compound was obtained as a white semi-solid (1.38 g) and the crude NMR 
spectra indicated a mixture of products. Thus, the mixture was purified by column 
chromatography, using 30-50 % EtOAc : hexane for elution. The desired compound 250 was 
obtained pure as a white semi-solid (0.326 g, 19 %). 
 
Rf = 0.10 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3) 0.61-0.67 (6 H, m, 3 × SiCH2), 
0.94-0.99 (9 H, m, 3 × CH2CH3), 1.33-1.42 (6 H, m, 3 × CH2CH3), 1.91 (3 H, s, CH3), 3.40 (1 
H, br s, OH-2' 
#
), 3.77-3.98 (2 H, m, H-5'), 4.17-4.23 (3 H, m, H-2', H-3' and H-4'), 5.29 (1H, 
br s, OH-3' 
#
), 5.93 (1 H, d, J = 3.5 Hz, H-1'), 7.67 (1 H, s, H-6), 10.21 (1 H, br s, NH);  δC 
(50 MHz, CDCl3) 12.48 (3 × SiCH2), 16.18 (CH3), 16.73 (3 × CH2CH3), 18.34 (3 × 
CH2CH3), 62.00 (C-5'), 70.50 (C-3'), 75.34 (C-2'), 85.51 (C-4'), 90.08 (C-1'), 110.59 (C-5), 
135.82 (C-6), 151.44 (C-2), 164.29 (C-4);  MS m/z (M
+
, 51 %) 828.79 (100), 850.88 (24), 
1260.64 (35), 1467.11 (15), 1674.63 (18), HRMS (+cESI) calculated for C19H35N2O6Si
+
: 
415.22589, found: [M + H]
+
 415.22569. 
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Note: assignments denoted with # are interchangeable. 
 
D.12 Preparation of 5'-O-(tert-butyldimethylsilyl)-5-methyluridine [251] 
 
The glassware and attachments were filled with a 5 % 
trimethylsilyl chloride : hexane solution and were allowed to 
stand at rt overnight. After this time, the glassware was oven-
dried, placed under high vacuum and allowed to cool to rt 
under an argon atmosphere. The 5-methyluridine 233 (4.02 
mmol, 1.04 g) and DMAP (0.1 eq, 0.402 mmol, 0.0514 g) 
were stirred with distilled pyridine (5 cm
3
) until a solution had 
formed. To this solution was then added the tert-butyldimethylsilyl chloride (1.1 eq, 4.43 
mmol, 0.673 g). The reaction mixture was then allowed to stir at rt under an argon atmosphere 
overnight (20 h). After this time, the reaction mixture was quenched by the addition of 
distilled water (5 cm
3
). After a few minutes of stirring, all of the solvents in the reaction 
mixture (including the water) were removed by evaporation. The residue obtained was 
partitioned between EtOAc (20 cm
3
) and distilled water (3 × 10 cm
3
). The organic fraction 
was dried over anhydrous Na2SO4, filtered and the solvent was removed in vacuo. The desired 
compound 251 was obtained pure as a white powder (1.39 g, 93 %) and as such, no further 
purification was required. 
 
Rf = 0.73 (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 709 (CH2 rocking), 812 (R2C=CHR), 
831 (Si-CH3), 1120 (-C-OH, C-O stretching), 1258 (Si-CH3), 1311 (-O-H, O-H bending), 
1362 and 1388 [-C(CH3)3, CH3 symmetrical deformations], 1432 and 1470 (-CH2 and -CH3, 
C-H deformations), 1645 (C=C conjugated with C=O), 1688 (-CONH-), 2928 (-CH3, C-H 
stretching), 2955 (-CH2, C-H stretching), 3067 (O-H stretching);  δH (300 MHz, CDCl3 : 
MeOD, 1 : 1 ratio) 0.15 and 0.16 [6 H, two s, Si(CH3)2], 0.96 [9 H, s, C(CH3)3], 1.91 (3 H, s, 
CH3), 3.86 and 3.95 (2 H, two dd, J = 2.1 and 11.6 Hz, H-5'), 4.07-4.15 (3 H, m, H-2', H-3' 
and H-4'), 5.96 (1 H, d, J = 5.0 Hz, H-1'), 7.57 (1 H, s, H-6), both NH and OH peaks were not 
observed in the spectrum;  MS m/z (M
+
, 75 %) 744.70 (49), 766.60 (14), 947.79 (10), 1134.41 
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(62), 1320.31 (60), 1506.34 (100), 1692.12 (74), 1877.92 (88), HRMS (+cESI) calculated for 
C16H29N2O6Si
+
: 373.17894, found: [M + H]
+
 373.17903. 
 
D.13 Preparation of 5'-O-(dimethylthexylsilyl)-5-methyluridine [252] 
 
The glassware used in the reaction was filled with a 5 % 
trimethylsilyl chloride : hexane solution and was allowed to 
stand at rt overnight. After this time, the glassware was oven-
dried, placed under high vacuum and allowed to cool to rt 
under an argon atmosphere. The 5-methyluridine 233 (3.93 
mmol, 1.02 g) and DMAP (0.1 eq, 0.393 mmol, 0.0522 g) 
were stirred with distilled pyridine (5 cm
3
) until a clear 
solution had formed. To this solution was then added the dimethylthexylsilyl chloride (1.1 eq, 
4.3 mmol, 0.85 cm
3
). The reaction mixture was then allowed to stir at rt under an argon 
atmosphere overnight (21 h). After this time, the reaction was quenched by the addition of 
distilled water (5 cm
3
) and the mixture was allowed to stir for a few minutes. The reaction 
mixture was then transferred to a round bottomed flask with excess EtOAc and all of the 
solvents (including the water) were removed by evaporation (rotary evaporator set to 60 
o
C). 
The residue obtained was then partitioned between EtOAc (10 cm
3
) and distilled water (3 × 
10 cm
3
). The organic fraction was then dried over anhydrous Na2SO4, filtered and the solvent 
was removed in vacuo. The crude compound 252 was obtained pure as a white solid (1.31 g, 
80 %) and as such, no further purification was required.  
 
Rf = 0.72 (50 % EtOAc : hexane);  δH (300 MHz, d6-DMSO : CDCl3, 1 : 1 ratio) 1.00 [6 H, 
s, Si(CH3)2], 1.75 [12 H, dd, J = 1.9 and 7.3 Hz, CH(CH)3)2 and C(CH3)2], 1.49 [1 H, sept, J = 
6.7 Hz, CH(CH3)2], 4.20 (3 H, s, CH3), 4.62 and 4.67 (2 H, two dd, J = 2.6 and 11.5 Hz, H-5'), 
4.77-4.79 (1 H, m, H-4'), 4.84-4.85 (2 H, m, H-2' and H-3'), 5.83 (1 H, d, J = 3.7 Hz, OH-2' #), 
6.14 (1 H, d, J = 5.2 Hz, OH-3' #), 6.73 (1 H, d, J = 5.2 Hz, H-1'), 8.22 (1 H, s, H-6), 12.13 (1 
H, br s, NH);  MS m/z (M + H
+
, 100 %) 256.93 (8), 445.07 (11), 845.07 (20), 867.33 (26), 
1067.67 (9), 1290.40 (9), HRMS (+cESI) calculated for C18H33N2O6Si
+
: 401.21024, found: 
[M + H]
+
 401.20987. 
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Note: assignments denoted with # are exchangeable. 
 
D.14 Preparation of 5'-O-(tert-butyldiphenylsilyl)-5-methyluridine [253] 
 
The glassware used in the reaction was filled with a 5 % 
trimethylsilyl chloride : hexane solution and was allowed to 
stand at rt overnight. After this time, the glassware was oven-
dried, placed under high vacuum and allowed to cool to rt 
under an argon atmosphere. The 5-methyluridine 233 (4.26 
mmol, 1.10 g) and DMAP (0.1 eq, 0.426 mmol, 0.0529 g) 
were stirred with distilled pyridine (5 cm
3
) until a solution had 
formed. To this solution was then added the tert-butyldiphenylsilyl chloride (1.1 eq, 4.69 
mmol, 1.22 cm
3
). The reaction mixture was then allowed to stir at rt under an argon 
atmosphere overnight (20 h). After this time, the reaction mixture was diluted with CH2Cl2 
(40 cm
3
) and extracted with a saturated NaHCO3 solution (2 × 40 cm
3
) followed by brine (40 
cm
3
). The combined organics were then dried over anhydrous Na2SO4, filtered and the solvent 
removed in vacuo. NMR spectra of the crude mixture showed that the desired product 253 
had formed, but that it was contaminated with pyridine. Thus, the mixture was purified by the 
azeotropic distillation of pyridine using toluene as the co-solvent. The desired compound 253 
was obtained pure as a white foam (2.11 g, 100 %). 
 
Rf = 0.68 (50 % EtOAc : hexane);  δH (300 MHz, CDCl3 : MeOD, 1 : 1 ratio) 1.12 [9 H, s, 
Si(CH3)3], 1.49 (3 H, s, CH3), 3.90 (1 H, dd, J = 2.3 and 11.6 Hz, H-5'), 4.03-4.11 (2 H, m, H-
4' and H-5'), 4.24-4.33 (2 H, m, H-2' and H-3'), 6.02 (1 H, d, J = 5.7 Hz, H-1'), 7.40-7.43 (6 H, 
m, H-3* and H-4*), 7.68-7.71 (4 H, m, H-2*), 7.82 (1 H, s, H-6), 8.53 (1 H, br d, J = 5.8 Hz, 
NH);  MS m/z (M + H
+
, 31 %) 227.00 (18), 287.07 (30), 305.07 (48), 419.07 (100), 541.13 
(55), 586.93 (10), 1037.07 (77), 1117.13 (10), 1308.13 (22), 1578.33 (26), 1837.67 (19), 
HRMS (+cESI) calculated for C26H33N2O6Si
+
: 497.21024, found: [M + H]
+
 497.20971. 
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D.15 Preparation of 1-[(6aR,8R,9S,9aR)-tetrahydro-9-hydroxy-2,2,4,4-tetraisopropyl-
6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl](5-methylpyrimidine)-2,4(1H,3H)-
dione [254] 
 
The glassware used in the reaction was filled with a 5 % 
trimethylsilyl chloride : hexane solution and was allowed to 
stand at rt overnight. After this time, the glassware was oven-
dried, placed under high vacuum and allowed to cool to rt 
under an argon atmosphere. A solution was prepared of 5-
methyluridine 233 (3.94 mmol, 1.02 g) in distilled pyridine (12 
cm
3
). The solution was then cooled to 0 
o
C in an ice-water bath 
before the addition of the 1,3-dichloro-1,1,3,3-
tetraisopropyldisiloxane (1.05 eq, 4.14 mmol, 1.33 cm
3
). The reaction mixture was then 
stirred at rt overnight (20 h). After this time, the reaction was quenched by the addition of 
distilled water (12 cm
3
). The mixture was then transferred to a round-bottomed flask using a 
small amount of EtOAc and all of the solvents were removed by evaporation (60 
o
C). The 
residue obtained was then partitioned between EtOAc (40 cm
3
) and distilled water (3 × 15 
cm
3
). The organic layer was dried over anhydrous Na2SO4, filtered and evaporated to yield a 
white foam. The crude foam was then purified by column chromatography, using 10-50 % 
EtOAc : hexane for elution. The desired compound 254 was obtained as a white foam (0.781 
g, 40 %). 
 
Rf = 0.53 (50 % EtOAc : hexane);  [α]D
21
 -2.8846
o
 (c = 1.04 in CH2Cl2);  νmax/cm
-1
 (thin film) 
791 (R2C=CHR), 1061 (C-OH, C-O stretching), 1247 (Si-CH), 1333 (O-H bending), 1385 [-
C(CH3)2, -CH3 symmetrical deformation], 1464 (-CH3, C-H deformation), 1640 (C=C 
conjugated with C=O), 1666 (-CONH-), 2893 (-C-H, C-H stretching), 2926 (-CH3, C-H 
stretching), 2964 (-O-H), 3068 (-CONH- in solution);  δH (300 MHz, CDCl3) 1.04-1.10 [28 
H, m, 4 × CH(CH3)2 and 4 × CH(CH3)2], 1.91 (3 H, s, CH3), 3.68 (1 H, d, J = 1.4 Hz, OH-2'), 
3.98-4.12 (2 H, m, H-5'), 4.14-4.23 (2 H, m, H-2' and H-4'), 4.33-4.37 (1 H, m, H-3'), 5.72 (1 
H, s, H-1'), 7.46 (1 H, s, H-6), 9.47 (1 H, br s, NH);  δC (50 MHz, CDCl3) 12.45, 12.57, 12.68 
and 12.93 (4 × SiCH), 16.81, 16.94, 16.96, 17.04, 17.22, 17.23, 17.33 and 17.41 [4 × 
CH(CH3)2], 60.24 (C-5'), 68.92 (C-3'), 74.97 (C-2'), 81.83 (C-4'), 91.07 (C-1'), 110.55 (C-5), 
6
NH
O
ON
3' 2'
1'
O
4'
OHO
5'O
Si
O
Si
254  
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135.61 (C-6), 150.17 (C-2), 163.97 (C-4);  MS m/z (M
+
, 78 %) 306.94 (7), 1000.67 (100), 
1518.10 (26), 1768.58 (12), HRMS (+cESI) calculated for C22H41N2O7Si2
+
: 501.24468, 
found: [M + H]
+
 501.24409. 
 
D.16 General procedure for the preparation of silanols 
 
A solution was prepared of the silyl chloride (usual scale: 750 mg, 1 eq) in Et2O (3 cm
3
 : 750 
mg starting material). To this solution was then added portion wise a solution of KOH (1.1 
eq) in a mixture of distilled water (2 cm
3
 : 750 mg starting material) and MeOH (0.5 cm
3
 : 
750 mg starting material). The solution warmed up after the addition and a white precipitate 
was immediately observed. The reaction mixture was then  allowed to stir at rt overnight (18 
h). After this time, the organic fraction was collected from the reaction mixture and the 
aqueous fraction was extracted with Et2O (3 × 10 cm
3
 : 750 mg starting material). The 
combined organics were then dried over anhydrous MgSO4, filtered and the solvent was 
removed in vacuo. NMR spectra were obtained for the crude mixtures to determine if further 
purification was required. 
 
Note: due to the low molecular masses and high volatility of the silanols prepared, LRMS and 
HRMS were not determined. 
 
D.16.1 Preparation of dimethylethylsilanol [255] 
 
The reaction was performed on 750 mg scale, using chlorodimethylethylsilane 
as the starting material, as described in Section D.16. No further purification 
was required and the pure compound 255 was obtained as a clear oil (0.0122 
g, 2 %). 
 
Si OH
255  
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Rf = sample was not observable by tlc (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 830 (Si-
CH2), 1220 (Si-CH2), 1370 (-CH3 symmetrical deformations), 2880 and 2921 (-CH2 and -
CH3, C-H stretching), 2965 (-O-H), 3510 (O-H stretching);  δH (300 MHz, CDCl3) 0.06 [6 H, 
s, Si(CH3)2], 0.47 (2 H, q, J = 7.9 Hz, SiCH2), 0.93 (3 H, t, J = 7.9 Hz, CH2CH3), OH peak not 
observed in spectrum;  δC (50 MHz, CDCl3) -0.65 (2 x CH3Si), 6.80 (CH3CH2), 9.62 (CH2). 
 
D.16.2 Preparation of triethylsilanol [176] 
 
The reaction was performed on 750 mg scale, using chlorotriethylsilane as the 
starting material, as described in Section D.16. No further purification was 
required and the pure compound 176 was obtained as a clear oil (0.565 g, 86 
%). 
 
Rf = sample was not observable by tlc (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 726 (-
CH2 rocking), 812 (Si-CH2), 894 and 1002 (Si-O), 1236 (Si-CH2), 1378 (-CH3 symmetrical 
deformation), 1413 (O-H bending), 1458 (-CH2 and -CH3, C-H deformations) 2876 and 2911 
(-CH2 and -CH3, C-H stretching), 2955 (-O-H), 3574 (O-H stretching);  δH (300 MHz, 
CDCl3) 0.52 (6 H, q, J = 7.9 Hz, 3 × SiCH2), 0.93 (9 H, t, J = 7.9 Hz, 3 × CH2CH3), OH peak 
not observed in spectrum;  δC (50 MHz, CDCl3) 6.40 (3 × CH2CH3), 6.80 (3 × SiCH2). 
 
D.16.3 Preparation of tripropylsilanol [256] 
 
The reaction was performed on 750 mg scale, using chlorotripropylsilane as 
the starting material, as described in Section D.16. No further purification 
was required and the pure compound 256 was obtained as a clear oil (0.722 
g, 100 %). 
 
Si OH
176  
Si OH
256  
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Rf = 0.90 (100 % EtOAc);  νmax/cm
-1
 (thin film) 709 (-CH2 rocking), 800 (Si-CH2), 895 and 
1002 (Si-O), 1218 (Si-CH2), 1375 (-CH3 symmetrical deformations), 1408 (-O-H bending), 
1460 (-CH2 and -CH3, C-H deformations), 2868 and 2926 (-CH2 and -CH3, C-H stretching), 
2954 (-O-H), 3574 (O-H stretching);  δH (300 MHz, CDCl3) 0.47-0.62 (6 H, m, 3 × SiCH2), 
0.96 (9 H, q, J = 7.3 Hz, 3 × CH3), 1.29-1.41 (6 H, m, 3 × CH2CH3), OH peak not observed in 
spectrum;  δC (50 MHz, CDCl3) 16.7 (3 × Si-CH2), 18.0 (3 × CH3), 18.3 (3 × CH2CH3). 
 
D.16.4 Preparation of triisopropylsilanol [257] 
 
The reaction was performed on 750 mg scale, using triisopropylsilyl chloride 
as the starting material, as described in Section D.16. No further purification 
was required and the pure compound 257 was obtained as a clear oil (0.686 g, 
98 %). 
 
Rf = 0.90 (100 % EtOAc);  δH (300 MHz, CDCl3) 1.04-1.06 [18 H, m, CH(CH3)2], 1.08 (1 H, 
br s, OH), 1.48-1.50 [3 H, m, CH(CH3)2];  δC (50 MHz, CDCl3) 13.5 (3 × CH), 18.5 (6 × 
CH3). 
 
D.16.5 Preparation of butyldimethylsilanol [258] 
 
The reaction was performed on 750 mg scale, using butyldimethylsilyl 
chloride as the starting material, as described in Section D.16. No further 
purification was required and the pure compound 258 was obtained as a 
clear oil (0.436 g, 66 %). 
 
Rf = 0.91 (100 % EtOAc);  νmax/cm
-1
 (thin film) 703 (-CH2 rocking), 820 (Si-CH2), 890 and 
1016 (Si-O), 1230 (Si-CH3), 1378 (-CH3 symmetrical deformation), 1412 (O-H bending), 
1465 (-CH2 and -CH3, C-H deformations), 2850 and 2919 (-CH2 and -CH3, C-H stretching), 
Si OH
257  
Si OH
258  
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2959 (-OH), 3575 (O-H stretching);  δH (300 MHz, CDCl3) 0.03 [6 H, s, Si(CH3)2], 1.48-1.53 
(2 H, m, SiCH2), 0.88 (3 H, t, J = 6.8 Hz, CH2CH3), 1.25-1.36 (4 H, m, CH2CH3 and 
SiCH2CH2), OH peak not observed in spectrum;  δC (50 MHz, CDCl3) 0.36 [Si(CH3)2], 13.83 
(CH2CH3), 18.11 (SiCH2), 25.52 (SiCH2CH2), 26.39 (CH2CH3). 
 
D.16.6 Preparation of tributylsilanol [259] 
 
The reaction was performed on 750 mg scale, using chlorotributylsilane 
as the starting material, as described in Section D.16. No further 
purification was required and the pure compound 259 was obtained as a 
clear oil (0.677 g, 98 %). 
 
Rf = 0.94 (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 731 (-CH2 rocking), 823 (Si-CH2), 
886 and 1081 (Si-O), 1231 (Si-CH2), 1377 (-CH3 symmetrical deformation), 1409 (O-H 
bending), 1464 (-CH2 and -CH3, C-H deformations), 2855 and 2919 (-CH2 and -CH3, C-H 
stretching), 2956 (-O-H), 3346 (O-H stretching);  δH (300 MHz, CDCl3) 0.47-0.62 (6 H, m, 3 
× SiCH2), 0.87-0.92 (9 H, m, 3 × CH3), 1.30-1.35 (12 H, m, 3 × SiCH2CH2 and 3 × CH2CH3), 
1.48 (1 H, br s, OH);  δC (50 MHz, CDCl3) 13.9 (3 × SiCH2), 14.7 (3 × CH2CH3), 25.4 (3 × 
SiCH2CH2), 26.5 (3 × CH2CH3).  
 
D.16.7 Preparation of triisobutylsilanol [260] 
 
The reaction was performed on 750 mg scale, using chlorotriisobutylsilane 
as the starting material, as described in Section D.16. No further 
purification was required and the pure compound 260 was obtained as a 
clear oil (0.679 g, 98 %). 
 
Si OH
259  
Si OH
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Rf = 0.94 (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 751 (-CH2 rocking), 831 (Si-CH2), 
872 and 1039 (Si-O), 1219 (Si-CH2), 1364 (-CH3 symmetrical deformation), 1401 (O-H 
bending), 1465 (-CH2 and -CH3, C-H deformations), 2867 and 2925 (-CH2 and -CH3, C-H 
stretching), 2952 (-O-H);  δH (300 MHz, CDCl3) 0.61 (6 H, d, J = 7.0 Hz, 3 × SiCH2), 0.96 
[18 H, d, J = 6.5 Hz, 3 × CH(CH3)2], 1.33 (1 H, br s, OH), 1.82-1.87 [3 H, m, 3 × CH(CH3)2];  
δC (50 MHz, CDCl3) 24.6 (3 × CH), 26.7 (3 × SiCH2), 27.4 (6 × CH3). 
 
D.16.8 Preparation of tert-butyldimethylsilanol [261] 
 
The reaction was performed on 770 mg scale, using tert-butyldimethylsilyl 
chloride as the starting material, as described in Section D.16. No further 
purification was required and the pure compound 261 was obtained as a 
colourless oil with some needles, but would not solidify completely even 
after standing (0.448 g, 72 %). 
 
Rf = sample was not observable by tlc (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 772 (-
CH2 rocking), 831 (Si-CH2), 864 and 1039 (Si-O), 1217 (Si-CH2), 1361 (-CH3 symmetrical 
deformation), 1407 (O-H bending), 1462 (-CH2 and -CH3, C-H deformations), 2884 and 2928 
(-CH2 and -CH3, C-H stretching), 2952 (-O-H), 3244 (O-H stretching);  δH (300 MHz, 
CDCl3) 0.08 [6 H, s, Si(CH3)2], 0.90 [9 H, s, C(CH3)3], 1.91 (1 H, br s, OH);  δC (50 MHz, 
CDCl3) -3.61 [Si(CH3)2], 17.97 [C(CH3)3], 25.63 [C(CH3)3]. 
 
D.16.9 Preparation of dimethylthexylsilanol [262] 
 
The reaction was performed on 750 mg scale, using dimethylthexylsilyl 
chloride as the starting material, as described in Section D.16. No further 
purification was required and the pure compound 262 was obtained as a 
clear oil (0.640 g, 95 %). 
Si OH
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Rf = sample was not observable by tlc (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 827 (Si-
CH), 875 and 1048 (Si-O), 1252 (Si-CH3), 1364 (-CH3 symmetrical deformation), 1409 (O-H 
bending), 1465 (-CH3, C-H deformations), 2867 and 2929 (-CH3, C-H stretching), 2976 (-
OH), 3298 (O-H stretching);  δH (300 MHz, CDCl3) 0.13 [6 H, s, Si(CH3)2], 0.86 [6 H, s, 
C(CH3)2], 0.89 [6 H, d, J = 6.9 Hz, CH(CH3)2], 1.60 (1 H, br s, OH), 1.63-1.66 [1 H, m, 
CH(CH3)2];  δC (50 MHz, CDCl3) -1.11 [Si(CH3)2], 18.56 [C(CH3)2], 20.30 [CH(CH3)2], 
24.87 [C(CH3)2], 34.13 [CH(CH3)2]. 
 
D.16.10  Preparation of trihexylsilanol [263] 
 
The reaction was performed on 750 mg scale, using 
chlorotrihexylsilane as the starting material, as described in 
Section D.16. No further purification was required and the pure 
compound 263 was obtained as a clear oil (0.716 g, 100 %). 
 
Rf = 0.85 (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 748 (-CH2 rocking), 822 (Si-CH2), 
890 and 1074 (Si-O), 1228 (Si-CH2), 1378 (-CH3 symmetrical deformation), 1409 (O-H 
bending), 1467 (-CH2 and -CH3, C-H deformations), 2852 and 2919 (-CH2 and -CH3, C-H 
stretching), 2957 (-O-H);  δH (300 MHz, CDCl3) 0.55-0.61 (6 H, m, 3 × SiCH2), 0.88 (9 H, t, 
J = 6.7 Hz, 3 × CH3), 1.28-1.40 (24 H, m, 3 × SiCH2CH2, 3 × SiCH2CH2CH2, 3 × 
CH2CH2CH3 and 3 × CH2CH3), 3.44 (1 H, br s, OH);  δC (50 MHz, CDCl3) 15.1 (3 × SiCH2), 
16.5 (3 × CH3), 23.9 (3 × SiCH2CH2), 24.7 (3 × CH2CH3), 33.0 (3 × CH2CH2CH3), 34.6 (3 × 
SiCH2CH2CH2). 
 
D.16.11  Preparation of cylcohexyldimethylsilanol [264] 
 
The reaction was performed on 750 mg scale, using 
chlorocyclohexyldimethylsilane as the starting material, as described in 
Si OH
263  
Si OH
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Section D.16. No further purification was required and the pure compound 264 was obtained 
as a clear oil (0.620 g, 92 %). 
 
Rf = sample was not observable by tlc (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 739 (-
CH2 rocking), 834 (Si-CH), 889 and 1062 (Si-O), 1250 (Si-CH3), 1379 (-CH3 symmetrical 
deformation), 1408 (O-H bending), 2846 and 2918 (-CH2 and -CH3, C-H stretching), 2957 (-
O-H);  δH (300 MHz, CDCl3) 1.60-1.73 (5 H, m, 5 × CH2), 1.02-1.11 (5 H, m, 5 × CH2), 
0.54-0.57 (1 H, m, Si-CH), 0.08 (6 H, s, 2 × Si-CH3);  δC (50 MHz, CDCl3) -2.2 (2 × SiCH3), 
26.8 (Si-CH), 27.1 (ring CH2), 27.5 (ring CH2), 27.9 ( ring CH2). 
 
D.16.12  Preparation of benzyldimethylsilanol [265] 
 
The reaction was performed on 750 mg scale, using 
benzylchlorodimethylsilane as the starting material, as described in 
Section D.16. No further purification was required and the pure 
compound 265 was obtained as a clear oil (0.608 g, 90 %). 
 
Rf = 0.95 (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 696 (-CH2 rocking), 760 (5 adjacent 
aromatic H), 836 (Si-CH2), 904 and 1070 (Si-O), 1317 (Si-CH3), 1405 (O-H bending), 1452 (-
CH2, C-H deformations), 1493 (aromatic H), 1601 (aromatic H), 2890 (-CH2, C-H stretching), 
3025 (aromatic H), 3082 (O-H stretching);  δH (300 MHz, CDCl3) 0.20 [6 H, s, Si(CH3)2], 
2.27 (2 H, s, SiCH2), 7.20 (2 H, d, J = 7.1 Hz, H-2*), 7.28 (1 H, t, J = 7.3 Hz, H-4*), 7.42 (2 
H, dd, J = 6.2 and 13.5 Hz, H-3*);  δC (50 MHz, CDCl3) 0.1 (2 × Si-CH3), 29.6 (Si-CH2), 
125.7 (C-4*), 129.8 (C-3*), 130.0 (C-2*), 145.5 (C-1*). 
 
  
Si OH
1*
265
2*
3*
4*
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D.16.13 Preparation of triphenylsilanol [266] 
 
The reaction was performed on 750 mg scale, using triphenylsilyl 
chloride as the starting material, as described in Section D.16. No further 
purification was required and the pure compound 266 was obtained as 
white solid (0.649 g, 93 %). 
 
Rf = 0.90 (50 % EtOAc : hexane);  m.p. 153-156 
o
C;  νmax/cm
-1
 (thin film) 774 (5 adjacent 
aromatic H), 917 and 1093 (Si-O), 1427 (O-H bending), 1485 and 1567 (aromatic H), 2912 (-
OH), 3020 (aromatic H), 3088 (O-H stretching);  δH (300 MHz, CDCl3) 2.72 (1 H, br s, OH), 
7.25-7.49 (9 H, m, 3 × H-3* and 3 × H-4*), 7.60-7.63 (6 H, m, 3 × H-2*);  δC (50 MHz, 
CDCl3) 127.8 (C-3*), 130.2 (C-4*), 135.0 (C-2*), 135.1 (C-1*). 
 
D.16.14  Preparation of 1,3-dihydroxy-1,1,3,3-tetraisopropyldisiloxane [268] 
 
The reaction was performed on 770 mg scale, using 1,3-dichloro-1,1,3,3-
tetraisopropyldisiloxane as the starting material, as described in Section 
D.16. No further purification was required and the pure compound 268 was 
obtained as white solid (0.662 g, 100 %). 
 
Rf = sample not observable by tlc (50 % EtOAc : hexane);  νmax/cm
-1
 (thin film) 837 (Si-CH), 
883 and 1057 (Si-O), 1249 (Si-CH), 1366 (-CH3 symmetrical deformation), 1384 (O-H 
bending), 1462 (-CH3, C-H deformations), 2866 and 2926 (-CH3, C-H stretching), 2952 (-
OH), 3349 (O-H stretching);  δH (300 MHz, CDCl3) 0.83-0.92 [4 H, m, 4 × CH(CH3)2], 0.95-
1.05 [24 H, m, 4 × CH(CH3)2], 2.71 (2 H, br s, 2 × OH). 
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1*
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Appendix E: 
Experimental Procedures – Relating to Chapter 6 
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E.1 General Procedure for Confocal Scanning Laser Microscopy (CSLM) 
 
E.1.1  Sample Preparation 
 
 General Culture Conditions 
 
For the untreated control cultures of S. aureus strain ATCC 25923 and B. cereus strain DL5, a 
single colony was taken from the previously prepared stock plates that had been sealed with 
Parafilm, placed inside polyethylene bags and stored at 4 
o
C until required (note: plates were 
subcultured every 21 days when in active use and were prepared fresh from new freezer 
stocks when long periods of time elapsed between assays). This single colony was used to 
inoculate 100 cm
3
 of fresh nutrient broth (prepared according to the manufacturer's 
instructions, autoclaved at 1 atm/121 
o
C for 20 min, poured and then incubated overnight to 
check for contamination). These conicals were then incubated at 37
o
C with shaking (150 rpm) 
for exactly 18 hours, before being used immediately for the preparation of the bacterial 
suspensions, described below.  
 
For the treated bacterial cultures, a single colony was taken from the stock plates that had 
been stored at 4 
o
C, and was used to inoculate 100 cm
3
 of nutrient broth as described above. 
These conicals were then incubated at 37 
o
C with shaking (150 rpm) for exactly 18 hours. 
After this time, the 18 hour bacterial cultures were diluted to 10
6
 cfu/mL based on the average 
viable count determined using the droplet plate technique described in Section C.4, 
Appendix C. Then 15 cm
3
 of the 10
6
 culture was placed aseptically into a McConkey bottle 
containing 15 cm
3
 of the desired compound dilution (compounds dissolved in DMSO, diluted 
with water and then stocks were used for serial dilutions in nutrient broth, procedure 
described in detail in Section C.5, Appendix C). These bottles were then incubated at 37
o
C 
for a further 18 hours, before being used immediately for the preparation of the bacterial 
suspensions, described in detail below 
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 General Procedure for the Preparation of Bacterial Suspensions 
 
After this time, 25 cm
3
 of each of the overnight cultures was placed in a 50 cm
3
 disposable 
plastic centrifuge tube (Corning, NY) and was sealed. The culture was then concentrated by 
centrifugation at 5000 rpm for 20 minutes - essentially a 15 minute run with time added to 
speed up and slow down the rotor. The supernatant was then removed and the pellet was 
resuspended in 2000 µL of a freshly prepared 0.85 % NaCl(aq) solution. 1000 µL of this 
solution was then added to a second centrifuge tube containing 19 cm
3
 of the 0.85 % NaCl(aq) 
solution. The mixture was then incubated at room temperature for 1 hour, with mixing by 
hand every 15 minute interval.  
 
The mixture was then concentrated by centrifugation at 5000 rpm for 20 minutes. The 
supernatant was decanted off and the pellet was resuspended in 1000 µL of 0.85 % NaCl(aq) 
solution. This was then added to a third centrifuge tube containing 19 cm
3
 of the 0.85 % 
NaCl(aq) solution and was gently mixed. The mixture was immediately concentrated by 
centrifugation at 5000 rpm for 20 minutes. The supernatant was again decanted off and the 
pellet was resuspended in 1000 µL of 0.85 % NaCl (aq) solution. This was then added to a 
fourth centrifuge tube, containing 9 cm
3
 of the 0.85 % NaCl(aq) solution.  
 
The optical density was then determined for both samples: 
 (i) 1000 µL of 0.85 % NaCl(aq) solution was placed in a disposable cuvette (BLANK) 
 (ii) 1000 µL of each bacterial solution (from the fourth centrifuge tube) was placed in 
       a disposable cuvette (SAMPLE) 
 (iii) optical density was measured at 670 nm (values obtained ranged from 0.82 - 1.15)  
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 General Procedure for Staining of Bacteria in Suspension 
 
Both components of the BacLight Kit (LIVE/DEAD BacLight Bacterial Viability Kit L7012, 
Molecular Probes, Leiden, the Netherlands, imported by Invitrogen SA) were allowed to 
warm to room temperature and were then centrifuged using the mini-spin for 10 seconds (to 
allow the contents of the vials to settle to the bottom). Then 10 µL of the SYTO9 dye and 10 
µL of the propidium iodide dye were placed in a autoclaved Eppendorf tube, and were mixed 
together by centrifugation on the mini-spin for 10 seconds to give the two-component dye 
mixture. 
 
Then 1000 µL of the bacterial suspension (from the fourth centrifuge tube, prepared as 
described above) was placed in an autoclaved Eppendorf tube and to this was then added 3 µL 
of the two-component dye mixture. The contents of the tube were then mixed by inversion 
and were incubated at room temperature in the dark for 15 minutes. 
 
5 µL of the stained bacterial suspension was then placed on a microscope slide and was 
covered gently with a coverslip. Slides were prepared in triplicate for each of the bacterial 
strains tested. The slides were placed carefully in a box covered with tin foil to keep them in 
the dark. The prepared slides were then viewed on a confocal scanning laser microscope. The 
protocol described above is based on the standard method for the BacLight Kit as supplied by 
the manufacturers.
E1 
 
E.1.2 Sample Analysis 
 
The prepared slides were viewed on an invert laser scan microscope (LSM 410, Carl Zeiss 
Jena, Germany) using 50 % laser intensity, with 488 nm and 563 nm as the excitation 
wavelengths and using a 63 × oil objective.  
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E.2 General Procedure for Scanning Electron Microscopy (SEM) 
 
E.2.1 Sample Preparation 
 
 General Culture Conditions - Untreated Controls 
 
For the untreated control cultures of S. aureus strain ATCC 25923, B. cereus strain DL5, P. 
aeruginosa strain ATCC 27853 and E. coli strain ATCC 25922, a single colony was taken 
from the previously prepared stock plates that had been sealed with Parafilm, placed inside 
polyethylene bags and stored at 4 
o
C until required (note: plates were subcultured every 21 
days when in active use and were prepared fresh from new freezer stocks when long periods 
of time elapsed between assays). This single colony was used to inoculate 100 cm
3
 of fresh 
nutrient broth (prepared according to the manufacturer's instructions, autoclaved at 1 atm/121 
o
C for 20 min, poured and then incubated overnight to check for contamination). These 
conicals were then incubated at 37
o
C with shaking (150 rpm) for exactly 18 hours, before 
being used immediately for the preparation of the bacterial suspensions, as described below. 
 
After this time, the 18 hour bacterial cultures were diluted to 10
6
 cfu/mL based on the average 
viable count determined using the droplet plate technique described in Section C.4, 
Appendix C. Then 1000 µL of the 10
6
 bacterial culture was placed aseptically into a 
McConkey bottle and this solution was then fixed with 1000 µL of a 3 % gluteraldehyde (aq) 
solution (prepared immediately prior to use, gluteraldehyde purchased from BDH), by 
allowing to stand at room temperature for exactly 24 hours. 
 
 General Culture Conditions - Treatment with Synthetic Compounds and Antibiotic 
 
For the treated bacterial cultures, a single colony was taken from the stock plates that had 
been stored at 4 
o
C, and was used to inoculate 100 cm
3
 of nutrient broth as described above. 
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These conicals were then incubated at 37 
o
C with shaking (150 rpm) for exactly 18 hours. The 
18 hour bacterial cultures were then diluted to 10
6
 cfu/mL based on the average viable count 
determined using the droplet plate technique described in Section C.4, Appendix C. Then 
1000 µL of the 10
6
 bacterial culture was placed aseptically into a McConkey bottle containing 
1000 µL of the desired compound dilution. The mixture was then incubated at 37 
o
C for 
exactly 22 hours.  
 
After this time, the cell suspension/compound dilution mixture (2000 µL in total) was fixed 
with 2000 µL of a 3 % gluteraldehyde(aq) solution, by allowing to stand at room temperature 
for exactly 24 hours. 
 
 General Dehydration Procedure 
 
In all cases, the fixed solution of either the bacterial cell suspension or the mixture of the 
bacterial cells plus compound dilution, were used for the dehydration procedure. Firstly, 2000 
µL of the suspension was gently sucked up into a 10 mL syringe. To this syringe was then 
attached a sterilized filter holder (PALL Life Sciences 13 mm Plastic Filter Holder) 
containing Millipore filter paper (Isopore Membrane Filters 0.2 µm GTTP). Once the 
suspension had been filtered through the Millipore filter paper, a sterile pair of tweezers were 
used to transfer the filter paper to the dehydration solutions.  
 
For the dehydration procedure, an ethanol dilution series was prepared using absolute ethanol 
(99 %) in de-ionised water. The ethanol dilution series used was as follows: 
 (i)  10 % ethanol in de-ionised water (v/v) 
 (ii)  20 % ethanol in de-ionised water (v/v) 
 (iii)  30 % ethanol in de-ionised water (v/v) 
 (iv)  40 % ethanol in de-ionised water (v/v) 
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 (v)  50 % ethanol in de-ionised water (v/v) 
 (vi)  60 % ethanol in de-ionised water (v/v) 
 (vii)  70 % ethanol in de-ionised water (v/v) 
 (viii)  80 % ethanol in de-ionised water (v/v) 
 (ix)  90 % ethanol in de-ionised water (v/v) 
 (x)  95 % ethanol in de-ionised water (v/v) 
 (xi)  100 % ethanol in de-ionised water (v/v) 
 
Initially, 5 mL of each of the ethanol solutions were placed in clean screw-cap bottles and 
these were then used. The procedure works by placing the filter paper sequentially in each of 
the ethanol solutions for 10 minute intervals that are accurately timed (in order from lowest 
concentration of ethanol to highest). The filter paper was then stored in the 100 % ethanol 
container and was immediately submitted for critical point drying. 
 
 Critical Point Drying and Sample Mounting 
 
Performed by members of the Microscopy Unit at Wits. Dried filter paper specimens were 
then cut in half using scissors and mounted directly onto double sided graphite tape, which 
was attached on one side to the metal holder. The two halves of the filter paper were mounted 
with one facing "up" and one facing "down" to ensure that the bacterial surface was visible on 
one of the half-moons (as illustrated in Figure E.1). The edges of the filter paper were then 
carefully sealed using graphite paste and allowed to dry open to the atmosphere, before being 
coated in a gold/palladium mixture by the members of the Microscopy Unit at Wits. Once the 
coating was completed, samples could be stored at room temperature in a desiccator until 
analysed. 
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Top Bottom
 
 
Figure E.1 Layout used when mounting filter paper for SEM 
 
E.2.2 Sample Analysis 
  
Our samples were mounted onto the brass holder using graphite paste that was dried under a 
warm lamp. These were then viewed on a scanning electron microscope (JSM-840, JEOL Ltd, 
Tokyo, Japan) and photographed using a standard 35 mm Nikon camera (black and white 
film, Ilford Pan F PLUS), with myself as the operator. Magnification, probe current and keV 
were manually adjusted when viewing the samples and as such are reported with the 
photographs themselves. The negatives were developed by a member of the Microscopy Unit 
and were then scanned using a EPSON Perfection 4870 Photo Scanner (thanks go to the 
Organometallic Research Group in the School of Chemistry at Wits for the use of their 
equipment) to obtain the data in the positive phase in the standard electronic format reported 
herein.  
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Appendix F: 
Experimental Procedures – Relating to Chapter 8 
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F.1 General Experimental Procedure for Multiple Protecting Group Additions 
 
Only one worked example will be included in this appendix for general reference purposes. 
The example chosen is that system containing the simplest of all the silicon-containing 
protecting groups used, triethylsilyl chloride. 
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Scheme F.1 Attempted synthesis of 5'-O-(triethylsilyl)uridine 273: (i) 1.1 eq triethylsilyl 
chloride, 0.1 eq DMAP, pyridine, rt, 18 h, 0 % 
 
When attempting the synthesis of compound 5'-O-(triethylsilyl)uridine 273 using the general 
procedure for the synthesis of 5'-O-silyl protected uridine derivatives (described in Appendix 
D, Section D.10) we obtained none of the desired product 273, but instead isolated a number 
of by-products showing multiple protecting group additions (compounds 274, 275 and 276). 
The results of the reaction are shown in detail in Scheme F.1. 
 
P a g e  | 418 
 
The full assignments for the 
1
H NMR spectrum (Table F.1) and the 
13
C NMR spectrum 
(Table F.2) are tabulated below for ease of reference. 
 
Table F.1 
1
H NMR Assignments for compounds 274, 275 and 276  
Position on Molecule Compound A          
(Either 274 or 275) 
Compound B         
(Either 274 or 275) 
Compound C   
(Identified as 276) 
H-1’ 5.96 ppm, d 5.98 ppm, d 5.86 ppm, d 
H-2’ 4.08-4.23 ppm, m 4.27-4.31 ppm, m 4.05-4.14 ppm, m 
H-3’ 4.08-4.23 ppm, m 4.27-4.31 ppm, m 4.05-4.14 ppm, m 
OH-2’ or OH-3’ 2.68 ppm, br d 2.96, br d N/A 
H-4’ 4.08-4.23 ppm, m 4.27-4.31 ppm, m 4.05-4.14 ppm, m 
H-5’ 3.90 ppm, dd 3.84 ppm, dd 3.74 ppm, dd 
H-5 5.69 ppm, d 5.70 ppm, d 5.68 ppm, d 
H-6 8.08 ppm, d 7.88 ppm, d 8.10 ppm, d 
NH 9.15 ppm, br s 8.96 ppm, br s 8.85 ppm, br s 
2’-O-Si(CH2CH3)3 0.61-0.70 ppm, m 0.64-0.70 ppm, m 0.65-0.70 ppm, m 
2’-O-Si(CH2CH3)3 0.93-0.99 ppm, m 0.96-1.01 ppm, m 0.93-1.02 ppm, m 
3’-O-Si(CH2CH3)3 0.61-0.70 ppm, m 0.64-0.70 ppm, m 0.65-0.70 ppm, m 
3’-O-Si(CH2CH3)3 0.93-0.99 ppm, m 0.96-1.01 ppm, m 0.93-1.02 ppm, m 
5’-O-Si(CH2CH3)3 0.61-0.70 ppm, m 0.64-0.70 ppm, m 0.65-0.70 ppm, m 
5’-O-Si(CH2CH3)3 0.93-0.99 ppm, m 0.96-1.01 ppm, m 0.93-1.02 ppm, m 
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Table F.2 
13
C NMR Assignments for compounds 274, 275 and 276  
Position on Molecule Compound A          
(Either 274 or 275) 
Compound B         
(Either 274 or 275) 
Compound C   
(Identified as 276) 
C-1’ 88.61 ppm 88.99 ppm 88.98 ppm 
C-2’ 70.20 ppm*  70.99 ppm$ 70.62 ppm# 
C-3’ 76.18 ppm* 75.50 ppm$ 76.33 ppm# 
C-4’ 84.62 ppm 85.07 ppm 84.14 ppm 
C-5’ 61.77 ppm 61.80 ppm 61.06 ppm 
C-2 150.30 ppm 150.53 ppm 150.19 ppm 
C-4 163.30 ppm 163.18 ppm 163.33 ppm 
C-5 102.02 ppm 102.30 ppm 101.52 ppm 
C-6 140.23 ppm 140.13 ppm 140.41 ppm 
2’-O-Si(CH2CH3)3 6.65 ppm** N/A
$$ 
6.67 ppm
## 
2’-O-Si(CH2CH3)3 4.42 ppm*** N/A
$$$ 
4.71 ppm
### 
3’-O-Si(CH2CH3)3 N/A** 6.72 ppm
$$ 
6.79 ppm
##
 
3’-O-Si(CH2CH3)3 N/A*** 4.69 ppm
$$$
 4.81 ppm
### 
5’-O-Si(CH2CH3)3 6.48 ppm** 6.66 ppm
$$
 5.77 ppm 
5’-O-Si(CH2CH3)3 4.09 ppm*** 4.17 ppm
$$$
 4.09 ppm 
Note: Values with the same superscript markers are interchangeable 
 
Identification of the by-products described above was conducted through the extensive use of 
NMR spectroscopy, specifically: 
1
H, 
13
C, COSY, HSQC, DEPT-135 and NOESY. 
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Unfortunately, even with the large amount of data at hand we were unable to unambiguously 
distinguish between compounds 274 and 275 – as the peaks for the protons on the sugar ring 
overlapped in the 
1
H NMR spectra. Further experiments would be required to distinguish the 
compounds (irradiation/NOE experiments or labeling experiments using, for example 
deuterium), at this moment we feel that they fall outside the scope of this thesis.  
 
 
